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Abstract 
Parkinson's disease (PD) is a neurodegenerative disorder that is characterised by uncontrollable shaking, 
muscular rigidity and cognitive impairment, due to low levels of dopamine caused by loss of dopamine 
containing neurons (DCN). The loss of DCN has been strongly associated with Caspase mediated 
apoptotic death. At present there are many studies that indicate exercise is beneficial in PD treatment, 
but there is a lack of research exploring the potential pathways, which exercise can activate and suppress 
to provide such positive and even negative effects.  
This study is the first to explore the effect of treadmill exercise on the level of Caspases, along with 
CAMK-IV protein in different brain regions of MPTP-treated rat model, using WB analysis. The results 
of this research has demonstrated reduction or completely suppression of some active Caspases, as well 
as, elevated amount of CAMK-IV in different brain regions of exercised PD animal model. To 
determine how exercise is reducing and inhibiting activation of Caspases, the first step was to identify 
how Caspases are stimulated, using ReNcell VM stem cell line that had been differentiated and treated 
with 6OHDA.  
 The results of the study demonstrated 6OHDA triggered Caspase mediated apoptotic death of dDCN 
via PERK ER stress and NFκB classical pathway. IF, WB and cell viability analysis, using a wide range of 
inhibitors, showed that Caspase-2 is activated by the PERK pathway of ER stress and NFB classical 
pathway in 6OHDA treated dDCN. 6OHDA triggered activation of Caspase- 8 by the classical pathway 
in NFB mediated death of dDCN. 6OHDA triggered Caspase-4 activation but the exact mechanism 
involved remains to be identified. Only through understanding the molecular pathways regulating death 
of DCN in PD, new potential targets for therapy may be identified, which may ultimately reduce further 
death of DCN and slow PD progression. This proposed study has the potential to seek for more 
efficient drugs, which can suppress Caspase activation by targeting key targets in the pathways that the 
Caspases follow. These new specific targeted drugs could be used with treadmill exercise to achieve 
maximum effect, by slowing down or inhibiting further death of DCN.  
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Chapter 1 
Introduction: The role of Caspases 
and Caspase pathways in PD 
pathogenesis  
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1.0 Parkinson’s disease (PD) 
 
Parkinson’s disease (PD) is a neurodegenerative disorder that affects 127000 people in the UK mostly 
aged over 50, although it is also able to affect people under age of 40. Patients diagnosed with PD have a 
lack of specific neurons that secrete the neurotransmitter dopamine in the pars compacta region of the 
substantia nigra (SNpc). Patients with PD have approximately 80% loss of dopamine containing neurons 
(DCN) at which time symptoms such as tremor, bradykinesia, rigidity and postural instability have 
already developed. The loss of dopamine interferes with normal control and coordination of movement. 
The most typical primary symptom that occurs is tremors at resting, which can affect the face, hands, 
arms or foot on one side of the body. Usually the PD patient may have constant shaking of one finger or 
hand when rested on their lap. Overtime it is possible that the tremor from one side of the body can 
progress to the opposite side. Often the tremor can be triggered by strong emotions such as stress or 
excitement (Gazewood et al 2013). 
 
Muscle rigidity is consistent resistance of the muscles to passive displacement throughout the entire joint 
motion. Muscle rigidity may to be due to decreased activity of inhibitory interneurons in the spinal cord, 
which would increase the excitability of motor neurons. Another reason for muscle rigidity may be due 
to elastic properties of muscle that are changed in PD secondary to disuse, causing muscle to stiffen 
independently of neural activation. Muscle rigidity results in stiffness of the neck, arms, legs and torso, 
leading to a reduction in movement. In some cases the rigidity can result in pain. Rigidity can affect the 
facial muscles leading to a lack of expression in the PD patient which may cause problems in 
communication and can affect their social life (Weerkamp et al 2013, Gazewood et al 2013, Cesaro and 
Defebvre 2014). 
 
Bradykinesia can cause lack of facial expression, difficulty in walking, speaking and getting into and out 
of chairs. Bradykinesia may be due to interference in cortical motor centres and excitatory circuits 
passing through the basal ganglia resulting in small and weak movements. The movement is slow and 
can interrupt the ease of carrying out daily tasks such as getting dressed, brushing teeth and cutting their 
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food. Speech can become slower and quieter causing problems in social situations. Repetitive 
movements such as finger tapping, typing and writing can become difficult for individuals suffering from 
PD due to the slowing of muscles. A significant symptom found in PD is the difficulty in maintaining a 
stable posture when standing upright. This increases the risk of falling which may cause injuries and 
sometimes hospitalisation. PD patients may also have difficulty in rising from a chair, pivoting and other 
balance movements. PD patients can often find it difficult to coordinate and plan ahead such as when 
walking (Weerkamp et al 2013, Cesaro and Defebvre 2014, Gazewood et al 2013).  
 
Non motor systems such as lack of sleep, loss of smell, fatigue and depression have also been seen PD. 
PD patients that do not have a strong support system can suffer from nutritional deficiencies and 
become malnourished.  Difficulty in swallowing food caused by the slow muscle movement can 
contribute to malnutrition. Fear, depression and anxiety can also be the result of diminished social life 
and lack of moral support. PD patients can also suffer from problems with memory and even dementia 
may occur. Freezing is a common sign in PD where the PD sufferer feels that they are temporarily 
immobile. Freezing can occur spontaneously in different situations such as walking, pivoting, going 
towards or sitting on a chair. This freezing symptom can increase the probability of the PD patient to fall 
(Weerkamp et al 2013).  
 
The rate of progression of PD from its mild to advanced form varies for each patient. Furthermore, in 
some cases PD patients find non motor symptoms such as depression and fatigue more difficult to cope 
with on a daily basis then motor symptoms such as muscle rigidity. Due to the nature of PD it is difficult 
to obtain an early diagnosis as the majority of the symptoms have already developed in the patient. 
However, there is a scale to define the progression of PD and can aid to determine how far the disease 
has developed such as mild, moderate or advanced PD. Patients with mild PD often have the tremor 
symptom is present mostly on one side of the body. Mild PD patients also have some issues with 
movement, but can still carry out daily activities and there may be some changes in facial expression and 
walking. At this stage, exercise and medication such as levo dopamine (L-DOPA) therapy can improve 
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mobility, balance, depression and other PD symptoms effectively (Cesaro and Defebvre 2014, 
Gazewood et al 2013, LeWitt 2015).  
 
The second stage of progression is moderate PD where there are episodes of freezing, issues with 
balance and tremors, rigidity or bradykinesia can occur on both sides of the body. Medication at the 
stage is still effective but side effects such as dyskinesias develop. Exercise still can improve and maintain 
good balance and movement. Advanced PD is the most severe form of PD, where the patient is unable 
to live independently by themselves and requires assistance to carry out all the daily activities. In 
advanced PD the patient is wheelchair bound or bedridden for the majority of the day. Cognitive 
memory is affected, which can result in memory loss, dementia and confusion. At this stage the side 
effects of the medication become more prominent (Cesaro and Defebvre 2014).  
 
Although intensive research has been conducted the actual cause of PD is still unknown, therefore the 
treatment available at present is of limited quality (Tomlinson et al 2012, Gazewood 2013, Weekamp et 
al 2013, LeWitt 2015, Ganat et al 2012, Rodríguez-Nogales et al 2015, Cooper et al 2012, Machado et al 
2012 ). However, a few theories to the aetiology of PD have been discussed. One of the many theories 
to the origin of PD is that PD may be the result of autoimmune cells that damage DCN of the brain. 
Speculating that the brain may spontaneously generate a chemical substance related to dopamine that 
can destroy nerve cells can extend this theory further. Further support for this view has come from an 
early investigation conducted by Bisaglia et al (2014), which suggested that nigral death could be the 
result of elevated levels of reactive oxidative species (ROS) and respiratory failure of the mitochondria. 
 
Zuo et al (2013) demonstrated that there is an association between PD and the level of calcium in the 
mitochondria. A change in the level of calcium increases the possibility of cell apoptosis. Former work 
by Mattson at el (2000) and Cesaro and Defebvre (2014) suggested that imbalances in homeostatic levels 
of calcium in the endoplasmic reticulum (ER) induce increased levels of toxicity and death of neuron 
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cells. These results have been strongly correlated with neurodegenerative disorders.  
 
Previous research conducted by Hald and Lotharius (2005), explored the relationship between 
inflammation and oxidative stress in PD. Monoamine oxidase induces catabolism of dopamine which is 
present inside the cell leading to the formation of dihydroxyphenylacetic acid (DOPAC), alongside 
hydrogen peroxide. Dopamine is subsequently converted to dopamine Y quinone via an antioxidant 
reaction, which takes place inside the cell. The formation of dopamine Y quinone interacts with protein 
sulphydryls causing an alteration in the redox buffer. The decrease in glutathione, increased outflow of 
hydrogen ions from the mitochondria and decreased levels of tyrosine hydroxylase (TH) contribute to 
the change in the content of the redox buffer. This modification decreases the ability of the buffer to 
remove oxidants caused by oxidative stress, leading to an accumulation of free radicals circulating the 
system, resulting in damage and destruction of neural cells. In addition, the impairment of adenosine 
triphosphate (ATP) synthesis can also participate in an increase in cell toxicity that causes the destruction 
of cells.    
 
Hydroxyl radicals are formed from hydrogen peroxide through the Fenton reaction. The hydroxyl 
radicals’ formed, increase and cause excessive levels of oxidative stress, leading to impairment and mass 
destruction of cells.  In addition, an increase in 4-hydroxyl-2-nonenal (HNE) which is formed as a by-
product in lipid metabolism induces a rise in oxidative stress and cell destruction, particularly in the SN 
of the PD individual. Excessive levels of HNE can alter the structure of proteins through covalent 
bonding. Furthermore, cell apoptosis and impairment of the mitochondria is the result of elevated levels 
of HNE in the system (Smith et al 2007).   
 
Recent research by Chinta et al (2008) revealed that the general decrease in vitamin E and glutathione 
and an increase in iron in the SN, can contribute to the imbalance of the redox buffer. In addition, by 
products (super oxides, hydrogen peroxide and hydroxyls) formed during metabolism, contribute to the 
impairment of mitochondrial function and ATP synthesis.  In the electron transport chain of the 
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mitochondria, complexes III and I produce the ROS super oxide. The super oxide is converted into 
hydrogen peroxide. As enzymes (peroxisomes) are destroyed, this contributes to an increase in hydrogen 
peroxide accumulation (as hydrogen peroxide cannot be removed). Subsequently, hydrogen peroxide 
enters the cytosol and can convert to hydroxyl by binding to ferrous ions. In addition, super oxides can 
interact with nitrogen oxides to produce peroxynitrite, which interfere with the normal function of key 
enzymes. This in turn can cause impairment of complexes I and IV in the electron transport chain of the 
mitochondria. The increase of free radicals can cause damage to the lipid bilayer of cells, resulting in the 
out flow of the cells inner content, which leads to cell lysis. In addition, peroxynitrite can induce 
fragmentation of DNA in cells as well as structural changes in amino acid residues of essential proteins.  
 
Ischiropoulos (2003a 2003b) suggests that ROS promote the production of mutated α synuclein in 
protein inclusions and in Lewy bodies, which contributes to the pathogenesis of PD. The α synuclein are 
insoluble products, which can aggregate easily, and can interfere with the transport of dopamine. In 
addition, α synuclein combined with mitochondrial impairment can contribute to apoptosis and cell 
destruction. Former work, by Emerit et al (2004) suggests that the central nervous system is much more 
susceptible to the effects of oxidative stress then other body systems. As previously stated that ROS are 
produced as byproducts of metabolism, this increases the probability of elevated levels of oxidative 
stress to occur. Three enzymes (inducible nitrite oxide synthase, neuronal nitrate synthase and 
endothelial nitrite synthase) convert nitrite and promote an inflammatory response, which in turn results 
in the demethylation and degeneration of neurons. In addition, ROS can also be produced by elevated 
activity of glutamate receptors. The increase in receptor activation is due to an increased influx of 
calcium ions accumulating the system. As the receptors undergo excessive stimulation, this activates the 
arachidonic acid cascade pathway, resulting in the production of ROS. This in turn causes damage to the 
neuronal cells through the impairment of the mitochondria.   
 
Previous work by Chandra et al (2002), suggested that oxidative stress can also be caused by oxidise 
substrates (such as P450 oxidase and xanthine oxidase), which can result in toxicity and cell lysis. As the 
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number of cells lysed increases, there is a decrease in synaptic activity. The total quantity of DCN is 
reduced substantially, causing PD symptoms in the individual.  Inhibition or low levels of the enzyme 
glutamine synthetase prevent the conversion of excessive glutamate to glutamine, resulting in a buildup 
of glutamate in the cells. This reaction induces the production of more ROS and proteolytic enzymes, 
resulting in high rate of death of neuronal cells to take place within a short duration. The elevated levels 
of ROS induce opening of the permeability transition pore (PTP) of the mitochondria to open, allowing 
an increase in the movement of molecules into the cytosol. Due to the imbalance of key electrons in the 
mitochondria, factors such as pro-Caspases, apoptosis initiating factor (AIF) and cytochrome c are 
activated. These factors contribute to further damage and destruction to cells (Gazewood et al 2013).   
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1.1 PD and Brain Regions  
 
1.1.1 PD and Brain Cortex 
The brain cortex is the outer covering of the brain, and folds to form lobes (parietal, occipital, temporal 
and frontal lobe) which have different functions (Figure 1.1). In general the brain cortex is involved in 
thought and action. The frontal lobe participates in planning, reasoning, some speech, motor function, 
problem solving and movement. The parietal lobe plays a role in movement, sensation, handwriting and 
recognition, whilst the occipital lobe is associated with visual processing. The temporal lobe related with 
memory, and recognition of auditory stimuli such as music and speech (Martini and Ober 2006, Martini 
et al 2014).  
(Martini 
F.H, Ober W. C,  2006, Martinis Atlas of The Human Body, 7th edition, San Francisco, Pearson Benjamin Cummings Ed Ltd pp 24) 
 
Figure 1.1: Lateral view of the brain cortex  
The parietal, occipital, temporal and frontal lobes together form the brain cortex. Each lobe specialises 
and has a different function (Martini and Ober 2006).  
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Research by Brazhnik et al (2012) explored the electrophysiology of the motor cortex and midbrain in 6-
hydroxydopamine (6OHDA) treated rats. 6OHDA-treated rats had suffered symptoms of freezing and 
difficulty in walking and turns on circular treadmill. Treadmill walking decreased the number of 
fluctuations of cortical oscillatory activity in the midbrain and motor cortex of 6OHDA-treated rats 
when compared to sedentary rats. Treadmill exercise was carried out and electrophysiological recordings 
of neuronal activity were documented. Rats underwent treadmill exercise for an hour, once a week for 
four weeks. For each session, rats walked on circular treadmill for 5 minutes followed by a 2 minute rest 
period.  In addition, a change in the direction of the circular treadmill was carried out to determine its 
effect on the midbrain.  The results showed that 6OHDA-treated rats that underwent treadmill exercise 
had reduced fluctuations of neuronal activity in the midbrain and improved motor control on the 
treadmill. 
 
Ho et al (2011) found male Wister rats exhibited PD symptoms after administering 1-methyl 4-phenyl 1, 
2, 3, 6-tetrahydropyridine (MPTP) injection. Immunohistochemical analysis revealed increased levels of 
interleukin-2 (IL-2) and lesions in the brain cortex, amydala and ventral and dorsal striatum. MPTP rats 
had suffered cognitive, motor and emotional impairment. The author concluded that the lesions found 
in MPTP brain cortex, amydala and striatum contributed to interference in normal cognitive, emotional 
and motor function. Previous work by Murray et al (2003) explored the effects of the α-amino-3-
hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) agonist, LY503430 in MPTP mouse and 6OHDA 
rat PD model. Immunohistochemical analysis portrayed less lesions and intact tissue of the prefrontal 
cortex and ventral midbrain of 6OHDA-treated Sprague Dawley rats and MPTP mice that had been 
treated with LY503430, compared to 6OHDA and MPTP PD model that had not been treated with 
LY503430. Growth factors such as glial derived growth factor (GDNF) and brain-derived growth factor 
(BDNF) have a crucial role in neuronal growth. GDNF protects survival of neurons, whilst BDNF 
prevents structural damage in cells. Tissue analysis revealed low levels of BDNF in PD animal model. 
However, a two fold increase in BDNF was found in the brain cortex of 6OHDA rat and MPTP mouse 
model that had been treated with LY503430. 
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1.1.2 PD and Cerebellum 
The cerebellum is comprised of the right and left cerebral hemisphere and plays a vital role in 
coordination of movement, posture and balance (Figure 1.2). The cerebellum stores routine patterns of 
movement (Martini and Ober 2006, Martini et al 2014). MRI testing has shown the cerebellum and 
striatum play a vital role in calculating and planning motor tasks and processing information from the 
temporal lobe of the brain in PD patients (Husarova et al 2011). Patients suffering from PD at early 
stage have reduced active cerebellum and striatum areas compared to healthy people (Husarova et al 
2011). Minks et al (2011) determined if the cerebellum has a critical role in the development and 
progression of PD and if it can be used as a target in PD treatment. In the study twenty PD participants 
were given two motor tasks to complete (a ball test and nine hole peg test) and were assessed on how 
quickly they completed each task. Stimulation of the cerebellum improved the voluntary movements in 
PD.  
 
(Martini F.H, Ober W. C,  2006, Martinis Atlas of The Human Body, 7th edition, San Francisco, Pearson Benjamin Cummings Ed Ltd pp 23) 
Figure 1.2 : Posterior view of the cerebellum  
The cerebellum is comprised of the left cerebral hemisphere and the right cerebral hemisphere with a 
longitudinal fissure. Frequent cross talk occurs between the two hemispheres so controlled movements 
can be carried out (Martini and Ober 2006).  
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Rolland et al (2007) examined the impact of loss of neurons from the nigrostriatum on the cerebellum 
and basal ganglia in MPTP monkey and 6OHDA rat PD model. A reduction of thalamic neurons was 
found in the motor cortex in MPTP monkey and 6OHDA rat PD model may have contributed low 
activity levels of the thalamus. The amount of thalamocortical neurons that had received input from the 
cerebellum had decreased by half in 6OHDA rats compared to control. The decrease in cerebellum 
activity can contribute to reduced levels of stimulation in the SN pars reticulata, thereby effecting 
dopamine levels in cells. MRI imaging analysis found an increase in metabolic activity in the motor 
cortex of 6OHDA lesion rats compared to the control. The author suggests the cerebellum- thalamic 
pathway could provide a better target site in PD treatment. An increase in monoamine oxidase activity 
was found in the cerebellum, hippocampus and striatum of MPTP mice (Gal et al 2005). 
 
Prevoius research by Shang et al (2004) found elevated levels of iron, nitric oxide, superoxide and active 
Caspase-3 levels in lysates of cerebellar neurons from MPTP rats. A reduction in the intracellular iron 
indicator, cytosolic aconitase was found in rats that had been injected with MPTP. A decrease in nitric 
oxidase synthase, superoxide synthase was detected in MPTP rat cerebellar neurons compared to control. 
Apoptotic death of MPTP cerebellar neurons was confirmed using terminal deoxynucleotidyl transferase 
dUTP nick end labelling (TUNEL) assay. Collectively the results indicated MPTP caused apoptotic 
death of rat cerebellar neurons via the accumulation of ROS, iron and a decrease in anti oxidant enzymes. 
The author concluded that the results of the study provide insight to how ROS can cause damage to 
neuronal cells in PD animal model (Shang et al 2004).   
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1.1.3 PD and Midbrain 
The brainstem is comprised of pons, medulla and midbrain (Figure 1.3). The midbrain participates in eye 
movement, and body movement alongside vision and hearing (Martini and Ober 2006, Martini et al 
2014). Immunofluorescence (IF) analysis has shown that DCN in the SNpc is more susceptible to 
6OHDA damage compared to cholinergic neurons (Pienaar and Berg 2013).  MPTP and 6OHDA 
promote increase in the concentration of zinc, leading to depleted ATP, essential growth factors 
resulting in damage of DCN in midbrain and striatum of PD rat animal model (Sheline et al 2013).  
 
 
(Martini F.H, 2006, The Fundamentals Of Anatomy And Physiology, 7th edition, San Francisco, Pearson Benjamin Cummings Ed Ltd pp 461) 
 
Figure 1.3 : Schematic view of the brainstem 
The midbrain also known as the mesencephalon, pons and medulla oblongata form the brainstem. Each 
unit of the brainstem has specialised functions and are required in regulating normal bodily functions 
(Martini and Ober 2006).  
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Chung et al (2011) planted induced pluripotent stem cells into the midbrain of 6OHDA Sprague-Dawley 
rat model. 6OHDA rats that had undergone surgery had reduced PD symptoms and improved 
behaviour. Docosahexaenoic acid was combined with stem cells and aided to establish successful 
differentiation of DCN. An increase in neuroprotective genes such as BDNF, GDNF, Nurr1 and B cell 
lymphoma 2 (BCL-2) and decrease in Caspase-3 activity were found in the cells. The author emphasises 
that implantation of DCN into midbrain could be used as an alternative in PD (Chung et al 2011, Rath 
et al 2013).Cell derived from human ventral mesencephalon have better survival rate and functional 
abilities and have the potential to be used as grafts in brain of PD patients (Rath et al 2013).  
 
Tanriover et al (2010) found a significant decrease of TH, GDNF and neurotonin in MPTP Wistar rats. 
A two fold increase in TH, GDNF and neurotonin was found in docosahexaenoic acid treated MPTP 
rats. docosahexaenoic acid increased GDNF and neurotonin  and protected DCN from damage in SN 
of MPTP Wistar rats. In addition, docosahexaenoic acid treated MPTP rats had improved balance and 
motor co-ordination, when compared to MPTP rats (Tanriover et al 2010). Hacioglu et al (2012) found 
docosahexaenoic acid protected further neuronal damage in the SN in MPTP male Wistar rats. MPTP 
rats had poor co-ordination and balance compared to MPTP rats that had been treated with 
docosahexaenoic acid. MPTP docosahexaenoic acid rats had elevated levels of BCL-2, TH and had 
intact tissues compared to PD animal model. Immunohistochemical analysis showed loss of neurons and 
an abundance of fibrils accumulated in the midbrain of MPTP rats.  
 
Decressac et al (2012) found high level of aggregated α-synuclein accumulated in lesions of the midbrain 
and striatum of 6OHDA rat. A decrease in TH was observed in the midbrain and striatum of 6OHDA 
rats when compared to the control. 6OHDA rats had slower performance, difficulty in walking and 
navigating around a maze when compared to control. Immunohistochemical analysis portrayed distorted 
axons and loss of neurons in the midbrain and striatum of PD animal model. 6OHDA, MPTP and 
rotenone encourage deletions of exons resulting in mutation of α-synuclein in PD model. A decrease in 
TH, proteasome function and increase in aggregated α-synuclein was observed in mesencephalic cultures, 
as well as striatum, SN and cortex of Sprague Dawley rats (Kalivendi et al 2010).  
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1.1.4 PD and Striatum 
The striatum comprised of caudate nucleus and the putamen (Figure 1.4). The striatum is involved in 
movement, cognitive function and motor control, learning, and vision (Martini and Ober 2006, Martini 
et al 2014). The dorsal striatum plays a key role in decision making via integration of various 
corticostriatal regions of the striatum, which are able to process and analyse information such as 
sensorimotor, cognitive, and emotional efficiently in PD patients, as well as PD in vivo and in vitro 
models (Balleine et al 2007). Current work has shown the Chinese herb, medecassoside protected 
neurons from damage by increasing BDNF, BCL-2 and glutathione synthase in PD animal model. 
Hydroxysafflor yellow increased BDNF and GDNF levels, which protected neurons from oxidative 
damage in the striatum of 6OHDA rat. Hydroxysafflor yellow elevated dopamine levels in striatal 
neurons of PD animal model (Han et al 2013).  
 
(Martini F.H, Ober W. C,  2006, Martinis Atlas of The Human Body, 7th edition, San Francisco, Pearson Benjamin Cummings Ed Ltd pp 18) 
Figure 1.4 : Coronal section showing the mesencephalon as well as caudate nucleus and 
putamen of the striatum  
The caudate nucleus and putamen form the striatum and is involved in regulating movement. Damage to 
the striatum has been associated with PD (Martini and Ober 2006).   
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Immunohistochemical analysis illustrated increased astrocytes, tumour necrosis factor (TNF) and 
oligomers of aggregated α-synuclein and reduced TH levels in the SN and striatum of MPTP and 
6OHDA rats (Dimant et al 2013, Lee et al 2013). Nociceptin/ orphemin damage of neurons striatum of 
6OHDA-treated rats. The protection of neurons provided by reduced nociceptin/ orphemin reduced 
the incidence of dyskinesias in PD animal model (Marti et al 2012).  
 
Castro et al (2013) found elevated TNF, IL-1β and -10 and low levels of nerve growth factor in 
hippocampus and striatum of MPTP rats. Atorvastatin increased nerve growth factor in striatum and 
hippocampus in MPTP rats. MPTP had caused motor impairment, loss in sense of smell, slower pacing 
when walking and difficulty keeping a constant balance in PD animal model. Castro et al (2012) 
observed that lithium chloride and valporate protected neurons from ROS damage in the striatum and 
cortex of MPTP Wister rats. A decrease in TH and increase in fibrils was observed in lesions of striatum 
and cortex of PD rat model and rat mesencephalic cultures (Castro et al 2012, Kim et al 2014). Low 
levels of glutathione peroxidase, superoxide dismutase, dopamine, TH and proteasome activity was 
detected in SN, striatum and cortex of MPTP rats (Sonsalla et al 2013).  
 
Aznavour et al (2012) found a decrease of active TH levels in the striatum of cats that had been induced 
with MPTP. MPTP cats had developed PD motor symptoms. PD patients have altered function of the 
basal ganglia causing difficulty in movement and carrying out daily activities. Functional MRI analysis of 
PD and non PD participants performing right hand movement tasks were carried out to detect any 
changes in movement initiation or inhibition in the striatum. It was found that PD patients had reduced 
motor activity in striatum and increased activity of pallidal at initiation stage, when compared to non PD 
patients. In addition, an increase in striatum cortical motor activity was found at resting stage in PD 
patients (Toxopeus et al 2012).  
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1.2 PD and Current Therapies   
 
1.2.1 Diet  
At present there is not enough strong clinical evidence demonstrating the impact of nutrition in PD. 
D’Orazio et al (2012) reviewed recent researched publications and found that alteration in diet can 
decrease the risk of many diseases such as cardiovascular, inflammatory and neurodegenerative disorders 
such as PD.  Diets enriched with carotenoids (astaxanthin and fucoxanthin) reduce toxicity in cells by 
binding to ROS, toxins and heavy metals, which may cause pathology of cells.  In addition, the binding 
of these β carotenoids protects peroxidation of lipids and phospholipids of cell membranes, which 
causes death of cells and other tissues. The increase of antioxidants in the diet such as vitamin E, vitamin 
C and phenols from fruits and vegetables reduce oxidants such as hydrogen peroxide, superoxynitrate, 
super oxide and nitric oxide, which are produced as by products in the cell (D’Orazio et al 2012, 
Mattson et al 2004).  
 
1.2.2 Drug therapy and PD  
PD patients are commonly treated with the drug L-DOPA combined with Carbidopa to ensure that L-
DOPA is not converted to dopamine before reaching the blood brain barrier and so maximum 
dopamine can be used. L-DOPA is used at early stages and its treatment is effective for around 5 years. 
However, as PD advances over time L-DOPA becomes ineffective to the patient and produces more 
side effects, such as dystonia and dyskinesias(LeWitt 2015). Other drug treatments that are available 
include dopamine agonists (apomorphine, pramipexole and ropinirole), monoamine oxidase inhibitors 
(selegiline and rasagiline), and anticholinergic medication (trihexphenidyl and benztropine mesylate). The 
most current drug, safinamide is at phase three of clinical testing and has the potential to prevent and 
improve cognitive and motor impairment at early stage of PD. Safinamide irreversibly binds to and 
suppress monoamine oxidase (MAO), alongside inhibiting glutamate activity and dopamine reuptake, 
thereby increasing dopamine levels in the brain (Fabbri et al 2015). Isradipine has been shown to be 
neuroprotective in PD animal model by suppressing calcium channels and is currently at phase two in 
clinical trials (Rodríguez-Nogales et al 2015, Singer 2012).  
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1.2.3 Stem cell research and PD  
Current research has explored the use of stem cells to produce neuronal grafts, as an option in PD 
treatment. DCN grafts were transplanted in 6OHDA-treated brain of PD rat, resulting in improvement 
of brain function (Aguila et al 2012). The transplantation of stem cells in PD patients could promote 
normal function of the brain. The presence of growth factors in stem cells leads to production of healthy 
stem lines. Stem cells lines that will be used in transplantation are specific DCN will have the potential to 
promote efficient synaptic communication and transmission in PD brain (Aguila et al 2012). Purification 
of stem cell prior to transplantation may decrease the probability of growing tumours leading to more 
successful grafts (Ganat et al 2012).  
 
1.2.4 Deep brain stimulation and PD  
Deep brain stimulation (DBS) is a surgical procedure that is used to reduce symptoms in patients 
suffering from severe PD, typically for eight to sixteen years. DBS is suitable for PD patients that are still 
responding to L-DOPA, are not cognitive impaired, have good health and have a supportive network. 
DBS reduced tremors, rigidity, dystonia, bradykinesia and dyskinesias in PD patients (Cooper et al 2012, 
Machado et al 2012). Six months of continuous DBS may be causing changes in pathways, which lead to 
step initiation suggesting that this may be the reason that DBS is able to decrease tremors but cannot 
improve gait or balance (Rocchi et al 2012). In contrast, a different study conducted by McNeely et al 
(2012) found combining drug therapy with DBS did not have any significant additional effects when 
compared to using one therapy, suggesting that similar pathways are influenced. 
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1.2.5 Exercise  
At present there are extensive studies looking at the effect of different types of exercise, from Nordic 
walking, Alexandra technique, Tai Chi to various forms of dance, such as tango, waltz and ballet.  
Collectively, all types of exercise have indicated improved rigidity, hand movements, facial expression, 
learning, self confidence and better quality of life in PD patients (Fritz et al 2011, Stallibrass et al 2002, 
Hackney and Earhart 2009a, Hackney and Earhart 2007, Hackney and Earhart 2010, Li et al 2012, 
Earhart, 2009b, Dreu et al 2012). In addition, concurrent music can provide steady gait and can improve 
PD patients to carry out dual or multitask, as music can be used an external cue that develops 
recognition in transfers and mobility in PD (Brown et al 2010).  Furthermore other approaches such as 
whole body massage, muscle strength exercise, participation in active theatre and community based 
exercise have shown positive effects in improving gait, mobility and balance (Heiberger et al 2011, 
Paterson et al 2005, Modugno et al 2010, C.Haas personal communication). Unconventional methods 
such as water based exercises have also shown signs in the improvement of postural stability, functional 
mobility, motor symptoms and reduced fear of falling in PD patients (Vivas et al 2011, Ayan and 
Cancela 2012).  
 
Tomsilon et al (2012) analysed various exercise regimes  (treadmill, cueing , dance , martial arts and 
physiotherapy) that were used in PD rehabilitation to determine which form of exercise was particularly 
suited in PD. Meta analysis revealed that there was no significant exercise regime that was preferred in 
PD treatment. In addition, exercise therapies used in patients suffering from PD were effective in overall 
treatment, when compared to PD patients that were not undergoing any exercise. PD patients that had 
exercise integrated into their treatment had better balance, mobility and improved gait compared to PD 
patients that led a sedentary lifestyle. Although the studies analysed by the author portray positive effects 
of exercise in PD, there were many factors which have to be considered such as small sample size, 
publication bias and not all studies were statistically significant.   
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Herman et al (2007) explored the effects of treadmill training on gait and mobility in PD rehabilitation. 
Treadmill training improved balance, gait and strength of muscles improving length of stride and 
velocity, which can decrease risk of freezing and falls.  In the study, nine patients (suffering from mild to 
moderate PD), endured treadmill training for 30 minute session 4 times a week for 6 weeks. Evaluations 
and adjustments to treadmill speed were carried out at the end of each week, based on the patients speed 
whilst walking on normal ground.  Patients had improved stride length, alongside stable walking speed 
on normal ground and a decrease in gait and number of falls was found. In addition, PD patients had an 
improved perception of their gait performance and had improved balance and mobility. The intensity 
and repetitiveness of treadmill training over a length of time provided the beneficial effects and may 
have contributed to better motor control.  
 
Canning et al (2012) determined the effectiveness and viability of home based treadmill training in 
participants suffering from mild PD. Twenty PD participants were randomly allocated to either carry out 
home based treadmill training or usual physical activity for six weeks. Home based treadmill was carried 
out for 40 minutes four times a week for six weeks. Patients were supported by a safety harness and 
were asked to hold the treadmill handle bars at all times. Muscle soreness, tiredness, number of falls, 
intensity and adaptability of exercise were explored, before and after the six week training with another 
six week follow up. Home based treadmill training increased PD patient’s confidence and quality of life. 
The main finding of the study showed that home based treadmill training was a safe and valid form of 
exercise which the mild PD patient could easily integrate into their lifestyle. PD patients will be able to 
use treadmill confidently as part of their exercise regime at home allowing flexibility and letting the PD 
patient work at their own pace. The screening and monitoring process will promote PD patients to carry 
out their exercise on the treadmill safely as possible.  
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1.2.5.1 Exercise in PD animal models 
Research by Zigmond et al (2012) had shown exercise to have positive effects in rat PD animal model. 
To determine the effect of exercise, male rats were segregated into four groups’ control, exercise, 
6OHDA and 6OHDA exercised. Rats underwent treadmill exercise for 12 weeks followed by 6OHDA 
injection then another 8 weeks of treadmill running. WB analysis revealed a reduction of 47% TH and 
49% TH in the SN and striatum in PD sedentary rats. Treadmill exercise prevented loss of TH positive 
striatal and SNpc neurons in PD Exercised induced (PD-Ex) rats. The author indicated that exercise 
may have increased gene expression of neurotrophic factors such as GDNF, BDNF, IGF1, FGF2 which 
protect DCN from damage by reducing ROS. Treadmill exercise may have promoted synthesis and 
release of dopamine by increasing the binding of dopamine receptors. Exercise promotes protection of 
synapses and increase superoxide dismutase, heat shock protein, catalase and glutathione peroxidase 
(Zigmond et al 2009, Frazzita et al 2013 Zigmond and Smeyne 2014). 
 
El Ayadi and Zigmond (2011) explored the role ROS in DCN of PD mouse model. 6OHDA caused 
formation of apoptotic bodies, chromation condensation and membrane shrinkage of the cytoplasm in 
mice mesencephalic cultures, illustrating that ROS promotes apoptotic death of DCN via oxidative 
stress. Mild exposure to ROS can provoke gene expression of prosurvival genes such as superoxide 
dismutase and Bcl-2. WB showed that 6OHDA-treated with methamphetamine in mice mesencephalic 
cultures had decreased amount of phosphorylated JNK, indicating that 6OHDA increases ROS 
production leading to apoptotic death of DCN via JNK pathway. 
 
Urgate et al (2003) showed that GDNF decreased 6OHDA toxicity in 6OHDA-treated mice 
mesencephalic cultures. Hoechst staining illustrated fragmentation of the nucleus and chromatin 
condensation, confirming 6OHDA promoted apoptotic death of DCN in PD animal model. GDNF 
protected a significant amount of DCN from neurotoxic damage indicating that oxidative stress 
contributes to death of DCN in PD animal model. Pothakos et al (2009) explored the influence of 
exercise in behaviour and coordination in PD mouse model.  Mice were segregated into four groups, 
untreated, exercise, MPTP-treated and MPTP-treated with exercise. Mice underwent treadmill exercise 
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for 12 weeks. The results portrayed that MPTP-treated mice had reduced step length, took longer time 
to complete a maze task, and had problems with balance and co-ordination. MPTP-treated mice that had 
undergone endurance exercise had completed the maze task in a shorter time frame, had better memory, 
increased step length, had improved gait, balance and co-ordination, indicating that endurance exercise 
provided beneficial effects in PD animal model.  
 
Immunohistochemical analysis demonstrated that lesions caused a decrease TH and loss of neurons 
from the striatum of MPTP-treated mice. High-performance liquid chromatography showed low levels 
of DOPAC in PD striatum but high DOPAC levels in PD-Ex striatum of PD mouse model. In addition, 
improved balance and motor performance was determined in Ex and PD-Ex. The author suggested that 
exercise promotes dopamine uptake, synthesis and release to be used by the synapses and reduces decay 
of dopamine (Petzinger et al 2007).  
 
Gorton et al (2010) found that forced treadmill exercise had more beneficial effects then voluntary wheel 
running in PD animal model. MPTP mice underwent treadmill or running wheel exercise for an hour 5 
days a week for 30 days.  MPTP decreased GDNF in caudate putamen, cortex , midbrain and  SNpc in 
mice. MPTP mice that underwent treadmill or wheel running had higher levels of GDNF in cortex, 
midbrain and SNpc. A decrease in striatal dopamine in was found in PD mice. An increase in dopamine 
levels were measured in striatal neurons of PD-Ex mice.  Treadmill exercise had prevented further loss 
of DCN, dopamine decay, reduced anxiety and maximised dopamine usage and enabled the ease of 
turning in PD mice. An increase in distance and velocity in was found in voluntary wheel running 
compared to forced treadmill in PD-Ex mice.  
 
Research has shown that four week treadmill exercise improved resting heart rate in MPTP-treated mice 
(Al-Jurrah et al 2007).  MPTP mice that had carried out treadmill training had better respiratory, normal 
ECG and elevated levels of citrate synthase in cardiac and skeletal muscle. WB analysis demonstrated a 
decrease in DOPAC, dopamine and TH levels were determined in the striatum and SN of MPTP mice. 
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In comparison, MPTP exercised mice had an increase in TH positive neurons in striatum and SN of PD-
Ex mice (Al-Jurrah et al 2007, Zhang et al 2013). 
 
Immunohistochemical analysis had also shown a reduction of TH in striatum and SN of 6OHDA-
treated rats (Anstrom et al 2007, Avila et al 2010). Work by Cohen et al (2003) found that exercise 
improved motor behaviour and protected neurons from damage in PD rat model.  6OHDA-treated rats 
had developed dyskineas and motor impairment. WB analysis showed an increase in dopamine, DOPAC 
and GDNF in the striatum of 6OHDA-treated exercised rats when compared to 6OHDA-treated 
sedentary rats. GDNF had protected striatal neurons from damage and increased the accumulation of 
dopamine to be used that improved motor activity in 6OHDA-treated rats (Zhang et al 2013a, Frazzita 
et al 2013). Howells et al (2005) found no significant difference protection of DCN from damage 
between 6OHDA-treated rats that underwent forced or voluntary exercise. 6OHDA-treated rats carried 
out exercise on a running wheel for one hour every day for two weeks. Immunohistochemical analysis 
revealed less lesions and increase in dopamine in the SNpc and striatum of exercised rats when 
compared to 6OHDA sedentary rats, indicating that exercise prevents loss and damage to DCN. 
Immunohistochemical analysis illustrated increased TH in the striatum of 6OHDA-treated rats that had 
treadmill exercise for an hour everyday for two weeks (Avila et al 2010). 
 
Tillerson et al (2001) had found 6OHDA-treated rats had low levels of dopamine and DOPAC and 
increased lesions in striatum. An increase in dopamine and DOPAC levels were determined in striatal 
neurons in 6OHDA rats that underwent motor training rats when compared to sedentary rats. Further 
work had demonstrated exercise had decreased degeneration of DCN and reduced shaking in 6OHDA-
treated rats when compared to 6OHDA-treated rats that did not exercise (Tillerson et al 2002). Research 
by Tajri et al (2010) had shown an increase in neurotrophic factors in exercised PD rat model. In the 
study, rats underwent treadmill exercise 30 minutes each day, 5 days a week for 4 weeks. 
Immunohistochemical analysis revealed lesions, loss TH positive neurons and damaged DCN in the 
SNpc and striatum of sedentary PD rats. In comparison, PD rats that had undergone treadmill exercise 
had intact tissues and more TH positive neurons in the SNpc and striatum. WB analysis revealed an 
 
- 23 - 
 
increase in BDNF and GDNF in striatum of exercised rats compared to sedentary rats. Cylinder and 
rotational test showed 6OHDA-treated rats had difficulty in turns and balance when compared to 
6OHDA-treated rats that had exercised. Increase in GDNF promoted protection to neurons from 
damage (Frazzita et al 2013). Former research by Mabandla et al (2004, 2010) found that exercise had 
increase in the release of neurotrophins as well as promoting the protection of dopaminergic neurons of 
the SN of PD rat model. In the study Evan rats were segregated into two groups’ 6OHDA-treated 
sedentary rats and 6OHDA-treated rats that underwent exercise. Rats underwent voluntary exercise on a 
running wheel for 30 minutes to 90 minutes every day for two weeks. 6OHDA-treated rats had reduced 
number of TH positive and dopamine levels in the SN. The author concluded that exercise had 
decreased loss of and protected DCN in 6OHDA-treated rats by releasing neurotrophins that protected 
neurons from damage. 
 
Previous research (Yoon et al 2007) had investigated the effects of treadmill exercise in 6OHDA-treated 
rats in PD animal model. In the study, rats separated into four groups control, exercise, 6OHDA and 
6OHDA exercised. Rats in exercised and 6OHDA-treated exercise underwent treadmill exercise 30 
minutes a day for two weeks. Immunohistochemical analysis showed an increase of TH in the SNpc and 
striatum of exercised and 6OHDA-treated exercised group in PD rat model. The amount of TH was 
reduced by half in the SNpc and striatum of PD sedentary rats. An increase of TH was determined in 
the SNpc and striatum of PD rats that had completed treadmill exercise. Furthermore, destruction of 
nerve terminals of DCN, in SNpc was observed in rats that had been treated with 6OHDA. A loss of 
striatal fibres were observed in 6OHDA-treated rat, indicating that 6OHDA had successfully damaged 
neurons in PD animal model. The study highlighted that PD rat model is an adequate model to use to 
study PD pathogenesis. Moreover, the study demonstrated that treadmill exercise can prevent loss of 
neurons in the SN and striatum of PD animal model (Frazzita et al 2013).  
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1.3 PD and Caspases  
 
The loss of DCN within the basal ganglia has been strongly associated with the activation of Caspases. 
Caspases (Caspase 1-14) are a family of cysteine proteases, which act as pro-apoptotic proteins that 
promote cell death, via activation of the Caspase cascade through the stimulation of various pathways. 
Initiator Caspases (Caspase-2,-8,-9 and-10) are able to activate executioner Caspases (Caspase-3,-6 and-7), 
resulting in death of cells via apoptotic routes (Figure 1.5). Moreover, Caspases can cleave and cause the 
stimulation of other members of the Caspase family resulting in eventual cell death. An imbalance 
between active pro-apoptotic:anti-apoptotic proteins results in pathogenesis. For example, prolonged 
stimulation of pro-apoptotic protein, such as Caspases, lead to programmed cell death, which 
contributes to apoptosis of DCN that  lead to onset of PD (Altieri 2010, Nakamura et al 2012, 
Chowdhury et al 2008, Chaudhry and Ahmed 2014). 
 
 
 
Figure 1.5 Caspase cascade  
Figure showing overview of Caspase cascade which results in apoptosis. Initiator Caspases such as 
Caspases-2,-8,-9 and-10 activate downstream executer Caspases such as Caspases-3,-6 and-7 leading to 
eventual apoptotic cell death (McIlwain et al 2013, Chowdhury et al 2008, Nakamura et al 2012) 
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1.3.1 Caspase structure and activation 
Caspases exist in most cells in a dormant state known as zymogens and can be activated through 
intrinsic or extrinsic routes such as mitochondrial, nuclear factor kappa beta (NFB) and ER stress 
pathways. The Caspase structure consists of four main domains: an N terminal polypeptide, a large 
subunit, a small subunit and a linker region (Figure 1.6). The linker region functions to join the small 
subunit with large subunit and is comprised of aspartate residues. The large subunit and small subunit 
join to form the COOH terminal domain. Caspases can be categorized into two main types; initiator 
Caspases and effecter Caspases (as upstream and downstream respectively). The differentiation of these 
Caspases is based on their attributes, such as the role of action and participation in the proteolytic 
Caspase cascade. Initiator Caspases have long prodomains, which permit joining of proteases to their 
specific activators (Altieri 2010, Yan and Shi 2005).  
 
Upon activation, the N terminal polypeptide and linker region of Caspases are dissociated,   inducing the 
large subunit and small subunit to form an active enzyme complex (Figure 1.6). The complex consists of 
specific sequences, which combine to form an active site that recognizes particular substrates necessary 
for enzymatic stimulation. The N terminal polypeptide is composed of particular amino acid sequences, 
which makes the enzyme unique and highly specific. The inner recognition sites of Caspases can be 
activated via proteolysis, which can be triggered by Caspase substrates and in some cases other caspases. 
Caspases have diverse prodomains of different lengths and sequences, alongside distinct binding sites, 
causing a variation in substrate specificity (Fan et al 2005, McIlwain et al 2013). Activation of Caspases is 
achieved, via proteolytic cleavage of the linker regions between the large subunit and the small subunits 
of the enzyme, allowing the subunits to bind together, to form heterodimers stimulating activation 
(Venderova and Park 2012, McIlwain et al 2013).  
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Figure 1.6 Caspase activation  
The Caspase protein comprises of the N terminal domain and carboxyl domain. The carboxyl domain 
consists of the large and small subunit which is connected by a linker region. Caspase stimulation from 
inactive state (zymogen) to active state is achieved via proteolytic cleavage of the linker regions between 
the large and small subunits of the enzyme, allowing the subunits to bind together, to form heterodimers 
stimulating activation. Once a Caspase is activated, it triggers action of other Caspases, via the Caspase 
cascade, leading to apoptotic cell death (Altieri 2010, Venderova and Park 2012, McIlwain et al 2013, 
Yan and Shi 2005).  
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1.4 Different pathways (NFB, ER stress, cJNK, p38) can stimulate activation of 
Caspases in DCN  
 
Inflammation, oxidative stress, genetic mutation, calcium imbalance and toxins promote activation of 
intrinsic and extrinsic pathways. Activation of p38, JNK, and mutation of PTEN induced putative kinase 
1 (PINK-1) gene triggers stimulation of intrinsic also known as the mitochondrial pathway. Activation of 
Caspases can be achieved through extrinsic routes, such as NFB and ER stress pathway. Caspases can 
activate each other via a cascade reaction.  Activation of NFB stimulates Caspase-8 activity leading to 
stimulation of active Caspase-3. Active Caspase-1 can also activate NFB indirectly leading to 
stimulation of other Caspases, such as, Caspase-8 followed by Caspase-3. Active Caspase-2 and active 
Caspase-8 participate in mitochondrial apoptosis pathway by converting B-cell lymphoma 2 homology 
domain 3 interacting-domain (BID) to truncate p15 BID (tBID). Subsequently, tBID binds to the pores 
of the mitochondria, thereby promoting the opening of mitochondrial PTP and release of cytochrome c. 
Cytochrome c binds to and stimulates Caspase-9, which in turn activates Caspase-3 (McIlwain et al 2013 
Nakamura et al 2012, Chowdhury et al 2008, Chaudhry and Ahmed 2014). 
 
 Activation of JNK and p38 can provoke opening of mitochondrial PTP and release of cytochrome c 
leading to the activation of Caspases-9 and -3. Active Caspase-2 promotes release of cytokines such as 
IL- 6 and-8, leading to stimulation of microglia and death of neuronal cells via apoptotic routes. 
Oxidative stress, toxicity and mutations of specific genes, such as Parkin E3 ligase can damage the 
ubiquitin-proteasome system (UPS), resulting in elevated levels of aggregated incorrectly folded proteins, 
which accumulate to form Lewy bodies alongside stimulating activation of Caspase-12. Active Caspase-
12 stimulates Caspase-9, which in turn results in stimulation of Caspase-3. Active Caspase-3 promotes 
fragmentation of DNA, shrinkage cell, formation of apoptotic bodies and death of cells. The mass 
destruction of DCN causes degeneration of neurones, resulting in PD (Nakamura et al 2012). 
Subsequent, pages describe such pathways (NFκB, mitochondrial and ER stress) and their role in 
Caspase activation in more detail.   
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Figure 1.7: Caspase pathways that lead to cell apoptosis resulting in PD  
Figure illustrates the involvement of various pathways that upon stimulation encourage cell death of 
DCN leading to the onset PD. Oxidative stress, environmental toxins, alongside genetic mutations and 
excitotoxicity can stimulate activation of different pathways such as inflammatory, JNK, NFB, p38, and 
ER stress. Subsequently, this provokes motivation of initiator Caspases, leading to activation of other 
Caspases, resulting in cell death and disease and progression of PD Altieri 2010, Venderova and Park 
2012, McIlwain et al 2013, Yan and Shi 2005, Nakamura et al 2012, Chowdhury et al 2008, Chaudhry 
and Ahmed 2014, Midwinter et al 2006, Flood et al 2011).  
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1.5 NFB Pathway  
 
NFB is an inducible transcription factor as it has the ability to bind to specific DNA sequences 
promoting transcription of genes that manufacture a variety of proteins. NFB is present in an inactive 
form in virtually all cells and tissues.  The NFB family is comprised of five members such as p105, 
p100, p65, c-Rel and Rel B. p100 and p105 are precursors for the active p50 subunit and p52 subunits 
respectively, and are long proteins that possess glycine rich regions (Figure 1.8). The glycine rich regions 
of the p100 and p105 precursors are cleaved and release the N terminal segment of the proteins leading 
to the active p50 and p52 forms (Midwinter et al 2006, Chowdhury et al 2008).  
 
In contrast, p65, c-Rel and Rel-B have transcriptional activation domain embedded within their C 
terminal region that promotes activation and regulation of these proteins in a different way. The p65, c-
Rel and Rel-B proteins can form homodimers and heterodimers with each other via their transcriptional 
activation domains. As the p50 and p52 homodimers lack the transcriptional activation domains they are 
unable to stimulate transcription when bound to DNA in the nucleus. In order for transcription to occur 
p50 or p52 need to form heterodimers with p65, c-Rel or Rel-B (Hayden and Ghosh 2009, Mattson et al 
2000). 
  
Normally, the C terminal Rel homology domain (RHD) binds to the ankyrin repeats that are situated 
within the IB, which prevents stimulation of NFB proteins The RHD of the NFB family proteins is 
comprised of 300 residues at the C terminal and contains all the elements necessary for the proteins to 
bind to DNA, to form dimers and to bind to IB proteins. The RHD contains the nuclear localising 
signal which promotes the binding of DNA when NFB is activated, resulting in transactivation of 
different target genes (Chowdhury et al 2008, Flood et al 2011).   
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Figure 1.8: Structure of NFB proteins  
The precursor’s p105, p100 and p65, c-Rel and Rel-B are the part of the NFB family and are present in 
the cytoplasm in an inactive form. The ankyrin repeats of p105 and p100 inhibit activation of these 
precursors. The transcriptional activation domain of p65, c-Rel and Rel-B promote different variation of 
dimers to be formed. Rel Homology domain binds to DNA, to form dimers and to bind to IB proteins 
(Midwinter et al 2006, Chowdhury et al 2008). 
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The IB family is also comprised of five members known as IB-α, IB-β, IB-γ, IB-ε and Bcl-3 
(Figure 1.9). The IB proteins regulate NFB by binding to and suppressing NFB activation.  IB 
consist of 5-10 ankyrin repeats that bind to the RHD of NFB and conceal the nuclear localization 
signal of NFB. The amino terminal of IB-α, IB-β and IB-γ all have a regulatory domain that 
contains two serines. During IB degradation the serine residues are phosphorylated by ubiquitin. IB-α 
phosphorylates at serine 32 and serine 36, whilst IB-β phosphorylates serine 19 and serine 23. The N 
terminal regulatory domain of IBs comprise of lysine residues which bind to polyubiquitin chain and 
are subsequently degraded (Memet 2006). 
 
IB proteins can bind to different combinations of NFB proteins. IB-α and IB-β binds to and 
suppresses the p50:p65 combination or p50:c-Rel combination of NFB proteins, which are found in 
most cell types. IB-ε binds and inhibits homodimers such as p65:p65 or c-Rel:c-Rel form of NFB, 
which are found in fewer cells. IB-γ inhibit the homodimer precursor p50:p50 in mouse model and its 
function is yet to be determined. Bcl-3 is different to members of the IB family as it can inhibit and 
also promote activation of the complex it binds to. Bcl-3 binds to homodimers p50:p50 or p52:p52 and 
promotes transcriptional activation when they enter the nucleus. The ankyrin repeats embedded in the C 
terminal of p100 and p105 function as inhibitors and cleavage at the glycine region converts p100 and 
p105 to the active p52 and p50 forms. The inhibitory protein IB binds to and suppresses the nuclear 
localising signal on NFB proteins thereby inactivating NFB:IB complex in the cells cytoplasm. 
When cells are stimulated IB is phosphorylated and catabolised, allowing the release and activation of 
NFB.  NFB enters the nucleus and binds to NFB promoter binding sites on genes thereby 
encouraging NFB response in gene expression (Midwinter et al 2006, Ghosh et al 2007). 
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Figure 1.9: Structure of IB proteins  
IB-α, IB-β, IB-γ, IB-ε and Bcl-3 are all part of the IB family which inhibit the activation of NFB 
proteins. IB proteins can bind and suppress different combinations of NFB proteins in the cytoplasm 
of cells (Midwinter et al 2006, Chowdhury et al 2008, Memet 2006). 
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The IKK (IB kinase) complex (700- 900 kDa) is composed of two catalytic subunits IKK-α, IKK-β 
and the regulatory subunit NFB essential modulator (NEMO). IKK-α and IKK-β share 52% genetic 
sequence and 65% catalytic domains. IKK-α and IKK-β contain a leucine zipper for protein – protein 
interactions, a helix loop helix domain which has a regulatory function and a kinase domain (Figure 1.10). 
External stimuli promote leucine zipper of IKK-α and IKK-β to form dimers. The helix to helix domain 
of IKK-α and IKK-β interact with kinase domain. In addition, NEMO triggers autophosphorylation of 
serine residues in the activation loop of IKK-α and IKK-β, leading to formation of dimers and binding 
of NEMO. IKK-α:IKK-β dimer binds to NEMO, via the NEMO binding domain in IKK-α and IKK-β, 
producing a NEMO:IKK-α:IKK-β structure, known as the IKK complex. IKK complex phosphorylates 
the N terminal region of IB at the serine residues 32 and 36. Degradation of IB occurs at the lysine 21 
and 22 residues by 26S proteasome. Degradation of IB exposes the nuclear localisation signal, which 
results in activation of NFB (Ghosh et al 2007, Li et al 2008). 
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Figure 1.10: Structure of IKK proteins  
IKK-α, IKK-β and NEMO are all part of the IKK proteins that form to make the IKK complex. IKK-α 
and IKK-β are the catalytic segment, whilst NEMO is the regulatory segment of the IKK complex. 
External stimuli promote the dimerization of IKK-α and IKK-β, followed with binding of NEMO via 
the NEMO binding domain which is embedded in the IKK-α and IKK-β structures (Ghosh et al 2007, 
Li et al 2008). 
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Extensive research has shown that NFB plays a key role in anti apoptotic pathways mainly in cancer cell lines 
(Section 1.5.3). Recent studies have shown that NFB is involved in triggering apoptotic death of cells (Section 
1.5.4). External stimuli such as environmental toxin, ROS, TNF, IL, ligands and lymphotoxin B are all able to 
trigger IKK complex to stimulate cytoplasmic NFB activation, either through the classical, alternative or 
atypical pathway (Figure 1.11 and discussed below). Active NFB enters the nucleus to promote transcription of 
different proteins such as Caspases, cytokines, receptors, growth factors, adhesion molecules and chemokines 
(Flood et al 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Active NFB increases transcription of different genes 
Different stimuli trigger activation of IKK complex, via classical, atypical or alternative pathway that 
results in stimulation of NFB. Active NFB provokes transcription of a wide variety of genes such as 
chemokines, cytokines, surface receptors, adhesion molecules and apoptotic regulators, which are used 
for different responses such as inflammatory (Chaudhry and Ahmed).  
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1.5.1 Classical Pathway triggers NFB activation  
In the classical pathway, external stimuli such as oxidative stress, ROS, TNF trigger activation of the 
protein NEMO. Active NEMO binds to IKK-α and IKK-β forming the IKK complex (Figure 1.12). 
This IKK complex interacts and degrades IB of IB of IB:NFB via proteasome degradation. IKK 
complex phosphorylates serine residues 32 and 36 at the N terminal region of IB from the NFB:IB 
complex. Phosphorylated IB binds to the E3IBα complex, which sends a signal to the ubiquitin 
protein E2 conjugating protein. The binding of E2 conjugating protein to IB results in degradation of 
IB occurs at the lysine 21 and 22 residues by 26S proteasome (Li et al 2008, Ghosh et al 2007).  
 
The release and degradation of IB exposes the nuclear localisation signal, which results in activation of 
NFB protein (p50:p65) through the formation of dimers. The nuclear localisation signal translocates 
active NFB from the cytoplasm into the cell nucleus. Subsequently, active NFB binds to the promoter 
and induces transcription of various genes (Li et al 2008, Ghosh et al 2007). The classical pathway, 
promotes NFB to enhance expression of apoptotic genes, such as FAS ligand, which activates Caspase-
8 in cells (Krumschnabel et al 2009, Li et al 2008, Reynolds et al 2007). For example, NFB promotes 
transcription of inducible nitric oxide synthetase (iNOS), which participates in the increase of 
intracellular calcium concentration in damaged cells, alongside ROS and nitric oxide production 
(Mattson and Mark 2007, Panet et al 2001). In addition, NFB promotes transcription of inhibitors of 
apoptosis, cytokines and neurotrophic factors (Lee et al 2001, Mattson and Meffet 2006). 
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Figure 1.12: The Classical Pathway of NFB 
In the cytoplasm of resting cell, IB binds to and inhibits NFB activation. External signals cause the 
activation of NEMO which binds to IKK-α and IKK-β forming the IKK complex. IKK complex binds 
to and releases IB from the IB:NFB complex, through phosphorylation. Phosphorylated IB is 
degraded by proteasome 26S. The release of IB exposes the nuclear localisation signal which promotes 
dimerization of p65:p50 (NFB proteins) and translocation of active p65:p50 from the cytoplasm to the 
nucleus. Active p65:p50 binds to specific DNA sequences resulting in transcription of genes (Midwinter 
et al 2006).   
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1.5.2 The Alternative Pathway 
In the alternative pathway, members of the TNF family such as lymphotoxin b, trigger NFB inducing 
kinase (NIK) activation. Active NIK binds to and activates IKK-α:IKK-α forming the IKK complex. 
IKK complex phosphorylates and removes IB from the p52:IB:Rel-B complex. IB is catabolised by 
proteasome 26S and p52:Rel-B is activated through dimerization. The p52: Rel-B dimer leaves the 
cytoplasm to enter the nucleus where it binds to DNA promoter site through and up regulates 
transcription of specific genes (Lee et al 2001, Jia and Misra 2007).  
 
 
Figure 1.13: Alternative Pathway NFB  
Extracellular stimuli triggers cell surface receptors resulting in NIK activation. Subsequently, NIK binds 
to and dimerises IKK-α forming the IKK complex. IKK complex phosphorylates and releases IB, 
which is subsequently degraded by ubiquitinylation. As the inhibitor IB is removed, p52 forms dimer 
with Rel-B and the p52:Rel-B dimer translocates to the nucleus promoting transcription of proteins 
(Midwinter et al 2006).   
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Recent work by Lee et al (2007) suggests the presence of a third pathway, known as the atypical pathway, 
can also activate NFB. This pathway is stimulated by UV radiation, which promotes proteasomes to 
degrade IB- through phosphorylation, resulting in the release and activation of NFB.  Active NFB 
enters the nucleus, binds to the promoter of DNA, initiating the process of transcription of cytokine 
receptor genes and cytokine genes.  The negative feedback system is used to catabolise the increased 
levels of NFB so that the level of transcription ceases. This is achieved by producing new IB- 
proteins that attach to NFB (Mattson et al 2000).  
 
1.5.3 The role of NFB in PD pathogenesis  
The role of NFB in cell death and survival is controversial (Yamamoto and Gaynor 2001, Cassarino et 
al 2000, Hunot et al 1997, Gao et al 2002, Flood et al 2007, Zhang et al 2012, DeErausquin et al 2003, 
Henn et al 2007, Ghosh et al 2007). A 60% increase in NFB activity was found in human SH-SY5Y 
neuroblastoma cells treated with MPTP, when compared to untreated cells. Translocation of NFB and 
increase in NFB binding activity was detected in the nucleus of treated cells. NFB increased 
expression of superoxide dismutase and promoted cell survival rather than death of MPTP-treated SH-
SY5Y cells (Cassarino et al 2000). Furthermore, Parkin activated NFB by phosphorylation of IB, 
thereby promoting transcription of pro survival genes. However, mutant Parkin phosphorylates IB and 
activate NFB, which caused death of human SH-SY5Y neuroblastoma cells (Henn et al 2007). 
Research by Lee et al (2001) found that NFB activation protected auto oxidized dopamine PC12 cells 
from apoptotic cell death in PD model. PC12 cells that had been transfected with p65 and p50 units of 
NFB had greater resistance to apoptotic death caused by auto oxide dopamine, when compared to 
PC12 cells that had not been transfected.  
 
In contrast, work by Gao et al (2002) found NFB activity promoted death of DCN in SN, through the 
inflammatory pathway. A selective loss of DCN and increase of active microglia was observed using 
double IF analysis, in ventral mesencephalic cultures of male Fischer rats that had been treated with the 
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inflammagen lipopolysaccharide. An increase in ROS such as superoxide and nitrite and IL were found 
in treated DCN cultures compared to untreated cultures. The authors suggested that the increase in ROS 
and NFB levels may result in selective and progressive death of DCN, which is relevant in 
neurodegenerative diseases such as PD.    
 
Previous research by Ghosh et al (2007) suggests that loss of dopamine secreting cells can be prevented 
by selectively suppressing activation of NFB. The mice used in the study were induced with the MPTP, 
to generate animal models that had PD symptoms. There was a significant increase in NFB activity 
found in SNpc of the MPTP induced mice. These findings were also established in PD patients, 
indicating that increased stimulation of NFB may play a vital role in the onset of PD. Double IF 
analysis showed high levels of p65 in astrocytes and microglia of midbrain of six to eight weeks old male 
mice that had been injected with MPTP, when compared to mice that received saline injection. Double 
IF analysis showed elevated levels of p65 in microglia the SN of PD patients when compared to age 
matched controls.  The MPTP mice were administered with peptide NBD (NFB essential modifier-
binding domain) injection intravenously to see if there was a difference in the level of NFB activity. A 
decrease in the level of NFB was found in the SN of the MPTP induced mice, indicating that the 
peptide NBD had successfully suppressed NFB activity. The NBD injection had prevented the binding 
of NEMO to IKK so the IKK complex could not be formed, thus the activity of NFB was suppressed. 
Furthermore, a decrease in the activation of microglia in the SN and an increase in overall motor 
function was found in the MPTP-induced mice via the administration of peptide NBD injection. The 
author also suggested that the reduced level of NFB through the NBD injection, had improved the 
quantity and secretion of dopamine secreting cells in the nigra of MPTP induce mice. In this way, the 
peptide NBD can be used therapeutically in the treatment of PD patients, via selectively suppressing the 
activation of NFB.  
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In addition, high levels of iNOS in SN along with increased nitrite in cerebrospinal fluid have been 
found in PD patients, indicating inflammatory damage of DCN. Active microglia produce cytokines IL-6 
and-1β as well as nitric oxide and ROS that trigger IKK complex, leading to NFB activation, via the 
release and degradation of IB. The ATP competitive inhibitor Compound A (7-[2-
(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-
2-one hydrochloride), competitively inhibits IKK-β kinase ability to phosphorylate IB, thereby 
preventing NFB activation and reducing death of DCN in SN in MPTP mouse model (Flood et al 
2007, Zhang et al 2012).  
 
DeErausquin et al (2003) found active NFB level in DCN of PD patients and suggested that 
excitotoxicity may have promoted stimulation of NFB. In addition, an increased in NFB 
translocation , ROS production, calcium levels and decrease IB expression was found in rat 
mesencephalic cultures that were exposed to glutamate receptor AMPA. IF analysis portrayed a 
significant loss of dendrites of rat mesencephalon DCN that were treated with AMPA, indicating that 
toxicity destroyed DCN. This shows that NFB has a dual role as it can protect and promote DCN 
from apoptotic death (Yamamoto et al 2001). 
 
Previous work by Hunot et al (1997) had indicated that ROS triggers NFB activation leading to 
apoptotic death of DCN via oxidative stress.  Double IF and Immunohistochemical analysis revealed 
p65 NFB translocation and staining in mesencephalon DCN of post-mortem brains of PD patients as 
well as in mesencephalon rat cultures that had been treated with ceremide. IF analysis showed increased 
levels of ROS and formation of apoptotic bodies in ceremide induced mesencephalic cultured cells using 
a specific molecular probe, 2',7'-dichlorodihydrofluorescein diacetate (DCDHF-DA) that emits a green 
light when it is oxidised. This strongly indicates that ROS is able to trigger NFB activation and 
apoptotic death of DCN through inflammatory pathway.  
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1.5.4 NFB pathway and Caspase Activation  
NFB has been strongly correlated with PD, through oxidative stress and the inflammatory pathway 
(Figure 1.14 and discussed on pages 39-41). NFB promotes complex formation between the pro 
apoptotic protein ASC (apoptosis associated speck like protein containing a CARD) and Ipaf a member 
of Apoptosis activating  family -1 (Apaf-1). The ASC: Ipaf formation binds to and activates Caspase-8, 
which in turn stimulates Caspase-3 (Mattson et al 2000, Mattson and Meffert 2006, Jia and Misra, 2007, 
Yamamoto et al 2001, Masumoto et al 2003).  
 
Figure 1.14 : Exploring Caspase activation in the NFB pathway  
NFB can be activated by different Caspases and can also promote activation of other Caspases via 
intrinsic (mitochondrial) route and extrinsic route leading to death of DCN and PD onset. Active 
Caspase-2 can trigger NFB activation which stimulates activation of Caspase-8 followed by Caspase-3 
activation, resulting in death of DCN and PD onset. Oxidative stress promotes protein misfolding and 
aggregation leading to DCN to become more susceptible to cell death (Giasson and Lee 2001). 
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Oxidative stress depletes ATP and nicotinamide adenine dinucleotide (NADH ) levels resulting in a 
decrease in TH and glutathione along with impairment of complex I of the mitochondria. Malfunction 
of the mitochondria leads to defects in ubiquitination. This contributes to the increase of Caspases-1,-3 
and -8 stimulation leading to loss of cells in the pars compacta of PD brain (Williams et al 2005, Chandra 
and Orreius 2002, Chaudhry and Ahmed 2014).   
 
 
 
 
1.5.4.1 Caspase-2 and NFB pathway  
Caspase-2 is a unique member of the Caspase family as it possesses a dual function, to promote or 
suppress cell death (Figure 1.14). Caspase-2 is able to promote apoptosis via stimulating Caspase-3 
activation either directly or indirectly triggering NFB activation (which subsequently activates Caspase-
8 followed by Caspase-3 activation). Moreover, Caspase-2 can promote formation of tBID (a pro 
apoptotic protein) which translocates to the mitochondrial membrane. The binding of tBID induces 
rearrangement of the lipid channels on the mitochondria, causing pores to form, thereby releasing the 
component cytochrome c. Cytochrome c binds to Apaf-1 via oligomerization, forming an apoptosome. 
The apoptosome recruits and thereby stimulates Caspase-9 followed by Caspase-3 activation. In addition, 
Caspase-2 prevents apoptosis by increasing Bcl-2 (anti apoptotic protein) activity (Wilms et al 2007, 
Chaudhry and Ahmed 2014) 
 
Lamkanfi et al (2006 and 2007) suggests that NFB interacts with the prodomain of Caspase-2 forming 
complexes with NFB through the recruitment of receptor interacting protein 1 (RIP). Caspase-2 
comprises of a p53-induced death domain (PIDD) which is activated in response to DNA damage. 
PIDD is able to bind to the RIP1 forming a PIDDosome complex which attaches and activates 
Caspase-2. The PIDD:RIP1:Caspase-2 complex is able to trigger NFB stimulation, promoting the 
transcription of pro-survival genes. However, substantial damage to DNA may result in Caspase-2 to 
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switch from protective to apoptotic function, promoting NFB to increase transcription of pro 
apoptotic genes. More specifically research has shown that Caspase-2 is able to promote mitogen 
activated protein kinase (MAPK) and NFB activation (Kumar 2007).  
 
1.5.4.2 Caspase-3 and NFB pathway   
Active Caspases-3 and-8 levels were found in DCN of the SN in post mortem brain of PD patients 
(Anderson 2001).  Karunakaran and Ravindranath (2009) discovered that p38 can influence activation of 
NFB in midbrain of MPTP-treated mice. Western blot (WB) analysis revealed that IB 
phosphorylation and translocation of NFB was prevented when p38 inhibitor, SB239063 was used in 
midbrain of PD animal model, indicating that p38 triggers the phosphorylation of IB resulting in 
activation of NFB. In addition, increased p65 NFB was found in the nucleus of MPTP mouse 
midbrain that had not been treated with the p38 inhibitor SB239063. WB analysis showed an increase in 
Caspase-3 activity in the midbrain of PD animal model that had not been treated with p38.  
 
Research by Jia and Misra (2007) observed NFB activation in the nucleus, alongside increase in 
hydrogen peroxide, Caspase-3 activation and production of superoxide in zinc ethylene 
bisdithiocarbamate fungicide (zineb), treated human neuroblastoma cells. The elevated ROS production, 
such as hydrogen peroxide and superoxide, alongside increased lipid peroxide was able to trigger 
activation of Caspases via NFB route leading to death of cells via apoptotic pathway. Moreover, 
reduced stimulation of antioxidant enzymes such as, superoxide dismutase and catalase were found in 
cells exposed to the pesticide zineb, suggesting that oxidative stress is able to trigger NFB apoptotic 
route and suppress antioxidant activity, leading to death of neuronal cells. The authors suggested that 
their findings are providing support for oxidative stress theory of PD pathogenesis, as environmental 
toxins may cause death of DCN and develop PD by inhibiting stimulation of antioxidant and activating 
pathways such as NFB. The accumulation of hydrogen peroxide interacts with superoxides leading to 
further manufacture of hydroxyl radicals, increasing lipid peroxidation and degradation of DNA and 
proteins (Karunakaran and Ravindranath 2009, Henn et al 2007). 
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1.5.4.3 Caspase-1 and NFB pathway 
Caspase-1 indirectly activates apoptosis via triggering NFB stimulation (thereby allowing Caspase-8 
followed by Caspase-3 activation), and by promoting catabolism of the Parkin gene, E3 ligase. The 
breakdown of E3 ligase induces impairment of UPS. The UPS plays an essential role in the degradation 
of incorrectly folded and defective proteins (see Section 1.7.2 for further details). It has been shown that 
6OHDA triggers phosphorylation of IB and translocation of p65 to the nucleus in SH-SY5Y 
neuroblastoma cells. IF and WB analysis that revealed 6OHDA triggered Caspase-3 activation and death 
of DCN through NFB pathway (Xiang et al 2011). Work by Panet et al (2001) revealed that NFB 
triggers apoptotic death of 6OHDA-treated dopamine induced PC12 cells. Elevated levels of 
translocated p65 NFB was found in 6OHDA-treated cells by flow cytometry analysis. A specific NFB 
inhibitor SN-50 was able to decrease apoptotic death of 6OHDA-treated cells suggesting that 6OHDA 
triggers NFB mediated death of cells. In addition, Caspase-1 inhibitor ICE and Caspase-3 inhibitor, 
CPP32, had decreased death of 6OHDA induced cells indicating that Caspases-3 and -1 are active in 
apoptotic death of 6OHDA induced cells. WB analysis showed an increase in survival in 6OHDA cells 
that had been treated with either the Caspase-3 inhibitor or Caspase-1 inhibitor. The study indicated that 
ROS triggers NFB activation and activation of Caspases-3 and -1, resulting in apoptotic death of DCN.  
 
1.5.4.4 Caspase-8 and NFB pathway  
NFB triggers expression of FAS ligand, leading to Caspase-8 activation and death of cells via apoptotic 
route (Mattson et al 2000, DeErausquin et al 2003). In addition, stimulation of the FAS receptor 
encourages activation of FAS death domain by cleavage of cysteine residues. Active FAS binds to and 
activates the death domain of Fas-associated death domain containing protein (FADD). Subsequently, 
active FADD binds to the death effecter domain of Caspase-8, thereby triggering activation of Caspase-8. 
FADD also promotes Caspase-8 binds to the death-inducing signalling complex (DISC), which interacts 
with activate NFB (Lamkanfi et al 2006 and 2007). However, studies by Mattson and Meffert (2006) 
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and Masumoto et al (2003) show that active NFB triggers Caspase-8 activation, leading to apoptotic 
cell death). 
 
 Research by Ho et al (2009) found that mutated leucine rich repeat kinase 2 (LRRK-2) interacts and 
triggers FADD leading to Caspase-8 activation and death of mouse cortical neurons. Caspase-8 induces 
apoptosis intrinsically via converting BID to tBID which translocate onto the membrane of the 
mitochondria, allowing the membrane PTP to open (Kruidering and Evan 2000). Research by Hartmann 
et al (2001) indicated that higher levels of Caspase-8 were found in the SN of PD patients when 
compared to normal individuals. This suggests that Caspase-8 activity contributes to the loss of DCN 
leading to the onset of PD. Prolonged stimulation of NFB may have caused Caspase-8 activation 
resulting in cell apoptosis via the inflammatory pathway.  
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1.6 Mitochondrial Pathway  
 
The mitochondria play a vital role in production of ATP, cellular processes and serves as a reservoir for 
calcium storage.  The mitochondrial respiratory chain possesses electron carriers (NADH/succinate) 
that transfer electrons to complexes in inner mitochondrial membrane (IMM). The transfer of electrons 
from complex 1 to complex 3, across the IMM forms a proton and electrochemical gradient, which aids 
to create the transmembrane potential of the mitochondria. The mitochondrial transmembrane potential, 
subsequently aids to create ATP production in complex 5. Impairment of the electron transport chain 
has been observed in fibroblasts and muscle of PD patients. Complex 1-3 produce ROS as a by product. 
During oxidative stress, oxygen and nitric oxide interact with accumulated ROS, forming peroxynitrite, 
which induces impairment of complexes 1-5, as well as increases leakage of proteins, leading to collapse 
of the membrane potential and impairment of the mitochondria (Jin et al 2012, Pislar et al 2013). 
 
The mitochondrial PTP is the opening and closing of a pore that permits ions and other solutes to 
traverse the inner membrane of the mitochondria (Figure 1.15). The opening of the mitochondrial PTP 
can be caused by various stimuli (such as elevated levels of oxidants, inorganic phosphates or calcium) 
(Chandra and Orrenius 2002). Hyperpolarisation of the IMM allows an increase in osmalarity and inner 
membrane potential. Cardiolipin, is a negatively charged phospholipid found embedded between the 
inner and outer membranes of the mitochondria. Cardiolipin binds cytochrome c to the IMM. However, 
during oxidative stress, the cardiolipin acyl chains are oxidised, allowing the release of cytochrome c 
from the IMM and into the cytosol. Hexokinases II and III prevent release of cytochrome c, thus 
dissociation of bound hexokinase triggers cytochrome c to translocate into the cytosol (Addobbo et al 
2009, Cheng et al 2010). The release of cytochrome c promotes Caspase activation and eventual death of 
the cell through the intrinsic route. Activated Caspases can induce changes in adjacent mitochondria, 
leading to a higher level of cytochrome c release (Soreq et al 2012).  
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Figure 1.15 : The mitochondrial permeability transition pore (PTP) 
Opening of the mitochondrial PTP causes an osmotic shift and peroxidation of cardiolipin, thereby 
releasing cytochrome c. The opening of the mitochondrial PTP and release of cytochrome c are the first 
steps to promote the activation of Caspases leading to mitochondrial mediated cell death (Chandra and 
Orrenius 2002, Soreq et al 2012, Addobbo et al 2009, Cheng et al 2010, Chaudhry and Ahmed 2014).  
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1.6.1 The mitochondria and Caspase-9 activation  
Oxidative stress, inflammation, genetic mutation can encourage the activation of one of the major 
pathways, such as the mitochondrial also known as the intrinsic pathway via the stimulation of different 
proteins. JNK and p38 are a group of MAPKs that play an essential role in apoptosis and are found in 
neuronal tissue. Activation of JNK has been strongly associated with development of neurodegenerative 
disorders, particularly PD (Cassarino 2000, Chaudhry and Ahmed 2014). In the JNK pathway, release of 
cytochrome c promotes binding of Caspase-9 to the JNK domain, forming complexes that stimulate 
Caspase-9, which in turn cleaves and activates Caspase-3 (Figure 1.16). In the p38 pathway, cytochrome 
c released from the mitochondrial PTP, encourages binding of the cytosolic protein, Apaf-1 to bind to 
Caspase-9, forming complexes that permit activation of Caspase-9. Subsequently, Caspase-9 stimulates 
Caspase-3 activity resulting in apoptosis of DCN (Chen 2008).  
 
Genetic mutation of specific genes such as PINK-1 or Parkin gene can result in impairment of the 
mitochondria leading to the release of cytochrome c. In the presence of ATP, cytochrome c induces the 
zymogen, pro-Caspase-9 to bind to Apaf-1, leading to the activation of Caspase-9. Subsequently, 
Caspase-9 promotes Caspase-3 activation resulting in cell death. (Kroemer and Blomgren 2007, Yang et 
al 2008, Fahn and Sulzer 2004, Haque et al 2008).  
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Figure 1.16: Exploring the mitochondrial pathway  
Activation of p38 and JNK, alongside mutation of PINK-1 gene trigger opening of mitochondrial PTP 
releasing cytochrome c. A decrease in ATP levels and the difference in the permeability of 
mitochondria’s inner membrane induce the opening of the PTP; thereby releasing cytochrome c. 
Cytochrome c binds to Apaf-1 via oligomerization in presence of ATP forming apoptosome. The 
apoptosome (cytochrome c:Apaf-1) recruits Caspase-9 binding and activation in the presence of ATP. 
Caspase-9 subsequently allows Caspase-3 activation to occur, resulting in mitochondrial mediated in 
DCN (Addabbo et al 2009, Andrabi et al 2008, Chaudhry and Ahmed 2014). 
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1.7 ER Secretory Pathway 
 
The ER is a site for calcium storage and gated release in response to hormones, growth factors and 
oxidative protein folding. Secretory, membrane proteins and glycoproteins comprised of N glycan 
coating which plays a vital role in the folding, transportation and metabolism are synthesised in the ER. 
ER chaperones such as protein disulphide isomerise 5 (PDI-5), ER protein 72 (ERp-72), ERp-61, ERp-
57, ERp-44, ERp-29, calnexin and calreticulin involved in proper formation of protein. PDI-5, ERp-72, 
ERp-61, ERp-57, ERp-44, ER-p29 are folding enzymes involved in disulphide bond formation in ER. 
Secretory proteins processed in the ER are transported to the Golgi apparatus and receive various 
modifications by enzymes located there (i.e. modifications of oligosaccharide chains and processing of 
peptide chains). Correctly folded proteins are transported to the Golgi body, whilst unfolded proteins are 
retained in the ER. Incorrectly folded proteins expose hydrophobic amino acid residues that should be 
located inside the protein and tend to form protein aggregates that possess toxic properties (Pereira 2013, 
Sano and Reed 2013).  
 
 The ER is the first compartment in the secretory pathway, which is responsible for the protein synthesis, 
modification and delivery. Proteins enter the ER on ribosomes that are translating mRNAs in 
polypeptide transients across the membrane of the ER where they enter in an unfolded state (Figure 
1.17). Subsequently, the unfolded proteins undergo a process of proper oxidative folding and exit from 
the ER, via ER Golgi intermediate compartment in vesicles that traffic to the Golgi body. In the Golgi 
body, sugars are added to the correctly folded proteins to enable specific functions of the protein, prior 
to exocytosis in the plasma membrane or secreted to the extracellular matrix. Proteins that are 
incorrectly folded are either retained in the ER or degraded in the ER by the UPS.  Polypeptides are 
extracted from the ER membrane and delivered to the cytosol for degradation by the proteasome 
through the ER associated protein degradation (ERAD) process (Sano and Reed 2013, Matus et al 2008). 
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Figure 1.17 : The Secretory Pathway  
In the ER, newly synthesised proteins undergo correct folding to ensure the production of mature 
functional proteins and to remove any potential formation of aggregates. Subsequently, the correctly 
folded mature proteins move from the ER to the Golgi body where they are modified and are then 
released to their specific locations. Proteins that are incorrectly folded are sensed by the ERAD pathway 
and then are subsequently degraded by the UPS (Wang and Takahasi 2007, Matus et al 2008, Pereira 
2013, Sano and Reed 2013). 
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1.7.1 ERAD process  
Incorrectly folded proteins are retained via the ERAD process and are progressed to the cytoplasm. The 
ERAD process comprises of four steps; recognition, retro-translocation, ubiquitination and degradation. 
ER stress occurs when ERAD fails to remove large amounts of incorrectly folded proteins that 
aggregate and become toxic (Pereira 2013).  
 
At recognition stage, correctly and incorrectly folded proteins are identified by ER chaperones in the 
calnexin and calreticulin cycle. Calnexin and calreticulin are involved in the folding of glycoprotein, via 
the calnexin and calreticulin cycle. Calnexin is a transmembrane protein and calreticulin luminal protein. 
In the calnexin and calreticulin cycle, specific oligosaccharides are added to polypeptides to carry out its 
functional properties. Following the addition of oligosaccharides, the enzymes glucosidase I and II 
remove excess residues, before calnexin and calreticulin bind to the fold the protein. The correctly 
folded protein is released from the calnexin and calreticulin cycle to the Golgi body. In addition, ER 
chaperones such as ER degradation enhancing α-mannosidase like protein (EDEM), osteosarcoma-9 
and XTP3 transactivated gene B identify and differentiate incorrectly folded polypeptides, from the 
correctly folded peptides (Pereira 2013, Sano and Reed 2013).  
 
The following step in ERAD is retro-translation, where the disulphide bonds of incorrectly folded 
proteins are cleaved by ER chaperones, PDI-5 and immunoglobulin binding protein (BiP). The unfolded 
structure is removed from the ER channels into the cytosol via derlin-1, p97 and valocin interacting 
membrane protein 1. Removal of sugars embedded in the incorrectly folded protein occurs, prior to 
UPS detection and degradation (Pereira 2013, Yoshida 2007) 
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1.7.2 UPS  
 
The UPS degrades a variety of intracellular proteins which have been incorrectly manufactured and have 
become unfolded/incorrectly folded proteins. The unfolded proteins are transferred from the ER to 
cytoplasm. In the presence of ATP, E1 (ubiquitin activating enzymes) binds to E2 (ubiquitin conjugating 
enzymes), which subsequently binds to E3 (ubiquitin protein ligase) to form a polyubiquitin chain that 
binds to defective proteins, which provokes a degradation signal (Figure 1.18). The degradation signal 
promotes 26S proteasome to catabolises target protein via proteolysis (Kahns et al 2003, Yamamoto et al 
2005). 26S proteasome consists of two main domains (19S cap and 20S core). The 19S domain identifies 
polyubiquitinated substrates and engulfs the polyubiquitinated chain, thereby triggering the process of 
protein degradation (Omura et al 2006, Giasson and Lee 2003, Wang and Takahasi 2007). 
 
 Parkin is also known as E3 ligase and plays a role in UPS. Parkin is comprised of two domains; two C 
terminal RING domains and an N terminal ubiquitin like domain. The C terminal is where the E2 
enzyme can attach to it and the N terminal detects the protein which is to be targeted for degraded via 
ubiquitination (Kim et al 2003).  
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Figure 1.18: Ubiquitin-Proteasome System (UPS) 
Figure showing the process of protein degradation by UPS.  In the presence ATP, E1 binds to E2 
followed by E3 forming a complex that can create polyubiquitin chain on defective proteins, which 
wraps around the defective protein, triggering a degradation signal. The proteasome is activated by the 
signal, binds to and catabolises the defective protein, which is embedded with the polyubiquitin chain, 
resulting in degradation of the protein (Yoshida 2007, Wang and Takahasi 2007). 
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Furthermore, when proteins are folded incorrectly, the hydrophobic regions are exposed, resulting in the 
formation of aggregates such as fibrils that are toxic and trigger ER stress (Figure 1.19 Rochet 2007, 
Yoshida 2007, Doyle et al 2011). Mutated DNA sequence causes the incorrect translation and formation 
of protein strands which produce a defective unfolded protein. The malfunctioning proteins accumulate 
and form β pleated sheets consisting of oligomers. The increase in protofibrils subsequently increases β 
amyloid levels allowing the formation of fibrils. The insoluble fibrils are able to aggregate and precipitate 
to form Lewy bodies, which is a key attribute found in PD patients (Doyle et al 2011, Skovronsky et al 
2006, and Moore et al 2005). 
 
Figure 1.19: Formation of Lewy Bodies  
Unfolded proteins that are not degraded by UPS are oligomerised and become insoluble fibrils that form 
Lewy bodies – a common feature found in PD pathogenesis (Doyle et al 2011).   
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1.7.3 ER Stress Pathway 
 
ER stress response can by triggered by; proteasome activity inhibition, cytosolic calcium accumulation 
and disruption of disulphide bind formation. ER stress response has four mechanisms to cope with 
mechanisms of accumulated unfolded proteins. The first step of ER stress is suppression of protein 
synthesis, which prevents any further accumulation of incorrectly folded proteins. The next step is 
transcriptional induction of ER chaperone genes to increase folding capacity. The following step is 
transcriptional induction of ERAD component genes to increase ERAD activity. The final step is 
induction of apoptosis to safely dispose of cells injured by ER stress to ensure the survival of the 
adjacent cells (Hetz 2012, Sano and Reed 2013). 
 
ER stress promotes activation of ERAD and Unfolded Protein Response (UPR). Subsequently, UPR 
triggers activation of the ER transmembrane proteins; Inosital requiring enzyme 1 (IRE-1), PKR-like ER 
kinase (PERK) and activating transcription factor 6 (ATF-6). UPR and ERAD work together to restore 
protein homeostasis. (Cali et al 2011, Lindholm et al 2006, Oakes et al 2006, Oshitari et al 2008). The 
UPR inhibits manufacturing of more incorrectly folded proteins by suppression of protein translation. In 
addition, protein chaperones are stimulated, allowing the refolding of incorrectly folded proteins (Doyle 
et al 2011).  
 
IRE1, ATF-6 and PERK contribute to ER mediated cell death and survival (Figure 1.20). In normal 
cells, BiP is attached to the luminal domains of IRE-1, ATF-6 and PERK, suppressing activation of 
these proteins and ER stress related pathways. During ER stress, BiP disassociates from IRE-1, PERK 
and ATF-6, thereby activating their individual pathways. Current research has shown that ER stress 
triggers these pathways as a domino effect rather than stimulating these pathways at the same time. ER 
stress triggers IRE1α route, followed by stimulation of ATF-6 pathway and finally activation of the 
PERK pathway. The activation of IRE-1, PERK and ATF-6 encourages removal of unfolded proteins, 
thereby restoring homeostasis of the ER and promoting cell survival (Jing et al 2012, Szegezdi et al 2006).  
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1.7.3.1 IRE-1 pathway  
IRE-1 consists of a luminal portion and a cytoplasmic portion and both have specific functions. The 
luminal portion senses unfolded proteins, whilst the cytoplasmic portion comprises of the kinase domain 
and RNase domain.  The imbalance of incorrectly folded chaperones and proteins triggers IRE-1 
stimulation. Activated IRE-1 promotes mRNA splicing for the transcription factor X box-binding 
protein 1 (XBP-1), resulting in translation of mature XBP-1. Subsequently, mature XBP1 is translocated 
to the nucleus, where it enhances transcription of PERK inhibitor P58IPK, ER chaperones, ERAD 
proteins, C/EBP homologous protein/growth arrest and DNA damage-inducible gene 153 
(CHOP/GADD153) and factors involved in protein degradation. P58IPK suppresses PERK translation 
thereby aiding to decrease the total level of accumulating protein and restoring ER homeostasis (Jing et 
al 2012, Holtz and O'Malley 2003,  Kudo 2003 and Doyle et al 2011) . 
 
In addition, activated IRE-1 binds to the adaptor protein (tumour necrosis factor receptor associated 
factor 2) TRAF-2, promoting the binding of apoptosis signal regulating kinase 1 (ASK-1) resulting in the 
formation of the IRE-1:TRAF-2:ASK-1 complex. The complex triggers MAPK activity followed by 
activation of JNK protein, via a series of cascade reaction, resulting in ER mediated cell apoptosis. 
Research has shown JNK activation can promote CHOP activation, as well as activation of Caspase-12, 
leading to apoptotic death (Jing et al 2012, Yoshida 2007 Doyle et al 2011, Oshitari et al 2008, Shibata 
and Kobayashi 2008). In addition, elevated levels of ROS can oxidise and cleave thioredoxin (TDX) of 
the ASK-1:TDX complex, allowing the release and activation of  ASK-1 and active ASK-1 activates 
JNK (Malhotra and Kaufman 2007).  Furthermore activated IRE-1 stimulates RIDD, which degrade 
mRNA proteins. IRE-1α can bind to Bcl-2 antagonist killer protein (BAK) and Bim, leading to 
mitochondrial apoptosis (Doyle et al 2011, Jing et al 2012, Ozcan and Tabas 2012). 
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1.7.3.2 ATF-6 pathway  
ATF-6 comprises of the luminal portion and a cytoplasmic portion and both have specific functions. 
The luminal portion senses unfolded proteins, whilst the cytoplasmic portion contains the kinase domain 
and a transcription activating domain. During ER stress, BiP disassociates from ATF-6 exposing the 
Golgi localisation signal sequence on ATF-6. Activated ATF-6 moves to the Golgi apparatus, via 
vesicular transport. In the Golgi apparatus ATF-6 is cleaved by site 1 serine protease and site 2 
metalloprotease, forming a cytoplasmic ATF-6 fraction (Ozcan and Tabas 2012, Yoshida 2007). The 
ATF-6 fraction translocates to the nucleus and binds to ER stress response element (ERSE), thereby 
promoting transcription of UPR genes, such as CHOP and XBP-1, alongside ER chaperones such as 
calrecticulin GRP78, GRP97 and BiP (Yoshida 2007). 
 
1.7.3.3 PERK pathway  
PERK has a luminal portion and a cytoplasmic portion and both have specific functions. PERK luminal 
portion senses unfolded proteins, whilst the cytoplasmic portion contains the kinase domain that 
activates after dissociation of BiP. Activated PERK promotes phosphorylation and inactivation of α 
subunit of eukaryotic translation initiation factor 2 subunit α (eIF-2), preventing further translation of 
new proteins, thereby reducing the amount of proteins accumulating in the ER. In addition, PERK 
promotes translation of activating transcription factor 4 (ATF-4), through phosphorylation of eIF-2. 
Subsequently, ATF-4 enters the nucleus and stimulates transcription of genes which restore ER 
homeostasis (Jing et al 2012, Rochet 2007, Wang and Takahashi 2007, Matus 2008).  
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Figure 1.20: The involvement of ER stress in apoptosis 
Figure showing the involvement of PERK, ATF-6 and IRE-1 transmembrane proteins triggered in ER 
stress. Active IRE-1 promotes transcriptional induction, splicing and formation of mature XBP1, which 
in turn activates CHOP protein.  Furthermore, TRAF-1 and ASK-1 bind to IRE-1 to form a complex 
which triggers activation of MAPK followed by stimulation of JNK.  Subsequently, active JNK 
promotes manufacture of cell death genes alongside activation of CHOP. In PERK pathway, α subunit 
of eIF-2, is inhibited via phosphorylation leading to stimulation of ATF-4 resulting in CHOP activation. 
In the ATF-6 pathway, ATF-6 is cleaved triggering activation of CHOP. Active CHOP provokes 
activates growth arrest and DNA damage-inducible gene 34 (GADD34), TRB3 and death receptor 5 
(DR-5) eventually resulting in death of cells (Hetz 2012, Sano and Reed 2013, Cali et al 2011, Lindholm 
et al 2006, Oakes et al 2006, Oshitari et al 2008, Doyle et al 2011, Yoshida 2007, Jing et al 2012, Szegezdi 
et al 2006, Malhotra and Kaufman 2007, Yamaguchi and Wang 2004, Szegezdi et al 2006, Rochet 2007, 
Wang and Takahashi 2007, Matus 2008, Holtz and O'Malley 2003, Ghosh et al 2012). 
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1.7.4 The role of CHOP in ER mediated death 
If PERK, ATF-6 and IRE-1 pathways are not effective to restore ER homeostasis, the final step is the 
activation of apoptotic pathway. The main factor to the triggering of the apoptotic pathway is 
stimulating activation of CHOP. Activated CHOP promotes transcription of growth arrest and 
GADD34, tribbles-related protein 3 (TRB3), ER oxidoreductin 1(ERO-1) and DR-5, contributing to 
death of cells via apoptotic pathway (Tiwary et al 2010, Szegezdi et al 2006, Malhotra and Kaufman 2007, 
Yamaguchi and Wang 2004). 
 
In ER mediated apoptosis, GADD34 regulates ER protein and eIF2-α biosynthesis, whilst, TRB3 
inhibits Akt, leading to stimulation of transcription factor FOXO3a, promoting activation of p53 up-
regulated modulator of apoptosis (PUMA) and neutrophil NADPH oxidase factor (Noxa), resulting in 
death of cells (Jing et al 2012, Zhou et al 2009, Doyle et al 2011, Ghosh et al 2012, Galehdar et al 2010).  
In addition, active DR-5 promotes activation of Caspase cascade resulting in cell death via apoptotic 
route. JNK can promote DR-5 stimulation increasing ER mediated death of cells (Oyadomari and Mori 
2004, Tiwary et al 2010, Yamaguchi and Wang 2004) 
 
Increased levels of ERO-1 encourage a hyperoxidative environment in the ER. Active ERO-1 stimulates 
the opening of the ER channel IP3R1, which promotes the release of calcium from the ER to the 
cytoplasm (Pagani et al 2000, Malhotra and Kaufman 2007, Jing et al 2012). The excessive accumulation 
of calcium in the cytoplasm can result in the binding of calcium binding proteins, such as Calpain, which 
can activate Caspases.  Hyperoxidation of ER leads to leakage of hydrogen peroxide to the cytoplasm, 
promoting increased levels of cytoplasmic ROS. Elevated ROS levels suppress ER disulphide isomerases 
thereby adding to accumulation of incorrectly folded proteins. CHOP can increase BCL-2 associated X 
protein (BAX) levels and Bim levels, inhibiting BCL-2 enhancing apoptotic cell death. In addition, the 
activation of PUMA and Noxa can inhibit BCL-2 activity (Malhotra and Kaufman 2007, Doyle et al 
2011, Ghosh et al 2012). 
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1.7.5 ER stress and Caspases  
The ER stores calcium and alteration of calcium homeostasis promotes abnormal protein folding leading 
to ER stress (Hara and Snyder 2007). Neurotransmitter receptor stimulation induces calcium ion release 
from the ER into the cytosol in neuronal cells. Research has shown that translocation of Caspase-7 from 
the cytosol to the ER surface provokes activation of the well known ER stress related protein Caspase-
12. Activated Caspase-12 in turn activates Caspase-9 and then Caspase-3. Imbalance of calcium 
promotes translocation of Calpain from the cytosol to the ER membrane, which cleaves and activates 
Caspase-12 (Fan et al 2005, Chaudhry and Ahmed 2014). 
 
Mutations of specific genes, such as mutation of α-synuclein have been strongly related to PD 
pathogenesis (Section 1.10). A study conducted by Smith et al (2005) revealed that mutation of the α 
synuclein gene, elevated Caspases-3, -9,-12 and ROS levels in PC12 cells. In addition, a reduction in 
proteasome activity and increase in defective proteins was found. The main findings suggested that 
mutant α-synuclein participates in apoptotic pathways, such as ER stress and mitochondrial dysfunction 
pathway (Figure 1.27). Substantial levels of DNA, protein and lipid damage caused by ROS and 
oxidative stress was found in PD patients. Elevated levels of incorrectly folded proteins present in 
oligodendrocytes can stimulate the activity of Caspase-12 through ER stress (Nakagawa and Yuan 2000). 
ER stress stimulates the UPR, enabling PERK to activate Caspase-12. Subsequently, Caspase-12 in turn 
activates Caspase-9 followed by Caspase-3, resulting in cell death (Sharma and Gow 2007, Sooka et al 
2007).  
 
Research by Oda et al (2007) found Calpain activated Caspase-4 in tunicamycin (a well known ER stress 
inducer) induced SK-N-SH cells. In addition, death of SH-SY5Y cells was observed via activation of 
Caspase-12 through the stimulation of CHOP pathway in ER mediated stress. Furthermore, active 
Caspase-4 induce ER mediated death of thapsigargin treated and tunicamycin treated SK-N-SH cells but 
not in SH-SY5Y cells. In contrast, SH-SY5Y cells induced with thapsigargin or tunicamycin was able to 
stimulate Caspase-12 apoptotic death via ER stress route. 
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Caspase dependent cell death in DCN cells has also been associated with ER stress pathway (Figure 
1.21). The ER is an organelle which stores calcium alongside folding and modification of proteins. 
Excessive calcium levels promote increase in Calpain activity resulting in Caspase stimulation. 
Translocation of Calpain from the cytosol to the ER membrane cleaves and activates Caspase-12 (Ghribi 
et al 2003, Omura et al 2006, Nakagawa and Yuan 2000). Genetic mutation of specific genes such as 
Parkin permits continuous stimulation of Parkin Associated Endothelin Receptor like Receptor (Pael-R), 
which in turn promotes ER stress, and contributes to formation of Lewy bodies in PD patients. This is 
due to the fact that mutant Parkin has impaired E3 ligase therefore Pael-R cannot be degraded (Omura 
et al 2006). 
 
In addition, Caspase-12 can be stimulated by other factors such as a mutation of Parkin, impairment of 
UPS or defect in the ER. Defect in ER elevates the quantity of incorrectly folded proteins. Incorrectly 
folded proteins are usually catabolised by UPS. Mutation of Parkin gene disrupts the degradation of 
incorrectly folded proteins which contributes to ER stress and Caspase-12 activation. The defective 
proteins can also form Lewy bodies which can be seen in PD patients. The elevated levels of incorrectly 
folded proteins provoke Caspase-12 activation which in turn stimulates Caspase-9 followed by Caspase-3 
motivation. Furthermore, the elevated level of defective proteins induces further ROS production, which 
contributes to mitochondrial impairment via complex I inhibition alongside ATP depletion. ROS can 
trigger proliferation of cytokines which activate microglia therefore causing higher level of cell apoptosis 
(Friedlander 2003, Kadowaki and Nishitoh 2013, Shimoke et al 2004).  
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Figure 1.21 ER stress triggers Caspase dependent death of DCN resulting in PD  
Calcium imbalance and ER stress promotes activation of Caspases via extrinsic route leading to death of 
DCN and PD onset.  Imbalance of calcium promotes activation of Calpains which activates Caspase-12. 
Subsequently, Caspase-12 activates Caspase-9 which stimulates Caspase-3 activation resulting in 
neuronal death. Impairment of UPS leads to accumulation of defective proteins which aggregate and 
forms Lewy bodies and activation of Caspase-12. Production of ROS derived from defective proteins 
can alter calcium homeostasis, promoting activation of calcium binding protein, Calpains. Calpain 
triggers Caspases-12 and-4, leading to Caspase-9 activation, followed by Caspase-3 activation, resulting in 
apoptosis. The high levels of ROS caused by accumulated incorrectly folded proteins can lead to 
impairment of mitochondria, leading to complex one inhibition and depletion of ATP. Impairment of 
mitochondria leads to activation of Caspase-9 through the binding of cytochrome c. Active Caspase-9 in 
turn binds to and triggers Caspase-3 stimulation, permitting death of cells via apoptotic route (Doyle et 
al 2011, Chaudhry and Ahmed 2014, Yoshida 2007).  
 
 
- 65 - 
 
1.8 The role of Calcium in PD 
 
Recent research has shown a connection between calcium and ER stress (Subramaniam and Chesselet 
2013, Malhotra and Kaufman 2007, Chowdhury et al 2008, Friedlander 2003, Kadowaki and Nishitoh 
2013).Excessive calcium leads to cell death via multiple potential pathways, including mitochondrial 
dysfunction, oxidative stress, ER dysfunction and abnormal calcium signalling (Figure 1.22). Ionic 
calcium is a critical signalling component in neurons and its cytoplasmic levels are tightly regulated. 
Calcium can be pumped to the extracellular components, mainly the ER and mitochondria 
(Subramaniam and Chesselet 2013). Mattson (2007) explored the relationship between intracellular 
calcium and the progression of PD.  The homeostatic imbalance of calcium promotes cell death of DCN 
via direct and indirect pathways. Apoptosis of DCN via oxidative stress, aggregation of α synuclein and 
perturbed energy metabolism induces a homeostatic imbalance of calcium ions. The alteration in the 
level of calcium ions present results in the impairment of neural communication and activity in the brain, 
leading to the pathogenesis of PD (Mattson et al 2004, Mattson 2007).    
 
Research conducted by Ton et al (2007) has shown no association between the use of antihypertensive 
drugs such as beta blockers and calcium channel blockers and the progression of PD. These findings do 
not support the notion that apoptosis of neural cells caused by the calcium dependent pathway can be 
prevented by the use of calcium channel blockers. A study performed by Bowser and Khakh (2004) 
portrays the importance of intracellular calcium in neuronal activity caused with the use of exogenous 
ATP. The results of the study show that an increase of intracellular calcium was achieved in interneurons 
of the striatum of mouse hippocampus by use of exogenous ATP. The increase of intracellular calcium 
subsequently generated action potentials leading to increased neural activity and release of 
neurotransmitter.  
 
An increase in physical and mental exercise and a decrease in calorie intake promotes an increase in 
neural activity, leading to an influx of calcium ions. The higher level of calcium present promotes 
activation of transcription factors and protein kinases. Activation of kinases helps to mediate stress 
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resistance, energy metabolism and plays a crucial role in maintaining ion homeostasis, thereby promoting 
neurogenesis and survival of neural cells. An excessive level of cellular calcium induces toxicity resulting 
in mass destruction of neuronal cells (Figure 1.22). This was revealed in cultured Schwaan cells and 
oligodendrocytes, where cell death occurred due to toxic calcium levels. The findings suggested that the 
increase release glutamate (via overactive glutamate receptors) had induced an excessive increase of 
calcium, which had resulted in neural apoptosis (Subramaniam and Chesselet 2013). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.22: Calcium mediated cell apoptosis 
Figure showing different factors that are involved in increased calcium levels resulting in cell apoptosis 
(as shown in text).   
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Calcium activates Calpain and Caspase activation. Membrane associated oxidative stress (MAOS) caused 
oxidative stress results in catabolism of lipid components of the membrane. Calcium activates BAX and 
p53 alongside release of cytochrome c and Caspase stimulation (Mattson 2007). In addition calcium can 
activate nitric oxidase synthase to produce nitric oxide. Subsequently, nitric oxide is able to suppress 
complex IV of the mitochondria, resulting in further elevation of ROS levels. The enhanced ROS levels 
can contribute to the leakage of calcium ions from the ER and mitochondria into the cytosol (Malhotra 
and Kaufman 2007).  
 
Overexpression of BCL-2 reduces intracellular calcium in the ER. In addition, BAX and BAK encourage 
the transfer of calcium from the ER thereby maintaining calcium homeostasis. When stimulated by 
apoptotic factors, the lipid units of the mitochondria change their structural shape. In contrast, ceramide 
channels are held together in ceramide columns via hydrogen bonding. In excitotoxicity, the plasma 
membrane calcium pump (PMCA) and Na/Ca exchanger can be cleaved by Caspases, resulting in cell 
death. Cleavage of PMCA and Na/Ca exchanger allows influx and elevated intracellular calcium levels, 
preventing opening of the mitochondrial PTP (Subramaniam and Chesselet 2013, Doyle et al 2011, 
Malhotra and Kaufman 2007).  
.  
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1.9 Apoptosis  
 
Final events of apoptosis  
Stimulation of intrinsic or extrinsic pathways encourages activation of Caspases resulting apoptotic death 
of cells. The final steps involved in apoptotic cell death are crucial and require the activation of Caspase-
3. Activation of Caspase-3 induces DNAses causing DNA fragmentation. In addition, Caspase-3 causes 
catabolism of proteins, thereby destroying the cytoskeleton of DCN. Caspase-3 inhibits DNA repair 
enzymes; therefore the structure of the cell cannot be repaired, resulting in cell apoptosis.  Cell apoptosis 
causes an accumulation of ROS, which can damage and cause death to nearby cells. This can lead to a 
mass destruction of DCN, and thereby the development of PD (Chowdhury et al 2008).  
 
Caspase-3 catabolises proteins that comprise to make the cytoskeletal structure, fodrin and actin, 
resulting in loss of cellular shape alongside loss of cellular adhesion, contributing to the decrease in cell 
volume and production of apoptotic bodies. Moreover, Caspase-3 activates Caspases-6 and -7, which 
play a vital role in cell apoptosis via digestion of specific cellular structures (Figure 1.23).  Caspase-6 
promotes the digestion of fibrous proteins, which is essential for the nuclear structure, and function, 
such as lamins, causing nuclear shrinkage and budding of the cell resulting in the formation of apoptotic 
bodies. Caspase-7 digests poly (ADP-ribose) polymerase (PARP), therefore DNA repair cannot be 
achieved. Caspase-3 can catabolise the DNA repair enzyme, DNA dependent protein kinase (DNA PK) 
into fragments, thereby preventing the cell to repair itself resulting in cell death (Venderova and Park 
2012). 
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Figure 1.23 : Apoptotic events caused by Caspase-3  
Caspase-3 promotes formation of apoptotic bodies’ increase in fragmentation of DNA and decrease in 
cell volume, via breakdown of actin and fodrin, alongside activation of Caspase-activated DNA (CAD), 
Caspases-6 and -7 (blue lines and green lines correspondingly). The formation of apoptotic bodies, 
chromatin condensation and breakdown of the cell structure, leads to release of ROS, affecting 
neighbouring cells, resulting in mass destruction of DCN in PD pathogenesis.  In normal cells the 
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DNAse complex is comprised of CAD and ICAD (inhibitory CAD) and is found to be inactive state. 
Caspase-3 cleaves ICAD from the CAD:ICAD complex, thereby initiating activity of DNAse, which 
promotes catabolism of nuclear DNA and chromatin resulting in decrease in cell volume and cell death. 
Subsequently, other organelles such as rough ER and Golgi complex are degraded via Caspases (by 
catabolism of Bap31, alongside golgin-160 and GRASP65). Moreover, the production of ROS during 
apoptosis promotes further destruction of nearby cells. ROS produced by the apoptotic cell are released 
and attack the phospholipid bilyar components of adjacent cells, promoting the formation of pores.  
Subsequently, the ROS are able to penetrate through the pores and cause further destruction to the cell 
via proteolysis of essential proteins and nucleic acids, resulting in further cell death. A mass destruction 
in DCN caused by prolonged Caspase-activation can contribute to the onset of PD (Venderova and 
Park 2012, Chowdhury et al 2008, Chaudhry and Ahmed 2014).  
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The morphology, presence and activation of specific proteins in apoptotic cells differ greatly when 
compared to normal cells (Figure 1.24). The ion content in normal cells aids to maintain the cellular 
structure of the cell to remain intact. A high level of potassium and a low level of sodium are found 
inside normal cells, so that an electrolyte balance can be maintained from the extracellular environment. 
Apoptotic cells are exposed to a hypertonic environment, which possesses an increase in extracellular 
osmotic strength. The increase in extracellular osmotic strength and imbalance of electrolytes, results in 
leakage of water and potassium ions inside the cell, causing the cell to shrink. The loss of potassium ions 
inside the cell activates Caspases and nucleases causing a loss in the cells architecture and subsequent 
apoptosis (Perier et al 2012). 
 
In addition, the phospholipid, phosphatidylserine is found embedded in the inner membrane of normal 
cells. However, in apoptotic cells phosphatidylserine redistributes from the inner membrane to both the 
inner and outer membrane, causing a loss of membrane asymmetry. The reallocation of 
phosphatidylserine triggers the phagocytosis response signal for macrophages. Furthermore, the 
impairment of the vital organelle, the mitochondria promotes the stimulation of the Caspase cascade in 
apoptotic cells, which is achieved through the intrinsic route. Moreover, Caspase and nuclease activity is 
stimulated in apoptotic cells but not in normal cells (Perier et al 2012, Venderova and Park 2012). 
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Image of neuron adapted and modified from Martini F.H, 2006, The Fundamentals of Anatomy and Physiology, 7th edition, San Francisco, 
Pearson Benjamin Cummings Ed Ltd pp 380 
 
 
Figure 1.24: A comparison in morphology of Normal and Apoptotic cells 
The normal cell is able to maintain is cellular structure due to homeostatic ion content and normal 
mitochondrial function, therefore Caspase and nuclease activity are not stimulated. In contrast, the 
apoptotic cell has a shift in ion content and mitochondrial dysfunction, thus there is an increase in 
activity of Caspases and nucleases (Perier et al 2012, Venderova and Park 2012). 
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In contrast, cells undergoing necrosis lose their architecture, via exposure to a hypotonic environment, 
causing the cell to swell and finally lyse. A short term injury to the cells promotes the cells to die via 
necrotic pathway. Necrotic cells can also trigger an inflammatory response when the wall of the cell is 
ruptured. In contrast, parts of the apoptotic cells break away in buds, which are eventually engulfed by 
phagocytes (Figure 1.25). Death of cells can be achieved via the necrosis or apoptosis route. Elevated 
levels of ROS promote necrosis, whilst lower ROS levels trigger apoptosis.  In the current study, the 
involvement of Caspases was observed in PD model. The death of DCN was examined and determined 
if death of DCN was apoptotic or necrotic route (Perier et al 2012, Venderova and Park 2012, 
Chowdhury et al 2008).  
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Image of neuron adapted and modified from Martini F.H, 2006, The Fundamentals of Anatomy and Physiology, 7th edition, San Francisco, Pearson 
Benjamin Cummings Ed Ltd pp 380 
 
 
Figure 1.25: A comparison in morphology of Necrotic and Apoptotic cells 
During normal apoptotic death there is cell shrinkage and chromatin condensation, leading to budding 
and formation of apoptotic bodies, which are phagocytised. In necrotic cell death, the cell swells, leading 
to leakage and blebbling resulting in cell lysis and inflammation (Perier et al 2012, Venderova and Park 
2012, Chowdhury et al 2008).  
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1.10 Neurotoxicity, gene mutation, Caspase and PD 
 
Elevated ROS levels can contribute to mutations of essential genes such as mitochondrial, ER stress 
related and PD related genes such as Parkin and α synuclein. The rise of ROS such as superoxides, 
hydroxyls and nitric oxide accumulating in DCN promote cleavage of DNA bases, via extracting 
hydrogen atoms and thereby, causing a shift in genetic sequence and production of mutated genes.  The 
mitochondrion is more susceptible to oxidative stress, as oxidants such as superoxide anion are often 
produced in the mitochondria’s inner membrane (Bogaerts et al 2008, Kroemar and Blomgren 2007). 
 
Research has shown that defects in mitochondrial genes contribute to the onset of PD (pages 75-78). 
Synaptic terminals have abundant levels of mitochondria present; therefore a significant level of ROS 
and ATP is also available in these areas (Kroemar and Blomgren 2007, Chaudhry and Ahmed 2014, 
Yang et al 2008, Bogaerts et al 2008).  A study conducted by Bender et al (2006) revealed that higher 
levels of mitochondrial DNA deletions were found in PD patients, when compared to the control. 
Located in brain, various tissues and specifically in the matrix and inner membrane space (IMS) of the 
mitochondria, DJ-1 functions as an anti oxidant by reducing hydrogen peroxide levels (Figure 1.26). 
Frameshift and missense mutations, alongside deletions and insertions of DJ-1 gene, contribute to early 
onset PD. Mutational DJ-1 leads to increase in oxidative stress and mitochondrial impairment, causing 
degeneration of DCN, resulting in PD (Bogaerts et al 2008, Yang et al 2008, Kroemar and Blomgren 
2007). 
 
 LRRK-2 also known as dardarin, is found in brain striatum and frontal cortex and is associated with 
nigrostriatal dopamine system. LRRK-2 functions as a kinase, which is located in the outer 
mitochondrial membrane (OMM) and cytoplasm (Figure 1.26). Mutated LRRK-2 which is found in the 
outside of the mitochondria contributes to toxicity and death of neurons that has been associated with 
PD (Bogaerts et al 2008, Yang et al 2008, Kroemar and Blomgren 2007). 
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HTRA-2 (high temperature requirement A2) is proapoptotic protease found in the IMS of the 
mitochondria, which plays a vital role in mitochondrial homeostasis (Figure 1.26). External stimuli such 
as environmental toxins, provokes HTRA-2 gene to transfer from the IMS to the cytosol, leading to 
Caspase activation (via disassociation of Caspase:IAP). Overexpression of HTRA-2 in mice has shown 
severe loss of motor neurons, via stimulation of the mitochondrial apoptosis pathway, resulting in 
symptoms similar to that of PD. Moreover, degeneration of striatal neurons caused by stimulation of 
Caspases has been observed in mice (Bogaerts et al 2008, Yang et al 2008, Kroemar and Blomgren 2007). 
Mutated HTRA-2 is translocated from the IMS to the cytoplasm where it promotes Caspase meditated 
death of cells via apoptotic pathway (Kroemar and Blomgren 2007, Chaudhry and Ahmed 2014).  
 
PINK-1 gene is located in the OMM and IMM and functions to decrease ROS levels and suppresses 
cytochrome c. Mutation of PINK-1 and mutation of Parkin allows production of ROS and release of 
cytochrome c, promoting death of cells via apoptotic route. Genetic mutation in Parkin and PINK-1 
gene has been strongly associated with the progression of PD, via mitochondrial dependent cell 
apoptosis (Fahn and Sulzer 2004, Chien et al 2013, Cookson 2004).  PINK-1 reduces oxidative stress 
levels by inducing TNF receptor associated protein 1 (TRAP-1) phosphorylation. TRAP-1 protects 
mitochondrial DNA damage, via acting as a chaperone (Yang et al 2008, Kroemer and Blomgren 2007). 
The view can be supported further by Wood-Kaczmar et al (2008) who found increased oxidative stress 
and mitochondrial impairment of knockout PINK-1 in human DCN and neuroblastoma cell line. 
Decreased releases of dopamine in the striatum of PINK-1 deficient mice have also been found 
(Nakamura and Edwards 2007, Kroemer and Blomgren 2007). In vivo and in vitro studies have revealed 
elevated neuronal loss caused by mutated PINK-1 gene that has endured MPTP treatment (Haque et al 
2008, Wood-Kaczmar et al 2008, Jin et al 2012).  
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Figure 1.26: The role of mutant mitochondrial genes in PD 
Figure showing the different mutated genes in relation to the mitochondria in PD pathogenesis. 
Oxidative stress promotes mutated DJ-1 gene to travel from the cytoplasm to the IMS and to the 
mitochondrial matrix, where it allows production of ROS. Mutated HTRA-2 is translocated from the 
IMS to the cytoplasm where it promotes Caspase meditated death of cells via apoptotic pathway. 
Mutated LRRK-2 which is found in the outside of the mitochondria contributes to toxicity and death of 
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neurons. PINK-1 gene is located in the OMM and IMM and functions to decrease ROS levels and 
suppresses cytochrome c. Mutation of PINK1 and mutation of Parkin allows production of ROS and 
release of cytochrome c, promoting death of cells via apoptotic route (Bogaerts et al 2008, Yang et al 
2008, Kroemar and Blomgren 2007, Chaudhry and Ahmed 2014, Cookson 2005, Samann et al 2009, 
Inamdar et al 2007, Matsuda et al 2013).  
 
 
 
 
 
 
1.10.1 Gene mutation and Caspase activation in PD  
The mitochondrion is more susceptible to oxidative stress, as oxidants such as superoxide anion are 
often produced in the IMM(Kroemer and  Blomgren 2007). Figure 1.27 indicates that mutation of 
PINK-1 promote mitochondrial impairment and the release of cytochrome c. Cytochrome c activates 
Caspase-9 followed by Caspase-3 leading to chromatin condensation alongside DNA fragmentation , 
resulting in destruction of DCN (Kroemer and  Blomgren 2007, Yang et al 2008, Fahn and Sulzer 2004, 
Haque et al 2008). IF analysis has shown degeneration of neurons and increase in Caspase activation in 
knockout PINK-1 in tunicamycin treated rat cortical neurons , indicating a strong link between ER 
stress, PINK-1 suppression and activation of Caspases (Samann et al 2009). In addition, the lack of 
histones in mitochondrial DNA, permit mitochondria to be more vulnerable to oxidative stress. The 
increased levels of hydrogen peroxide, leads to lipid peroxidation, whilst elevated levels of peroxynitrate 
results in DNA damage. Reduced levels of DNA polymerase was observed in PD animal model, 
suggesting suppression of DNA excision repair function (Yang et al 2008, Fahn and Sulzer 2004, 
Kroemar and Blomgren 2007). The majority of mutations of the PINK-1 gene are missense mutations 
that are autosomal in PD patients (Cookson 2005). Furthermore defects in PINK-1 have resulted in 
degeneration of muscles via mitochondrial apoptotic route (Inamdar et al 2007, Matsuda et al 2013).  
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Parkin plays a vital role in maintaining mitochondrial homeostasis, alongside UPR in ER. Mutation of 
Parkin gene can result in ER stress or oxidative stress induced cell death (Perez et al 2005, Perez and 
Palmiter 2005). Defects of Parkin gene result in impairment of UPS inducing a rise in incorrectly folded 
proteins and triggering of the unfolded stress response (USR) leads to activation of Caspase-12 (Figure 
1.27). Subsequently, active Caspase-12 stimulates Caspase-9 followed by Caspase-3 stimulation, inducing 
apoptotic cell death and release of ROS. Elevated levels of ROS damage nearby cells causing a mass 
destruction of DCN contributing to the onset of PD (Shimoke et al 2004, Chowdhury et al 2008, Shibata 
and Kobayashi 2008, Kudo 2003). As described in Figure 1.27 active Caspases encourage stimulation of 
other Caspases, via a cascade reaction, leading to cell death. IF analysis had showed enlargement of 
followed by collapse of the mitochondria in mutated Parkin and PINK-1 Drosophila cell lines and 
tissues, indicated that Parkin and PINK-1 are required to stabilize maintenance of mitochondria, thereby 
suppressing cell death of neuronal cells, via preventing the release of cytochrome c (Poole et al 2008, 
Yang et al 2008, Cookson et al 2008, Lim and Tan 2007).  
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HTRA-2 DJ-1 
CASPASE-12 
ACTIVATION 
CASPASE-3 
ACTIVATION 
CASPASE-9 
ACTIVATION 
CELL APOPTOSIS 
PINK- 1 
Figure 1.27: Environmental toxins cause mutations of genes resulting in Caspases dependent 
apoptotic death of DCN  
Environmental toxins can contribute to mutations of various genes ( Chae 2004). Mutated Parkin can 
activate Caspases through intrinsic and extrinsic route resulting in apoptotic cell death. Mutated Parkin 
(E3 ligase) leads to activation of Caspase-12, which leads to a cascade reaction of Caspases (Caspase-9 
activation followed by activation of Caspase-3) resulting in cell apoptosis.  Mutated PINK-1 and Parkin 
provoke cytochrome c release, leading to activation of Caspases-9 and-3, resulting in apoptotic dell death.  
Mutation of HTRA-2 activates Caspases through translocation of HTRA-2 from the IMS to the cytosol. 
Mutation of DJ-1 gene leads to elevated ROS and mitochondrial impairment, resulting in stimulation of 
Caspases and mitochondrial mediated death of neuronal cells (Cookson et al 2008, Chowdhury et al 
2008, Shibata and Kobayashi 2008)  
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1.10.2 The Role ROS in Caspase activation  
Exposure to environmental toxins (such as MPTP exposure), oxidative stress and inflammation can 
trigger activation of various pathways such as JNK, p38 and NFB pathway, which subsequently 
initiates the activation of Caspases, leading to cell apoptosis and resulting in development of diseases 
such as PD (Wang et al 2005). Furthermore, an imbalance in ROS:antioxidant enzymes contribute to cell 
death, leading to the onset of PD. Accumulation of ROS such as superoxides promotes manufacture of 
peroxynitrate, leading to damage of DNA damage, chromatin condensation, lipid peroxidation, 
contributing to mutation of E3 ligase, which results in the impairment of the UPS. UPS dysfunction 
allows the accumulation of incorrectly folded proteins and other toxic compounds resulting ER stress 
mediated cell death and PD onset. ER stress can activate Calpain activation resulting in stimulation of 
Caspases (Matus et al 2008, Sano and Reed 2013, Figure 1.28).  
 
Increased levels of reactive nitrite species (RNS) and reactive chloride species (RCS) can directly activate 
Caspase mediated cell death (Nakamura et al 2012, Chowdhury et al 2008). Furthermore, injured 
neurons release signal that stimulate microglial activation that release cytokines (such as IL-6,-β and -α), 
which stimulates Caspase activation. In addition, cytokines promotes expression of iNOS, provoking the 
formation of nitric oxide with superoxide resulting in manufacturing of peroxynitrate (Chowdhury et al 
2008, Figure 1.28). In addition, increased iron levels encourage Caspase mediated cell death. Iron 
encourages the conversion of hydrogen peroxide to hydroxide contributing to stimulation of Caspase 
mediated cell death. Increase in iron, ROS and decrease in anti oxidative such as glutathione enhance the 
production of superoxides, which permit oxidative damage of proteins, DNA and lipids resulting in cell 
death (Moron and Castilla-Cortazar 2012).  
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Figure 1.28: The involvement of ROS in Caspase mediated cell death 
Figure showing the involvement of ROS in Caspase activation and cell apoptosis. Iron can promote 
hydrogen peroxide to convert to hydroxyl radicals contributing to oxidative stress by increasing 
manufacture of ROS. Elevated ROS promotes nitric oxide to bind to superoxide to produce 
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peroxynitrate which results in damage to DNA, mutation of chromosomes, lipid peroxidation and 
enzyme defects. Mutation of E3 ligase caused by peroxynitrate damage leads to impairment of UPS, 
resulting in high levels of defective proteins, accumulating in the ER promoting ER stress. ER stress can 
activate Calpains (and vice versa) leading to motivation of other Caspases, via Caspase cascade reaction, 
resulting in axonal degeneration via apoptotic pathway. The apoptotic neuron triggers injury signal that 
activates microglia promoting release of cytokines such as IL-6 and-8.  Subsequently, IL provokes 
Caspase activation, as well as increase expression of iNOS, which promotes formation of nitric oxide. 
Exposure to excessive RNS provoke high nitric oxide levels (via excitoxicity ) that interact with 
superoxide to produce peroxynitrate and radicals which can dysfunction complex IV followed by 
Complex I activity of the mitochondria, leading to mitochondrial mediated apoptosis through Caspase 
activation (Moron and Castilla-Cortazar 2012, Chowdhury et al 2008, Wang et al 2005, Matus et al 2008,  
Sano and Reed 2013, Hetz 2012). 
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Research by Liou et al (2005) found a significant rise in Calpain, AIF, Caspases-9 and-3 activities in 
MPTP-treated PC12 cells. In addition, a substantial increase in JNK pathway stimulation was found in 
these cells. The results of this study suggested that the increased accumulation of Calpain in cells 
provoked AIF. AIF entered the cytosol and adhered to the mitochondrial surface, promoting the release 
of cytochrome c leading to activation of Caspases-9 and-3, resulting in cell death. These findings were 
also found in MN9D cells. DNA fragmentation, chromatin condensation and presence of apoptotic 
bodies that was observed in both cell lines confirmed that cell death occurred via mitochondrial 
dependent apoptosis pathway. The enhanced release of cytochrome c, alongside impaired ATP levels, 
encouraged production of ROS, which contributed to further cell death.  
 
The protein, α synuclein is abundantly found in presynaptic terminals of neurons and in cerebral spinal 
fluid and plays a vital role in synaptic maturation and neuronal plasticity (Chowdhury et al 2008). A study 
conducted by Smith et al (2005) revealed that mutant α synuclein elevated Caspases-3, -9, -12 and ROS 
levels in PC12 cells. In addition a reduction in proteasome activity was found. The main findings of the 
study suggested that mutant α synuclein participates in both ER stress and mitochondrial dysfunction 
pathways. Substantial levels of DNA, protein and lipid damage caused by ROS and oxidative stress was 
found in PD patients. ER stress stimulated USR, enabling PERK (an ER transmembrane kinase) to 
activate Caspase-12. Subsequently, Caspase-12 activated Caspase-9, followed by stimulation of Caspase-3, 
resulting in cell death.  
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1.11 The Use of MPTP-Treated Rat Animal Model in PD Pathogenesis   
 
Present and past research has shown the use of MPTP-treated and 6OHDA-treated rat model to 
investigate PD pathogenesis (Section 1.2.5.1).  Recent research by Xu et al (2013) has demonstrated the 
direct use of MPTP in brain of rat model to study neurotoxicity and has provided further insight into 
PD pathogenesis. MPTP treatment in rats had reduced the expression of BCL-2, BDNF, glutathione 
synthase and dopamine antioxidants. In addition, MPTP rats has shown damaged DCN, difficulty in 
movement and coordination , strongly indicating that MPTP rat model is  a relevant model for 
investigating PD pathogenesis (Frazzita et al 2013). Immunohistochemical analysis has revealed loss of 
neurons, accumulation of fibrils and increase in lesions formed in the SNpc region of rat brain that had 
been treated directly with MPTP and 6OHDA, when compared to untreated rats. A decrease in number 
of TH positive neurons and dopamine levels were seen in SNpc of 6OHDA-treated rats compared to 
MPTP rats, indicating that 6OHDA-treated rat model is preferable to study the advanced stage of PD, 
where a prominent sign of memory impairment is observed.  The author suggested that MPTP rat model 
is suitable model to study early onset of PD as its motor symptoms and loss of neurons are similar to 
that of early phase PD (Ferro et al 2005).   
 
Bellissimo et al (2004) investigated the memory performance of MPTP-treated rats with relevance to PD. 
The author showed administration of MPTP in the brains of rats exhibited signs that are typically seen in 
PD and can be used as a model to study and explore PD pathogenesis.  Current research by Friend and 
Keefe (2013) have used PD rat model to examine damage to striatal neurons caused by exposure to 
methamphetamine. Methamphetamine had decreased dopamine levels in the striatum in PD rat model. 
Perez et al (2002) demonstrated that mutated α-synuclein had decreased TH, dopamine, DOPA and 
dopamine synthesis in homogenates of rat striatum, indicating that the effect of genetic mutation can be 
studied using PD rat model.    
 
MPTP animal model is considered as a suitable model to use when referring to PD as it has the 
advantage of portraying the complex mechanisms, which contribute to PD pathogenesis. The rodent 
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MPTP model demonstrates the neurochemical and neuropathological changes which occur in PD, whilst 
monkey MPTP model provides significant information on behavioural changes in PD (Bohlen and 
Halbach 2006).  Recent research by Bazzu et al (2013) explored the regulation of D1 dopamine receptor 
in MPTP PD rat model. The study also found MPTP reduced TH activity in SNpc of rats. Bazzu et al 
(2013) research has used the systemic administration of MPTP in rats which is a newly developed model 
to study PD pathogenesis. This project which has been in collaboration with Professor Jozef Langford 
has used systemic administration of MPTP to develop a new PD rat model which brings uniqueness and 
originality to this thesis.  
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1.12 The use of ReNcell VM in previous studies  
 
Previous research in PD has relied on the use of animal models and different cell lines, which have 
advantages and some limitations(Kroemer and Blomg 2007). ReNcell VM is a progenitor cell line 
derived from the midbrain of fourteen week old human foetus, which has recently been established to be 
used as an ideal model to study PD (Donato et al 2007).  The transcription factor, myc used in ReNcell 
VM provides more karotype phenotype stability even after different passages decreasing the variability 
which other cell lines and donor tissues have to encounter. This increases the reliability in results and can 
be used to study the effect of different drugs , neurotoxicity and neurological diseases. Research by 
Donato et al (2007) has shown positive staining for the neurotransmitter TH, alongside the release of 
dopamine from these cells. TH converts precursor L-DOPA to dopamine in the brain and reduced TH 
levels in PD brain has been observed. Additionally, work by Massachusetts (2008) has explored the 
relationship of mutant PINK-1 (gene that has been strongly associated with Caspase activation) in PD 
using this dopaminergic cell line. Massachusetts’ results demonstrated the mechanistic link of mutant 
PINK-1 gene and PD onset by suppressing PINK-1 in ReNcell VM. PINK-1 suppression in ReNcell 
VM increased ROS levels, leading to the collapse of the mitochondria and activation of Caspase resulting 
in death of DCN. These vital markers (mitochondrial impairment, presence of Caspases and ROS) of 
cell death have been found in other cell lines and PD animal models, supporting its suitability as a model 
to study PD (Kroemer and Blomg 2007, Yang et al 2008, Fahn and Sulzer 2004, Haque et al 2008). Thus, 
ReNcell VM offers a better representation of DCN therefore providing a gateway of new possibilities 
which animal models and other cell lines have been limited to. 
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1.13 Investigating Caspase Death Mechanisms in PD model 
Current research has shown that exercise in PD patients indicates improvement in not only decreasing 
key features that are present in PD such as gait, tremors and bradykinesia, but they also improve quality 
of life of the PD patient in terms of forming social networks and can integrate well into the PD patients 
lifestyle (Heiberger et al 2011, Fritz et al 2011, Vivas et al 2011, Ayan and Cancela 2012, Hackney and 
Earhart 2009a, Hackney and Earhart 2007, Hackney and Earhart 2010, Li et al 2012, Modugno et al 
2010, Dreu et al 2012, Brown et al 2010). Although there are extensive clinical studies carried out on 
treadmill exercise in PD patients (Section 1.2.5), there is a lack of biochemical understanding to how 
exercise is affecting PD patients at a cellular level. What key proteins can exercise affect and can 
different types of exercise increase or decrease these proteins has not yet been determined.   
 
There is a lack of research exploring the potential pathways, which exercise can activate and suppress to 
provide such positive and even negative effects. Only through discovering what key proteins are 
important in Caspase activation and establishing, which pathways Caspases are involved in that result in 
death of DCN, can improved therapies and treatments be created. In addition, establishing which 
pathways the Caspases follow and understanding the key events that occur in Caspase activation new 
targets for treatment can be achieved. These new specific targeted drugs could be used with treadmill 
exercise to achieve maximum effect, by slowing down or inhibiting further death of DCN.  
 
Aim: The current study explores the effect of treadmill exercise on Caspases, along with CAMK-IV 
protein in different brain regions of MPTP rat model, using WB analysis. More specifically, to determine 
the effect treadmill exercise had on activation of Caspases-1,-2,-3,-8,-9 and -12 in the cerebellum, brain 
cortex, midbrain and striatum of PD animal model. 
The study explores the potential pathways that results in Caspase mediated death of dopamine 
containing neurones in relevance to Parkinson’s disease. It is an attempt to identify the major pathways 
which cause Caspase mediated death and to establish key proteins involved in each pathway with the 
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motive to eventually find targets that can be used and manipulated to safely slow down apoptotic death 
of differentiated ReNcell VM stem cell line.  
 
Objectives 
WB analysis was used to determine the presence and absence of activated Caspase-1, -2, -3, -8, -9 and -
12 in cerebellum, brain cortex, midbrain and striatum of PD-Ex animal model. 
To establish differentiated ReNcell VM as a suitable PD model to study cell death mechanisms with 
administration of 6OHDA.  
Co localisation studies, IF, WB and Caspase colorimetric analysis was performed to demonstrate 
6OHDA triggers Caspase mediated death of dDCN. 
Cell viability, double IF and WB analysis using specific inhibitors were used to identify specific potential 
pathways that promotes Caspase activation resulting in apoptotic death of 6OHDA dDCN. 
More specifically, salubrinal, IKK , benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-
fluoromethylketone ( zVDVADfmk) , benzyloxycarbonyl -LE(OMe)VD (OMe)- fluoromethylketone 
(zLEVDfmk) and benzyloxycarbonyl -Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone (zIETDfmk) 
inhibitors were used to determine role of PERK, NFB, Caspases-2, -4 and -8 in PD cell model.  
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Materials and Method 
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2.0 General Reagents  
 
Following suppliers were used for the reagents including Sigma Dorset UK, Millipore Hertfordshire UK, 
Abcam Cambridge UK, Vector Laboratories Peterborough UK, Perbio Science Northumberland UK, 
Xograph Gloucestershire UK, Invitrogen Paisley UK, Fisher Scientific Leicestershire UK and Severn 
Biotech Worcestershire UK. A more detailed description of all reagents can be found in Appendix 1. 
 
2.1 Antibodies  
 
Primary and secondary antibodies; (AB1872) Anti-Caspase-1, (AB7979) Anti-Caspase-2, (AB3623, 04-
439) Anti-Caspase-3, (AB52183, AB97318)Anti-Caspase-4, (AB25897)Anti-Caspase-8, (04-444) Anti-
Caspase-9, (AB62484) Anti-Caspase-12, (04-1078) Anti CAMK-IV, (MAB3026) Anti-NFB, (12-348) 
Goat-Anti-Rabbit HRP, (AP192P ) Donkey-Anti-Mouse HRP,  (MAB318, AB152) Anti-TH, (AP192F) 
Donkey-Anti-Mouse IgG FITC, (AB6791)Sheep-Anti-Rabbit IgG FITC, (AQ300F) Sheep-Anti-Mouse 
IgG FITC, (AP123R) Goat-Anti-Rabbit IgG Rhodamine, (AQ300R) Sheep-Anti-Mouse IgG Rhodamine 
were purchased from Abcam Cambridge UK and Millipore Hertfordshire UK. A more detailed 
description of all antibodies can be found in Appendix 1. 
 
2.2 Inhibitors  
 
Inhibitors; (SC-202332) Salubrinal, (401479) IKK, (218744) zVDVADfmk, (218755) zLEVDfmk, 
(218759) zIETDfmk, (G7351) zVADfmk were obtained from Santa Cruz Biotechnology Heidelberg 
Germany, Merck Chemicals Nottingham UK and Promega Southampton UK correspondingly. A more 
detailed description of all inhibitors can be found in Appendix 1. 
 
The IKK inhibitor used in this project was specifically chosen as it irreversibly binds to IKK-α and IKK-
β complex thereby preventing activation of NFB of the classical pathway in cells (Merck Chemicals Ltd 
UK 2011). Salubrinal selectively inhibits protein phosphatase 1 (PP1) which prevents the 
dephosphorylation of eIF2-α, thereby preventing activation of PERK pathway of ER mediated death of 
cells (Santa Cruz Biotechnology 2011). The inhibitor zVADfmk irreversibly binds to fluoromethylketone 
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peptide sequence α-aspartyl-α-glutamylvalylaspartic acid of Caspase protein thereby preventing death of 
dDCN (Promega 2010).  zVDVADfmk irreversibly binds to fluoromethylketone peptide sequence 
Benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethylketone of Caspase-2, resulting in 
suppression of Caspase-2 activity in cells(Merck Chemicals Ltd UK 2008). The specific Caspase-4 
inhibitor zLEVDfmk,  reversibly binds to aldehyde peptide sequence N-Acetyl-L-leucyl-L-α-glutamyl-N-
[(2S)-1-carboxy-3-oxo-2-propanyl]-L-valinamide blocking the Caspase-4 activity in cells (Merck 
Chemicals Ltd UK 2011). The Caspase-8 inhibitor, zIETDfmk irreversibly binds to fluoromethylketone 
peptide sequence of the Caspase-8 protein, resulting in suppression of Caspase-8 activity in cells (Merck 
Chemicals Ltd UK 2011). 
 
2.3 Animal work  
 
Procedure for training and MPTP injection were carried out by collaborators Jozef Langfort and 
Malgorzata Chalmoniuk at Dr Jozef Langfort laboratories Medical Research Centre, Polish Academy of 
Sciences, Warsaw, Poland. All experimental procedures involving rat care and experimentation were 
performed in accordance with the European Communication Council Directive. Protocols for the 
care and use of  laboratory animals were approved by local Ethical Committee for Animal Experiments 
at Nenki Institute, Warsaw, Poland (Ethical Approval Appendix 2). For this study, special 
consideration was given to use the minimum number of  animals required to achieve statistical 
significance and all efforts were made to minimize animal suffering.  Rats were housed in temperature 
controlled room under 12 hour daylight/ night cycle at animal breeding facility. Rats were fed rodent 
chow and water ad libitum to consume at regular intervals.  
 
2.3.1 Segregation and treatments of rats  
The following procedure was carried out by collaborators Jozef Langfort and Malgorzata Chalmoniuk at 
Dr Jozef Langfort laboratories Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland. 
For the study, eight weeks old Wistar male rats (250g-290g) from the animal breeding facility within 
the Polish Academy of  Sciences, Medical Research Centre were used (n=4 for each group).  The rats 
were segregated to endure four conditions; control (untreated and un-trained (C), trained (Ex), MPTP-
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treated (PD) and PD-Ex (MPTP-treated and trained). Rats that were segregated to the C group received 
saline injection intraperitoneally (i.p.) and remained sedentary. In the Ex group rats ran on motor-driven 
rodent treadmill for 28 m x min-1 for 1 hour every day for 6 weeks and received saline injection (i.p.). 
In the PD group, rats did not exercise and after 6 weeks rats received three injections of  MPTP in 
saline at 2 hours intervals in a total dose 60mg/kg (i.p.). In the PD-Ex group, ran on motor-driven 
rodent treadmill for 28 m x min-1 for 1 hour every day for 6 weeks. Following completion of  the 6th 
week of  training, rats received three injections of  MPTP in saline at 2 hours intervals in a total  dose 
60mg/kg (i.p.). Rats were sacrificed on 14 days after the MPTP injection. Prior to sacrifice, all rats 
were deeply anaesthetised with sodium pentobarbital. Rats were sacrificed by decapitation and the 
brains were removed. The entire brain was quickly removed from the skull and dissected on an ice-cold 
glass petri dish. The brains were preserved with 30% sucrose with phosphate buffer. Different parts 
of  brain were snap-frozen in liquid nitrogen and stored at -80C and shipped to the University of  
Bedfordshire, Luton, UK.  
 
2.3.2 BCA Protein Assay 
Protein concentration of all samples (C, Ex, PD and PD-Ex) was determined using Bicinchoninic acid 
(BCA) method. All studied regions i.e. cerebellum, brain cortex, midbrain and striatum) from each 
sample was placed on ice, whilst carrying out homogenisation. Samples were homogenised in presence 
of homogenising buffer (20mM Tris HCl pH 7.4, 2mM EGTA, 1mM DDT, protease inhibitors 
containing 1µg/ml leupeptin, 2µg/ml antipain, 2µg/ml chymostatin, 2µg/ml pepstatin, 3mM 
benzamidine, 200µg/ml phenylmethylsulfonylfluoride (PMSF), using Dounce homogeniser. All samples 
were transferred to labelled centrifuge tubes. Homogenised samples were ultracentrifuged at 100 000 x g 
for 70 minutes at 4°C. The supernatant was removed and BCA (Pierce Biotechnology Rockford IL USA) 
protein assay was carried out. Serial dilutions of BSA standards and homogenised samples were prepared 
in 96 well plates. Working reagent, containing sodium carbonate anhydrous and copper II sulphate 
pentahydrate, was added to all wells and the microplate was incubated in 37°C incubator for 30 minutes. 
The absorbance was detected using the programme Stingray at 570nm wavelength (microplate reader). 
The data was analysed and the amount of protein was determined prior to WB analysis.     
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2.3.3 Protein Detection and Measurement using WB  
Sodium dodecyl sulphate polyacrylamide gel (SDS-PAGE;12%) was prepared using vertical gel casting 
chamber and then transferred to electrophoresis tank. Loading buffer and dithiothreitol (DTT) were 
added to 50µg of protein from all samples (C, Ex, PD and PD-Ex group) were centrifuged at 1000 RMP 
for 5 minutes. Subsequently, all samples were placed in hot plate at 100°C for 5 minutes, before loading 
onto 12% SDS gel. SDS Running buffer was added to the electrophoresis tank and all samples were SDS 
PAGED at 200 volts for an hour. The blot module was assembled and transfer buffer was added prior 
to carrying out immunoblotting at 350 mAmps for 90 minutes. Coomaisse Brilliant Blue was used to 
stain the resolving gel whereas the nitrocellulose membrane was stained with Ponceau stain solution to 
determine successful transfer of proteins. Non-specific binding was blocked by incubating the 
nitrocellulose membrane with 1% milk solution for 30 minutes. Subsequently, the membrane was 
incubated with primary antibody cleaved Anti-Caspase-3 antibody (1:1500, Millipore Hertfordshire UK) 
overnight at 4°C.  Serial washes of the membrane were performed using Phosphate Buffered Saline 
Tween 20 (PBS-T). The membrane was incubated with secondary antibody, Goat-Anti-Rabbit HRP 
(1:1000, Millipore Hertfordshire UK) for 2 hours at room temperature (RT). Enhanced 
chemiluminescent (ECL, Perbio Science Northumberland UK) comprising of 1.5ml Peroxide Solution & 
1.5ml Luminol Enhancer Solution was prepared and transferred onto the membrane for 5 minutes. The 
membrane was wrapped in cling film and placed into the cassette along with a Kodak X-ray film 
(FMXOB0101824, Xograph Gloucestershire UK).  The membrane was exposed to the X-ray film for 5 
minutes before developing. Kodak X-ray film was placed in Kodak developer solution for 4 minutes, 
rinsed under tap water followed by placing into Kodak fixing solution for 8 minutes. Band analysis was 
carried out using a densitometer (GS800, Bio-Rad Hertfordshire UK) which is described in further detail 
below (Section 2.3.4). For each experiment the membrane was reprobed with the house keeping gene 
Gylceraldehyde-3-Phosphate Dehydrogenase (GAPDH) via strip and reprobe method (Section 2.3.5). It 
was essential that GAPDH was used as a reference guide to normalise the data prior to statistical analysis 
(Section 2.3.4). 
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2.3.4 Detection and Statistical Analysis  
Band analysis was carried out using a densitometer (GS800, Bio-Rad Hertfordshire UK). Blots of good 
quality, which had less background noise, were scanned using GS800 scanner. Immunoblots were 
detected and quantified using Quantity One analysis software. The band lanes and each band was 
detected automatically using Quantity One software at default settings and the raw densitometric 
intensity values were obtained. The densitometric values for the experimental samples were normalised 
against the house keeping gene, GAPDH  to determine the densitometric ratio , prior to carrying out 
statistical analysis (T test p<0.05, ANOVA p<0.05).  A total of five independent experiments were 
conducted and the average of all three experiments was determined to finalise the end conclusion.   
 
2.3.5 Strip and Reprobe of Membrane using Different Antibodies  
To determine the presence and absence other Caspase proteins such as Caspase-1,-2,-3, -8,-9 and -12 
and CAMK-IV (in some cases), as well as using the house keeping gene GAPDH as a reference guide, 
the membrane was stripped of the antibody by incubating the membrane with stripping buffer (1mM 
EGTA, 200mM glycine) for 20 minutes followed by serial wash with PBS Tween 20. Reprobing the 
membrane with a different antibody was achieved by incubating the membrane with the primary 
antibody (active Anti-Caspase-9, 1:1000, Millipore Hertfordshire UK) and secondary antibody (Goat-
Anti-Rabbit HRP, 1:1000, Millipore Hertfordshire UK). The subsequent steps to develop Caspase-9 via 
X-ray film were achieved using the same conditions as stated above (Section 2.3.3).  
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2.4 ReNcell VM Human Neural Progenitor Cell Line 
 
ReNcell VM is a newly developed cell line derived from human ventral mesencephalon brain region of 
fourteen week old foetus, which has the ability to differentiate into dopaminergic/dopamine containing 
neurons (dDCN) purchased from Millipore Hertfordshire 
UK (SCM008). 
 
2.4.1 Preparation of laminin coated flasks, well plates and chamber slides 
To ensure that ReNcell VM Human Neural Progenitor cells adhered to the surface, 96 well plates, 2 well 
chamber slides, 8 well chamber slides, T75 and T25 flasks were coated with Laminin from Engelbreth-
Holm-Swarm murine sarcoma basement membrane (L2020 Sigma Dorset UK) in Dulbecco's Modified 
Eagle Medium (DMEM) (D5796 Sigma Dorset UK) (20 µg/ml) and were left to incubate in 37°C 5% 
CO2 incubator for four hours. Following 4 hour incubation, excess laminin solution was removed from 
the coated tissue culture ware and the apparatus were rinsed with PBS.  
 
2.4.2 Culturing of ReNcell VM 
Prewarmed ReNcell Neural Stem Cell (NSC) maintenance media (SCM005, Millipore Hertfordshire UK) 
was transferred into T75 laminin coated flask and left in 37°C incubator. ReNcell VM vial was thawed in 
37°C water bath and transferred to a sterile 15 ml conical tube with use of 1 ml pipette. Prewarmed 
ReNcell NSC Maintenance Medium (comprised of human tansferrin, putrescine dehydrochloride, tri 
iodo thyronine, L thyroxine, progesterone, DMEM/F12, glutamine, L glutamine, human serum albumin, 
human recombinant insulin, tri-iodo-insulin, sodium selenite, heparin and corticosterone) was gradually 
added to the 15ml conical tube containing ReNcell VM. Cells were resuspended and centrifuged at 
12000 RMP for 5 minutes at 4°C. The supernatant was removed and cells were suspended in 5ml of 
ReNcell NSC Maintenance Medium (pre-warmed to 37°C) containing freshly added Epidermal Growth 
Factor (EGF) (GF144, Millipore Hertfordshire UK) and Fibroblast Growth Factor basic, human 
recombinant (FGF) (GF003, Millipore Hertfordshire UK). ReNcell VM was pipetted into the laminin-
coated T75 tissue culture flask that was pre-incubated in the 37°C incubator. ReNVM cells were left to 
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incubate overnight at 37°C in 5% CO2 incubator. The medium was replaced the following day with fresh 
ReNcell NSC Maintenance Medium (prewarmed to 37°C) containing 0.4µl FGF and 3µl EGF. The 
medium (containing FGF and EGF) for ReNcell VM was changed every other day and cells were left to 
grow until they were 80% confluent.  
 
2.4.3 Sub culturing of ReNcell VM  
ReNcell VM was left to grow until they were 80% confluent after which they were subcultured in freshly 
prepared laminin coated flasks. Pre warmed ReNcell NSC Maintenance Medium containing 0.4µl FGF 
and 3µl EGF was added to the freshly prepared laminin coated flasks and was left at 37°C 5% CO2 
incubator. The old ReN media was removed from laminin-coated T75 flasks containing the confluent 
layer of ReNcell VM cells. Cold PBS was pipette slowly into the flask from the side to avoid detaching 
the cells.  PBS was used to wash the cells after which the PBS was discarded.  To detach ReNVM cells 3 
ml of accutase (A6964, Sigma Dorset UK) was added to the flask and was left to incubate for 5 minutes 
in a 37°C incubator.  The detached cells were transferred into a 15ml centrifuged tube and the cells were 
centrifuged at 12000 RPM for 5 minutes at 4°C. The supernatant was discarded and ReNcell NSC 
Maintenance Medium containing 0.4µl FGF and 3µl EGF was added to the cells. Cells were counted 
using a haemocytometer. Cells were plated in fresh laminin-coated flasks in ReNcell NSC Maintenance 
Medium containing 0.4µl FGF and 3µl EGF. The next day freshly prepared ReNcell NSC Maintenance 
Medium containing 0.4µl FGF and 3µl EGF replaced the old medium and cells were left to incubate as 
normal. The medium was exchanged with fresh ReNcell NSC Maintenance Medium containing FGF 
and EGF every other day. 
 
2.4.4 Preparation of ReNcell VM stocks   
To prepare stocks of ReNcell VM old medium was removed from laminin-coated T75 flasks containing 
the confluent layer of ReNcell VM cells. Cold PBS was added to the flask to wash cells. After cells were 
washed PBS was discarded and 3ml of accutase was added to the flask and was left to incubate in a 37°C 
incubator for 5 minutes. Prewarmed ReNcell NSC Maintenance Medium was added to the flask 
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containing detached cells. ReNcell VM was centrifuged at 12000R PM for 5 minutes at 4°C and the 
supernatant was discarded.   ReNVM NSC Freezing Medium (SCM007, Millipore Hertfordshire UK) 
was added to the cells (1ml) and cells were aliquoted into labelled 1.5ml cryovials. All cryovials were 
placed in alcohol bath (containing isopropanol) and stored at -80°C. 
 
2.5 General Methods for PD cell model  
 
2.5.1 Drug treatment  
Initially the concentration of each inhibitor had to be established prior to carrying out the main 
experiments. To determine appropriate concentration range for each inhibitor previous research was 
explored that had used the specific inhibitor. The concentration of the inhibitor was determined whilst 
the exposure time was kept at 2 hour time interval to coordinate with 6OHDA (H116, Sigma Dorset 
UK) drug treatment.  
 
For all neurotoxicity experiments dDCN were approximately 80% confluent when exposed to 100µM 
6OHDA for 2 hours. Subsequently, drug treatment was stopped with the removal of the media 
containing 100µM 6OHDA and replaced with fresh ReNcell maintenance media. Untreated and treated 
dDCN were left in 37°C CO2 incubator overnight. The following day the main experiment was carried 
out.  For some assays dDCN were exposed to 100µM 6OHDA as well as an inhibitor such as IKK, 
salubrinal or Caspase specific. In other experiments dDCN were treated with 100µM 6OHDA, along 
with a combination of two or more specific inhibitors.    
 
2.5.2 Determining Caspase expression in 6OHDA dDCN  
dDCN were cultured in laminin coated 8 well chamber slides until they had reached 80% confluence. 
dDCN were treated with 6OHDA with or without a specific inhibitor or with two inhibitors for 2 hours. 
Subsequently, drug treatment was stopped by removing the old media and replacing it with fresh 
ReNcell maintenance media. Untreated and treated dDCN were left overnight in CO2 incubator for 
recovery (Chaudhry and Ahmed 2013).  
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Untreated and treated dDCN underwent fixation with 4% paraformaldyde for 15 minutes prior to 
washing with cold PBS.  Subsequently, dDCN were treated with Triton X-100 for 10 minutes and 
blocked with 10% goat serum (S-1000, Vector Labs Peterborough UK). dDCN were serial washed with 
cold PBS ( 3 x 5 minutes ) and were left to incubate overnight with primary antibodies at 4oC.  The 
following morning, dDCN were washed with PBS (3 × 5 minutes) and incubated with secondary 
antibodies for two hours at RT. Cells were mounted using vectorshield mounting medium (158127, 
Vector Labs Peterborough UK) and were viewed under a Meiji MT6000 fluorescent microscope 
(Mazurek Warwickshire, UK) (Chaudhry and Ahmed 2013). 
dDCN and 6OHDA dDCN were counted under x 20 magnification in 5 fields of vision per area 
(1.428mm x 1.092mm) of untreated and treated dDCN. The FITC excitation wavelength of 470nm and 
emission wavelength of 520nm demonstrated cells that were positively stained with green dye. In 
comparison, cells that were red stained were due to rhodamine excitation of 550nm and emission 
wavelength of 640nm. To analyse co localisation data effectively, cells that were in the same field and 
were stained positive for red dye and green dye were counted dDCN. Cell numbers are expressed as the 
mean per selected field from the wells. Three independent experiments were performed for each sample 
prior to statistical analysis (T test, p<0.05) (Chaudhry and Ahmed 2013). 
 
2.5.3 Determining the amount of Caspase activation in 6OHDA dDCN using WB analysis  
dDCN were grown in laminin coated T25 flasks until they had reached 80% confluence. dDCN were 
exposed to100µM 6OHDA and treated different inhibitors such as zVADfmk, IKK or salubrinal 
inhibitor for 2 hours. Fresh media was replaced and dDCN were left to recover overnight at 37°C in 
CO2 incubator.  Cells were detached from laminin coasted flasks with the aid of accutase and collected in 
labelled centrifuge tubes. Cells were centrifuged at 12000RPM for 8 minutes and the supernatant was 
removed.   The pellet containing the cells was lysed with lysis buffer (HEPES, NaCl, EGTA, 
glycerophosphate 10% glycerol, 1% Triton,1mM PMSF, 1mM DTT, protease inhibitors)  and protein 
concentration was measured using the BCA kit (Pierce Biotechnology Rockford IL USA). 
Fifty micrograms protein was loaded on 12% gel prior to SDS PAGE (40 minutes at 200 volts), followed 
by immunoblotting on PVDF membrane (90 minutes at 350mAmps).To ensure complete transfer of 
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proteins from the resolving gel to PVDF membrane, immmunostaining was carried out. The PVDF 
membrane was stained with Ponceau whilst the gel was stained with Coomassie brilliant blue. The 
membrane was blocked with 1% skimmed milk for an hour followed by incubation with primary 
antibodies overnight at 4oC. The next day the membranes were washed with PBS-T (3 x 2 minutes), 
prior to incubation with secondary antibody for an hour at RT. After washing the membranes with 
PBST, ECL HRP solution (Perbio Science Northumberland UK) was added to the membrane for 4 
minutes, prior to exposing the membrane to X ray. X ray was scanned in densitometer scanner (GS800 
Biorad Hertfordshire UK). Band detection and statistical analysis was carried out using the same 
methods previously described in Section 2.3.4. In addition, to normalise the data prior to statistical 
analysis the PVDF membrane was reprobed with GAPDH via strip and reprobe method (Section 2.3.5). 
 
2.5.4 Determining activation of Caspases-2,-4 and-8 in NFB classical pathway and ER stress 
using in 6OHDA dDCN via 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide assay 
(MTT) assay  
dDCN were grown in 96 well plates and were left until 80% confluence. dDCN were treated with 
different combinations of inhibitors along with 6OHDA for 2 hours after which fresh media was 
replaced and cells were left to recover overnight (Section 2.5.1). The following day old media was 
replaced with fresh media prior to the addition of 10µl of MTT (BT30006 Cambridge BioScience 
Cambridge UK) per well. All samples were left to incubate at 37°C for 4 hours in a 37°C CO2 incubator. 
The formazan complex formed was broken by pipetting the dye crystals up and down in each well. 
Subsequently, samples were placed in microplate reader and the programme Stingray was used to 
determine the readings of samples at 575nm wavelength. The readings were normalised prior to 
statistical analysis at p<0.05 using ANOVA and student T test.  A total of 24 replicates were made for 
each untreated and treated dDCN per experiment.  A total of three independent experiments were 
conducted and the average of all three experiments was determined to finalise the end conclusion.   
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Chapter 3 
The Effect of Treadmill Exercise on 
Caspases in PD Animal Model  
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3.0 PD and CAMKIV 
Calmoduline is a ubiquitous calcium binding proteins, which activates enzymes and undergoes 
conformational changes upon binding with calcium ion.  Calcium/calmodulin-dependent protein 
kinases (CAMKs) have been found in all eukaryotic cells. CAMK-IV is a multifunctional enzyme that 
plays an essential role in release and synthesis of neurotransmitters, axonal transport and regulating 
signal transduction in neural cells (Wayman et al 2008).  
 
Redmond and Gosh (2005) explored the role of CAMK-IV in the growth of dendrites in corticol 
neurons and found CAMK-IV stimulated growth of dendrites, via calcium dependent mechanisms. 
Ribar et al (2000) observed the appearance of symptoms such as tremors, and loss of motor control 
in CAMK-IV knockout mice which correlate with the symptoms of PD.  
 
Research by Suntoo et al (2003) has shown that during exercise calcium ions are released from the 
sarcoma of muscle cells and bind to calcium binding proteins CAMKs. The binding of CAMKs 
during exercise suppresses activation of the Caspase pathway, thereby preventing cell death. The 
study indicated that exercise had increased dopamine synthesis in the brain of PD animal model, via 
the calmodulin dependent pathways. The level of calcium in the serum had increased significantly, 
resulting in the transfer of calcium to the brain, inducing the synthesis of dopamine. The elevated 
levels of dopamine regulated a diverse range of brain functions, indicating that exercise may improve 
some symptoms of PD. 
 
Research by Akimoto et al (2004) signifies that CAMKs have a role in skeletal muscle plasticity. When 
the levels of CAMK-IV were compared to mice that were in an exercise state to mice that were 
sedentary, it was found that the mice that were active had increased levels of CAMK-IV present in the 
skeletal muscle. This contributed to the higher rate of contractibility of skeletal muscle and, in addition 
fibre switching was observed.  
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3.1 Exercise, Caspase and PD  
In the last few years, much progress has been made in understanding the effect of physical exercise on 
improvement of different diseases including PD (Chapter 1 Section 1.2.5). Exercise has been shown to 
improve neuromuscular interaction, neurogenesis and trophic factors, leading to initiate functional and 
morphological changes in both normal and injured brain (Chapter 1 Section 1.2.5). These changes are 
predominantly found in various motor regions of the brain that include motor cortex, basal ganglia, 
cerebellum and red nucleus (Graybiel 2005,  De Zeeuw and Yeo 2005, Holschneider et al 2007).  
  
Lee et al (2003) found that treadmill exercise had decreased Caspase-3 activity in the striatum of 
intracerebral haemorrhaged rats.  Rats underwent treadmill exercise for 30 minutes every day for 10 days. 
The results showed that sedentary rats had greater loss of neurons in the striatum, increased Caspase-3 
activity and bigger size haemorrhage compared to rats that had exercised. Exercise had decreased the 
size of haemorrhage, lowered Caspase-3 activity and prevented loss of striatal neurons.  
 
IF analysis has shown an increase in Caspase-3 activation, formation of apoptotic bodies and 
degeneration neurons of spinal cord in rotenone induced rats. TUNEL staining confirmed that rotenone 
induced apoptotic death of spinal neurons in rats. WB analysis demonstrated high levels of active 
Calpain and Caspase-3 in spinal cord rotenone treated rat homogenates, signifying that rotenone 
triggered apoptotic death of spinal cord neurons via Caspase and Calpain mediated death in PD rat 
model (Samantary et al 2003).  
 
IF analysis revealed loss of TH positive cells of 6OHDA and MPTP-treated rat mesencephalic cultures. 
The broad Caspase inhibitor zVADfmk had prevented loss of TH positive cells in the midbrain of 
6OHDA and MPTP rat, indicating that loss of DCN is Caspase mediated. WB analysis had revealed 
increase in active Caspases-3 and -9 as well cytochrome c in PD rat animal model, indicating Caspase 
mediated death of DCN is via intrinsic pathway (Han et al 2003). 
 
 
- 104 - 
 
Immunohistochemical and WB analysis revealed high levels of Caspase-3 in MPTP-treated rat 
mesencephalon cultures, demonstrating that Caspase-3 is active in DCN of PD animal model. IF 
analysis revealed formation of apoptotic bodies and loss of TH positive cells, indicating MPTP triggered 
Caspase mediated death of DCN in the midbrain of PD rat model (Hartmann et al 2000). WB analysis 
showed high levels of active Caspases-3 and 9 in MPTP-treated striatum mice homogenates, indicating 
that MPTP triggered activation of Caspases-3 and -9 in striatum of mice in PD animal model. IF analysis 
revealed formation of apoptotic bodies, destruction and loss of striatal neurons in MPTP mice, 
signifying that MPTP triggered apoptotic death of cells (Zhang et al 2013b).  
 
WB analysis revealed elevated amounts of cytochrome c and BAX and a decrease of BCL-2 in striatum 
of 6OHDA-treated rat. Lipid peroxidation of 6OHDA-treated rat striatum was confirmed with lipid 
peroxidation markers thiobarbituric. Caspase specific assays measured elevated levels of Caspases-3 and -
9 activity in 6OHDA-treated striatum of PD rat model. Enzyme-linked immunosorbent (ELISA) 
analysis revealed higher levels of cytokines TNF-α and IL-1β in 6OHDA-treated rat striatum. The 
antioxidant, piperine had inhibited lipid peroxidation, TNF-α, -1β, cytochrome c, BAX, Caspases-3 and -
9 activities in the striatum of 6OHDA-treated rats, indicating 6OHDA triggers Caspase-3 and 9 
mediated apoptotic death of striatal neurons, through mitochondrial and inflammatory routes via 
oxidative stress (Shrivastava et al 2013).  
 
Elevated Capases-3,-8 and -9 activities were found in heart ventricle homogenates of hypoxic sedentary 
rats.  WB analysis demonstrated decrease in BCL-2 and increase in BAX levels in non exercised hypoxic 
rats. Treadmill running for an hour everyday for 5 weeks had decreased lipid peroxidation, BAX, 
mitochondrial swelling, Caspases-3,-8 and -9 activities whilst increasing superoxide dismutase and BCL-2 
levels in the heart ventricles of hypoxic rats. These findings signified that exercise can prevent Caspase 
mediated apoptotic death of the heart (Magalhaes et al 2014). 
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Schulz (2006) suggested that to facilitate survival of nigrostriatal dopaminergic neurons, the major 
Caspase stimulation pathway (the mitochondrial apoptosis pathway) should be suppressed, as prevention 
of individual Caspases can only encourage short term survival of neuronal cells. Murlastis et al (2007) 
observed that exercise reduced ER stress in Ischemic Sprague- Dawley rats, when compared to the 
control. In addition, reductions in ER stress protein levels were found in the exercised Ischemic rats 
when compared to the sedentary rats. Furthermore, mice which endured regular exercise had an 
increased quantity of dendritic growth in cortical neurons and synapses present when compared to the 
control group. In addition, a decrease in DNA oxidative damage and lipid peroxidation was found 
(Mattson et al 2004) 
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3.2 Relevance of Treadmill Exercise on Caspases in MPTP animal model 
Current research shows that exercise is an effective treatment and reduces symptoms of PD (Ayan and 
Cancela 2012, Heiberger et al 2011, Fritz et al 2011, Vivas et al 2011, Hackney and Earhart 2010, Li et al 
2012, Dreu et al 2012,).  There are extensive clinical studies carried out on treadmill exercise in PD 
patients, showing that treadmill exercise decreases PD symptoms, at the same time, it has positive effect 
on the quality of life of PD patients in terms of forming social networks (Paterson et al 2005, Brown et 
al 2010, C.Haas personal communication). Overall, exercises show some improvement in decreasing key 
features of PD, such as gait, tremors and bradykinesia (Chapter 1 Section 1.2.5).  Although there are 
extensive clinical studies carried out on treadmill exercise in PD patients, there is a lack of biochemical 
understanding as to how exercise is affecting PD patients at a cellular level. Effect of exercise on 
expression or inhibition of different proteins has not been determined yet. There is a lack of research 
exploring the potential pathways, which exercise may activate and suppress to provide such positive and 
even negative effects. 
 
The current study is the first to explore the effect of six week treadmill exercise on active Caspases, 
along with CAMK-IV protein in different brain regions. More specifically, the level of various Caspases 
(Caspase-1,-2,-3,-8,-9 and -12) was explored in different brain regions such as cerebellum, brain cortex, 
midbrain and striatum of C, Ex, PD and PD-Ex animal model. The presence and absence of different 
Caspases along with CAMK-IV in brain regions of PD animal model after undergoing six week treadmill 
exercise was carried out to determine the influence of exercise and its beneficial effects in PD so that new 
therapies can be made.  
 
Aim: To determine the presence and absence of active and cleaved Caspases-1,-2,-3,-8,-9,-12 and 
CAMK-IV in PD-Ex brain cortex, cerebellum, midbrain and striatum of PD rat animal model.   
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3.3 Method : Determining the Effect of Endurance Exercise on Caspase and CAMK-
IV Activities in C, Ex, PD and PD-Ex Animal Model 
3.3.1 Endurance training, segregation and treatment of rats  
Procedure for training, segregation and MPTP injection performed by collaborators Jozef Langfort and 
Malgorzata Chalmoniuk at Dr Jozef Langfort laboratories Medical Research Centre, Polish Academy of 
Sciences, Warsaw, Poland.  Rats were housed in temperature controlled room under 12 hour daylight/ 
night cycle at animal breeding facility. Rats were fed rodent chow and water ad libitum to consume at 
regular intervals. 
 
For the study, eight weeks old Wistar male rats) were segregated into four groups (n=4 for each group) 
to endure four conditions; control (untreated and un-trained (C), trained (Ex), MPTP-treated (PD) and 
PD-Ex (MPTP-treated and trained). Rats that were categorised to the C group received saline injection 
(i.p.) and remained sedentary (Figure 3.1). In the Ex group rats ran on motor-driven rodent treadmill for 
28 m x min-1 for 1 hour every day for 6 weeks and received saline injection (i.p.). In the PD group, rats 
did not exercise and after 6 weeks rats received three injections of MPTP in saline (i.p.) at 2 hours 
intervals in a total dose 60mg/kg. In the PD-Ex group, rats ran on motor-driven rodent treadmill for 28 
m x min-1 for 1 hour every day for 6 weeks. Following completion of the 6th week of training, rats 
received three injections of MPTP in saline (i.p.) at 2 hours intervals in a total dose 60mg/kg. Rats were 
sacrificed on 14 days after the MPTP injection. Prior to sacrifice, all rats were deeply anaesthetised with 
sodium pentobarbital. Rats were sacrificed by decapitation and the brains were removed and regions 
were dissected on ice. Different brain regions were collected, snap-frozen in liquid nitrogen and stored at 
-80C prior to being shipped to the University of Bedfordshire, Luton, UK.  
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Figure 3.1 : Segregation and treatments of C, Ex, PD, PD-Ex groups in PD animal model 
Sixteen male Wistar rats were categorised in groups of four and each segregated group (C, Ex, PD, PD-
Ex) was exposed to specific conditions. Rats in the C group remained sedentary and received saline 
injection (i.p.). Ex group underwent treadmill training every day for one hour for six weeks and received 
saline injection (i.p.). PD group did not exercise and received systemic MPTP injection in saline (i.p.). 
PD-Ex group had undergone treadmill training every day for an hour for six weeks. After completion of 
treadmill exercise PD-Ex group received systemic MPTP injection in saline (i.p.). Procedures carried out 
by collaborators Jozef Langfort and Malgorzata Chalmoniuk at Dr Jozef Langfort laboratories Medical 
Research Centre, Polish Academy of Sciences, Warsaw, Poland.   
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3.3.2 BCA Protein Assay and WB 
All brain regions i.e. cerebellum, brain cortex, midbrain and striatum from each group were 
homogenised followed by ultracentrifuged at 100 000 x g for 70 minutes at 4°C. The supernatant was 
removed and protein concentration was determined via BCA (Pierce Biotechnology Rockford IL USA) 
protein assay. All samples (50µg protein) were loaded on 12% SDS gel and were SDS-PAGED at 200 
volts for an hour. Proteins were transferred from the resolving gel to nitrocellulose membrane via 
immunoblotting (350 mAmps for 90 minutes), followed by 30 minute blocking with 1% milk solution. 
Subsequently, the membrane was incubated with primary and secondary antibodies for overnight at 4°C 
and 2 hours at RT respectively. Primary antibodies; Anti-Caspase-1(1:50, Abcam Cambridge UK), Anti-
Caspase-2 (1:250, Abcam Cambridge UK), Anti-Caspase-3 (1:1000, Millipore Hertfordshire UK), Anti-
Caspase-8(1:1000, Abcam Cambridge UK), Anti-Caspase-9 (1:1000, Millipore Hertfordshire UK, Anti-
Caspase-12 (1:500, Abcam Cambridge UK), Anti-CAMK-IV(1:2500, Millipore Hertfordshire UK), and 
secondary antibody Goat-Anti-Rabbit HRP (1:1000, Millipore Hertfordshire UK) were used. Membranes 
were incubated with ECL solution (Perbio Science Northumberland UK) for 5 minutes, prior to 
exposure and development via X-ray film (FMXOB0101824, Xograph Gloucestershire UK). Band 
analysis was carried out using a densitometer (GS800, Bio-Rad Hertfordshire UK). Blots were 
normalised against GAPDH prior to statistical analysis (ANOVA p<0.05, T test p<0.05 Chapter 2 
Section 2.3.4). In some instances stripping and reprobing with other antibodies was carried out (Chapter 
2 Section 2.3.5). A more detailed account of these procedures and reagents used can be found in Chapter 
2 Section 2.1 and Section 2.3 and Appendix 1 correspondingly.  
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3.4 Results  
The aim for this part of the project was to determine the effect of six week treadmill exercise on 
Caspases-1, 2,-3,-8,-9 and -12 in the cerebellum, brain cortex, midbrain and striatum of PD animal 
model. Caspase-1 was not detected in any regions (brain cortex, striatum, cerebellum and midbrain) of C, 
Ex, PD and PD-Ex Rat. This indicated that Caspase-1 was not present in the brain in this PD model. To 
ensure that Caspase-1 was not present in PD animal model the PVDF membrane was stripped and 
reprobed with another antibody GAPDH. The membrane showed positive staining of GAPDH 
antibody. In addition, the antibody concentration to detect Caspase-1 was increased to maximise any 
binding of Caspase-1 from the samples, but there was no presence of Caspase-1 in the brain regions of 
C, Ex, PD and PD-Ex group. Furthermore, the sample concentration was also increased so that the 
Caspase-1 protein present in the samples would bind to the antibody. However, there was detection of 
Caspase-1 from the highly concentrated antibody. Ponceau staining of PVDF membrane and Coomaisse 
staining of the resolving gel had showed successful transfer of all the proteins in the gel onto the 
membrane. Fewer washes with PBST were carried out between antibody incubation times to determine 
if Caspase-1 protein was detected in PVDF membrane. Furthermore, a lower concentration of blocking 
buffer containing 0.1% milk solution was used as it may have been that the blocking reagent had blocked 
all the specific and non specific binding sites. Different blocking buffer was also tried but still there was 
no detection of Caspase-1 in the brain regions of C, Ex, PD and PD-Ex group. Collectively, the work 
suggested that Caspase-1 is not detected in any regions of the brain in PD animal model.  
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WB analysis was performed to detect and measure the amount of active Caspase-2 in the brain cortex of 
PD-Ex animal model. Caspase-2 is an initiator Caspase, which when activated promotes stimulation of 
other downstream proteins such as Caspase-3 resulting in cell death (Chaudhry and Ahmed 2014). 
ANOVA (p<0.01) and T test (p<0.05) had shown a difference in the amount of Caspase-2 present in 
brain cortex of PD and PD-Ex animal model. A 32% increase in the amount of active Caspase-2 was 
detected in the brain cortex of PD sedentary rats, indicating that MPTP may have triggered Caspase-2 
activation in the brain cortex. In contrast, a significant reduction in active Caspase-2 levels was present in 
brain cortex of PD-Ex group, indicating that exercise may have reduced active Caspase-2 activation in 
brain cortex of PD animal model (Figure 3.2).   
 
Figure 3.2: The effect of Exercise on active Caspase-2 in brain cortex of PD animal model  
A) Illustrative example of GAPDH in brain cortex of PD animal model  
B) Illustrative example of active Caspase-2 in brain cortex of PD animal model 
C)  Active Caspase-2 was present in the brain cortex of C, Ex, PD and PD-Ex rats. A significant amount of 
active Caspase-2 had decreased (41% reduction) in brain cortex of PD-Ex group compared to PD brain 
cortex (p<0.01), indicating that treadmill exercise may have reduced active Caspase-2 in the brain cortex 
of PD animal model. Means of five experiments ± SEM shown. Table of densitometry values and 
statistical analysis can be found in Figure 3.3, Appendix 3. 
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WB analysis was carried out to determine the effect of treadmill exercise on Caspase-3 in the brain 
cortex in PD animal model. Caspase-3 is a late marker of apoptotic death in cells and has been 
associated with death of DCN in PD pathogenesis in vivo and in vitro analysis (Chaudhry and Ahmed 
2014). A significant rise in cleaved Caspase-3 was observed in brain cortex of PD rats that did not 
undergo treadmill exercise, suggesting that MPTP may have triggered Caspase-3 dependent death in the 
brain cortex (ANOVA p<0.05, T test p<0.05). In contrast, endurance exercise had reduced Caspase-3 
levels in PD-Ex brain cortex, indicating that exercise may have reduced Caspase-3 activity in the brain 
cortex, thereby reducing apoptotic death of neurons (Figure 3.4).    
 
Figure 3.4 : Treadmill Exercise reduces cleaved Caspase-3 in PD animal brain cortex 
A) Illustrative example of GAPDH in brain cortex of PD animal model 
B) Illustrative example of cleaved Caspase-3 in brain cortex of PD animal model 
C) Cleaved Caspase-3 was present in the brain cortex of C, Ex, PD and PD-Ex rats. A 22% decrease of 
cleaved Caspase-3 amount was detected in brain cortex of Ex group when compared to the C group. In 
comparison, 23% increased level of Caspase-3 was detected in brain cortex of sedentary PD samples, 
indicating that MPTP can increase Caspase-3 levels in brain cortex of PD model. On the other hand, 
Treadmill exercise significantly decreased cleaved Caspase-3 levels in brain cortex of PD-Ex group (50 % 
reduction, p<0.01) compared to PD group. Means of five experiments ± SEM shown. Table of 
densitometry values and statistical analysis can be found in Figure 3.5, Appendix 3. 
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To further explore the effect of exercise on Caspases in the brain cortex in PD animal model, Caspase-
8 protein was examined. Caspase-8 is another initiator Caspase, which upon activated promotes 
stimulation of other downstream proteins such as Caspase-3 resulting in death of DCN (Chaudhry and 
Ahmed 2014). The results illustrated presence of high levels of active Caspase-8 in brain cortex of PD 
rats, highlighting that MPTP may have triggered activation of the initiator Caspase-8, which may result 
in activation of other proteins via the Caspase cascade (ANOVA p<0.05, T test p<0.05). In 
comparison, a significant decrease in Caspase-8 was measured in PD-Ex group, indicating that exercise 
might have promoted survival and have reduced death of cortical neurons in PD rat samples (Figure 
3.6).   
 
Figure 3.6 : Low levels of Caspase-8 found in exercised brain cortex of PD animal model 
A) Illustrative example of GAPDH in brain cortex of PD animal model 
B) Illustrative example of active Caspase-8 in brain cortex of PD animal model 
C) Active Caspase-8 was present in the brain cortex of C, Ex, PD and PD-Ex rats. Similar Caspase-8 levels 
were found in brain cortex of sedentary (C group) and exercise (Ex group) rats. The amount of Caspase-
8 had increased in brain cortex of PD rats that did not exercise by 29%. A significant decrease in 
Caspase-8 levels was found in brain cortex of PD rats that endured treadmill exercise for six weeks (49% 
reduction, p<0.01), compared to PD group. Means of five experiments ± SEM shown. Table of 
densitometry values and statistical analysis can be found in Figure 3.7, Appendix 3. 
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WB analysis was used to determine the amount of active Caspase-9 present in the brain cortex of C, Ex, 
PD and PD-Ex rats. Previous research has shown activation of Caspase-9 to be associated with the 
mitochondrial pathway leading to activation of other downstream proteins such as Caspase-3 resulting in 
cell death (Fan et al 2005, Chaudhry and Ahmed 2014). Similar levels of active Caspase-9 were detected 
in brain cortex of the C, Ex and PD group, indicating that MPTP had no significant influence on 
Caspase-9 activity in brain cortex (p>0.05). Interestingly, a significant rise in the amount of active 
Caspase-9 was measured in the brain cortex of PD-Ex group when compared to PD group (p<0.05), 
suggesting that treadmill exercise may have triggered Caspase-9 activity in brain cortex in PD animal 
model (Figure 3.8).   
 
Figure 3.8 : Endurance exercise can increase active Caspase-9 levels in brain cortex of PD 
animal model 
A) Illustrative example of GAPDH in brain cortex of PD animal model 
B) Illustrative example of active Caspase-9 in brain cortex of PD animal model 
C) Active Caspase-9 was present in the brain cortex of C, Ex, PD and PD-Ex rats. Similar amount of active 
Caspase-9 were in brain cortex of C, Ex and PD animal model (100%, 102% and 109%). A siginifcant 
increase of active Caspase-9 levels were determined in brain cortex of PD-Ex group compared to PD 
group (26% increase, p<0.01). Means of five experiments ± SEM shown. Table of densitometry values 
and statistical analysis can be found in Figure 3.9, Appendix 3. 
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The influence of endurance exercise on the amount of Caspase-12 in brain cortex in PD animal model 
was determined via WB analysis. Activation of Caspase-12 has been associated with ER stress pathway 
that contributes to death of cells (Doyle et al 2011, Yoshida 2007). In addition, active Caspase-12 
promotes Caspase-9 stimulation, bypassing the intrinsic mitochondrial route, resulting in Caspase-3 
activation and cell death (Fan et al 2005). Elevated levels of cleaved Caspase-12 were detected in brain 
cortex of PD sedentary rats when compared to the C group, indicating that MPTP may have trigger 
Caspase-12 activation in brain cortex of PD rat (ANOVA p<0.05, T test p<0.05). Furthermore, a 
significantly reduced the amount of cleaved Caspase-12 was measured in the brain cortex of PD-Ex 
group, suggesting that exercise may have decreased cell death associated with Caspase-12 activation 
(Figure 3.10).   
 
Figure 3.10 : Cleaved Caspase-12 is decreased exercised brain cortex of PD animal model 
A) Illustrative example of GAPDH in brain cortex of PD animal model 
B) Illustrative example of cleaved Caspase-12 in brain cortex of PD animal model 
C) Cleaved Caspase-2 was present in the brain cortex of C, Ex, PD and PD-Ex rats. Caspase-12 was found 
in similar levels in brain cortex of C and Ex group. A 29% increase in the amount of Caspase-12 was 
found in brain cortex of PD rats indicated MPTP had triggered Caspase-12 activity in rat brain cortex 
(p<0.01). A 54% decrease in Caspase-12 levels was measured in brain cortex of PD-Ex rats compared to 
PD rats (p<0.01). Means of five experiments ± SEM shown. Table of densitometry values and statistical 
analysis can be found in Figure 3.11, Appendix 3. 
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The current study was extended further by investigating the presence and absence of active Caspases in 
the cerebellum of C, Ex, PD and PD-Ex rats. There was no significant difference in the amount of 
active Caspase-2 in the cerebellum of PD rats compared to the C group (p>0.05), suggesting that MPTP 
had not promoted Caspase-2 activation in the cerebellum of PD animal model. In contrast, a significant 
decrease (p<0.05) in active Caspase-2 levels was determined in the cerebellum of PD-Ex group when 
compared to the PD group; this indicated that exercise may have reduced Caspase-2 activity in the 
cerebellum (Figure 3.12).    
 
Figure 3.12: The effect of Exercise on Caspase-2 in cerebellum of PD animal model 
A) Illustrative example of GAPDH in cerebellum of PD animal model 
B) Illustrative example of active Caspase-2 in cerebellum of PD animal model 
C) Active Caspase-2 was present in the cerebellum of C, Ex, PD and PD-Ex rats. No significant difference 
in the amount of active Caspase-2 was present in the C and PD rat cerebellum (p>0.05). Graph shows a 
reduction in the amount of active Caspase-2 (66% decrease) present in the cerebellum of PD rats that 
underwent treadmill training (p<0.05), compared to PD sedentary rats. Means of five experiments ± 
SEM shown. Table of densitometry values and statistical analysis can be found in Figure 3.13, Appendix 
3. 
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WB analysis was used to measure the amount of cleaved Caspase-3 levels in the cerebellum of PD and 
PD-Ex animal model. The results demonstrate an increase in the amount of cleaved Caspase-3 in the 
cerebellum of PD group compared to C group (ANOVA p<0.05, T test p<0.05), indicating that MPTP 
up regulated Caspase-3 activity in the cerebellum. Furthermore, there was a lower amount of cleaved 
Caspase-3 present in cerebellum of PD-Ex group compared to PD group, indicating that exercise may 
have lowered Caspase-3 activity in the cerebellum of PD animal model (Figure 3.14).   
 
Figure 3.14 : Cleaved Caspase-3 is reduced in cerebellum of PD-Ex animal model 
A) Illustrative example of GAPDH in cerebellum of PD animal model 
B) Illustrative example of cleaved Caspase-3 in cerebellum of PD animal model 
C) Cleaved Caspase-3 was present in the cerebellum of C, Ex, PD and PD-Ex rats. Graph shows MPTP 
had increased the amount of cleaved Caspase-3 in the cerebellum of PD group compared to C group 
(27% increase, p<0.01), signifying that MPTP triggers Caspase-3 activity in cerebellum of PD animal 
model. In comparison, a 38% decrease in cleaved Caspase-3 was measured in cerebellum of PD-Ex rat 
compared to PD group (p<0.05). Means of five experiments ± SEM shown. Table of densitometry 
values and statistical analysis can be found in Figure 3.15, Appendix 3. 
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The influence of endurance exercise on the amount Caspase-8 in cerebellum in PD animal model was 
determined via WB analysis. Elevated levels of active Caspase-8 were detected in cerebellum of PD 
sedentary rats when compared to the C group, indicating that MPTP may have triggered Caspase-8 
activity (ANOVA p<0.05, T test p<0.05). A significant decrease in active Caspase-8 was measured in the 
cerebellum of PD-Ex group compared to PD group suggesting that endurance exercise may have 
decreased Caspase-8 activity in the cerebellum of PD animal model (Figure 3.16).   
 
Figure 3.16 : Active Caspase-8 is decreased in cerebellum of PD-Ex animal model 
A) Illustrative example of GAPDH in cerebellum of PD animal model 
B) Illustrative example of active Caspase-8 in cerebellum of PD animal model 
C) Active Caspase-8 was present in the cerebellum of C, Ex, PD and PD-Ex rats. Graph shows sedentary 
PD rats had higher amount of active Caspase-8 present in the cerebellum compared to C cerebellum 
(25% increase, p<0.01). In contrast a 27% decrease in active Caspase-8 levels was measured in the 
cerebellum of PD rats that underwent treadmill training (p<0.01) when compared to PD group. Means 
of five experiments ± SEM shown. Table of densitometry values and statistical analysis can be found in 
Figure 3.17, Appendix 3. 
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The amount of active Caspase-9 level was determined in the cerebellum of PD rats that underwent 
endurance exercise, using WB analysis. No difference in the amount of active Caspase-9 was found in 
the cerebellum of the PD group compared to the C group (p>0.05), indicating that MPTP did not 
increase Caspase-9 levels in the rat cerebellum. In contrast to the other Caspases explored, such as 
Caspases-2,-3 and-8, which showed decreased the levels of these Caspases in PD-Ex group, an increase 
in active Caspase-9 was in cerebellum of PD-Ex group (p<0.05), indicating that treadmill exercise may 
have increased Caspase-9 activity in the cerebellum of PD animal model (Figure 3.18).   
 
Figure 3.18 : Active Caspase-9 is increased exercised cerebellum of PD animal model 
A) Illustrative example of GAPDH in cerebellum of PD animal model 
B) Illustrative example of active Caspase-9 in cerebellum of PD animal model 
C) Active Caspase-9 was present in the cerebellum of C, Ex, PD and PD-Ex rats. Similar level of active 
Caspase-9 was determined in C and MPTP-treated cerebellum (100%, 111% p >0.05), suggesting that 
MPTP did not amplify Caspase-9 activity in the cerebellum. A 28% increase of active Caspase-9 was 
observed in the PD-Ex cerebellum compared to the PD group (p<0.05). Means of five experiments ± 
SEM shown. Table of densitometry values and statistical analysis can be found in Figure 3.19, Appendix 
3. 
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WB analysis was used to determine the amount of cleaved Caspase-12 present in the cerebellum of C, 
Ex, PD and PD-Ex rats. The results demonstrate elevated levels of cleaved Caspase-12 in the cerebellum 
of PD sedentary rats compared to C group (p<0.05) indicating that MPTP may have further increased 
Caspase-12 activity in the cerebellum. In contrast, a significant reduction in cleaved Caspase-12 was 
measured in the cerebellum of PD-Ex group compared to PD group (p<0.05), indicating that exercise 
may have lowered Caspase-12 activity in the cerebellum of PD animal model (Figure 3.20).    
 
Figure 3.20 :  Low levels of cleaved Caspase-12 detected  in exercised cerebellum of PD animal 
model 
A) Illustrative example of GAPDH in cerebellum of PD animal model 
B) Illustrative example of cleaved Caspase-12 in cerebellum of PD animal model 
C) Cleaved Caspase-12 was present in the cerebellum of C, Ex, PD and PD-Ex rats. A 32% increase in 
cleaved Caspase-12 was detected in cerebellum of PD animal model compared to C group (p<0.05). 
Cleaved Caspase-12 levels were decreased by 46% in cerebellum of PD-Ex group compared to PD 
group brain (p<0.01). Means of five experiments ± SEM shown. Table of densitometry values and 
statistical analysis can be found in Figure 3.21, Appendix 3. 
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The results had shown some changes in the amount of specific Caspases after six week treadmill exercise 
in cerebellum and brain cortex of PD animal model. However, the midbrain that contains the SN, may 
give a better indication of the influence of exercise on active Caspases in PD. The next aim was to 
determine the effect of exercise on Caspases in the midbrain of PD animal model. The results portray a 
significant increase in the amount of active Caspase-2 present in midbrain of PD rats (p<0.01), 
highlighting that MPTP may have triggered activation of the initiator Caspase-2, which may result in 
activation of other proteins via the Caspase cascade. In comparison, Caspase-2 was absent in the 
midbrain of PD-Ex group, indicating that endurance exercise may have completely inhibited Caspase-2 
activity in the midbrain of PD animal model (Figure 3.22).   
 
Figure 3.22 : Caspase-2 is absent in exercised midbrain of PD animal model 
A) Illustrative example of GAPDH in midbrain of PD animal model 
B) Illustrative example of active Caspase-2 in midbrain of PD animal model 
C) Active Caspase-2 was present in the midbrain of C, Ex, and PD animal model. The midbrain of C  and 
Ex group rats had similar levels of active Caspase-2. A significant increase (53% increase) in the amount 
of active Caspase-2 was found in midbrain of PD animal model compared to C group (p<0.01). Active 
Caspase-2 was absent in midbrain of PD rats that underwent treadmill exercise.  Means of five 
experiments ± SEM shown. Table of densitometry values and statistical analysis can be found in Figure 
3.23, Appendix 3. 
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WB analysis was used to determine the amount of cleaved Caspase-3 present in the midbrain of C, Ex, 
PD and PD-Ex rats. The results portray a rise in cleaved Caspase-3 levels in the midbrain of sedentary 
PD rat, compared to C group, indicating that MPTP may have promoted further activation of Caspase-3 
in the midbrain (p<0.01). A significant decrease in cleaved Caspase-3 was measured in the midbrain of 
PD-Ex group, compared to PD group, signifying that exercise may have encouraged the decrease of 
Caspase-3 activity in the midbrain (p<0.01, Figure 3.24).  
 
 
Figure 3.24: Reduced cleaved Caspase-3 Amount determined in PD-Ex rat midbrain  
A) Illustrative example of GAPDH in midbrain of PD animal model 
B) Illustrative example of cleaved Caspase-3 in midbrain of PD animal model 
C) Cleaved Caspase-3 was present in the midbrain of C, Ex, PD and PD-Ex rats. Elevated amount of 
cleaved Caspase-3 (39% increase) was observed in midbrain of PD animal model. A significant decrease 
in cleaved Caspase-3 was found in the midbrain of PD rats that underwent endurance exercise (50% 
reduction, p<0.01) when compared to midbrain of PD sedentary rats. Means of five experiments ± SEM 
shown. Table of densitometry values and statistical analysis can be found in Figure 3.25, Appendix 3. 
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WB analysis was performed to detect and measure the amount of active Caspase-8 in the midbrain of 
PD and PD-Ex animal model. Elevated levels of active Caspase-8 were detected in the midbrain of PD 
sedentary rats, indicating that MPTP may have further enhanced Caspase-8 stimulation in the midbrain 
of PD animal model (ANOVA p<0.05, T test p<0.05). In contrast, active Caspase-8 was not detected in 
the midbrain of PD rats that underwent six week treadmill training, indicating that exercise may have 
inhibited Caspase-8 activation in the midbrain (Figure 3.26).  
 
Figure 3.26 : Active Caspase-8 is absent in exercised midbrain of PD animal model  
A) Illustrative example of GAPDH in midbrain of PD animal model 
B) Illustrative example of active Caspase-8 in midbrain of PD animal model 
C) Active Caspase-8 was present in the midbrain of C, Ex, PD and PD-Ex rats. Reduced levels of active 
Caspase-8 (17% decrease) were observed in midbrain of Ex group, when compared with C group. A 
45% increase of active Caspase-8 was found in midbrain of PD animal model compared to C group 
(p<0.05). Active Caspase-8 was absent in midbrain of PD-Ex animal model. Means of five experiments 
± SEM shown. Table of densitometry values and statistical analysis can be found in Figure 3.27, 
Appendix 3. 
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The influence of endurance exercise on the amount active Caspase-9 in midbrain in PD and PD-Ex 
animal model was determined via WB analysis. Elevated levels of active Caspase-9 were detected in 
midbrain of PD sedentary rats when compared to the C group (p<0.01), indicating that MPTP further 
stimulates Caspase-9 activation in the midbrain of PD rat. Furthermore, a reduction in the amount of 
active Caspase-9 was measured in the midbrain of PD-Ex group when compared to the PD group, 
suggesting that exercise may have decreased Caspase-9 activity in the midbrain of PD animal model 
(Figure 3.28).   
 
Figure 3.28 : Reduced levels of active Caspase-9 levels in PD-Ex rat midbrain 
A) Illustrative example of GAPDH in midbrain of PD animal model 
B) Illustrative example of active Caspase-9 in midbrain of PD animal model 
C) Active Caspase-9 was present in the midbrain of C, Ex, PD and PD-Ex rats. A lower amount of active 
Caspase-9 was present in Ex group when compared to C group, indicating that exercise may have 
decreased Caspase-9 activity by 28% in rat midbrain.  High levels of active Caspase-9 (23% increase) 
were measured in the midbrain of Parkinsonian rats when compared to C group, indicating that MPTP 
amplifies Caspase-9 activity in the midbrain of PD animal model. A 47% decrease in the amount of 
active Caspase-9 was detected in midbrain of PD-Ex group when compared to PD group (p<0.05).  
Means of five experiments ± SEM shown. Table of densitometry values and statistical analysis can be 
found in Figure 3.29, Appendix 3. 
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WB analysis was used to determine the amount of cleaved Caspase-12 present in the midbrain of C, Ex, 
PD and PD-Ex rats. The results illustrated elevated levels of cleaved Caspase-12 in the midbrain of PD 
sedentary rats compared to C group (p<0.01) indicating that MPTP further increased Caspase-12 activity 
in the midbrain. In contrast, a significant reduction in cleaved Caspase-12 was measured in the midbrain 
of PD-Ex group compared to PD group (p<0.01), indicating that exercise may have lowered Caspase-12 
activity in the midbrain of PD animal model (Figure 3.30).  
 
Figure 3.30 : Endurance exercise lowered cleaved Caspase- 12 levels in rat PD midbrain 
A) Illustrative example of GAPDH in midbrain of PD animal model 
B) Illustrative example of cleaved Caspase-12 in midbrain of PD animal model 
C) Cleaved Caspase-12 was present in the midbrain of C, Ex, PD and PD-Ex rats.  A 26% reduction in 
cleaved Caspase-12 was observed in the midbrain of Ex group, when compared to C group. Elevated 
levels of cleaved Caspase-12 (62% increase, p<0.05) were found in midbrain of PD group when 
compared to C group. A significant decrease in cleaved Caspase-12 levels was found in the midbrain of 
PD rats that underwent treadmill exercise compared to sedentary PD rats (p<0.05). Means of five 
experiments ± SEM shown. Table of densitometry values and statistical analysis can be found in Figure 
3.31, Appendix 3. 
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The final region that was explored was the striatum, which is associated with PD. WB analysis was used 
to detect and measure the level of active Caspase-2 in the striatum of PD-Ex animal model (Figure 3.32). 
A significant rise in the amount of active Caspase-2 was present in striatum of PD rats that did not 
undergo treadmill exercise, suggesting that MPTP further stimulated Caspase-2 activity in PD rat 
striatum (ANOVA p<0.05, T test p<0.05). In contrast, Caspase-2 was absent in PD-Ex striatum, 
indicating that exercise may have suppressed Caspase-2 activity in the striatum in PD animal model.  
 
Figure 3.32 : Caspase-2 is absent in exercised striatum of PD animal model 
A) Illustrative example of GAPDH in striatum of PD animal model 
B) Illustrative example of active Caspase-2 in striatum of PD animal model 
C) Active Caspase-2 was present in the striatum of C, Ex and PD rats. A 31% decrease in active Caspase-2 
was detected in the striatum of rats that had done endurance exercise when compared to sedentary rats. 
Furthermore, a higher amount of active Caspase-2 was found in striatum of PD group, when compared 
to C group, indicating that MPTP amplified Caspase-2 activity in the striatum of PD animal model (42% 
increase, p<0.05). Active Caspase-2 was not detected in striatum of PD rats that had endured treadmill 
exercise Means of five experiments ± SEM shown. Table of densitometry values and statistical analysis 
can be found in Figure 3.33, Appendix 3. 
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The influence of endurance exercise on the amount cleaved Caspase-3 in striatum in PD animal model 
was determined via WB analysis. The results illustrated elevated levels of cleaved Caspase-3 in the 
striatum of PD rats that did not exercise compared to C group (p<0.01) indicating that MPTP further 
increased Caspase-3 activity in the striatum. In contrast, a significant reduction in cleaved Caspase-3 was 
measured in the striatum of PD-Ex group compared to PD group (p<0.01), indicating that exercise may 
have lowered Caspase-3 activity in the striatum of PD animal model (Figure 3.34).  
 
Figure 3.34 : Low levels of cleaved Caspase-3 found in striatum of PD-Ex animal model 
A) Illustrative example of GAPDH in striatum of PD animal model 
B) Illustrative example of cleaved Caspase-3 in striatum of PD animal model 
C) Cleaved Caspase-3 was present in the striatum of C, Ex, PD and PD-Ex rats. A 23% decrease in the 
amount of cleaved Caspase-3 was determined in the striatum of Ex group when compared to C group. 
The amount of cleaved Caspase-3 levels had increased by 18% in the striatum of PD group when 
compared to C group (p<0.05). Low levels of cleaved Caspase-3 were observed in striatum of PD rats 
that underwent six week endurance exercise (p<0.05), when compared to PD group. Means of five 
experiments ± SEM shown. Table of densitometry values and statistical analysis can be found in Figure 
3.35, Appendix 3. 
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The amount of active Caspase-8 was determined in the striatum of PD-Ex animal model. Elevated levels 
of active Caspase-8 were detected in the striatum of PD sedentary rats, indicating that MPTP increases 
Caspase-8 activation in striatum of PD animal model (ANOVA p<0.05, T test p<0.05). In contrast, 
active Caspase-8 was not detected in the striatum of PD rats that underwent six week treadmill training, 
indicating that exercise may have inhibited Caspase-8 activity in the striatum of PD animal model (Figure 
3.36).    
 
Figure 3.36 : Active Caspase-8 is absent in exercised striatum of PD animal model 
A) Illustrative example of GAPDH in striatum of PD animal model 
B) Illustrative example of active Caspase-8 in striatum of PD animal model 
C) Active Caspase-8 was present in the striatum of C, Ex and PD rats. A reduced amount of active 
Caspase-8 (23% decrease) was detected in the striatum of Ex rat group when compared to C rat group. 
A 22% rise in active Caspase-8 levels was found in striatum of non exercised PD animal model when 
compared to the C group (p<0.05). Active Caspase-8 was not detected in the striatum of exercised PD 
animal model.  Means of five experiments ± SEM shown. Table of densitometry values and statistical 
analysis can be found in Figure 3.37, Appendix 3. 
 
0 
50 
100 
150 
Treatment 
D
e
n
s
it
o
m
e
tr
ic
 
 R
a
ti
o
 (
%
) 
p = 0.03 
GAPDH 
ACTIVE CASPASE-8 
 
STRIATUM 
C EX PD PD-EX 
MPTP ( PD ) - - + + 
TRAINED ( Ex ) - + - + 
 
36 KDA 
55 KDA 
A) 
B) 
C) 
 
- 129 - 
 
WB analysis was carried out to determine the amount of active Caspase-9 levels present in the striatum 
of C, Ex, PD and PD-Ex animal model (Figure 3.38). The results showed that the amount of active 
Caspase-9 had increased in striatum of PD rats, when compared to C group, highlighting that MPTP 
may have triggered activation of the mitochondrial associated Caspase-9 protein in the striatum of PD 
animal model ( ANOVA p<0.05, T test p<0.05). Additionally, the amount of active Caspase-9 had 
significantly reduced in PD-Ex group, when compared to PD group (p<0.01), indicating that endurance 
exercise may have decreased Caspase-9 activity in the striatum of PD animal model.  
 
Figure 3.38 : Exercise decreases active Caspase-9 in the striatum of PD animal model 
A) Illustrative example of GAPDH in striatum of PD animal model 
B) Illustrative example of active Caspase-9 in striatum of PD animal model 
C) Active Caspase-9 was present in the striatum of C, Ex, PD and PD-Ex rats.  A 19% decrease in active 
Caspase-9 was found in striatum of Ex group, when compared to the C group. In contrast, an increased 
amount of active Caspase-9 was found in the striatum of sedentary PD rats when compared to the C 
group (15% increase, p<0.05). A 55% decrease in active Caspase-9 was determined in striatum of PD-Ex 
group when compared to PD group (p<0.01). Means of five experiments ± SEM shown. Table of 
densitometry values and statistical analysis can be found in Figure 3.39, Appendix 3. 
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WB analysis was used to investigate if there was an increased or decreased active Caspase-12 levels in the 
striatum of PD animal model. A significant rise in cleaved Caspase-12 was present in the striatum of PD 
group, when compared to the C group; highlighting that MPTP may have amplified further activation of 
the ER associated Caspase-12 protein in the striatum of PD animal model (ANOVA p<0.05, T test 
p<0.05). In comparison, Caspase-12 was absent in PD-Ex group, indicating that exercise may have 
inhibited Caspase-12 activity in the striatum of PD animal model (Figure 3.40).   
 
Figure 3.40 : Cleaved Caspase-12 is absent in exercised striatum of PD animal model 
A) Illustrative example of GAPDH in striatum of PD animal model 
B) Illustrative example of cleaved Caspase-12 in striatum of PD animal model 
C) Cleaved Caspase-12 was present in the striatum of C, Ex, and PD rats. The striatum of Ex group had 
lower levels of Caspase-12 (22% decrease) present, when compared to C group. Elevated levels of 
cleaved Caspase-12 (69% increase, p<0.01) were found in striatum of PD group when compared to C 
group. Cleaved Caspase-12 was not detected in striatum of PD rats that underwent treadmill exercise. 
Means of five experiments ± SEM shown. Table of densitometry values and statistical analysis can be 
found in Figure 3.41, Appendix 3. 
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The results had indicated a general decrease the level of different Caspases in different brain regions in 
PD-Ex animal model (Figure 3.2- Figure 3.6, Figure 3.10-Figure 3.16, Figure 3.20-Figure 3.38). The next 
aim was to determine the effect of exercise on the presence of calcium binding protein, CAMK-IV in 
these brain regions of PD animal model. The results demonstrated no significant difference in the 
amount of active CAMK-IV in the cerebellum of PD animal model, when compared to the control 
(p>0.05), indicating that MPTP did not substantially increase or decrease CAMK-IV activity in the 
cerebellum. A significant increase (p<0.05) in the amount of active CAMK-IV was measured in the 
cerebellum of PD-Ex group, compared to PD group  indicating that exercise may be  increasing CAMK-
IV activity in cerebellum of PD animal model (Figure 3.42).    
 
Figure 3.42 : The effect of Exercise on active CAMK-IV levels in PD rat cerebellum 
A) Illustrative example of GAPDH in cerebellum of PD animal model 
B) Illustrative example of active CAMK-IV in cerebellum of PD animal model 
C) Active CAMK-IV was present in the cerebellum of C, Ex, PD and PD-Ex rats. A 4% increase in the 
amount of active CAMK-IV was determined in the cerebellum of Ex group, when compared to C 
group. The amount of active CAMK-IV levels had decreased by 20% in the cerebellum of PD group 
when compared to C group (p>0.05). An increase active CAMK-IV was determined in PD-Ex 
cerebellum by 31 % (p<0.05), when compared to PD group. Means of five experiments ± SEM shown. 
Table of densitometry values and statistical analysis can be found in Figure 3.43, Appendix 3. 
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WB analysis was carried out to detect and measure CAMK-IV activity in the brain cortex of PD animal 
model that had undergone endurance exercise (Figure 3.44).  No significant difference in the amount of 
active CAMK-IV was measured in brain cortex of PD sedentary rats when compared to the C brain 
cortex, indicating that MPTP did not notably up regulate or down regulate CAMK-IV activity in the 
brain cortex of PD animal model. In comparison, a significant increase in active CAMK-IV was detected 
in PD-Ex group, indicating that exercise may be promoting an  increase in CAMK-IV activity in brain 
cortex of PD animal model (T test p<0.05).  
 
Figure 3.44 : Active CAMK-IV is increased exercised brain cortex of PD animal model 
A) Illustrative example of GAPDH in brain cortex of PD animal model 
B) Illustrative example of active CAMK-IV in brain cortex of PD animal model 
C) Active CAMK-IV was present in the brain cortex of C, Ex, PD and PD-Ex rats. A similar level of active 
CAMK-IV was measured in the brain cortex of Ex group and C group. The amount of active CAMK-IV 
levels had reduced by 19% in the brain cortex of PD group when compared to C group (p>0.05). High 
levels active CAMK-IV was determined in PD-Ex brain cortex (44% increase, p<0.05), when compared 
to PD group. Means of five experiments ± SEM shown. Table of densitometry values and statistical 
analysis can be found in Figure 3.45, Appendix 3. 
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WB analysis was used to determine the amount of CAMK-IV present in the midbrain of C, Ex, PD and 
PD-Ex rats (Figure 3.46). Endurance exercise, consisting of six week treadmill training had shown a 
decrease of active CAMK-IV in the midbrain of PD group, when compared to the C group(p<0.05); 
highlighting that MPTP may have discouraged further activation of CAMK-IV protein in the midbrain 
of PD animal model. In comparison, high levels of active CAMK-IV were present in PD-Ex group, 
suggesting that exercise may have promoted CAMK-IV activity in the midbrain of PD animal model 
(ANOVA p<0.05, T test p<0.05). 
 
Figure 3.46 : Treadmill exercise amplifies CAMK-IV activity in midbrain PD animal model 
A) Illustrative example of GAPDH in midbrain of PD animal model 
B) Illustrative example of active CAMK-IV in midbrain of PD animal model 
C) Active CAMK-IV was present in the midbrain of C, Ex, PD and PD-Ex rats. An increase in the amount 
of active CAMK-IV (18% increase) was found in the midbrain of Ex rat group, when compared to Ex 
rat group. CAMK-IV levels had diminished by 52% in the midbrain of PD rats when compared to C 
midbrain (p<0.01). High levels of active CAMK-IV were observed in midbrain of PD rats that 
underwent six week endurance exercise (p< 0.01) when compared to PD sedentary rats. Means of five 
experiments ± SEM shown. Table of densitometry values and statistical analysis can be found in Figure 
3.47, Appendix 3. 
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Further work was carried out to determine if endurance exercise had an increase or decrease of active 
CAMK-IV in the striatum of PD animal model (ANOVA p<0.05, T test p<0.05). The results showed a 
significant amount of active CAMK-IV had decreased in striatum of PD rats, when compared to C 
group, highlighting that MPTP may interfere with the activation of CAMK-IV protein in the striatum of 
PD animal model (p<0.01). Additionally, the amount of active CAMK-IV had significantly increased in 
PD-Ex group, when compared to PD group (p<0.01), indicating that endurance exercise may have 
increased CAMK-IV activity in the striatum of PD animal model (Figure 3.48).    
 
Figure 3.48 : Elevated Active CAMK-IV levels in exercised striatum of PD animal model 
A) Illustrative example of GAPDH in striatum of PD animal model 
B) Illustrative example of active CAMK-IV in striatum of PD animal model 
C) Active CAMK-IV was present in the striatum of C, Ex, PD and PD-Ex rats. An 11% increase in active 
CAMK-IV was determined in rat striatum of Ex group when compared to C group. The amount of 
active CAMK-IV levels had reduced by 67% in the striatum of PD group when compared to C group 
(p<0.01). High levels active CAMK-IV was determined in PD-Ex striatum (p<0.01), when compared to 
PD group. Means of five experiments ± SEM shown. Table of densitometry values and statistical 
analysis can be found in Figure 3.49, Appendix 3. 
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3.5 Discussion  
This is the first study to determine the effect of six week treadmill exercise on Caspases -1,-2,-3,-8,-9 and 
-12 in the cerebellum, brain cortex, midbrain and striatum of PD animal model. In general there was a 
decrease in Caspase activity in different brain regions of PD rats that underwent six week endurance 
exercise (Figure 3.2- Figure 3.6, Figure 3.10-Figure 3.16, Figure 3.20-Figure 3.38). 
 
A study conducted by Lin et al (2000) showed that Caspase-1 was present in low levels in untreated 
mouse mesencephalic cultures brain. WB analysis illustrated that Caspase-1 was present in the midbrain 
of mouse model. In comparison, higher levels of Caspase-3 followed by Caspase-12 were found in the 
untreated midbrain of mouse model.  In contrast, work carried out by Usha et al (2000) Caspase-1 was 
not detected in the SN of MPTP-treated mice. MPTP was administered twice at day 1, 2 and 7 prior to 
extracting DNA of the SN and nucleus caudate putamen of mice. DNA fragmentation was confirmed in 
SN and nucleus caudate putamen of MPTP mice using DNA ladder after SDS-PAGE, indicating 
apoptotic death of DCN. However, immunohistochemical studies did not detect presence of Caspase- 1 
activity in the SN of MPTP mouse model. In comparison, high levels of cleaved Caspase-3 were found 
in MPTP-treated SN, indicating that MPTP triggers activation of Caspase-3 leading to DNA 
fragmentation and death of DCN.   The results of the current study provide further support to Usha et 
al (2000) study as Caspase-1 was absent in all regions of C , Ex, PD and PD Ex animal model.  
 
In a previous study, WB analysis demonstrated an increased in Caspases-3 and -7 in with MPTP-treated 
rat cerebellum, indicating that MPTP triggered death of neurons, via apoptotic route as Caspase-3 is a 
well known apoptotic marker (Iwashita et al 2007, Shang et al 2004). Similarly, the results of the current 
study had shown an increase of Caspases-3,-8 and-12 activities in cortex and cerebellum regions that 
were treated MPTP, indicating that MPTP stimulated Caspase activation in cerebellum region of PD 
animal model (Figure 3.4-Figure 3.6, Figure 3.10, Figure 3.14-Figure 3.16 and Figure 3.20). Furthermore, 
the current study is the first to demonstrate MPTP did not significantly enhance stimulation of 
Caspases-2 and -9 in the cerebellum of PD animal model (Figure 3.12 and Figure 3.18). The reduction of 
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active and cleaved Caspases-2,-3,-8 and-12 in PD-Ex rat cerebellum and cortex, indicated that endurance 
exercise may have decreased Caspase activity in the cerebellum of PD animal model (Figure 3.2-Figure 
3.6, Figure 3.10-Figure 3.16 and Figure 3.20).   
 
Lumini-oliveira et al (2009) investigated the effect of treadmill training on skeletal muscles in male Wistar 
rats. Rats underwent endurance exercise using motor driven treadmill for one hour 5 days a week for a 
total of 14 weeks. Results showed increased activation of the mitochondria apoptosis marker Caspase-9, 
increased mitochondria PTP opening, cytochrome c, succinate, swelling of mitochondria and calcium 
accumulation in skeletal muscle homogenates of exercised rat, indicating apoptotic death of skeletal 
muscle cells were due to mitochondrial pathway. The author concluded that apoptotic death of muscle 
cells was required to improve overall muscle strength and function in rats.   
 
In the current study, an unexpected finding was determined when exploring Caspase-9 activity in the 
cerebellum of PD animal model. An increase in active Caspase-9 was determined in PD-Ex cortex and 
cerebellum, indicating that endurance exercise may have increased Caspase-9 activity in the cerebellum 
of PD animal model (Figure 3.8 and Figure 3.18). Similar to Lumini-oliveira et al (2009) research, the 
increase of Caspase-9 activation in cerebellum and cortex by endurance exercise may be associated to the 
specific role of Caspase-9 in mitochondrial pathway (Chowdhury et al 2008). Although, ROS level was 
not directly determined in this study, MPTP is known to cause a high acculturation of ROS production 
by inhibiting mitochondrial complexes, which contributes to stimulation of the apoptotic death (Shang 
et al 2004, Xu et al 2013). 
 
Lo et al (2012) found MPTP-treated rat mesencephalic cultures had increased levels of ROS, Caspase-9 
and -3 activities, when compared to untreated cultures, indicating that MPTP promotes Caspases-9 and 3 
activation in midbrain of PD animal model.  Immunohistochemical analysis revealed large inclusions and 
decrease in TH levels in MPTP rat midbrain when compared to untreated midbrain. IF and flow 
cytometry analysis showed positive staining with Annexin confirming MPTP triggered apoptotic death 
of neurons.  Previous research by Pain et al (2008) has shown increased Caspase-9 activity in the 
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midbrain and SN of MPTP-induced PD rat model. WB analysis revealed an increase and amount of 
active Caspases-9 and -3 in midbrain and SN of MPTP induced rats, suggesting MPTP triggered 
activation of Caspases-9 and-3 in midbrain and SN. IF analysis showed large lesions, loss of neurons as 
well as increased expression of Caspases-9 and -3 in MPTP-treated midbrain and SN. Moreover, a 
reduction of caspases-9 and-3 was determined in MPTP midbrain sections that had been treated with a 
JNK inhibitor TAT-JBD, indicating that MPTP promotes activation of caspases-9 and -3 through JNK 
pathway resulting in loss of midbrain and striatal neurons. Similarly to the findings of Pain et al (2008) 
and Lo et al (2012), the current study had illustrated high Caspases-9 and -3 levels as well as Caspase-12 
in the midbrain of PD animal model, indicating that MPTP had amplified Caspases-3, -9 and -12 
activation in the midbrain (Figure 3.24, Figure 3.28-Figure 3.30).  
 
WB and Colorimetric assays revealed increase of Caspase-3 activity in 6OHDA-treated rat 
mesencephalic culture, indicating Caspase-3 is actively involved in death of DCN of PD animal model. 
Furthermore, immunohistochemical analysis revealed a decrease in TH level of MPTP-treated rat 
mesencephalic culture, indicating that MPTP decreased dopamine levels in the midbrain of PD rat (Kim 
et al 2012).  In comparison to Pain et al (2008) and Kim et al (2002) research, the current study showed a 
reduction in Caspases-3, -9 and -12 were observed in midbrain of MPTP rats that had endured six week 
treadmill exercise, suggesting that exercise may have reduced activation of Caspases in the midbrain of 
PD animal model (Figure 3.24, Figure 3.28-Figure 3.30).   
 
Previous research by Hartmann et al (2001) has shown the suppression of Caspase-8 activity had 
reduced neuronal apoptotic death of MPTP-treated rat mesencephalic cultures. TUNEL, WB and 
Colorimetric assays illustrated an increase of Caspase-8 activities in MPTP-treated rat midbrain when 
compared to untreated midbrain, suggesting that an increase in Caspase-8 activation resulting in 
apoptotic death of neurons in the midbrain of PD animal model. Immunohistochemical analysis 
portrayed a decrease in TH expression, loss of neurons and presence of fibrils in MPTP rat midbrain 
(Hartmann et al 2001). In comparison, the current study demonstrated that MPTP further promoted 
activation of Caspases-2 and -8 in MPTP-treated rat midbrain (Figure 3.22 and Figure 3.26). 
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Furthermore, absence of Caspases-2 and -8 in the PD-Ex midbrain indicated that exercise may have 
suppressed Caspase-2 and -8 activities in the midbrain of PD animal model (Figue 3.22 and Figuer 3.26). 
The exact mechanism of how this could be achieved is unclear.  
 
Former work by Choi et al (2011) showed increase of nitrate, ROS and Caspase-3 activities in 6OHDA 
rat mesencephalic cultures and MPTP rat striatum, signifying that oxidative stress promotes death of 
neurons in PD animal model. Furthermore, immunohistochemical analysis showed decrease of TH 
expression and damage to striatal neurons and mesencephalic culture exposed with MPTP. In the 
current study, high levels of active and cleaved Caspases-2,-3,-8,-9 and -12 were determined in MPTP-
treated rat striatum, indicating that MPTP promoted up regulation of Caspase activity in the striatum 
(Figure 3.32-Figure 3.40). Similar to Choi et al (2011), the current study showed an increase of Caspase-3 
level in the rat striatum that had been treated with MPTP (Figure 3.34). This is the first study 
demonstrating the absence of Caspases-2,-8 and -12 in PD-Ex striatum, signifying that six week treadmill 
exercise may have suppressed Caspases-2,-8 and -12 activities in the striatum PD animal model (Figure 
3.32, Figure 3.36 and Figure 3.40).  
 
WB and IF analysis showed decrease of Caspase-8 and -3 levels in the liver of rats that had endured 
treadmill training for an hour every day for  five weeks. A decrease in mitochondrial swelling and ROS 
levels were also determined in liver homogenates of rats that had exercised compared to non exercised 
rats, indicating that exercise had positive effects (Ascensao et al 2012). Although ROS level was not 
measured in this study, treadmill exercise may have reduced accumulation of ROS, which may have 
decreased activation of Caspases in these brain regions in PD animal model. Research by Ascensao et al 
(2011) had shown that treadmill exercise decreased Caspases-3 and -9 activities and increased superoxide 
dismutase in rat heart and liver homogenates, indicating that exercise can reduce oxidative stress and loss 
of cells. Based on a similar idea by Ascensao et al (2011), in the current study endurance exercise may 
have increased levels of antioxidants, which may have reduced ROS accumulation resulting in a decrease 
in activation of Caspases in brain regions of PD animal model.  
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Collectively, the results indicated that six weeks treadmill exercise had reduced the level of specific 
Caspases in different brain regions in PD animal model (Figure 3.2-Figure 3.6, Figure 3.10-Figure 3.16, 
Figure 3.20-Figure 3.40). More specifically, exercise had greatly affected the midbrain and striatum of PD 
animal model by either significantly inhibiting or completely suppressing Caspase-2, -3, -8, -9 and -12 
activities (Figure 3.22 –Figure 3.40). However, as the original sample size (n=16) is small these findings 
must be looked at with caution. A larger sample size (n=50) would be a more realistic representation of 
these findings. In addition, knockdown of specific Caspases such as Caspase-2, -3, -8, -9 and -12 in PD-
Ex animal model would give a better representation if exercise can indeed suppress Caspases activation 
or if there is an different factor such as GDNF, BDNF is involved in suppression of Caspase activation.  
 
To develop this project further, the amount of CAMK-IV was determined in cerebellum, brain cortex, 
midbrain and striatum of C, Ex, PD and PD-Ex group (Figure 3.42-Figure 3.48). Previous work has 
shown that during exercise, calcium ions from the sacroplasma of muscle are released into the 
bloodstream, where they bind to calcium binding proteins, CAMKs. The level of calcium:CAMK-IV 
complexes formed contributes to the activation of the CAMK cascade pathway, resulting in increased 
synthesis of neurotransmitter TH which is required to release dopamine (Suntoo et al 2003). 
 
At present there is no study that specifically explores the amount of CAMK-IV in the cerebellum, brain 
cortex, midbrain and striatum of Parkinsonian rats that had undergone endurance exercise. A decrease in 
active CAMK-IV was found in MPTP rat cerebellum and brain cortex, but this reduction of active 
CAMK-IV was not significant (Figure 3.42-Figure 3.44). In contrast, a significant increase in active 
CAMK-IV was determined in PD-Ex cerebellum and brain cortex, indicating that treadmill exercise may 
have increased CAMK-IV activity in cerebellum and brain cortex of PD animal model (Figure 3.42-
Figure 3.44). Low levels of active CAMK-IV were measured in MPTP-treated midbrain and striatum, 
indicating that MPTP significantly reduced CAMK-IV activity in the midbrain and striatum of PD 
animal model (Figure 3.46-Figure 3.48). Higher levels of active CAMK-IV were determined in PD-Ex 
midbrain and striatum, indicating that treadmill exercise may have further increased CAMK-IV activity 
in the midbrain and striatum of PD animal model (Figure 3.46-Figure 3.48). 
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See et al (2001) explored the link between CAMK-IV and Caspase induced apoptosis in granule cells of 
the cerebellum of mouse model. Active CAMK-IV promoted survival of neurons and prevented cell 
death caused by potassium deprivation in granuale cells. CAMK-IV encouraged cell survival via CAMK-
IV: CREB and maintaining electrolyte homeostasis, thereby decreasing the probability of Caspase 
dependent apoptosis in potassium deprived cells. The decrease levels of Caspases in PD-Ex regions may 
be due to the participation of CAMK proteins, which inhibit Caspase activation and may promote 
neuronal survival. Additionally, treadmill exercise may have increased the amount of CAMK-IV in 
different brain regions of PD animal model, by encouraging the binding of calcium to CAMK-IV, which 
may have resulted in production and release of dopamine. This could aid to decrease the symptoms such 
as tremor, which is associated with PD pathogenesis. In addition, previous research has indicated that 
the calcium-CAMK complex suppresses the stimulation of Caspase activation, through an unknown 
mechanism (See et al 2001). 
 
 The results of the study are similar to research carried out by H.Ali (personal communication), who had 
found increased levels of CAMK II (another member of the CAMKs family) in muscles of exercised rats. 
In addition, WB analysis had shown increased levels of CAMK-II in the midbrain of PD rats that had 
underwent endurance exercise. The author concluded that CAMK-II activity is amplified by treadmill 
exercise and can protect DCN from further damage in the PD midbrain. The author had also explored 
the effect of treadmill exercise on CAMK-II in the striatum. WB analysis had shown a significant rise in 
CAMK-II in PD-Ex striatal DCN, indicating that exercise increases CAMK II activity in striatal DCN 
(H.Ali, personal communication). The findings of the current study are in parallel to H.Ali’s research. 
WB analysis revealed low levels of CAMK-IV in MPTP induced PD rat striatum, indicating that MPTP 
reduced CAMK-IV activation which may have contributed to loss of striatal neurons (Figure 3.48). 
Treadmill exercise may have increased CAMK-IV activity and may lead to protection of neurons in the 
in the midbrain and striatum of PD animal model (Figure 3.46-Figure 3.48).   
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Collectively the results indicated that MPTP increased activities of Caspases and decreased CAMK-IV 
activation in cerebellum, brain cortex, midbrain and striatum in PD animal model model (Figure 3.42-
Figure 3.48). Overall, six weeks treadmill exercise had decreased Caspase activation and increased 
CAMK-IV activation in these regions in PD model (Figure 3.50). More specifically, endurance exercise 
had significantly reduced Caspase-2, -3, -8,-9 and -12 activities, whilst increasing CAMK-IV activity in 
the rat striatum and midbrain of PD animal model model (Figure 3.22 –Figure 3.40 and Figure 3.46-
Figure 3.48). The increased activation CAMK-IV may have reduced activation of Caspases through a 
mechanism which has yet to be established. Exercise may have suppressed Caspase activity through a 
CAMK-IV route or it may have inhibited Caspase activation by inhibiting a pathway which is common 
to all Caspases, thereby preventing further loss of cells in these regions (Suntoo et al 2003, Wayman et al 
2008, See et al 2001, Reymond and Ghosh 2005).  
 
Former research (McIlwain et al 2013) has shown that Caspase activation is associated with both 
intrinsic and extrinsic pathways (Chapter 1 Section 1.3- 1.10). The absence of specific Caspases such as 
Caspase-2, -8 and -12 in PD-Ex midbrain and striatum, indicated that exercise may have the potential to 
suppress NFB and ER stress pathways (Figure 3.50). A study carried out by Mattson et al (2004) 
revealed mice, which endured regular exercise had an increased quantity of dendritic growth in cortical 
neurons and synapses present when compared to the control group. In addition, a decrease in DNA 
oxidative damage and lipid peroxidation was found. In the current study, it is possible that treadmill 
exercise may aid in reducing ROS and promote growth of dendrites and improve synaptic 
communication. The improvement of efficient synaptic communication and dopamine release could 
potentially decrease some symptoms, such as muscle rigidity and facial palsy, thereby improving muscle 
tone and coordinated movement in PD. Additionally, this current study has shown that treadmill 
exercise increased CAMK-IV level and may be involved in the process that results in release of 
dopamine from neurons (Figure 3.50).   
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Figure 3.50 : The Potential Effect of Exercise on CAMK and Activation of Caspases via 
Mechanisms of Cell Death  
 Environmental toxins, oxidative stress and inflammation are able to trigger intrinsic (mitochondrial) or 
extrinsic (NFB and ER) pathways promoting the activation of specific Caspases. Activation of 
Caspases results in apoptotic death of DCN, causing degeneration of neurons and the loss of synaptic 
communication leading to PD pathogenesis. Exercise encourages calcium binding to CAMKs which 
promote production of TH leading to synthesis of catecholamines such as dopamine. CAMKs can 
suppress Caspase activation through an unknown mechanism. Increased dopamine levels and decreased 
death of DCN can reduce some symptoms of PD such as muscle rigidity (See et al 2001, Suntoo et al 
2003, Reymond and Ghosh 2005, Ribar et al 2000, Wayman et al 2008, Akimoto et al 2003). 
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The results of this research had addressed the need to explore the Caspase family and how they are 
activated in greater detail. The results have opened up further questions as to how different Caspases are 
activated, do they all have a common stimulus or are they activated by specific events, such as, 
mitochondrial collapse, ER stress or NFB over activity. There have not been any studies which explore 
the possibilities of cross talk of Caspase specific pathways in DCN. In order to determine how exactly 
exercise may reduce or suppress Caspase activation in cells, the process of activation of Caspases needs 
to be established first. Through understanding how Caspases are activated can key proteins be identified 
and targeted to suppress Caspase mediated death and promote survival of cells. Following this, how 
exercise can effect Caspase pathways can then be discovered and at which time point exercise suppresses 
Caspase activation can be determined. Treadmill exercise may have decreased ROS level leading to a 
decrease in stimulation of Caspases and Caspase pathways which may reduce and protect death of cells 
(See et al 2001, Suntoo et al 2003, Reymond and Ghosh 2005, Ribar et al 2000, Wayman et al 2008, 
Akimoto et al 2003 Figure 3.50).  
There also exists a possibility that exercise may be suppressing upstream proteins such as PERK, Calpain 
or NFκB, or unknown proteins that trigger activation of Caspases or it may be directly targeting the 
Caspases itself. In addition, treadmill exercise may be indirectly suppressing Caspases by activating other 
proteins that effect Caspases. For example, exercise may be triggering activation of CAMK-IV and the 
activation of CAMK-IV may directly suppressed Caspase activation and not exercises itself. Exercise 
may be acting as an initiator that triggers different proteins or maybe it activates specific proteins that 
directly suppress Caspase activation which may lead to a decrease in death of DCN. Another possibility 
is that exercise triggers proteins, which stimulate other proteins that activate another generation of 
proteins leading to suppression of Caspases (Chaudhry and Ahmed 2014, See et al 2001, Suntoo et al 
2003, Reymond and Ghosh 2005, Ribar et al 2000, Wayman et al 2008).  
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Figure 3.51: Exercise may decrease activation of Caspases by effecting ER and NFB pathway  
Exercise promotes release and binding of calcium to CAMK leading to TH synthesis. Elevated TH 
increases dopamine levels in the brain that may reduce symptoms of PD (pink lines). Exercise may also 
decrease ROS levels which may lead to a reduced stimulation of pathways such as JNK, ER stress, 
NFB and p38 pathway, resulting in decreased activation of Caspases and apoptotic death of DCN (blue 
lines). The effect of ROS on the ER stress and NFB pathway alongside specific Caspases-2,-8 and -12 
will be further explored in DCN (green lines).  
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3.6 Conclusion  
At present, there are many studies that indicate that exercise is beneficial in PD treatment from a social 
aspect as well as decreasing PD symptoms such as rigidity, gait and improvement in balance (Chapter 1 
Section 1.2.5 and Section 3.1). However, there is a lack of research exploring how exactly exercise can 
provide such benefits. To date there is no research that investigates the potential pathways, which 
exercise may be influencing to provide such positive and even negative effects. The current study 
explores the effect of treadmill exercise on active Caspases, along with CAMK-IV protein in specific 
brain regions (Figure 3.2-Figure 3.48).  
 
Treadmill exercise may have had positive effects in PD animal model via presence of CAMK-IV and 
absence of various Caspases in different regions (brain cortex, cerebellum, midbrain and striatum) of the 
brain (Figure 3.2-Figure 3.48). The activation of CAMK-IV may inhibit Caspase activation in the brain 
cortex, midbrain and striatum, through exercise may help to reduce further cell death (Suntoo et al 2003 
and Figure 3.50). CAMK may also encourage increase dopamine synthesis and release alongside inducing 
communication from the preganglionic neuron to the postganglionic neuron (Suntoo et al 2003, 
Akimoto et al 2004, Redmond and Gosh 2005, Ribar et al 2000, Wayman et al 2008).  
 
The improvement of efficient synaptic communication and dopamine release may have the potential to 
decrease some symptoms (such as muscle rigidity and facial palsy) thereby improving muscle tone and 
coordinated movement in PD (Akimoto et al 2004, Suntoo et al 2003, Redmond and Gosh 2005). 
Stimulation of intrinsic (mitochondrial) or extrinsic (ER stress or NFB) pathways trigger activation of 
specific pathways (Chaudhry and Ahmed 2014, Hetz 2012, Sano and Reed 2013, Cali et al 2011, Oshitari 
et al 2008, Doyle et al 2011, Yoshida 2007, Jing et al 2012, Malhotra and Kaufman 2007, Holtz and 
O'Malley 2003). Manipulation of these pathways may inhibit Caspase activation, thereby reducing death 
of DCN (Figure 3.51).  The effect of ROS on the ER stress and NFB pathway alongside specific 
Caspases-2,-8 and -12 will be further explored in DCN in following Chapters.  
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Chapter 4 
Examining Caspase Activation using 
ReNcell VM stem cells: 
Exploring Cell Death Pathways  
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4.0 ReNVM dopaminergic cell line  
Previous work by Miljan (2007) had compared the neural stem cell lines ReNcell VM and ReNcell CX. 
ReNcell VM is derived from the ventral mesencephalon region, whilst ReNcell CX is generated from the 
cortical regions of the fourteen week old human foetus brain. Both ReNcell VM and ReNcell CX 
maintain a stable genotype and phenotype across many passages during cell culture as they are 
transduced with the oncogene myc. In addition, both cell lines have a reliable competency to 
differentiate into neuronal cells. Moreover, withdrawal of growth factors EGF and FGF promote 
differentiation to occur in both cell lines (Miljan 2007).  
 
Following differentiation, ReNcell CX cells were spread across the plate whereas differentiated ReNcell 
VM cells were grown in clusters and formed neurospheres. Furthermore, WB analysis showed ReNcell 
lines were positive for the neural stem marker nestin. In addition, WB and IF analysis illustrated that 
only differentiated ReNcell VM cells were positively stained for TH, indicating that ReNcell VM and not  
ReNcell CX  can differentiate into DCN. The formation of neurospheres after differentiation promotes 
the generation of action potentials in ReNcell VM line. Differentiated ReNcell VM had constant active 
currents that were inhibited by tetrodotoxin, indicating the presence of active sodium and potassium 
voltage channels are required to generate action potentials in these cells (Donato et al 2007).   
 
Differentiated ReNcell VM has been used to study PD pathogenesis at a cellular level (Miljan et al 2008).  
An increase in glutathione, free radicals and death of cells were observed in differentiated ReNcell VM 
that had PINK-1 gene suppressed. Electron microscopy portrayed abornmalities in the mitochondria 
and aggregation of toxic deposits in PINK-1 gene suppressed ReNcell VM, indicating mutation of 
PINK-1 promotes cell death via oxidative stress which has also been found in other PD models. 
Furthermore, research by Massachusetts (2008) had demonstrated mechanistic link of mutant PINK-1 
gene and PD onset by suppressing PINK-1 in ReNcell VM.  
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4.1 ReNVM dopaminergic cell line as PD model 
The results from the previous Chapter showed mostly decreased activation of different Caspases in 
different brain regions of PD animal model (Chapter 3 Figure 3.2- Figure 3.6, Figure 3.10-Figure 3.16, 
Figure 3.20-Figure 3.38). This finding subsequently posed further questions that needed to be answered. 
The main question arise from the results obtained from the animal model was how does treadmill 
exercise reduce activation of Caspases, is exercise directly suppressing Caspases itself or is it inhibiting 
the pathway of Caspases. Furthermore, is exercise inhibiting specific proteins, which indirectly suppress 
Caspase activation, thereby reducing death of DCN? The initial step to answer these questions was to 
examine how Caspases are activated in DCN. More specifically, the aim was to determine which pathway 
or pathways are causing Caspase activation and can these pathways encourage stimulation of each other? 
In attempt to answer these questions, the first step was to establish how Caspases are activated in DCN 
of PD model. To achieve this, the aim was to explore the pathway or pathways that trigger Caspase 
activation in DCN of PD model. Specifically; the aim was to determine the activation of Caspases in 
6OHDA induced differentiated ReNcell VM (dDCN). 6OHDA is a well known neurotoxin used in PD 
animal and cell models, which produces ROS that selectively destroys DCN and inhibits the 
mitochondrial electron chain complexes I and IV, leading to neuronal damage by producing ROS. 
6OHDA induces neurotoxicity onto the nigrostriatal dopaminergic system, thereby promoting death of 
DCN, therefore can establish a good model to study PD pathogenesis (Denault et al 2007).  
As there are many pathways such as intrinsic and extrinsic that can potentially trigger Caspase activation 
leading to death of DCN, the aim of this project was to explore the potential involvement of the ER 
stress and NFB pathways in Caspase activation of 6OHDA induced DCN. There has been extensive 
research already done on the intrinsic route, mitochondrial pathway in PD pathogenesis compared to ER 
stress and NFB (Chapter 1 Section 1.4 -1.7). The aim was to look at the impact that ER stress and 
NFB pathway has on Caspase activation and if it can result in death or protection of 6OHDA induced 
dDCN. The effect of ROS on the ER stress and NFB pathway alongside specific Caspases will be 
further explored in DCN in subsequent Chapters. 
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This research is the first to demonstrate the involvement of Caspase activation and pathways in 
differentiated ReNcell VM. In order to determine the key proteins and what pathways trigger Caspase 
activation in DCN, a PD model had to be established. Subsequently, Caspase activation and apoptotic 
death of the established PD model had to be confirmed before reaching the main aims of this study. The 
following pages demonstrate and confirm that Caspases-2,-3, and -8 follow Caspase mediated death of 
6OHDA-treated dDCN. 
 
Main Aim: To demonstrate 6OHDA triggered Caspase mediated apoptotic death of dDCN. 
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4. 2 Method : Determining Caspase Mediated Cell Death of 6OHDA Induced dDCN 
4.2.1 Differentiation of ReNcell VM to dDCN 
ReNcell VM were cultured and differentiated into DCN (dDCN) after withdrawal of EGF (GF144, 
Millipore Hertfordshire UK) and FGF (GF003, Millipore Hertfordshire UK). As recommended by the 
manufacturer (Millipore Hertfordshire UK). The medium was changed every second day and cells were 
left for 2–3 days to grow until they had reached 80% confluence. To determine if dDCN had 
successfully differentiated into dDCN, the common marker TH (MAB318, 1:1500, Millipore 
Hertfordshire UK) was used. dDCN were fixed with 4% parformaldehyde for 15 minutes and were 
washed with cold PBS. Subsequently, dDCN were treated with Triton X-100 for 10 minutes and blocked 
with 10% goat serum (S-1000, Vector Labs Peterborough UK) for 40 minutes prior to primary antibody 
Anti-TH (1:1500, Millipore Hertfordshire UK) incubation for overnight at 4oC. The following morning, 
dDCN were washed with PBS (3 × 5 minutes) and incubated with secondary antibody Donkey-Anti-
Mouse IgG FITC (1:500, Millipore Hertfordshire UK) for two hours at RT. Cells were mounted using 
vectorshield mounting medium (158127, Vector Labs Peterborough UK) and were viewed under a Meiji 
fluorescent microscope (Mazurek Warwickshire UK). Statistical analysis was carried out as described in 
Chapter 2 Section 2.5.2. A more detailed account of the reagents used can be found in Chapter 2 Section 
2.1 and Appendix 1. 
 
4.2.2 Administration and optimisation of 6OHDA in dDCN 
dDCN were exposed to different concentrations of 6OHDA (50µM, 100µM, 150µM and 200µM) at 
different time intervals (30min, 1 hour, 1 hour 30 min, 2 hour, 2 hour 30min, 3 hour, 3 hour 30 minute, 
4 hour and 5 hour). After each given exposure time, 6OHDA drug treatment was stopped by removing 
6OHDA and replacing with fresh media. Optimisation of 6OHDA was carried out using MTT assay 
(BT30006, Cambridge BioScience, Cambridge UK) and the absorbance was read at 570nm using 
microplate reader.   
 
4.2.3 Determining apoptosis in dDCN using TUNEL Assay  
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To determine if 6OHDA stimulates death of dDCN via apoptotic or necrotic pathway TUNEL assay 
(482830K, Trevigen Maryland USA) was used. Various inhibitors (salubrinal, IKK, zVADfmk, 
zVDVADfmk, zLEVDfmk and zIETDfmk) were used with 6OHDA to determine if the inhibitor 
protects 6OHDA mediated death of dDCN. A more detailed account of the reagents used can be found 
in Chapter 2 Section 2.2 and Appendix 1. 
 
4.2.3.1 Administration and inhibition of dDCN    
dDCN were cultured and treated with 100µM 6OHDA, 100µM 6OHDA and 30µM salubrinal (Santa 
Cruz Biotechnology Heidelberg Germany), 100µM 6OHDA and 70µM IKK (Merck Chemicals 
Nottingham UK), 100µM 6OHDA and 50µM zVADfmk (Promega Southampton UK), 100µM 6OHDA 
and 20µM zLEVDfmk (Merck Chemicals Nottingham UK), 100µM 6OHDA and 80µM zIETDfmk 
(Merck Chemicals Nottingham UK), 100µM 6OHDA and 20µM zVDVADfmk (Merck Chemicals 
Nottingham UK), for 2 hours after which the given treatments were replaced with fresh media. dDCN 
were left overnight in CO2 incubator at 37°C.  
 
4.2.3.2 TUNEL assay used to verify apoptotic death of dDCN  
6OHDA-treated and untreated dDCN were centrifuged at 1000 x g for 7 minutes at RT followed by 
fixing with 3.7% formaldehyde for 7 minutes. Subsequently, dDCN plate was centrifuged at 1000 x g for 
7 minutes at RT and dDCN were washed with PBS. 100% methanol was placed in dDCN for 20 
minutes at RT, after which dDCN were washed with PBS. Treated and untreated dDCN were 
centrifuged as normal and the PBS was replaced with Protein K and was left to incubate for 15 minutes. 
TACSNucleaseTM Solution was added to the untreated samples and was incubate for 40 minutes. All 
samples were washed twice with PBS followed by centrifugation. Hydrogen peroxide (30%) was added 
to treated and untreated dDCN for 4 minutes to suppress endogenous activity. Treated and untreated 
dDCN were washed with distilled water and were centrifuged at 1000 x g for 5 minutes. Labelling buffer 
was added to all dDCN for 5 minutes following centrifugation. The labelling buffer was replaced with 
labelling Reaction solution. The microplates were placed in a humidified chamber to incubate for an 
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hour at 37°C. TdT Stop Buffer was added to all samples for 5 minutes to stop labelling reaction after 
which the microplates were centrifuged and the buffer was removed. Treated and untreated dDCN were 
serial washed with PBS and then centrifuged 1000 x g for 5 minutes. Treated and untreated dDCN were 
incubated with HRP Solution for 10 minutes. PBST (0.1%) was used to wash samples followed by 
centrifuging the plate between each wash. Subsequently, TACS-Sapphire was added to treated and 
untreated dDCN and the samples were incubated for 30 minutes in the dark. The addition 0.2 N HCl 
was used to stop the reaction and the absorbances were read at 450 nm. Statistical analysis (ANOVA 
p<0.05, T test at p<0.05) was carried out to determine the apoptotic death of 6OHDA-treated dDCN.  
 
4.2.4 6OHDA triggers Caspase mediated death of dDCN 
To determine if 6OHDA provoked Caspase mediated death of dDCN, the CaspACE assay system kit 
(G7351, Promega Southampton UK) was used. In addition, IF analysis was carried out to determine if 
Caspase-2(Abcam Cambridge UK), Caspase-3(04-439, Millipore Hertfordshire UK) and Caspase-8 
(Abcam Cambridge UK) are activated expressed in 6OHDA TH positive cells.  
 
4.2.4.1 Determining the effect of zVADfmk on 6OHDA-treated dDCN 
To check if 6OHDA stimulated Caspase mediated cell death in dDCN, Caspase detection kit was used 
following manufacturer’s instructions (G7351 caspACE assay system, Promega Southampton UK). 
Briefly, cells were treated with 100µM 6OHDA in the presence of 50µM zVADfmk for 2 hours, after 
which fresh media was replaced and cells were left to recover overnight. Cells were washed in ice cold 
PBS, resuspended in lysis buffer, following freeze thaw cycles to produce lysates. The lysates were 
centrifuged and the extracts obtained were detected for Caspase activity using DEVD-pNA substrate via 
the colorimetric method, absorbance was measured at 405nm.   
 
4.2.4.2 Determining presence of Caspases-2,-3 and-8 in untreated (-6OHDA) and treated 
(+6OHDA) dDCN  
IF was used to determine if Caspases-2,-3 and-8 are expressed in untreated and treated 6OHDA dDCN 
with similar methodology as described above (Section 4.2).  The primary antibodies; cleaved Anti-
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Caspase-3 (1:1000, Millipore Hertfordshire UK), active Anti-Caspase-2 (1:2000, Abcam Cambridge UK), 
active Anti-Caspase-8 (1:2000, Abcam Cambridge UK), and Anti-TH (1:1500, Millipore Hertfordshire 
UK) were used overnight at 4C. Secondary antibodies; Donkey-Anti-Mouse IgG FITC (1:500, Millipore 
Hertfordshire UK), Goat-Anti-Rabbit IgG Rhodamine (1:2500 Millipore Hertfordshire UK) were used 
for two hours at RT prior to mounting and viewing the cell under the IF microscope. Three independent 
experiments were performed for each sample. Semi quantitative analysis (p<0.05, T test) to determine 
the change in TH positive and Caspase positive dDCN was carried out as described in Chapter 2 Section 
2.5.2. A more detailed account of the reagents used can be found in Chapter 2 Section 2.1 and Appendix 
1. 
 
4.2.4.3 Caspases-2 and-8 can stimulate Caspase-3 activation of 6OHDA dDCN 
The dDCN were treated with 100µM 6OHDA and 50µM zVADfmk as described above. Cells were 
lysed and protein concentration was measured using the BCA kit (Pierce Biotechnology, Rockford, IL, 
USA). Fifty micrograms protein was loaded on 12% gel prior to SDS PAGE, followed by 
immunoblotting on PVDF membrane. The membrane was blocked with 1% skimmed milk for an hour 
followed by incubation with primary antibodies; cleaved Anti Caspase-3 (1:1500, Abcam Cambridge UK), 
active Anti-Caspase-2 (1:2500, Abcam Cambridge UK), active Anti-Caspase-8 (1:1000, Abcam 
Cambridge UK) for overnight incubation at 4oC. The following day, membranes were incubated with 
secondary antibody, Goat-Anti-Rabbit HRP (1:1000, Millipore Hertfordshire UK) for an hour at RT. 
After washing the membranes with PBST, the ECL HRP detection system was employed as described 
by the supplier (Perbio Science Northumberland UK). Immunoblots bands were quantified with a 
densitometer scanner (GS800, Biorad Hertfordshire UK). Five independent experiments were 
performed for each treatment. Statistical analysis was carried out at p<0.05 using student T test followed 
by strip and reprobe with the house keeping gene GAPDH (Chapter 2 Section 2.3.4 and Chapter 2 
Section 2.3.5 correspondingly). A more detailed account of the reagents used can be found in Chapter 2 
Section 2.2 and Appendix 1. 
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4.3 Results 
ReNcell VM was differentiated in to dopaminergic cells by withdrawal of growth factors (EGF and FGF) 
after two weeks of culture. To ensure that the cells were dopaminergic, the dopamine marker TH was 
used. Figure 4.1 portrays positive TH staining which indicates that the cells had been successfully 
differentiated into dopaminergic cells (Chaudhry and Ahmed 2013).  
 
 
 
 
 
 
Figure 4.1: Differentiated ReNVM cells are dopaminergic  
To ensure that cells had differentiated into DCN, TH, a marker for dopaminergic neurons was used. 
The Figure shows positive staining for TH indicating successful differentiation of ReNcell VM into 
dDCN. The cell body (white arrow) and dendrites (red arrow) showed positive staining for TH.  
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The next aim was to establish a suitable PD model with the administration of the neurotoxin 6OHDA in 
dDCN. 6OHDA is transported into the nerve terminals via dopamine transporter. At the nerve 
terminals of DCN, 6OHDA produced ROS resulting in degradation of dopaminergic cells. 6OHDA was 
used to induce neurotoxicity, thereby subsequent experiments could be carry out successfully when 
exploring cell death mechanisms in dDCN. Various concentrations of 6OHDA (50µM, 100µM, 150µM 
and 200µM) were used at different time intervals (30min, 1 hour, 1 hour 30 min, 2 hour, 2 hour 30min, 3 
hour, 3 hour 30 minute, 4 hour and 5 hour) to determine the optimal conditions to create PD model for 
further neurotoxicity experiments.  Figure 4.2 illustrated a significant decrease in 6OHDA-treated 
dDCN, when compared with untreated 6OHDA dDCN (Chaudhry and Ahmed 2013).  
 
Figure 4.2: 6OHDA toxicity in dDCN 
Optimisation of 6OHDA was carried out using MTT assay.  Various concentrations of 6OHDA (50µM, 
100µM, 150µM and 200µM) were used at different time intervals (30min - 5 hour) to determine the 
optimal conditions. The Figure illustrates a significant decrease of cell survival in 6OHDA-treated 
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dDCN, when compared with untreated dDCN. dDCN exposed at 200µM  had 59.1% survival  in  cell 
number at 30 minute time interval, when compared to dDCN treated with 50µM 6OHDA (98.6%) , 
100µM 6OHDA (92.7%)  and 150µM 6OHDA (86.2%) at the same time interval. Administration of 
6OHDA at 30 minute time interval was too early to detect the effect of Caspases and there was above 
85% survival of dDCN (when using concentration 50µM, 100µM and 150µM 6OHDA). Although 
administration of 200µM 6OHDA at 30 minute time interval showed 59.1% dDCN survival the 
exposure was quick and the effect of Caspases may have been lost, therefore this concentration was not 
used. After cells had been exposed to 6OHDA for three hours at different concentrations, there was a 
significant reduction in dDCN survival (less than 30% cell number), therefore the effect of Caspases 
would be hard to determine as most cells have died. In addition, it would be hard to determine effect of 
Caspases if the number of dDCN to begin with was less than 30%, therefore this time frame and 
concentrations of 6OHDA were not used. To establish a suitable PD a balance was required to see the 
effect Caspases had on 6OHDA dDCN and to have enough dDCN to use in the experiments. The 
optimal conditions used to induce neurotoxicity in dDCN in order to establish a PD model for further 
work, was to treat dDCN with 100µM 6OHDA at 2 hour time interval. Administration of 100µM 
6OHDA at 2 hour time interval in dDCN provided the balance to see the effect of Caspases in adequate 
number of cells (57% dDCN survival). Table of values can be found in Figure 4.3, Appendix 4. 
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To determine if 6OHDA caused induction of Caspases-2, 3 and 8 in treated dDCN double IF study 
using Anti Caspases-2,-3,-8 along with Anti-TH antibody was carried out (Chaudhey and Ahmed 2013, 
Figure 4.4). The presence of Caspases in untreated dDCN was not surprising as Caspases are required 
for normal cellular function. Figure 4.4 shows positive staining of Caspases-2,-3 and -8 of 6OHDA-
treated dDCN. A loss in dendrites and formation of apoptotic bodies was observed in all 6OHDA-
treated cells, suggesting 6OHDA had destroyed dendrites of DCN. Active Caspase-2 (red stain) was 
expressed approximately half of untreated dDCN. In 6OHDA dDCN, Caspase-2 was actively expressed 
in more TH positive dDCN. Cleaved Caspase-3 (red stain) was expressed in low levels of TH positive 
dDCN. In contrast, a significant increase in the number of cleaved Caspase-3 was observed in 6OHDA-
treated dDCN. Similar findings were established when determining Caspase-8 expression in untreated 
and 6OHDA-treated dDCN. Active Caspase-8 (red stain) was present in less than half of TH positive 
dDCN (green stain).6OHDA-treated dDCN had elevated levels of active Caspase-8 present indicating 
6OHDA promotes an increased induction of Caspase-8 in dDCN. 
 
Figure 4.4 : 6OHDA triggered Caspase-2, -3 and -8 activation in dDCN  
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Active Caspase-2 (red stain) expression was found in more in half of untreated TH positive (green stain) 
dDCN.  Active Caspase-2 expression was increased in TH positive 6OHDA-treated dDCN, suggesting 
6OHDA caused activation of Caspase-2 resulting in cell death. In comparison, cleaved Caspase-3 (red 
stain) was observed in all 6OHDA-treated dDCN, but was found only in some untreated dDCN, 
indicating that 6OHDA enhanced Caspase-3 mediated cell death.  Moreover, active Caspase-8 (red stain) 
was expressed in some untreated dDCN, indicating that in normal cellular processes active Caspase-8 is 
present.  Active Caspase-8 was present in more 6OHDA-treated dDCN, compared to untreated dDCN, 
indicating that 6OHDA provokes Caspase-8 activity in dDCN.   
Positive staining for cell bodies (White Arrow) and budding of apoptotic bodies (Blue Arrow ) was 
observed in untreated (- 6OHDA) and treated (+ 6OHDA) dDCN. 
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Quantification analysis revealed that 6OHDA stimulated the increase in active Caspases-2,-3 and -8 in 
dDCN (Figure 4.5). 6OHDA had elevated the proportion of Caspase-2 in TH positive 6OHDA-treated 
dDCN, indicating an increase in Caspase-2 activity.  A significant increase in the proportion of TH cells 
that were Caspase-3 positive in treated dDCN signified that 6OHDA promoted induction of Caspase-3 
resulting in death of dDCN. An increase in the proportion of active Caspase-8 in TH positive 6OHDA-
treated dDCN, demonstrated that 6OHDA stimulates further Caspase-8 activity in dDCN.  
 
 
Figure 4.5: 6OHDA amplified expression of activated Caspases-2,-3 and-8 in dDCN 
Graph showing that the proportion of active Caspase-2 TH positive, cleaved Caspases-3 TH positive 
and activated Caspase-8 TH positive cells had significantly increased after 6OHDA treatment (p<0.05). 
Means of five experiments ± SEM shown. Table of values and statistical analysis can be found in Figure 
4.6, Appendix 4. 
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Co-localisation studies revealed the presence of Caspase-2 and -3 in the same cell in untreated and 
treated dDCN (Chaudhry and Ahmed 2013, Figure 4.7). Active Caspase-2 was present in more untreated 
dDCN, compared to cleaved Caspase-3. However, in 6OHDA-treated dDCN, more cells were stained 
positive for Caspase-3 compared to Caspase-2. 6OHDA may have triggered Caspase-2, leading to the 
activation of Caspase-3 in dDCN. In contrast, low levels of Caspase-3 and -8 were found in untreated 
dDCN. A significant increase in the number of cells that were both Caspase-3 and -8 positive increased 
in 6OHDA-treated dDCN. 6OHDA may have provoked activation of upstream Caspase-8, which 
subsequently led to activation of downstream Caspase-3 in dDCN. 
 
 
 
 
 
 
 
 
Figure 4.7 : 6OHDA triggered activation of Caspase-2, -8 and followed by Caspase-3 in dDCN  
Double IF staining signified the presence of higher expression of Caspase-2 (red stain), compared with 
Caspase-3 (green stain) in untreated dDCN. In contrast, 6OHDA-treated dDCN showed more 
Caspase-3 and less Caspase-2 expression. Untreated dDCN revealed low levels of active Caspase-8 
positive (red stain) and active Caspase-3 positive (green stain) cells. A significant rise in active Caspase-
3 and-8 expressions was determined in 6OHDA-treated dDCN. Collectively the results indicate 
6OHDA stimulates activation of Caspases-2 and -8 followed by Caspase-3 in dDCN. Positive staining 
for cell bodies (White Arrow) in untreated (- 6OHDA) and treated (+ 6OHDA) dDCN. Table of 
values and statistical analysis can be found in Figure 4.8, Appendix 4. 
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To investigate if 6OHDA could cause Caspase-mediated cell death of dDCN, a broad Caspase-inhibitor 
zVADfmk was used. zVADfmk significantly reduced level of dying cells that had been treated with 
6OHDA (p <0.05, Figure 4.9). zVADfmk irreversibly binds to the cysteine residue of Caspases, thereby 
decreasing Caspase-activation and Caspase-dependent cell death of 6OHDA dDCN. The result 
successful demonstrated 6OHDA caused cell death of dDCN and the death of cells is Caspase 
dependent, therefore it is a good model to use to study Caspases in PD.   
 
 
Figure 4.9: Determining the effect of zVADfmk in 6OHDA-treated dDCN  
Graph showing that the common Caspase inhibitor zVADfmk considerably reduced cell death by 
approximately 50% (p<0.05) of dDCN, which had been treated with 6OHDA and zVADfmk (purple 
bar), when compared to dDCN treated with 6OHDA only (green bar). Means of five experiments ± 
SEM shown. Table of values and statistical analysis can be found in Figure 4.10, Appendix 4. 
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The next aim was to identify which Caspases are stimulated by 6OHDA in dDCN.  In order to 
determine if specific Caspases can be inhibited following 6OHDA-induced toxicity in dDCN, the 
universal inhibitor, zVADfmk was used. zVADfmk significantly reduced activation of Caspase-2 (Figure 
4.11), Caspase-3 (Figure 4.13) and Caspase-8 (Figure 4.15) in 6OHDA-treated dDCN. zVADfmk 
reduced the amount of active Caspase-2 in 6OHDA-treated dDCN by 41%, when compared to dDCN 
that were treated with 6OHDA only (Figure 4.11, p<0.05). Similarly, zVADfmk decreased cleaved 
Caspase-3 and active Caspase-8 by 88% and 74% respectively compared to 6OHDA treated dDCN 
(Figure 4.13, p<0.05 and Figure 4.15, p<0.05). Collectively, the results suggested that all studied 
Caspases-2,-3 and-8 play an active role in 6OHDA-mediated death of dDCN. This supports data 
obtained from IF analysis and confirms the involvement of these Caspases in this PD model. 
 
Figure 4.11: zVADfmk decreased the amount of active Caspase-2 in 6OHDA-treated dDCN  
A) Illustrative example of GAPDH in untreated, zVADfmk, 6OHDA, zVADfmk+6OHDA treated dDCN.  
B) Illustrative example of active Caspase-2 in untreated, zVADfmk, 6OHDA, zVADfmk+6OHDA treated 
dDCN.  
C) Graph showing the common Caspase inhibitor zVADfmk significantly reduced amount of active 
Caspase-2 (41 % reduction, p<0.05) of treated 6OHDA dDCN, when compared to dDCN treated with 
6OHDA only. Means of five experiments ± SEM shown. Table of densitometry values and statistical 
analysis can be found in Figure 4.12, Appendix 4. 
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Figure 4.13: zVADfmk decreased cleaved Caspase-3 levels in 6OHDA-treated dDCN 
A) Illustrative example of GAPDH in untreated, zVADfmk, 6OHDA, zVADfmk+6OHDA treated dDCN.  
B) Illustrative example of cleaved Caspase-3 in untreated, zVADfmk, 6OHDA, zVADfmk+6OHDA 
treated dDCN.  
C) Graph showing zVADfmk significantly decreased cleaved Caspase-3 in treated dDCN (88% reduction, 
p<0.05), compared to 6OHDA-treated dDCN. Means of five experiments ± SEM shown. Table of 
densitometry values and statistical analysis can be found in Figure 4.14, Appendix 4. 
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Figure 4.15:  6OHDA stimulates increased Caspase-8 activity in dDCN 
A) Illustrative example of GAPDH in untreated, zVADfmk, 6OHDA, zVADfmk+6OHDA treated dDCN.  
B) Illustrative example of active Caspase-8 in untreated, zVADfmk, 6OHDA, zVADfmk + 6OHDA 
treated dDCN.  
C) Graph showing zVADfmk reduced active Caspase-8 in 6OHDA mediated death (74% reduction, 
p<0.05) compared to 6OHD induced dDCN. Means of five experiments ± SEM shown. Table of 
densitometry values and statistical analysis can be found in Figure 4.16, Appendix 4. 
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The results had indicated 6OHDA triggers Caspase mediated death of dDCN. The subsequent aim was 
to determine if 6OHDA caused death of dDCN by necrosis or apoptosis pathway, using TUNEL assay. 
In the damaged cell, the activation of Caspase-3 catabolises the ICAD of the ICAD-CAD complex, 
thereby releasing and activating CAD (refer to page 68-70 for further details). Active CAD splices DNA 
into fragments, which is a key trait of apoptotic death. The Tacs TdT enzyme detects the DNA 
fragments of the damaged cell. The results showed that 6OHDA significantly encouraged death of 
dDCN through apoptotic pathway (p<0.01, Figure 4.17). IF and WB analysis had shown 6OHDA 
triggered activity of Caspases-2, 3 and-8 in dDCN. To further explore this area a more interesting 
method was used. 6OHDA dDCN were treated with different types of inhibitors to gain a better 
understanding which proteins are present in the apoptotic cell death pathways. 
 
 ANOVA and T test analysis (p<0.05) revealed a significant difference the level of apoptotic death of 
6OHDA dDCN with different treated inhibitors.  Salubrinal a specific inhibitor of the PERK ER stress 
pathway had prevented 6OHDA-treated dDCN from apoptotic death. 6OHDA triggered 36% apoptotic 
death of salubrinal treated dDCN, indicating that the PERK ER stress pathway is a potential pathway 
involved in cell death (p<0.01, Figure 4.17). dDCN that were treated with 6OHDA and the specific IKK 
inhibitor that suppresses the activation of the NFκB classical pathway, had shown 65% apoptotic cell 
death (p<0.01, Figure 4.17). Previous data had shown the universal inhibitor, zVADfmk had decreased 
Caspases-2,-3 and -8 activities in 6OHDA dDCN. 6OHDA+ zVADfmk treated dDCN had 25% 
apoptotic death of dDCN, confirming that 6OHDA triggers Caspases resulting in death of dDCN via 
apoptotic rather than necrotic routes (p<0.01, Figure 4.17). 
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The results had shown Caspase-2 was active in 6OHDA dDCN. This finding was extended further using 
a Caspase-2 specific inhibitor zVDVADfmk. 6OHDA+zVDVADfmk treated dDCN shown 34% 
apoptotic cell death, confirming its involvement in apoptotic death of dDCN (p<0.01, Figure 4.17). 
Similarly, Caspase-8 specific inhibitor, zIETDfmk was used in 6OHDA-treated dDCN. 
6OHDA+zIETDfmk treated dDCN, had 61% level of apoptotic cell death, indicating that 6OHDA 
stimulates Caspase-8 activity resulting in death of dDCN via apoptosis (p<0.01, Figure 4.17). To extend 
the idea of Caspase mediated death of 6OHDA dDCN further, another potential Caspase was explored. 
zLEVDfmk is an inhibitor that can specifically inhibit Caspase-4 activity.  6OHDA+zLEVDfmk treated 
dDCN, had shown 44% apoptotic cell death, indicating that 6OHDA triggers Caspase-4 activity in 
dDCN (p<0.01, Figure 4.17).  
 
Figure 4.17: 6OHDA provokes apoptotic death of dDCN  
To determine if 6OHDA stimulated death of dDCN via apoptotic or necrotic pathway, TUNEL assay 
was used. Various inhibitors (salubrinal, IKK, zVADfmk, zVDVADfmk, zLEVDfmk and zIETDfmk) 
were used with 6OHDA, to determine if the inhibitor decreased 6OHDA mediated death of dDCN. 
6OHDA triggered death of dDCN, via apoptotic route. The graph illustrates that different inhibitors 
reduced apoptotic death of dDCN at various rates. Proportion of apoptotic dDCN was determined by 
TUNEL absorbance at 450nm. Means of three experiments ± SEM shown. Table of values and 
statistical analysis can be found in Figure 4.18, Appendix 4. 
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6OHDA triggered NFB, PERK, Caspases-2,-3,-4 and -8 activities resulting in apoptotic death of 
dDCN (Figure 4.19). The results have demonstrated 6OHDA promotes activation of Caspases-2 and -8 
leading to stimulation of Caspase-3 dDCN.  6OHDA may have stimulated a variety of pathways or these 
pathways may be interlinked resulting in apoptotic death of dDCN. Furthermore, Caspases-2,-3,-4 and -
8 may be involved in one or many of these pathways or may be activating one another resulting in 
apoptotic death of 6OHDA-treated dDCN.  
 
 
 
 
 
 
 
 
 
Figure 4.19: 6OHDA promotes apoptotic death of dDCN via different pathways 
6OHDA triggered Caspase mediated apoptotic death of dDCN. The results have indicated 6OHDA 
stimulates NFB classical pathway, PERK ER stress pathway and Caspases-2,-3,-4 and -8 that eventually 
result in apoptotic death of dDCN. The next steps are to identify if these Caspases pathways are related 
to NFB pathway or PERK ER stress pathway in 6OHDA-treated dDCN. Furthermore, the remainder 
of this study is to determine how 6OHDA triggers Caspase activity and if there is any cross talk between 
these Caspases or the different pathways that result in death of dDCN via apoptotic route.   
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4.4 Discussion  
The aim of the current study was to establish successful PD model to investigate cell death mechanisms 
using ReNcell VM that had differentiated into DCN. Figure 4.1 shows positive staining for TH 
indicating that after the withdrawal of growth factors EGF and FGF, ReNcell VM had successfully 
differentiated into DCN. This method was adopted from research by Donato et al (2007) who had used 
TH as a marker to determine if the ReNcell VM had differentiated into DCN after removal of growth 
factors. In Donatos et al (2007) research it was found that the dDCN from the ReNcell VM had grown 
in bunches which allowed them to form neurospheres and promoting the generation of action potentials. 
In addition, research by Jaegar et al (2013) further demonstrated undifferentiated ReNcell VM was 
shown to be spread across the plate with many cell bodies of round appearance and short axons and 
dendrites, whilst differentiated ReNcell VM had grown in bunch like manner, with longer dendrites and 
axons and smaller cell bodies. In the current study, dDCN had also grown in a bunch like state with 
elongation of axons, dendrites and formation of neurospheres similar to Donato et al (2007) and Jaegar 
et al (2013) research. 
 
The production of ROS has been strongly linked to PD pathogenesis, via the oxidative stress theory 
(Shih et al 2011). In order to make a suitable model to study PD, the initial step was to optimise the 
concentration of 6OHDA in dDCN. PD patients suffer from an 80% loss of DCN in the SNpc region 
of the brain. However, if this model to study PD, had 80% loss of DCN, it would be difficult to study 
cell death mechanisms as the majority of cell death had already occurred.  Therefore, an earlier time 
frame was required and a 50% loss of DCN was chosen as there would be enough cells to carry out 
experiments and determine the cell death mechanisms occurring in DCN (Figure 4.2).  
 
The current study is the first to demonstrate 6OHDA stimulates Caspase mediated death via apoptotic 
route in ReNcell VM that had been differentiated into DCN (Chaudhry and Ahmed 2013). Current 
research by Jaegar et al (2013) had demonstrated positive staining for apoptosis in differentiated ReNcell 
VM and formation of apoptotic bodies using Hoechst staining. Moreover, WB analysis showed an 
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increase in cleaved Caspase-3 and BAX activity in 6OHDA dDCN, indicating that 6OHDA stimulated 
BAX and Caspase-3 activity resulting in death of dDCN. The findings from the current study confirmed 
6OHDA triggered death of dDCN through an apoptotic rather than a necrotic route using TUNEL 
assay (Figure 4.17). TUNEL assay detected death of dDCN by measuring the amount of fragmented 
DNA caused by active Caspase-3. 6OHDA triggered Caspase-3 a well known apoptotic marker, which 
promoted the breakdown of ICAD-CAD complex via the catabolism of ICAD Venderova and Park 
2012, Chowdhury et al 2008, Chaudhry and Ahmed 2014). The release of CAD encouraged the splicing 
of DNA into fragments resulting in breakdown of the cells architecture of 6OHDA dDCN (see page 68-
72). In addition, this is the first study to demonstrate that 6OHDA triggered NFB, PERK, Caspases-2,-
4 and -8 activity resulting in death of dDCN using TUNEL assay. The results further emphasise 
6OHDA promoted death of dDCN, via apoptotic route as an increase of cleaved Caspase-3 was found 
in dDCN after exposure to 6OHDA. This finding was further highlighted in IF analysis where the 
destruction of dendrites and membrane blebbing was observed in 6OHDA-treated dDCN (Figure 4.4). 
 
Research by Li et al (2010) showed positive staining for condensed nuclei in apoptotic ReNcell CX that 
were treated with 6OHDA using Hoechst 33342. 6OHDA-treated ReNcell CX cells had shown 
apoptotic cell death using Annexin V FITC stain via IF analysis. Annexin V FITC detected 
phosphatidylserine on the outer membranes of cells indicating 6OHDA triggered apoptosis in ReNcell 
CX. Propidium iodide positive staining was found in nuclear and chromatin of apoptotic cells of 
ReNcell CX cell line. WB analysis detected a rise on Caspases-3 and-8 in 6OHDA-treated ReNcell CX, 
indicating that 6OHDA promotes Caspase mediated death of ReNcell CX cells. 
 
Although the current study used differentiated ReNcell VM then ReNcell CX, similar findings were 
determined to the above study. Comparable to Li et al (2010) research, IF and WB analysis illustrated 
6OHDA had enhanced activation Caspases-2,-3 and -8 activation in dDCN (Figuer 4.4 –Figure 4.7 and 
Figure 4.11-Figure 4.15). Furthermore, co-localization studies had shown that 6OHDA triggers 
activation of Caspases-2 and-8 followed by Caspase-3 in dDCN (Figure 4.7). In addition, the Caspase 
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inhibitor, zVADfmk substantially reduced active Caspases-2,-3 and -8 in 6OHDA-treated dDCN, 
indicated that 6OHDA amplified activation of Caspases-2,-3 and -8 in dDCN (Figure 4.9). Collectively, 
the results illustrated that a successful PD model had been established to study cell death pathways 
which result in Caspase mediated apoptotic death of 6OHDA dDCN (Chaudhry and Ahmed 2013). 
 
 
4.7 Conclusion  
Results from the previous Chapter showed presence and absence of many active Caspases in brain 
regions of PD animal model (Chapter 3 Figure 3.2- Figure 3.6, Figure 3.10-Figure 3.16, Figure 3.20-
Figure 3.38). However, as the findings of active Caspases varied from each brain region after exercise in 
PD animal model, it was difficult to determine whether exercise had directly caused the decrease of 
active Caspase or if there was another factor involved.  It had become clear that a better understanding 
of Caspases and how they are activated needed to be established. In order to determine how Caspases 
are stimulated and which routes they follow, the first step was to establish if Caspases are present in 
differentiated ReNcell VM. 6OHDA had successfully promoted Caspase mediated death of dDCN, 
establishing an accomplished PD model to study cell death mechanisms (Chaudhry and Ahmed 2013). 
IF, WB and zVADfmk confirmed 6OHDA triggered Caspase mediated apoptotic death of dDCN 
(Chaudhry and Ahmed 2013). Results from the TUNEL assay aided to give a better insight to potential 
pathways such as NFκB classical pathway, PERK ER stress pathway, Caspases-2,-3,-4 and -8 that cause 
apoptotic death of 6OHDA dDCN (Figure 4.17- Figure 4.19). The subsequent aim was to identify how 
and if these Caspases, PERK ER stress and NFB pathways are influenced by each other in 6OHDA-
treated dDCN. Furthermore, the remainder of the current study was to determine how 6OHDA triggers 
Caspase activity and if there is any cross talk between these Caspases or the different pathways that 
result in death of dDCN via apoptotic route.  The following Chapter explored the potential role of 
NFB classical pathway and its involvement with specific Caspases such as Caspases-2,-4 and -8 in 
6OHDA dDCN.  
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6OHDA triggers Caspase mediated 
death of dDCN via NFB pathway: A 
tale of Two Caspases 
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5.0 NFB pathway in Caspase activation and PD pathogenesis  
The role of NFB in cells is controversial as activation of NFB can promote or prevent death of DCN 
(Ghosh et al 2007, Yamamoto and Gaynor 2001, Cassarino et al 2000, Hunot et al 1997, Gao et al 2002, 
Flood et al 2007, Zhang et al 2012, DeErausquin et al 2003, Henn et al 2007). Research by Asanuma et al 
(2004) found elevated levels NFB and cytokines in striatum and cerebrospinal fluid of PD patients. In 
addition, an increase in ferrous ions, alongside a decrease in glutathione oxidase was found in SN and 
striatum of PD patients. Collectively the author concluded microglial activation and release of ROS such 
as hydrogen peroxide promotes motivation of NFB, promoting release of cytokines and activation of 
pro apoptotic proteins, such as Caspases that result in death of DCN. In contrast,  work by Cassarino et 
al (2000) had shown that increased translocation of NFB in MPTP-treated human SH-SY5Y 
neuroblastoma cells had increased expression of superoxide dismutase which promoted survival rather 
than death of DCN. Furthermore, PC12 cells that had been transfected with p65 and p50 units of NFB 
had greater resistance to apoptotic death caused by auto oxide dopamine when compared to PC12 cells 
that had not been transfected, demonstrating that NFB has a dual role as it can protect and promote 
DCN from death (Cassarino et al 2000).  
 
Research by Li et al (2008) showed that an increase amount of translocated p65 NFB was found in 
SNpc region of 6OHDA-treated rat via IF analysis. TUNEL staining had confirmed that 6OHDA had 
triggered an apoptotic pathway, leading to death of DCN in SN in PD animal model. Bilobalide reduced 
death of DCN in SN of 6OHDA-treated rats when compared to control (6OHDA induced brain that 
had no bilobalide). In addition, bilobalide decreased the level of translocated p65 NFB in SN that was 
caused by 6OHDA treatment, suggesting that 6OHDA triggers NFB activation resulting in apoptotic 
death of DCN in the SN of PD animal model.  In addition, bilobalide has the ability to prevent further 
apoptotic death of DCN in the SN of PD model by inhibiting the activation of NFB (Li et al 2008).  
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An increase in NFB and Caspase-3 activity was observed in cultured PC12 cells, when exposed to high 
ROS levels and dopamine metabolites. Translocation of p65 and p50 NFB proteins was also observed 
after dopamine treatment, indicating that NFB aids to promote Caspase mediated apoptotic death of 
neurons in the SN of PD patients (Jia and Misra 2007, Tanaka et al 2001). Previous work by Asanuma et 
al (2004) suggested that activated microglia and hydrogen peroxide stimulates NFB, allowing release of 
cytokines and activation of pro apoptotic proteins such as Caspases. Elevated levels of NFB and 
cytokines were found in striatum and cerebrospinal fluid of PD patients.  
 
Furthermore, WB analysis revealed elevated BAX, p53, Caspase-3, cytochrome c, p65 NFκB levels in 
murine stem cells that had been exposed to L-DOPA. Flow cytometry , Annexin staining and cell 
viability assays revealed apoptotic death of cells that had been exposed to L-DOPA at 12 and 24 hours, 
indicating that L-DOPA is causing death of cells, through activation of Caspase-3 in NFκB and 
mitochondrial mediated apoptotic cell death. A significant decrease in Caspase-3, cytochrome c, BAX 
and p65 NFκB levels were measured in cells that had been treated with L-DOPA and pergolide. 
Pergolide had partially suppressed apoptotic cell death from occurring by inhibiting L-DOPA toxicity 
(Liu et al 2004).  
 
Previous research has shown a link between the Caspase activation and NFκB pathway. WB analysis, IF 
and luciferase activity showed increased levels of active Caspases-7,-8, -10 and p65 NFκB levels in 
transfected cells extracts.  In addition, there were no significant changes in Caspases-1, -2 and -9 levels, 
suggesting that NFκB had encouraged activation of Caspases-7, -8 and -10 in cells (Chaudhary et al 
2000). 
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5.1 Determining the relevance of NFB pathway in 6OHDA-treated dDCN  
Results from the previous Chapter indicated that 6OHDA triggered Caspase mediated apoptotic death 
of dDCN (Chapter 4 Figure 4.4-Figure 4.19). Furthermore, 6OHDA stimulated activation of Caspases-
2,-3 and -8 in dDCN, but how these Caspases are stimulated had not yet been established (Chapter 
Figure 4.4). The remainder of this project was to identify, which specific pathways were stimulating 
Caspase activation in 6OHDA-treated dDCN. More specifically, the aim was to determine if 6OHDA 
triggered one main pathway or several pathways were involved and if any of these pathways overlapped, 
or encouraged further activation of each other, leading to activation of Caspases, which resulted in 
apoptotic death of dDCN.  
 
The findings from Chapter 4 suggested NFκB pathway is involved in death of 6OHDA-treated dDCN 
(Figure 4.17-Figure 4.19). The initial aim of this Chapter was to confirm 6OHDA triggers NFB 
pathway in dDCN and if NFκB classical pathway is the main route that results in apoptotic death of 
dDCN. Another aim was to determine if suppression of NFκB classical pathway using IKK can reduce 
death and increase survival of 6OHDA-treated dDCN.  
 
Previous research has already suggested a link between NFB and Caspases-2,-3 and 8 activation in 
DCN (Chapter 1 Section 1.5.4). The aim of the current study was to identify specific Caspases that 
trigger or are activated by NFκB classical pathway in 6OHDA dDCN. To date there have not been any 
studies that have looked at these specific Caspases, along with NFB in differentiated ReNcell VM stem 
cell line. This study focuses on the role of Caspases-2,-4,-8, in relation to NFB classical pathway in 
6OHDA-treated dDCN, using specific inhibitors IKK, zLEVDfmk, zIETDfmk and zVDVADfmk. 
 
Main Aim:  To determine if 6OHDA triggered Caspase activation through NFB mediated apoptotic 
death of dDCN.  
 
 
 
- 175 - 
 
5.2 Method : The involvement of NFB classical pathway in 6OHDA mediated death 
of dDCN  
5.2.1 Determining presence of NFκB in untreated and treated 6OHDA using IF analysis  
IF was used to establish if cleaved NFB (MAB3026 Millipore Hertfordshire UK) is present in TH 
positive dDCN after exposure to 100µM 6OHDA. dDCN were grown and exposed to 100µM 6OHDA 
for 2 hours, after which fresh media was replaced and cells were left to recover overnight. Cells were 
fixed with 4% parformaldehyde for 15 minutes and were washed with cold PBS. Subsequently, cells were 
treated with Triton X (10 minutes) and blocked with 10% goat serum for 40 minutes prior to primary 
antibody  (Anti-TH 1:1500, Millipore Hertfordshire UK) and cleaved Anti-NFB -( 1:1500, Millipore 
Hertfordshire UK ) incubation, overnight at 4oC and secondary antibody ( Sheep Anti-Rabbit IgG FITC 
1:800, Millipore Hertfordshire,  UK) ( Sheep-Anti-Mouse IgG Rhodamine, 1:300, Millipore 
Hertfordshire UK) incubation for two hours at RT. Cells were mounted using vectorshield mounting 
medium and were viewed under a Meiji fluorescent microscope.  
Furthermore, Co-localisation studies were performed to determine if NFB and Caspases were present 
in the same cell by using  primary antibodies Anti-NFB (1:1500, Millipore Hertfordshire UK), cleaved 
Anti-Caspase-3 (1:1000, Millipore Hertfordshire UK), active Anti-Caspase-2 (1:2000, Abcam Cambridge 
UK), active Anti-Caspase-8 (1:2000, Abcam Cambridge UK), and secondary antibodies, Sheep-Anti-
Mouse IgG FITC (1:2000 Millipore Hertfordshire UK), Goat-Anti-Rabbit IgG Rhodamine (1:2500, 
Millipore Hertfordshire UK). The expression of active Caspases-2,-4,-8 and NFB were determined in 
cells that were treated with 6OHDA + IKK dDCN. dDCN and 6OHDA dDCN were treated with 
either 70 µM IKK and with specific Caspase inhibitors such as 80µM zIETDfmk, 20µM zVDVADfmk 
and 20µM zLEVDfmk as described in Section 2.5.3 and stained for IF. A more detailed account of the 
reagents used can be found in Chapter 2 Section 2.1 Appendix 1. 
  
5.2.2 Detecting NFκB amount in untreated and 6OHDA-treated dDCN using WB analysis   
dDCN were grown and exposed to 100µM 6OHDA in dDCN, after which fresh media was replaced 
and cells were left to recover overnight. Cells were lysed and protein concentration was measured using 
the BCA kit. Fifty micrograms protein was loaded on 12% gel prior to SDS PAGE, followed by 
immunoblotting on PVDF membrane. The membrane was blocked with 1% skimmed milk for an hour 
followed by incubation with primary antibody, cleaved Anti-NFB (1:5000, Millipore, Hertfordshire, UK) 
 
- 176 - 
 
for overnight at 4oC. The membranes were washed with PBST and incubated with Donkey-Anti-Mouse 
HRP (1:6000, Millipore, Hertfordshire, UK) for an hour at RT. After washing the membranes with 
PBST, antibody binding was detected using ECL and immunoblots bands were quantified with a 
densitometer scanner (GS800, Biorad). Statistical analysis was carried out at p<0.05 using student T test 
followed by strip and reprobe with the house keeping gene GAPDH (Chapter 2 Section 2.3.4 and 
Chapter 2 Section 2.3.5 correspondingly). Five independent experiments were performed for each 
treatment.  
Furthermore, cells were treated with 100µM 6OHDA and 70µM IKK as described below (Section 5.2.3). 
Primary antibodies, cleaved Anti-NFB (1:5000, Millipore Hertfordshire, UK), active Anti-Caspase-2 
(1:2500, Millipore Hertfordshire UK), active Anti-Caspase-4 (1:4000, Abcam Cambridge UK), active 
Anti-Caspase-8 (1:1000, Millipore Hertfordshire, UK) along with secondary antibodies Donkey-Anti-
Mouse HRP (1:6000, Millipore Hertfordshire UK), Goat-Anti-Rabbit HRP (1:1000, Millipore 
Hertfordshire UK) were used to detect the presence, absence and level of protein in untreated and 
6OHDA-treated dDCN. Statistical analysis was carried out as described in Chapter 2 Section 2.3.4. A 
more detailed account of the reagents used can be found in Chapter 2 Section 2.1 - Section 2.2 and 
Appendix 1. 
 
5.2.3 Measuring NFκB Caspases-2,-3 and -8 activities in 6OHDA-treated dDCN  
Optimal conditions for the IKK treatment (70µM for 2 hours exposure) were determined by treating 
100µM 6OHDA dDCN with different IKK concentrations (10µM - 120µM) and measuring cell survival 
using MTT assay (BT30006, Cambridge Bioscience, UK). For further analysis in determining if 
Caspases-2,-4, and -8 are active in NFB classical pathway in untreated and treated dDCN, the IKK 
inhibitor was used. dDCN and 6OHDA dDCN were treated with either or both 70µM IKK or Caspase 
inhibitors such as Caspase-2 inhibitor (20µM zVDVADfmk), Caspase-4 inhibitor (20µM zLEVDfmk), 
Caspase-8 inhibitor (80µM zIETDfmk)for 2 hours, prior to measuring cell survival using  MTT assay 
and statistical analysis as described in Chapter 2 Section 2.5.4. A more detailed account of the reagents 
used can be found in Chapter 2 Section 2.2 and Appendix 1. 
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5.3 Results  
 
The aim was to determine if 6OHDA triggers death of dDCN via NFB pathway. Double IF analysis 
was done to determine if NFB was actively present in untreated and 6OHDA-treated dDCN. Cleaved 
NFB was present in untreated TH positive dDCN, indicating that NFB is active normal cellular 
processes (Figure 5.1). The presence of cleaved NFB in untreated DCN is not surprising as NFB is a 
diverse transcription factor, which is required for many other cellular functions. Administration of 
100µM 6OHDA in cells, led to the destruction of dendrites in TH positive dDCN. The presence of p65 
subunit of NFB in majority TH positive treated dDCN indicated that 6OHDA enhanced further 
activation of NFB in TH positive dDCN.  
 
 
 
Figure 5.1: Presence of NFB in untreated and 6OHDA-treated dDCN 
Figure shows positive staining for TH (green) for untreated and treated dDCN, indicating that cells are 
dopaminergic.  Positive staining for cleaved p65 subunit NFB (red) was found in untreated and treated 
dDCN. Untreated dDCN had lower proportion of cleaved NFB in TH positive cells. However, in 
6OHDA-treated dDCN there was an increase in the number of cleaved NFB present in TH positive 
cells, indicating that 6OHDA promoted further NFB activity. The cell body (white arrow) showed 
positive staining in untreated (- 6OHDA) and treated (+ 6OHDA) dDCN. 
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Quantitative analysis portrayed a difference in the number of p65 NFκB cells expressed in TH positive 
untreated and 6OHDA-treated and untreated dDCN. P65 NFB was expressed in 54%  of TH positive 
dDCN, indicating that NFB is active in normal cellular processes. 6OHDA significantly increased the 
proportion of cleaved NFB in dDCN, illustrating 6OHDA triggers further activation of NFκB in 
dDCN (p<0.05, Figure 5.2). 
 
 
Figure 5.2 6OHDA amplifies NFκB activity in dDCN  
Graph illustrating the proportion of p65 NFκB expressed in TH positive untreated and treated dDCN. 
p65 NFκB was expressed in approximately 54% of TH positive untreated dDCN. However, more cells 
expressed p65 NFκB after exposure to 6OHDA, indicating that 6OHDA further enhances NFκB 
activity in dDCN. Means of three experiments ± SEM shown. Table of values and statistical analysis can 
be found in Figure 5.3, Appendix 5. 
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To quantify the amount of NFB present in 6OHDA-treated and untreated dDCN, WB analysis was 
performed. Cleaved NFB was present in 6OHDA untreated dDCN, further confirming that NFB is 
actively present in DCN because it may be transcribing genes that are needed for other cellular processes. 
Furthermore, WB analysis showed a substantial increase in the amount of cleaved NFB present in 
6OHDA-treated dDCN compared to untreated dDCN(p<0.05), indicating that 6OHDA amplified 
NFB activation in more than half of dDCN (Figure 5.4).  
 
Figure 5.4: 6OHDA provokes further activation NFB in dDCN 
A) Illustrative example of cleaved GAPDH in untreated and 6OHDA treated dDCN.  
B) Illustrative example of cleaved NFB in untreated and 6OHDA treated dDCN.  
C) Graph showing the amount of cleaved NFB, which is present in 6OHDA untreated and treated 
dDCN. A significant increase in cleaved NFB levels was found in dDCN that were treated with 
6OHDA. The blue bar represents dDCN that were not treated with 6OHDA. The pink bar symbolises 
dDCN that were treated with 100µM 6OHDA. Means of five experiments ± SEM shown. Table of 
densitometry values and statistical analysis can be found in Figure 5.5, Appendix 5. 
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Co localisation studies were carried out to determine if specific Caspases, along with NFB, were 
present in the same untreated and 6OHDA-treated dDCN. Active Caspase-2 and cleaved NFB were 
present in many of the same untreated dDCN. However, the amount of active Caspase-2 present in 
NFκB positive dDCN substantially increased after 6OHDA treatment. Fewer untreated cells were 
Caspase-3 positive than were p65 NFκB positive, whereas there were many cells positive for Caspase-3 
after 6OHDA treatment. Likewise, active Caspase-8 positive cells were more frequent in NFκB positive 
6OHDA dDCN than in untreated p65 NFκB positive dDCN. 6OHDA triggered a further increase in 
Caspase-2,-3 and -8 and NFB activity in the same cell location of dDCN (Figure 5.6). 
 
Figure 5.6: Presence of active Caspases-2,-3 and-8 in NFB positive untreated and 6OHDA-
treated dDCN 
Figure shows positive staining for NFB (green) and positive staining for Caspases-2,-3 and -8 (red) in 
untreated and treated 6OHDA dDCN. Caspase-2 was located in many p65 NFB positive untreated 
dDCN. A higher expression of cleaved Caspase-3 was observed in p65 NFκB positive 6OHDA treated 
dDCN when compared to untreated dDCN. Caspase-8 was found in low levels in untreated dDCN, but 
an increase of Caspase-8 was determined in p65 NFκB positive 6OHDA treated dDCN. Positive 
staining for cell bodies (White Arrow) in untreated (-6OHDA) and treated (+ 6OHDA) dDCN. 
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Quantitative analysis revealed a positive correlation between Caspase-2,-3,-8 and NFB in treated dDCN. 
ANOVA and T test analysis revealed statistical difference in the proportion of p65 positive cells that 
express active Caspases in dDCN before and after exposure to 6OHDA (Figure 5.7).  The graph 
portrayed 20-45% of untreated p65 positive cells expressed these Caspases-2, -3 and -8 in dDCN (45%, 
31% and 34% respectively).. However, after 6OHDA treatment 50-100% of p65 positive cells expressed 
Caspases-2,-3 and -8 (p<0.05).Collectively the results shown a positive indication that Caspases-2,-3 and 
-8 are involved in NFB mediated death of 6OHDA dDCN.  
 
Figure 5.7: 6OHDA amplified active Caspases-2,-3 and -8 expression in NFκB positive dDCN 
Graph showing the proportion of p65 NFκB positive cells that expressed active Caspases-2,-3 and-8 in 
untreated and 6OHDA-treated dDCN. The proportion of active Caspases-2,-3 and-8 was expressed in 
less than half of p65 positive untreated dDCN. There was a significantly increased proportion of active 
Caspases-2,-3 and-8 expressed in more than half of p65 NFB positive cells after 6OHDA treatment. 
6OHDA increased induction of cleaved NFB in dDCN, suggesting involvement of NFB pathway in 
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death of dDCN.. Means of three experiments ± SEM shown. Table of values and statistical analysis can 
be found in Figure 5.8, Appendix 5. 
An IKK inhibitor that specifically suppresses the NFB classical pathway was used in dDCN that had 
been treated with 6OHDA. This was carried out to determine if 6OHDA triggered NFB classical 
pathway in dDCN. Different concentrations of IKK inhibitor was used in dDCN that had been treated 
with 6OHDA dDCN. IKK had prevented the classical pathway of NFB in 6OHDA-treated dDCN, 
demonstrating that 6OHDA stimulates NFB classical pathway. Prevention of NFB classical pathway 
significantly promoted more survival of 6OHDA-treated dDCN (p<0.05). Even at a high concentration, 
IKK did not completely inhibit death of all 6OHDA-treated dDCN, indicating that 6OHDA triggers 
another route or many other routes that result in apoptotic death of dDCN, as death of dDCN was still 
occurring (Figure 5.9).  
 
Figure 5.9: IKK can prevent death of 6OHDA-treated dDCN 
Determining if further survival of 6OHDA-treated dDCN can occur by increasing the concentration of 
inhibitor IKK. A rapid increase in the amount of cells survived in 6OHDA-treated dDCN, was found 
when 6OHDA dDCN were treated with 70µM IKK, indicating that the NFB classical pathway is 
involved in death of 6OHDA dDCN. The increase in IKK inhibitor dose from 80µM IKK to 120µM 
IKK did not provide further cell survival of 6OHDA dDCN, indicating other routes are causing death 
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of dDCN. Means of three experiments ± SEM shown. Table of values and statistical analysis can be 
found in Figure 5.10, Appendix 5. 
To confirm that 6OHDA triggers additional pathways other then NFB classical pathway which results 
in death of dDCN, two inhibitors were used. A universal Caspase inhibitor zVADfmk and a specific 
NFB inhibitor IKK were used to determine if death of 6OHDA-treated cells is caused by one Caspase 
pathway (NFB pathway) or if other pathways are also contributing to the death of dDCN. IKK 
significantly suppressed death of 6OHDA-treated dDCN. However, zVADfmk significantly further 
prevented death of 6OHDA-treated dDCN. The increase in cell survival was found when zVADfmk 
was used additionally to IKK, suggesting that two different cell death pathways are activating and 
causing apoptotic cell death of dDCN. This indicates that although NFB classical pathway is important 
in apoptotic death of dDCN, there are other Caspase related pathways that are also contributing to death 
of 6OHDA-treated dDCN (Figure 5.11).   
 
 
 
Figure 5.11: zVADfmk and IKK decreased death of 6OHDA-treated dDCN 
6OHDA dDCN that were treated with zVADfmk and IKK had more survival of cells (73% cell survival) 
by inhibiting NFκB and Caspase mediated death. Proportion of cells surviving was determined by MTT 
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absorbance at 570nm. Means of three experiments ± SEM shown. Table of values and statistical analysis 
can be found in Figure 5.3, Appendix 5.12. 
The classical, alternative and atypical pathway stimulate NFB activation. To further confirm that 
6OHDA triggers the activation of NFB classical pathway and not the NFB alternative or NFB 
atypical pathway in treated dDCN, the NFB classical pathway inhibitor, IKK was used. IKK inhibitor 
was to determine if complete suppression of NFB could be achieved by inhibiting the classical pathway 
in 6OHDA dDCN.  IKK inhibited activation of NFB by suppressing the NFB classical pathway in 
6OHDA untreated and treated dDCN (Figure 5.13). 
 
Figure 5.13: The effect of IKK on cleaved NFB in untreated and 6OHDA-treated dDCN 
A) Illustrative example of GAPDH in untreated, IKK, 6OHDA, IKK + 6OHDA treated dDCN.  
B) Illustrative example of cleaved NFB in untreated, IKK, 6OHDA, IKK + 6OHDA treated dDCN.  
C) Quantitatively, a significant increase in cleaved NFB was detected in 6OHDA-treated dDCN compared 
to untreated dDCN (p<0.01). The absence of cleaved NFB was observed in IKK treated, 
6OHDA+IKK treated dDCN; suggest that NFB classical pathway is actively involved in death of 
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dDCN. Means of three experiments ± SEM shown. Table of densitometry values and statistical analysis 
can be found in Figure 5.3, Appendix 5.14 
 
Results from previous Chapter had shown that Caspase-8 is active in 6OHDA-treated dDCN. In 
addition, results from double IF analysis had shown a strong positive correlation in active Caspase-8 and 
NFB positive dDCN. To determine the importance of Caspase-8 activation in NFκB mediated cell 
death in 6OHDA dDCN, cells were treated with specific Caspase-8 inhibitor zIETDfmk and IKK 
inhibitor. The results demonstrated that 6OHDA dDCN that were treated with zIETDfmk, IKK or 
both IKK and zIETDfmk had similar levels of cell survival, suggesting 6OHDA triggered NFκB and 
Caspase-8 activation via the same pathway in dDCN (Figure 5.15).   
 
Figure 5.15: Determining Caspase-8 activity in 6OHDA-treated dDCN 
zIETDfmk inhibited  Caspase-8 activity and  promoted 63% survival of 6OHDA-treated dDCN. IKK 
promoted 61% survival of 6OHDA-treated dDCN by suppressing NFB classical pathway. The 
combination of zIETDfmk and IKK promoted similar survival of (64% cell survival) of 6OHDA-
treated dDCN, indicating no additional benefit of targeting both Caspase-8 and NFB. Proportion of 
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cells surviving was determined by MTT absorbance at 570nm. Means of three experiments ± SEM 
shown. Table of values and statistical analysis can be found Figure 5.3, Appendix 5.16 
Further analysis was carried out to determine if combining IKK and zIETDfmk inhibitors can promote 
more survival of 6OHDA-treated dDCN can be achieved, then just using one inhibitor. The 
combination of IKK and zIETDfmk inhibitor had no additional benefit to further increase survival of 
6OHDA-treated dDCN, indicated that Caspase-8 and NFB are following the same NFB classical 
pathway (p>0.05, Figure 5.17).  
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Figure 5.17: IKK suppressed Caspase-8 activity in 6OHDA-treated dDCN 
There was no further cell survival of 6OHDA dDCN, was determined when zIETDfmk was added with 
IKK (p>0.05, comparison 6), indicating Caspase-8 and NFB are both following the NFB classical 
pathway. Similarly there was no additional benefit in survival of 6OHDA dDCN when IKK was added 
to zIETDfmk (p>0.05 comparison 5), indicating that the IKK is targeting both Caspase-8 and NFκB 
activity in dDCN. There was no additional benefit of more cell survival when Caspase-8 inhibitor and 
NFB inhibitor were combined, signifying there is one pathway that was contributing to death of 
6OHDA dDCN. Furthermore, only the IKK inhibitor was required to be used to suppress the same 
pathway so survival of 6OHDA dDCN could be achieved. Proportion of cells surviving was determined 
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by MTT absorbance at 570nm. Means of three experiments ± SEM shown. Table of values and 
statistical analysis can be found in Figure 5.3, Appendix 5.16 
 
Co-localisation studies were carried out to investigate if suppression of Caspase-8 activity can inhibit 
NFB activation or vice versa in dDCN. Caspase-8 was found active in only in untreated and 6OHDA-
treated dDCN (Figure 5.18). Active Caspase-8 was present in a greater proportion of 6OHDA-treated 
dDCN, indicating that 6OHDA triggers Caspase-8 in dDCN. Furthermore, active Caspase-8 was absent 
in IKK treated, zIETDfmk treated, 6OHDA+IKK treated, 6OHDA+ zIETDfmk treated, 
6OHDA+IKK +zIETDfmk treated dDCN. However, NFB was present in 6OHDA+zIETDfmk 
treated dDCN, demonstrating that inhibiting Caspase-8 activation using zIETDfmk inhibitor did not 
suppress NFB classical pathway in dDCN. This indicated that activation of Caspase-8 is dependent 
upon stimulation of NFB resulting in death of dDCN.  
 
 
 
Figure 5.18: The effect of IKK on active Caspase-8 expressed in NFB positive untreated and 
6OHDA-treated dDCN 
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NFB was present in untreated and 6OHDA-treated dDCN (green). There were more NFB positive 
cells in 6OHDA-treated dDCN, when compared to untreated (-6OHDA) dDCN, suggesting 6OHDA 
further enhances translocation of NFκB resulting in death of dDCN, via NFB classical route. Active 
Caspase-8 was present in untreated and 6OHDA-treated dDCN (red). There were more active Caspase-
8 positive cells in 6OHDA-treated dDCN, when compared to untreated (- 6OHDA) dDCN, signifying 
that 6OHDA provokes up regulation of Caspase-8 activity in dDCN.  Furthermore, active Caspase-8 
was present in the same NFB positive cells which had been exposed to 6OHDA, suggesting that 
NFB and Caspase-8 interact with one another leading to death of dDCN.   
NFB was absent in IKK treated, 6OHDA+IKK treated dDCN, confirming that 6OHDA triggers 
NFB activation via NFκB classical pathway and suppression of NFB classical pathway can inhibit 
NFB mediated death of dDCN. Similarly, active Caspase-8 was not detected in IKK treated, 
6OHDA+IKK treated dDCN. This indicates that inhibiting the NFB pathway can suppress Caspase-8 
activity in dDCN. Stimulation of Caspase-8 is dependent on activation of NFB classical pathway in 
dDCN.  
NFB was present in zIETDfmk treated, 6OHDA+ zIETDfmk treated dDCN, suggesting that 
suppression of Caspase-8 activity does not influence NFB activation and NFκB activation is 
independent of Caspase-8 stimulation in dDCN. In contrast, active Caspase-8 was absent in zIETDfmk 
treated, 6OHDA+zIETDfmk treated dDCN, signifying that zIETDfmk had competitively inhibited 
Caspase-8 activity in dDCN. NFB was absent in IKK+zIETDfmk treated, 
6OHDA+IKK+zIETDfmk treated dDCN. Caspase-8 was not found in IKK+zIETDfmk treated,  
6OHDA+ IKK+ zIETDfmk treated dDCN. IKK had suppressed both NFB and Caspase-8 activity in 
untreated and 6OHDA-treated dDCN. Caspase-8 activation can be suppressed by directly inhibiting 
Caspase-8 or via inhibiting NFB classical pathway in untreated and 6OHDA-treated dDCN. Positive 
staining for cell bodies (White Arrow) in untreated (- 6OHDA) and treated (+ 6OHDA) dDCN. Table 
of values and statistical analysis can be found in Figure 5.19, Appendix 5. 
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WB analysis was carried out to confirm that IKK inhibitor can completely suppress activation of 
Caspase-8 in 6OHDA-treated dDCN. Active Caspase-8 was found in untreated and 6OHDA-treated 
dDCN. A higher amount of active Caspase-8 was detected in 6OHDA-treated dDCN, suggesting 
6OHDA triggered further activation of Caspase-8 in dDCN. Active Caspase-8 was not detected in IKK 
treated, 6OHDA+IKK treated dDCN, suggesting inhibiting NFB classical pathway can also inhibit 
activation of Caspase-8 in dDCN (Figure 5.20). 
 
 
 
Figure 5.20 : The effect of IKK on active Caspase-8 in untreated and 6OHDA-treated dDCN  
A) Illustrative example of GAPDH in untreated, IKK, 6OHDA, IKK + 6OHDA treated dDCN.  
B) Illustrative example of active Caspase-8 in untreated, IKK, 6OHDA, IKK + 6OHDA treated dDCN.  
C)  Quantitatively, a higher amount of active Caspase-8 was detected in 6OHDA-treated dDCN compared 
to untreated dDCN (p<0.05). The absence of active Caspase-8 in IKK treated, 6OHDA+IKK treated 
dDCN, suggest that Caspase-8 activity is dependent upon NFB classical pathway. Means of three 
experiments ± SEM shown. Table of densitometry values and statistical analysis can be found in Figure 
5.21, Appendix 5. 
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Results from previous Chapter had illustrated that the proportion of active Caspase-2 increased in 
6OHDA dDCN. In addition, co localisation studies had shown a high expression of active Caspase-2 
present in NFκB positive dDCN. The subsequent aim was to determine if suppression of Caspase-2 
activity, using specific Caspase-2 inhibitor zVDVADfmk could slow death and increase survival of 
6OHDA dDCN. The results demonstrated that 6OHDA+ zVDVADfmk treated, 6OHDA+ IKK + 
zVDVADfmk dDCN had similar levels of cell, suggesting 6OHDA stimulates NFκB and Caspase-2 
through the same route in dDCN (Figure 5.22). 
 
Figure 5.22: Determining Caspase-2 activity in 6OHDA-treated dDCN 
6OHDA triggered Caspase-2 activation in dDCN. 6OHDA+ IKK treated dDCN promoted 57% 
survival by inhibiting the NFB classical pathway (p<0.05). A further increase in cell survival, via 
suppressing Caspase-2 activity was found in 6OHDA+zVDVADfmk treated dDCN (75% cell survival 
p<0.05). 6OHDA+IKK+ zVDVADfmk treated dDCN promoted 78% cell survival (p<0.05), by 
inhibiting activity of Caspase-2 and NFB classical pathway. Proportion of cells surviving was 
determined by MTT absorbance at 570nm. Means of three experiments ± SEM shown. Table of values 
and statistical analysis can be found in Figure 5.23, Appendix 5 
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A closer examination of the results confirmed that Caspase-2 and NFκB are activated in the same 
pathway in 6OHDA-treated dDCN.  Suppressing Caspase-2 pathway in addition to NFB classical 
pathway had no added effect to more cells surviving, indicating that there one pathway (p>0.05). 
6OHDA+ IKK+ zVDVADfmk treated dDCN did not provide further cell survival, suggesting 
6OHDA triggers Caspase-2 and NFB classical pathway activity through the same mechanism, resulting 
in death of dDCN (Figure 5.24).  
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Comparison 1 + + - - 0.0004 
Comparison 2 + - + - 0.002 
Comparison 3 + - - + 0.0001 
 
Comparison 4 
- + + - 0.03 
 
Comparison 5 
- + - + 0.004 
 
Comparison 6 
- - + + 0.449 
 
Figure 5.24: 6OHDA triggers Caspase-2 activation in dDCN via NFB classical pathway 
There was no further cell survival when zVDVADfmk was added to 6OHDA+ IKK treated dDCN 
(Comparison 6 p>0.05), indicating Caspase-2 and NFB are both following the same pathway. There 
was no additional benefit of more cell survival when Caspase-2 and NFKB inhibitors were combined, 
signifying that there is one pathway that was contributing to death of 6OHDA dDCN. This can be 
explained as if the pathways were different a greater survival of 6OHDA-treated dDCN would have 
occurred when both inhibitors were used together.  Proportion of cells surviving was determined by 
MTT absorbance at 570nm. Means of three experiments ± SEM shown. Table of values and statistical 
analysis can be found in Figure 5.23, Appendix 5 
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Co localisation study was carried out to determine if active Caspase-2 and cleaved NFB were present in 
the same dDCN and if Caspase-2 is acting upstream or downstream in NFB classical pathway (Figure 
5.25). Active Caspase-2 was detected in only untreated and 6OHDA-treated dDCN. Furthermore, active 
Caspase-2 was absent in IKK treated, zVDVADfmk treated, 6OHDA+IKK treated, 
6OHDA+zVDVADfmk treated, 6OHDA+IKK +zVDVADfmk dDCN. However, NFκB was present 
in zVDVADfmk treated dDCN, 6OHDA+zVDVADfmk treated dDCN, indicating NFB is activated 
upstream and Caspase-2 is activated downstream in 6OHDA-treated dDCN, as Caspase-2 inhibitor did 
not inhibit NFB activity.  
 
Figure 5.25: IKK can inhibit Caspase-2 activation in untreated and 6OHDA-treated dDCN 
NFB was present in untreated and 6OHDA-treated dDCN (green). There were more NFB positive 
cells in 6OHDA-treated dDCN, when compared to untreated (-6OHDA) dDCN, suggesting 6OHDA 
further enhances NFB expression resulting in death of dDCN. Active Caspase-2 was present in 
untreated and 6OHDA-treated dDCN (red). NFB and Caspase-2 were present in the same cell bodies 
in 6OHDA-treated dDCN, indicating 6OHDA promotes further interactions of Caspase-2 and NFB in 
resulting in death of dDCN. 
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NFB was absent in IKK treated dDCN, 6OHDA+IKK treated dDCN, signifying that inhibiting IKK 
complex suppresses NFB classical pathway in dDCN. Similarly, active Caspase-2 was not detected in 
IKK treated dDCN, 6OHDA+IKK treated dDCN. This indicates that NFκB is acting as upstream and 
by inhibiting the NFB classical pathway; activation of Caspase-2 can also be suppressed in dDCN.  
NFB was present in zVDVADfmk treated, 6OHDA+zVDVADfmk treated dDCN, suggesting that 
even with the suppression of Caspase-2; the NFκB classical pathway is still active in dDCN.  In contrast, 
active Caspase-2 was absent in zVDVADfmk treated, 6OHDA+zVDVADfmk treated dDCN, 
signifying that Caspase-2 activity is successfully suppressed in dDCN when using Caspase-2 inhibitor. 
NFB was absent in IKK+ zVDVADfmk treated dDCN, 6OHDA+IKK+zVDVADfmk treated 
dDCN. Caspase-2 was not found in IKK+ zVDVADfmk treated dDCN, 6OHDA+IKK + 
zVDVADfmk treated dDCN. IKK had suppressed both NFB and Caspase-2 activity in untreated and 
6OHDA-treated dDCN. Caspase-2 activation can be suppressed by directly inhibiting Caspase-2 or via 
inhibiting NFB classical pathway in untreated and 6OHDA-treated dDCN. IKK inhibitor is more 
effective in minimising death of 6OHDA dDCN via suppressing both NFκB and Caspase 2 activation. 
Positive staining for cell bodies (White Arrow) in untreated (- 6OHDA) and treated (+ 6OHDA) dDCN. 
Table of values and statistical analysis can be found in Figure 5.26, Appendix 5. 
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To confirm if IKK inhibitor suppressed Caspase-2 activation of treated dDCN, WB analysis was carried 
out (Figure 5.27). An increase of active Caspase-2 was measured in 6OHDA-treated dDCN, compared 
to untreated dDCN, demonstrating that 6OHDA amplified Caspase-2 activation in dDCN. Active 
Caspase-2 was absent in IKK treated, 6OHDA+IKK treated dDCN, indicating that activation of 
Caspase-2 follows the NFB classical pathway in dDCN. IKK suppressed Caspase-2 activation in 
dDCN, illustrating that 6OHDA triggers stimulation of Caspase-2 resulting in NFκB mediated death of 
dDCN.   
 
 
Figure 5.27: IKK suppressed activation of Caspase-2 in untreated and 6OHDA-treated dDCN  
A) Illustrative example of GAPDH in untreated, IKK, 6OHDA, IKK + 6OHDA treated dDCN.  
B) Illustrative example of active Caspase-2 in untreated, IKK, 6OHDA, IKK + 6OHDA treated dDCN.  
C) Quantitatively, a significant increase in active Caspase-2 was detected in 6OHDA-treated dDCN, 
compared to untreated dDCN (p<0.05). The absence of active Caspase-2 in IKK treated, 
6OHDA+IKK treated dDCN, suggest that Caspase-2 activity is dependent upon NFB classical 
pathway. Means of three experiments ± SEM shown. Table of densitometry values and statistical 
analysis can be found in Figure 5.28, Appendix 5. 
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The results had showed that 6OHDA triggers activation of Caspases-2 and-8, via NFB classical 
pathway. In addition, the findings had shown that NFB is acting upstream and these two Caspases are 
activated downstream in the NFB classical pathway in 6OHDA-treated dDCN. It was of interest to 
determine the impact of suppressing NFκB, Caspases-2 and -8 activities would have on cell death and 
survival of 6OHDA-treated dDCN. ANOVA and T test analysis indicated a significant difference in 
survival of 6OHDA dDCN that were treated with zVDVADfmk, zIETDfmk and IKK (p <0.01, Figure 
5.29, Appendix 5).  
No additional effect in cell survival was measured in 6OHDA zIETDfmk +IKK treated dDCN, 
suggesting that activation of Caspase-8 is completely dependent on NFB classical pathway and 
blocking NFB classical pathway will suppress Caspase-8 activation in dDCN. There was no significant 
difference to slow death and promote cell survival in 6OHDA+ zIETDfmk +IKK dDCN, indicating 
that the use of IKK inhibitor can suppress both NFKB and Caspase-8 activity in dDCN(p >0.01, Figure 
5.30).  
 
zVDVADfmk and IKK reduced death of 6OHDA-treated dDCN compared to IKK alone (p<0.05 
Figure 5.30). Combining IKK and zVDVADfmk, increased protection of 6OHDA-treated dDCN from 
apoptotic death 6OHDA-treated dDCN using IKK on its own. IKK, zVDVADfmk and zIETDfmk 
inhibited activation of NFB, Caspases-2 and-8 in 6OHDA-treated dDCN. However, the combination 
of zVDVADfmk with IKK did not completely suppress death of 6OHDA-treated dDCN, indicating 
6OHDA is promoting activation of other pathways.  
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Figure 5.30: Suppression of Caspases-2,-8 and NFB classical pathway promote further 
protection and survival of 6OHDA-treated dDCN  
IKK suppressed Caspase-8 and NFKB pathway of 6OHDA-treated dDCN. IKK and zVDVADfmk 
protected more cells from death of 6OHDA-treated dDCN, indicating that both these inhibitors are 
required to suppress Caspase-2 and NFκB activity in dDCN. IKK and zVDVADfmk inhibitor was more 
effective to slow death and increase survival of 6OHDA-treated dDCN then zIETDfmk inhibitor. 
Proportion of cells surviving was determined by MTT absorbance at 570nm. Means of three 
experiments ± SEM shown. Table of values and statistical analysis can be found in Figure 5.29, 
Appendix 5. 
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A further analysis of the findings showed increased levels of cell survival of 6OHDA+IKK+ 
zVDVADfmk treated dDCN, compared to 6OHDA+IKK+zIETDfmk treated dDCN (Figure 5.31). A 
closer examination of Caspase-2 activity in relation to NFB classical pathway indicated that Caspase-2 
is dependent on stimulation of NFB classical pathway (Figure 5.31). There amount cell survival of 
6OHDA+IKK+zVDVADfmk treated dDCN, compared to 6OHDA+zVDVADfmk treated dDCN 
(Comparison 9 p>0.05), is not statistically significant, indicated activation of Caspase-2 is dependent on 
NFB pathway. This indicates 6OHDA stimulates Caspases-8 and-2 activation separately in NFB 
classical pathway and that neither Caspases are dependent on each other to become activated.  
 
Treatment 
1 
Treatment 
2 
Treatment 
3 
Treatment 
4 
Treatment 
5 
Treatment 
6 
 
 
6OHDA 
IKK 
 
6OHDA 
zVDVADfmk 
 
6OHDA 
zIETDfmk 
6OHDA 
IKK 
zVDVADfmk 
6OHDA 
IKK 
zIETDfmk 
 
6OHDA 
IKK 
zVDVADfmk 
zIETDfmk 
 
p-value 
obtained 
 
Comparison 
1 
+ + - - - - 0.001 
 
Comparison 
2 
+ - + - - - 0.848 
 
Comparison 
3 
+ - - + - - 
 
0.002 
Comparison 
4 
+ - - - + - 0.063 
Comparison 
5 
+ - - - - + 0.001 
Comparison 
6 
- - - + + - 
0.003 
 
Comparison 
7 
- - - + - + 
0.522 
 
Comparison 
8 
- - - - + + 
0.002 
 
Comparison 
9 
- + - + - - 
0.247 
 
Comparison 
10 
- - + - + - 
0.482 
 
 
Figure 5.31: 6OHDA triggers activation of Caspases-2 and-8 independently in NFκB Classical pathway of dDCN 
No additional survival and death of cells was determined in 6OHDA+zVDVADfmk+IKK treated 
dDCN, when compared to 6OHDA+IKK+zVDVADfmk+ zIETDfmk treated dDCN (Comparison 7 
 
- 198 - 
 
p>0.05), indicating that IKK can successfully inhibit Caspase-8 and NFκB activity in 6OHDA-treated 
dDCN.  A difference in survival and death of cells was determined in 6OHDA+ zIETDfmk +IKK 
treated dDCN, when compared to 6OHDA+IKK+zVDVADfmk+ zIETDfmk treated dDCN 
(Comparison 8 p<0.05), indicating that IKK and zVDVADfmk  need to be used together to successfully 
inhibit Caspase-2 and NFκB activity in 6OHDA-treated dDCN.   There was no difference in cell 
survival in 6OHDA+zVDVADfmk treated dDCN compared to 6OHDA+IKK+zVDVADfmk treated 
dDCN, indicating that 6OHDA triggers Caspase-2 activation through NFκB mechanisms causing 
apoptotic death of dDCN (Comparison 9 p>0.05). Similarly there was no added effect when cells were 
treated with 6OHDA+IKK+ zIETDfmk , compared to 6OHDA+zIETfmk indicating that Caspase-8 is 
depended upon NFκB activation in 6OHDA-treated dDCN (Comparison 10 p>0.05).Proportion of 
cells surviving was determined by MTT absorbance at 570nm. Means of three experiments ± SEM 
shown. Table of values and statistical analysis can be found in Figure 5.29, Appendix 5. 
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Collectively, the results suggest that 6OHDA triggers NFB mediated death of dDCN. 6OHDA 
stimulates NFB activation, which in turn stimulates Caspases-2 and-8 activities in dDCN (Figure 5.32). 
The results have shown that NFB is activated upstream, whilst Caspases are activated downstream in 
6OHDA-treated dDCN. IKK inhibitor has the ability to completely suppress NFB classical pathway 
which subsequently inhibits Caspases-2 and-8 activities in 6OHDA-treated dDCN. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.32 : NFB activates Caspases-2 and -8 in 6OHDA mediated death of dDCN 
Figure showing active Caspases-2 and-8 is involved in NFĸB mediated cell death of 6OHDA-treated 
dDCN. The activation of Caspases-2 and-8 is independent of each other in NFB classical pathway of 
6OHDA-treated dDCN. NFB promoted activation of Caspases-2 and-8 separately in 6OHDA-treated 
dDCN.  
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Results from previous Chapter had shown Caspase-4 inhibitor, zLEVDfmk had decreased apoptotic 
death of 6OHDA-treated dDCN, indicating 6OHDA triggered Caspase-4 activation in dDCN. The 
significance of Caspase-4 activity was determined in NFκB meditated death of dDCN. The findings 
illustrated that further cell survival was achieved in 6OHDA+IKK+zLEVDfmk treated dDCN, 
indicating 6OHDA triggers Caspase-4 and NFB activation via different mechanisms dDCN (Figure 
5.33). 
 
 
Figure 5.33 : Determining Caspase-4 activation in 6OHDA-treated dDCN 
Cells were treated with 6OHDA+IKK, 6OHDA+zLEVDfmk, 6OHDA+IKK+zLEVDfmk, to 
determine if suppression of Caspase-4 and NFB activity promoted survival of dDCN. 6OHDA+IKK 
treated dDCN promoted 53% cell survival by inhibiting the NFB classical pathway. A further increase 
in cell survival, via suppressing Caspase-4 activity was found in 6OHDA+zLEVDfmk treated dDCN 
(60% cell survival). 6OHDA+IKK+zLEVDfmk treated dDCN promoted more cell survival (77% 
survival), by inhibiting both Caspase-4 and NFB classical pathway activities. Proportion of cells 
surviving was determined by MTT absorbance at 570nm. Means of three experiments ± SEM shown. 
Table of values and statistical analysis can be found in Figure 5.34, Appendix 5 
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It was important to further explore to if Caspase-4 activity is influenced by NFB classical pathway in 
6OHDA dDCN. More survival and reduced death of cells was achieved in 6OHDA+zLEVDfmk 
+IKK treated dDCN. Suppression of Caspase-4 pathway in addition to NFB classical pathway had an 
added effect in more cells surviving, indicating that there are two pathways.  The results suggested that 
Caspase-4 is not following NFB classical pathway and could be activated by another pathway, resulting 
in death of 6OHDA-treated dDCN (Figure 5.35).  
 Treatment 1 Treatment 2 Treatment 3 Treatment 4  
 6OHDA 
6OHDA 
IKK 
6OHDA 
zLEVDfmk 
6OHDA 
IKK zLEVDfmk 
p-value obtained 
Comparison 1 + + - - 0.00001 
Comparison 2 + - + - 0.000002 
Comparison 3 + - - + 0.00002 
 
Comparison 4 
- + + - 0.001 
 
Comparison 5 
- + - + 0.00002 
 
Comparison 6 
- - + + 0.001 
 
Figure 5.35: IKK does not suppress Caspase-4 activation in 6OHDA-treated dDCN 
Survival of 6OHDA dDCN increased when IKK was added to zLEVDfmk, indicating that NFB 
classical pathway does not influence stimulation of Caspase-4 in 6OHDA-treated dDCN (comparison 5 
p<0.01). Further survival and decrease in death of 6OHDA dDCN was achieved when zLEVDfmk was 
added to IKK, indicating that 6OHDA stimulated Caspase-4 and NFκB classical pathways via different 
mechanisms (comparison 6 p<0.01). The additional effect of more cells survival when Caspase-4 
inhibitor and IKK inhibitor were combined indicates that there are two pathways that are contributing 
to death of 6OHDA dDCN. Furthermore, both inhibitors are required to be used to suppress both 
pathways so more cell survival can be achieved. Proportion of cells surviving was determined by MTT 
absorbance at 570nm. Means of three experiments ± SEM shown. Table of values and statistical analysis 
can be found in Figure 5.34, Appendix 5. 
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Double IF analysis was carried out to determine if active Caspase-4 and cleaved NFB are present in the 
same untreated and 6OHDA-treated dDCN (Figure 5.36).  It was important to determine if the Caspase-
4 inhibitor, zLEVDfmk suppressed cleaved NFB in 6OHDA-treated dDCN. The results portrayed 
that active Caspase-4 was not often present in cells that were stained positive for p65 NFB of untreated 
and 6OHDA-treated dDCN, indicating that NFB and Caspase-4 activation are most likely not 
interacting with one another. Active Caspase-4 was present in untreated, IKK treated, 6OHDA-treated, 
6OHDA+IKK treated dDCN, demonstrating that IKK did not suppress Caspase-4 activation in dDCN. 
This puts forward the notion that Caspase-4 is not following the NFκB classical pathway of 6OHDA-
treated dDCN, indicating that another pathway is causing death of dDCN via Caspase-4 activation. 
6OHDA triggers activation of Caspase-4 and NFB through two separate signalling pathways causing 
apoptotic death of dDCN.  
 
Figure 5.36: Determining the effect of IKK on Caspase-4 expressed in NFB positive cells in 
6OHDA-treated dDCN 
Presence of cleaved NFB was observed untreated and 6OHDA-treated dDCN (green). Active Caspase-
4 was present in untreated and 6OHDA-treated dDCN (red). There were more cells that were stained 
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positive for active Caspase-4 in 6OHDA-treated dDCN, when compared to untreated (- 6OHDA) 
dDCN, indicating 6OHDA amplified activation of Caspase-4 in dDCN. Active Caspase-4 and cleaved 
NFB were mostly detected in different untreated and 6OHDA-treated dDCN, suggesting there is a 
decreased possibility that Caspase-4 and NFB interact with each other in dDCN.  
NFB was not detected in IKK treated, 6OHDA+IKK treated dDCN, suggesting NFB is dependent 
on phosphorylation of IKK complex and removal of IB so it can be activated in dDCN. In contrast, 
active Caspase-4 detected in IKK treated, 6OHDA+IKK treated dDCN, indicating that inhibiting the 
NFB classical pathway does not influence Caspase-4 activity in dDCN. 6OHDA triggers Caspase-4 
activity through a different pathway that is not related to NFB classical pathway in dDCN.  
NFB was present in zLEVDfmk treated, 6OHDA+zLEVDfmk treated dDCN, suggesting that NFB 
activation is independent of Caspase-4 stimulation in dDCN. The suppression of Caspase-4 activity does 
not influence NFB activation in dDCN. In comparison, active Caspase-4 was absent in zLEVDfmk 
treated, 6OHDA+zLEVDfmk treated dDCN, signifying that zLEVDfmk had competitively suppressed 
Caspase-4 activity in dDCN. NFB was absent in untreated and 6OHDA+IKK+ zLEVDfmk treated 
dDCN treated dDCN. Caspase-4 was not found in IKK+ zLEVDfmk treated, 
6OHDA+IKK+zLEVDfmk treated dDCN. IKK had suppressed NFB activity, whilst zLEVDfmk 
inhibited Caspase-4 activation in untreated and 6OHDA-treated dDCN. Positive staining for cell bodies 
(White Arrow) in untreated (- 6OHDA) and treated (+ 6OHDA) dDCN. Table of values and statistical 
analysis can be found in Figure 5.37, Appendix 5. 
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WB analysis was carried out to determine if IKK could suppress Caspase-4 activity in 6OHDA-treated 
dDCN (Figure 5.38). Active Caspase-4 was present in untreated, IKK treated, 6OHDA and 
6OHDA+IKK treated dDCN. A higher amount of active Caspase-4 was detected in 6OHDA-treated 
dDCN compared to untreated dDCN, suggesting 6OHDA triggered further activation of Caspase-4 in 
dDCN. IKK did not prevent nor reduce the amount of Caspase-4 in 6OHDA-treated dDCN, 
illustrating that IKK does not influence Caspase-4 activation. The ineffectiveness of IKK against 
activation of Caspase-4 further supports the notion that Caspase-4 is independent of NFB mediated 
death of treated dDCN. 6OHDA triggered Caspase-4 activation, but this was being achieved, through a 
different route and not via NFB classical pathway. 
 
 
Figure 5.38: IKK does not inhibit Caspase-4 activation in 6OHDA-treated dDCN 
A) Illustrative example of GAPDH in untreated, IKK, 6OHDA, IKK + 6OHDA treated dDCN.  
B) Illustrative example of active Caspase-4 in untreated, IKK, 6OHDA, IKK + 6OHDA treated dDCN.  
C) Quantitatively, a substantial increase in active Caspase-4 was detected in 6OHDA-treated dDCN, 
compared to untreated dDCN (p<0.05). IKK neither prevented nor reduced the amount of active 
Caspase-4 in present in IKK treated, 6OHDA+IKK treated dDCN (p>0.05), indicating that NFB 
classical pathway does not influence Caspase-4 stimulation in 6OHDA-treated dDCN. Means of three 
experiments ± SEM shown. Table of densitometry values and statistical analysis can be found in Figure 
5.39, Appendix 5.3. 
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The results showed NFB classical pathway influences activation Caspases-2 and-8 but not of Caspase-4 
in 6OHDA-treated dDCN. The next aim was to determine if maximum survival could be achieved by 
further suppression Caspases-2,-4,-8 and NFB activities in 6OHDA-treated dDCN. 6OHDA dDCN 
were treated with different combinations of IKK, zVDVADfmk, zLEVDfmk and zIETDfmk. ANOVA 
analysis illustrated a considerable difference in survival of 6OHDA dDCN that were treated with 
zVDVADfmk, zIETDfmk, zLEVDfmk and IKK (p <0.01, Figure 5.40, Appendix 5). Subsequent T 
tests were used to identify key inhibitors that had the most effect in promoting survival and slowing 
death of 6OHDA dDCN. The results demonstrate that the use of Caspase inhibitors, zLEVDfmk and 
zVDVADfmk, along with IKK provide more protection and survival of 6OHDA-treated dDCN then 
using a single inhibitor or two inhibitors (p<0.05 Figure 5.41). 
Additional cell survival of 6OHDA dDCN was determined when IKK was added with zLEVDfmk, 
demonstrating that IKK has an additional effect to slow death and promote cell survival (p<0.05 Figure 
5.41). More cell survival of was found in 6OHDA+IKK+zLEVDfmk treated dDCN, signifying that 
both inhibitors can promote further survival and slow death of 6OHDA dDCN, via suppressing two 
different routes. The additional effect of more cells survival when Caspase-4 inhibitor and NFĸB 
inhibitor are combined indicates that there are two pathways that are contributing to death of 6OHDA 
dDCN. 
In contrast, similar cell survival was determined in 6OHDA + IKK +zIETDfmk treated dDCN, when 
compared to 6OHDA + IKK treated dDCN or 6OHDA + zIETDfmk treated dDCN, indicating 
NFB directly influences Caspase-8 activity (p>0.05 Figure 5.41). The amount of cell survival was not 
significant when zIETDfmk inhibitor was added to IKK inhibitor, suggesting the addition of 
zIETDfmk did not provide an additional effect to slow death and increase survival of 6OHDA-treated 
dDCN(p>0.05 Figure 5.41). There was no significant difference to slow death and promote cell survival 
in 6OHDA + IKK + zIETDfmk treated dDCN, indicating that the use of IKK inhibitor can suppress 
both NFB and Caspase-8 activity, therefore zIETDfmk is not required to inhibit death of dDCN. 
A higher cell survival rate was determined in 6OHDA + IKK + zVDVADfmk treated dDCN when 
compared to 6OHDA + IKK treated dDCN p<0.05 Figure 5.41), indicating that Caspase-2 may be 
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activated by another pathway as well as NFB pathway. This can be explained further as the results 
previously demonstrated that activation of Caspase-2 is dependent on stimulation of the NFB pathway. 
However, cell survival analysis has shown that a greater survival of 6OHDA-treated dDCN, when both 
NFB and Caspase-2 is suppressed, indicating that there may be another factor which can activate 
Caspase-2. Combining all inhibitors reduced death of treated dDCN then using solely IKK (p<0.01 
Figure 5.41). The results suggest that IKK+ zVDVADfmk +zLEVDfmk provided better survival of 
6OHDA-treated dDCN.  
 
Figure 5.41: Suppression of Caspases-2,-4,-8 and NFB classical pathway promoted further cell 
survival of 6OHDA-treated dDCN 
6OHDA dDCN were treated with different combinations of IKK, zVDVADfmk, zLEVDfmk  and 
zIETDfmk to determine if maximal cell survival could be achieved by suppression of Caspases-2,-4,-8 
and NFB activity. Similar cell survival was determined in 6OHDA+ IKK treated dDCN, 6OHDA+ 
zIETDfmk  dDCN, 6OHDA +IKK + zIETDfmk dDCN (cell survival 56%, 57% and 56%). In 
comparison, further cell survival was achieved in 6OHDA-treated dDCN that were treated with 
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zVDVADfmk inhibitor (70%, cell survival). In addition, a greater cell survival was measured in 6OHDA 
+ zLEVDfmk +IKK treated dDCN compared to IKK (84% cell survival). 6OHDA +IKK+ 
zVDVADfmk+ zLEVDfmk +zIETDfmk treated dDCN promoted 86% survival of cells. Proportion of 
cells surviving was determined by MTT absorbance at 570nm. Means of three experiments ± SEM 
shown. Table of values and statistical analysis can be found in Figure 5.40, Appendix 5. 
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The next aim was to determine if there was any cross talk between Caspase-2,-4,-8 and NFB in the 
NFB classical pathway of 6OHDA-treated dDCN (Figure 5.42, Appendix 5). More specifically the aim 
was to determine if activation of Caspase-4 could influence the others Caspases such as Caspase-2 and -8 
in 6OHDA dDCN. To achieve this aim, a combination of different treatments consisting of specific 
inhibitors such as zVDVADfmk, zIETDfmk and IKK were used in 6OHDA-treated dDCN.  Moreover, 
further survival of 6OHDA dDCN, was determined when IKK was added with zVDVADfmk and 
zLEVDfmk, demonstrating that these three inhibitors are required to be used to suppress pathways, 
thereby promoting cell survival and slowing death. 
 
The results showed a greater cell survival was achieved in 6OHDA + IKK + zLEVDfmk+ zIETDfmk 
+ zVDVADfmk treated dDCN,, when compared to 6OHDA +IKK + zVDVADfmk treated dDCN 
(Comparison 8, p<0.01, Figure 5.42, Appendix 5), indicating  activation of Caspase-2 is dependent on 
NFB classical pathway , but other pathways or factors cause death of in 6OHDA-treated dDCN. 
Collectively the data has demonstrated that 6OHDA stimulates NFB classical pathway which promotes 
activation of Caspases-2 and-8 separately and one Caspase is not dependent on the other, resulting in 
death of dDCN. Although there was an increase in cell survival of 6OHDA +IKK + zLEVDfmk + 
zIETDfmk + zVDVADfmk treated dDCN, when compared to 6OHDA + IKK + zLEVDfmk treated 
dDCN, the increase was not statistically significant  (Comparison 9, p>0.05, Figure 5.42, Appendix 5), 
indicating the greatest cell survival is achieved by combining IKK and zLEVDfmk with zVDVADfmk.   
 
In comparison, a difference in cell survival measured in 6OHDA +IKK + zLEVDfmk+ zIETDfmk + 
zVDVADfmk treated dDCN, when compared to 6OHDA + IKK + zIETDfmk treated dDCN, 
indicating that activation of Caspase-8 is completely dependent on stimulation of NFB classical 
pathway in 6OHDA dDCN and another factors and pathways are involved in death of 6OHDA dDCN 
(Comparison 10, p<0.05, Figure 5.42, Appendix 5). This finding emphasises that IKK inhibitor is more 
beneficial to use to block Caspase-8 activity and NFB classical pathway compared to using zIETDfmk 
inhibitor, as the zIETDfmk inhibitor would suppress Caspase-8 activity only in 6OHDA-treated dDCN.  
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A comparison between 6OHDA+IKK+zLEVDfmk treated dDCN and 6OHDA+IKK+zVDVADfmk 
treated dDCN (Comparison 11, p<0.05, Figure 5.42, Appendix 5) revealed that Caspase-4 activity does 
not directly influence Caspase-2 activity and the stimulation of these Caspases are most likely through 
different mechanisms.  Furthermore, 6OHDA+IKK+zVDVADfmk treated dDCN increased cell 
survival, when compared to 6OHDA+IKK+zIETDfmk treated dDCN (Comparison 12, p<0.05, Figure 
5.42, Appendix 5), indicating activation of that Caspases-2 is not dependent on and activation on 
Caspase-8 and vice versa dDCN. 6OHDA+IKK+zLEVDfmk treated dDCN provided greater cell 
survival, when compared to 6OHDA+IKK+zIETDfmk treated with dDCN (Comparison 13, p<0.01, 
Figure 5.42, Appendix 5), indicating that 6OHDA triggers Caspases-4 and-8 activation in dDCN, 
through different mechanisms and one Caspase is not dependent on the other to be activated. 
 
There was no significant difference in cell survival in 6OHDA +zVDVADfmk treated dDCN, when 
compared to 6OHDA + IKK + zVDVADfmk treated dDCN (Comparison 14, p>0.05, Figure 5.42, 
Appendix 5), confirming NFκB is required to stimulation Caspase-2 activity in dDCN. In contrast, there 
was a difference in cell survival of 6OHDA+zLEVDfmk treated dDCN, when compared to 6OHDA + 
IKK + zLEVDfmk treated dDCN, suggesting that NFκB and Caspase-4 follow different cell signalling 
pathways causing death of 6OHDA dDCN(Comparison 15, p<0.01, Figure 5.42, Appendix 5). 
Additionally, no additional effect in cell survival was found in 6OHDA+ zIETDfmk treated dDCN, 
when compared to 6OHDA + IKK + zIETDfmk treated dDCN, signifying NFκB and Caspase-8 
follow the same apoptotic pathway in 6OHDA dDCN(Comparison 16, p>0.05, Figure 5.42, Appendix 
5). 
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Collectively, the results demonstrate that 6OHDA triggered Caspases-2 and -8 activation resulting NFκB 
mediated death of dDCN. NFĸB separately stimulated Caspases-2 and-8 activation in 6OHDA dDCN. 
Furthermore, another factor apart from NFκB classical pathway seems to activate Caspase-2 resulting in 
death of 6OHDA dDCN. IKK inhibitor completely suppressed Caspases-2 and -8 by preventing 
activation of NFκB in 6OHDA dDCN. Although it is has been confirmed that Caspase-4 plays an active 
role in death of 6OHDA-treated dDCN, the exact route and how Caspase-4 is activated in 6OHDA 
dDCN remains to be established. The results also suggest 6OHDA stimulates other route leading to 
apoptotic death of dDCN (Figure 5.43). 
 
 
 
 
 
 
 
Figure 5.43: The involvement of Caspases-2,-4 and -8 in NFB mediated death of 6OHDA-
treated dDCN 
6OHDA triggered NFB classical pathway leading to activation of Caspases-2 and-8 in dDCN. NFB 
classical pathway promoted activation of Caspases-2 and-8 independently in 6OHDA-treated dDCN. In 
comparison, NFB classical pathway did not influence activation of Caspase-4, suggesting that Caspase-
4 is active in another route (such as ER stress). In addition, the combination of Caspase-4 inhibitor and 
IKK increased cell survival of 6OHDA-treated dDCN, indicating that there are two separate pathways 
that are causing apoptosis of 6OHDA-treated dDCN.  
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5.4 Discussion  
 
The main aim was to determine the influence of NFκB classical pathway in Caspase mediated death of 
6OHDA-treated dDCN. The results demonstrated that 6OHDA triggers NFB pathway leading 
activation of Caspases-2,-3 and -8 resulting in apoptotic death of dDCN (Figure 5.43). The results of the 
current study demonstrated that NFκB promotes apoptotic death rather than survival of 6OHDA-
treated dDCN (Figure 5.1-Figure 5.13). Double IF and WB analysis illustrated 6OHDA amplified NFκB 
activity in dDCN (Figure 5.1-5.7). These finding are similar to previous work carried out by Ye et al 
(2013) and Xiang et al (2011) who had found that 6OHDA triggered phosphorylation of IB and 
translocation of p65 to the nucleus in SH-SY5Y neuroblastoma cells. IF and WB analysis revealed 
6OHDA triggered Caspase-3 activation and death of DCN through NFB classical pathway (Ye et al 
2013, Xiang et al 2011). 
 
Work by Jia and Misra (2007) demonstrated increased Caspase-3 levels in zineb induced SHSY5Y cells, 
indicating that environmental toxin cause Caspase dependent death of neuronal cells. Quantificatation of 
p50 NFB from nuclear extracts of zineb induced SHSY5Y cells was carried out using ELISA. 
Colorimetric analysis revealed increase hydrogen peroxide and superoxide, levels in pesticide induced 
neuronal cells.  Furthermore, research by Tsui et al (2011) found an increase in Bax, cytochrome c, p38, 
NFκB, Caspase-3 levels in PC12 cells that had been exposed to hydrogen peroxide over a time course. 
WB analysis revealed elevated cleaved Caspase-3, PARP and NFκB p65 levels at 10, 12 and 24 hours 
demonstrating that exposure to toxins promotes apoptotic death of cells through over activity of NFκB. 
In comparison to Jia and Misra (2007) and Tsui et al (2011) the findings of this current study has 
demonstrated  an increase in Caspase-3 activation that were expressed in NFκB cell of 6OHDA-treated 
dDCN, indicating that 6OHDA promotes Caspase-3 stimulation through NFκB pathway in dDCN 
(Figure 5.6-Figure 5.7).  
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The results of this study have shown an increase in p65 NFκB, Caspases-2,-3 and -8 in 6OHDA-treated 
dDCN (Figure 5.6-Figure 5.7). Furthermore, IF, WB and inhibitor analysis had demonstrated that 
activation of Caspase-2 and -8 was dependent on NFB pathway and the suppression of NFB pathway 
inhibited stimulation of thesis Caspases in 6OHDA dDCN (Figure 5.15-Figure 5.32). These findings are 
in parallel to research carried out by Liu et al (2004), who found increased levels of cytochrome c, p65 
NFκB, Caspases-3,-8 and -9 in PC12 cells treated with MPTP, indicating that MPTP triggered activation 
of Caspases-3,-8 and -9 via mitochondrial and NFB  pathways resulting in cell death. 
 
Work by Panet et al (2001) illustrated 6OHDA triggered NFB mediated apoptotic death of dopamine 
induced PC12 cells. Furthermore, reduced death of 6OHDA cells was achieved using a specific NFB 
inhibitor SN-50, suggesting that 6OHDA triggers NFB mediated death of cells. Moreover, WB analysis 
showed an increase in survival of 6OHDA cells that had been treated with either the Caspases-3 or-1 
inhibitor, signifying that ROS triggers NFB activation and activation of Caspases-3 and -1, resulting in 
apoptotic death of DCN. Work by Masumoto et al (2003) had found NFB over activity was 
encouraged by elevated levels of the pro apoptotic protein ASC.  Elevated levels of Caspase-8 and NFκB 
p65 were determined in cells treated with ASC, indicating that over expression of ASC promoted 
apoptotic cell death through NFB and Caspase-8 mechanisms.IKK had inhibited NFB p65 and 
Caspase-8 apoptotic death of cells that had been exposed to ASC and Ipaf. 
 
In comparison, the current study has illustrated 6OHDA triggers activation of NFκB classical pathway 
resulting in Caspase mediated apoptotic death of dDCN using specific inhibitors. IF, WB and inhibitor 
cell viability assays using NFB, Caspases-2 and -8 specific inhibitors demonstrated NFB stimulates 
Caspases-2 and -8 in 6OHDA dDCN (Figure 5.15-Figure 5.32).  This study had also found that IKK 
had inhibited NFB and Caspase-8 as well as Caspase-2 activation and apoptotic death of 6OHDA 
dDCN (Figure 5.18-Figure 5.20 and Figure 5.25-Figure 5.27).  
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Research by Wilms et al (2003) and Lamkanfi et al (2006 and 2007) demonstrated that Caspase-2 can 
trigger NFB activation resulting in Caspase-3 activation and death of cells. Active Caspase-2 forms the 
PIDD:RIP-1:Caspase-2 complex that promotes NFB stimulation. However, the findings of this 
research suggest that NFκB promotes activation of Caspase-2 in dDCN (Figure 5.32).  IF, WB and 
inhibitor cell viability assays had demonstrated that suppression of NFB pathway had inhibited 
Caspase-2 activation in dDCN, signifying that NFB is activated upstream and Caspase-2 is stimulated 
downstream in 6OHDA dDCN (Figure 5.22-Figure 5.32). 
 
Work by Ho et al (2009) has showed a decrease in death of cortical neurons from E16 mice that had 
knocked down Caspase-8. RNAi was used to inhibit and silence Caspase-8 activity in cortical neurons 
and WB analysis had shown that inhibition of Caspase-8 had reduced death of cortical neurons, 
emphasising that activation of Caspase-8 results in death of cortical neurons. Further work using WB 
analysis showed increased Caspase-8 levels and absence of Caspase-2 in striatal lysates of LRRK-2 PD 
patient. This indicated that mutated LRRK-2 promoted Caspase-8 dependent death of striatal DCN in 
PD.  
 
In comparison, the results of the current study demonstrated 6OHDA had triggered Caspases-2 and-8 
activation leading to death of dDCN (Figure 5.32). zVDVADfmk and zIETDfmk inhibited Caspases-2 
and-8 activities thereby promoting survival and reducing death of 6OHDA-treated dDCN (Figure 5.30-
Figure 5.32). In addition, the findings of this research have clearly demonstrated that NFB stimulates 
activation of Caspases-2 and-8 leading to death of 6OHDA-treated dDCN (Figure 5.15-Figure 5.32).  
Ho et al (2009) research had collected specific PD brain samples that had been associated with mutated 
LRRK-2 gene so only the effect of mutated effect of LRRK-2 gene on Caspases could be determined. In 
comparison, this research focussed on specific Caspases and how they are activated after administration 
of 6OHDA, and therefore explored the environmental and not genetic aspect, which results in death of 
dDCN.  
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To date this is the first research that determined the effect of NFB classical pathway on Caspase-4 
activation in 6OHDA-treated dDCN. The aim of this research was to determine if 6OHDA triggers 
Caspase-4 activation resulting in NFB mediated death of dDCN. The results demonstrated that 
6OHDA triggered Caspase-4 activation, but this was not achieved through NFB classical pathway 
(Figure 5.33-Figure 5.41). Overall, IF analysis had illustrated that Caspase-4 and NFB were present 
mostly in different untreated and 6OHDA-treated dDCN, indicating that they are independent of each 
other (Figure 5.36). Further work using IKK had shown that Caspase-4 was still active in 6OHDA-
treated dDCN, and IKK inhibitor was ineffective in suppressing Caspase-4 activation (Figure 5.36). WB 
analysis portrayed IKK inhibitor had no effect in suppressing Caspase-4 activity, signifying that Caspase-
4 does not follow NFB classical pathway (Figure 5.38 ). To confirm this, the combination of IKK and 
zLEVDfmk prevented further death and increased more cell survival of 6OHDA-treated dDCN, then 
using one inhibitor alone (Figure 5.33). The additional effect measured when combining both inhibitors 
highlighted that 6OHDA triggers NFB and Caspase-4 activation through different pathways resulting 
in death of dDCN(Figure 5.33-Figure 5.34). NFB did not inhibit all cell death, therefore it is plausible 
that another parallel death signalling pathway involved (Figure 5.9- Figure 5.11 and Figure 5.43). The 
next Chapter will attempt to determine what this other pathway is. 
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5.5 Conclusion  
Collectively, the results have shown that 6OHDA had triggered activation of NFB, via the classical 
pathway (Figure 5.1- Figure 5.4 and Figure 5.9-Figure 5.13). Subsequently, active NFB promoted 
activation of Caspases-2 and-8 separately; resulting in death of 6OHDA-treated dDCN (Figure 5.32 and 
Figure 5.43). A closer examination using IF, WB and inhibitor cell viability assays illustrated that 
suppression of NFB classical pathway inhibits stimulation of Caspases-2 and -8, resulting in an increase 
in survival of 6OHDA dDCN (Figure 5.15 –Figure 5.32). Furthermore, 6OHDA triggered Caspase-4 
activation independently to the NFB classical pathway causing apoptotic death of dDCN (Figure 5.33-
Figure 5.38). Inhibitor cell viability assays revealed suppressing NFB, Caspases-2 and-4 activation using 
IKK, zVDVADfmk and zLEVDfmk inhibitors resulted in slow death and a greater survival of 6OHDA 
dDCN (Figure 5.41- Figure 5.42). IF, WB and inhibitor cell viability assays revealed that NFB classical 
pathways is one of the main routes that lead to Caspase mediated death of 6OHDA dDCN (Figure 5.1- 
Figure 5.4 and Figure 5.9-Figure 5.13).  However, the results have also demonstrated that 6OHDA 
triggers other routes that result in apoptotic death of dDCN (Figure 5.9 – Figure 5.11 and Figure 5.43).  
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Chapter 6 
6OHDA triggers ER mediated death of 
dDCN:  The Legend of ER stress 
pathway  
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6.0 The Effect of Salubrinal on Caspases in ER mediated death of cells   
 
Activation of ER stress pathways is required in normal cellular processes (Chapter 1 Section 1.7). 
Research has shown that failure to remove defective proteins promotes formation of toxic aggregates 
provoking stimulation of the ER stress pathways; IRE-1, PERK and ATF-4, in aid to restore cell 
homeostasis and survival (Todd et al 2008). However, unsuccessful restoration of cell homeostasis 
encourages the activation of death mechanisms leading to ER mediated death of cells, which has been 
recently been associated with PD pathogenesis and is currently being explored (Oakes and Papa 2014). 
 
6OHDA and 1-Methyl 4-Phenylpyridinium (MPP+) can mimic the key attributes of PD (such as Lewy 
body formation, mitochondrial dysfunction and ROS production) and so are commonly used 
neurotoxins to study in vivo and in vitro PD models (Bohlen and Halbach 2006, Ferro et al 2005, 
Brazhnik et al 2012, Murray et al 2003, Pienaar and Berg 2013). Holtz and O’Malley (2003) found 
6OHDA triggers stimulation of PERK, ATF-6 and IRE-1 pathways resulting ER mediated death of cells. 
WB and IF analysis revealed a substantial increase of active CHOP, BiP, XBP-1, p-JNK, p-EIF2α, p-
PERK and Caspases-3 levels in 6OHDA-treated MN9D cells. A gradual increase in p-JNK, CHOP, 
XBP-1 and Caspase-3 were determined from 6 hour to 12 hours in 6OHDA-treated MN9D cells. In 
comparison elevated levels of p-EIF2α, BiP and Caspase-3 was determined in MPP+ induced MN9D 
cells. The results demonstrated that 6OHDA and MPP+ activated CHOP via UPR in MN9D cells. In 
addition, oxidative stress, impairment of the mitochondria and high accumulation of proteins were 
found in 6OHDA-treated and MPP+ treated cells (Holtz and O’Malley 2003).  
Research by Lee et al (2010) demonstrated elevated levels of CHOP, p-PERK, p-IRE-1, p-EIF2α and 
XBP-1 in tunicamycin induced SK-N-SH cells via WB and IF analysis. Colorimetric Caspase specific 
assays revealed a gradual increase of Caspases-4 and -3 activities in neuronal cells that had been treated 
with tunicamycin. Salubrinal significantly decreased p-EIF2α, CHOP, Caspases-3 and -4 activity and 
protected tunicamycin treated cells from damage (Lee et al 2010).  
 
 
- 218 - 
 
Research by Arduíno et al (2009) measured Caspase-2,-3,-4 and -9 activation using Caspase specific 
colorimetric substrates such as ac-VDVAD-fmk, ac-DEVD-fmk, ac-LEVD-fmk and ac-LEDH-fmk in 
lysates of MPTP induced neuronal cells. The results showed that Caspase-4 activity increased by 40% 
after 24 hours of MPTP exposure in neuronal cells. Furthermore, Caspase-2 activity increased by 30% in 
6 hour MPTP induced cells and rose by a further 25% after 24 hour MPTP exposure to cells. Moreover, 
Caspases-3 and -9 activities were lower in 2 hour exposed MPTP-treated cells compared to untreated 
cells. However, a significant rise in the level of Caspases-3 and -9 activities was found in cells that had 
been exposed to MPTP after 24 hours. WB analysis revealed an increase in active BiP at 2 hour MPTP 
exposure, followed by gradual decrease of active BiP from 2 hour to 24 hour, where at 24 hours BiP was 
at normal basal levels. IF analysis demonstrated an increase in calcium levels in the ER and mitochondria 
of thapsigargin and MPTP-treated cells using Fura-2AM. Collectively the results demonstrated that 
MPTP triggers leakage of calcium from the ER into the mitochondria provoking activation of Caspases-
2,-3,-4 and -9 resulting in death of neuronal PD cells.  
 
Work by Colla et al (2012a) found that oligomers of α synuclein accumulated in the ER promoted 
activation of ER stress in transgenic mice model. WB analysis revealed high levels of aggregated α 
synuclein in ER microsomal and mitochondrial fractions alongside increased fragmentation of Golgi 
body in the midbrain of transgenic mouse model. Furthermore, the PERK inhibitor, salubrinal, 
decreased the amount of aggregated α synuclein in ER microsomal and mitochondrial fractions 
alongside reduced fragmentation of Golgi body of transgenic mouse model, indicating that aggregated α 
synuclein providing a signal to trigger ER stress. Further work (Colla et al 2012b) showed similar results 
in human brain tissues and in transgenic mouse model. WB and Immunohistochemical analysis showed 
elevated levels p-EIF, Caspases-12,-9 and -3 and aggregated α synuclein in human tissues and in ER 
microsomal neuroblastoma cell line. Salubrinal decreased the level of Caspases and accumulated toxic 
oligomers of α synuclein, indicating α synuclein triggers PERK pathway of ER stress leading to Caspase 
activation and death of DCN.  
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Work by Smith et al (2005) found that mutant A53T α synuclein accumulated in the ER promoted 
activation of ER stress in PC12 model. Further analysis using 2', 7’-dichlorofluorescein diacetate 
(DCFDA) probe indicated high ROS levels in the cytosol of mutant A53T α synuclein cells.  Inhibitor 
analysis using specific zDEVDfmk, zIETDfmk and zLEHDfmk inhibitors determined the increased 
activation of Caspases-3 and-9 but not Caspase-8 in that mutant A53T α synuclein cells indicating that 
mutated form of α synuclein promoted activation of Caspase-3 and-9 dependent death of DCN.  WB 
analysis revealed high levels of p-eIF2-α, GRP78, CHOP and Caspase-12 after 5 days in mutant A53T α 
synuclein PC12 cells. The author concluded that knock down of Caspase-12 increased cell survival, 
indicating that Caspase-12 participates in ER stress mediated death of DCN. Salubrinal partially inhibited 
death of DCN, indicating that ER stress caused death of DCN but other pathways such as the 
mitochondrial pathway also contributed to death of DCN. WB analysis demonstrated a significant 
increase in active p-EIF2α, ATF-4, CHOP and Caspase-3 in tunicamycin, thapsigargin and 6OHDA 
induced SH-SY5Y cells (Hara et al 2011). 6OHDA triggered a higher elevation in Caspase activity in 
cells compared to cells that were treated with tunicamycin or thapsigargin. A significant decrease was 
found in Caspase-3, p-EIF2α and CHOP in 6OHDA, tunicamycin and thapsigargin cells that had been 
treated with salubrinal (Hara et al 2011). Research by Chinta et al (2009) demonstrated that paraquat 
induced ER mediated death of DCN caused through oxidative stress. Oxidative stress contributed to the 
misfolding and impairment of proteins leading to initiation of ER stress. IF and WB analysis revealed the 
ability of salubrinal to protect neurons that had been treated with paraquat. Salubrinal had significantly 
reduced p-eIF2α, CHOP, XBP-1 and Caspase activation in paraquat induced N27 dopaminergic cell line. 
Furthermore, work by Jiang et al (2010) demonstrated that salubrinal had prevented ER stress mediated 
apoptosis, alongside accumulation and aggregation of α-synuclein in sodium butyrate treated PD cells. 
Sodium butyrate promoted accumulation of aggregated α-synuclein in SHSY5Y cells resulting in 
activation of Caspase-3. WB analysis showed high levels of cleaved Caspase-3 after 24 hours and IF 
analysis revealed aggregated deposits of incorrectly folded proteins in sodium butyrate treated cells. WB 
analysis demonstrated that salubrinal had suppressed death of sodium butyrate treated cells.  
 
 
- 220 - 
 
6.1 Determining the Relevance of PERK Associated ER stress Pathway in 6OHDA-
treated dDCN  
Chapter 5 had indicated that classical NFB pathway plays a vital role in initiating death of 6OHDA-
treated dDCN (Chapter 5 Figure 5.1-Figure 5.4 and Figure 5.9-Figure 5.13). In addition, the results had 
demonstrated that activation of Caspases-2 and -8 are dependent upon NFB activation by 6OHDA in 
dDCN, indicating that NFB is acting upstream to Caspases-8 and-2 (Chapter 5 Figure 5.15- Figure 
5.31). It was also found that NFB triggered activation of Caspases-2 and-8 through different routes and 
that Caspases-8 and-2 are not dependent, nor enhance each other’s activation (Chapter 5 Figure 5.32 and 
Figure 5.43). In contrast, NFB pathway did not affect activation of Caspase-4 in 6OHDA-treated 
dDCN and so the next aim was to determine how Caspase-4 is activated (Figure 5.43).  It was also found 
that blocking classical NFB pathway did not completely promote survival of 6OHDA dDCN and 
death of treated dDCN was still occurring (Chapter 5 Figure 5.9- Figure 5.11 and Figure 5.41-Figure 
5.42). Similar to NFB, the role of ER stress in cells is controversial as activation of PERK can promote 
or prevent death of DCN (Oakes and Papa 2014, Pereira 2013, Matus et al 2008, Todd et al 2008, Hetz 
2012, Sano and Reed 2013).   
 
Results from the Chapter 4 had shown the potential involvement of ER stress in apoptotic death of 
6OHDA-treated dDCN (Chapter 4 Figure 4.17- Figure 4.19). The next aim was to explore the potential 
influence of PERK ER stress on Caspases-2,-4 and -8 in apoptotic death of 6OHDA-treated dDCN.  At 
present there is no research that has explored the potential link between PERK ER stress and NFB in 
DCN. The following Chapter investigates if NFB classical pathway and PERK ER stress pathway 
encourages up regulation or have any impact on each other’s pathway in treated 6OHDA dDCN. 
 
Main aim: To determine if 6OHDA triggered activation of Caspases-2,-4 and -8 in PERK ER stress 
pathway resulting in apoptotic death of dDCN. 
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6.2 Method: Investigating the influence of PERK pathway on Caspases-2,-4 and -8 in 
death of 6OHDA-treated dDCN 
 
6.2.1 Determining if activities of PERK and Caspases-2,-4 and -8 in 6OHDA-treated dDCN  
Similar methods were used as described in Chapter 5 to determine the influence of PERK pathway on 
each specific Caspase. Optimisation of salubrinal (Santa Cruz Biotechnology Heidelberg Germany) dose 
was established via treating 6OHDA dDCN with different concentrations of salubrinal (30µM - 120µM 
salubrinal) for 2 hour, after which fresh media was replaced and cells were left to recover overnight. 
dDCN and 6OHDA were cultured and treated 30µM salubrinal with different combinations of specific 
Caspase inhibitors such as 20µM zVDVADfmk (Merck Chemicals Nottingham UK), 20µM zLEVDfmk 
(Merck Chemicals Nottingham UK) or 80µM zIETDfmk (Merck Chemicals Nottingham UK) for 2 
hours, after which fresh media was replaced and cells were left to recover overnight.  Cells viability was 
determined and measured using MTT assay and statistical analysis as described in section 2.5.4. 
To determine the potential link between NFκB and PERK ER mediated death of 6OHDA dDCN, cells 
were treated either with 30µM salubrinal, 70µM IKK  and 50µM zVADfmk before measuring cell 
viability using MTT assay. ANOVA and T test (p<0.05) were performed as described in Chapter 2 
Section 2.5.4. A more detailed account of the reagents used can be found in Chapter 2 Section 2.2 and 
Appendix 1. 
 
6.2.2 Investigating if salubrinal can inhibit expression of active Caspases-2,-4 and -8 in 6OHDA-
treated dDCN using IF analysis  
 dDCN and 6OHDA were cultured and treated 30µM salubrinal and specific Caspase inhibitors such as 
20µM zVDVADfmk, 20µM zLEVDfmk or 80µM zIETDfmk for 2 hours, after which fresh media was 
replaced and cells were left to recover overnight. Cells were fixed with 4% parformaldehyde for 15 
minutes and were washed with cold PBS. Subsequently, cells were treated with Triton X (10 minutes) 
and blocked with 10% goat serum for 40 minutes prior to overnight incubation primary antibodies Anti-
TH (1:1500, Millipore Hertfordshire UK), active Anti-Caspase-2 (1:2000, Abcam Cambridge UK), active 
Anti-Caspase-4 (1:4000, Abcam UK), active Anti-Caspase-8 (1:2000, Abcam Cambridge UK) at 4oC. The 
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membrane was incubated with secondary antibodies Donkey-Anti-Mouse IgG FITC (1:500, Millipore 
Hertfordshire UK), Goat-Anti-Rabbit IgG Rhodamine (1:2500, Millipore Hertfordshire UK) for two 
hours at RT. Cells was mounted using vectorshield mounting medium and were viewed under a Meiji 
fluorescent microscope prior to statistical analysis as described in Chapter 2 Section 2.5.2. A more 
detailed account of the  reagents used can be found in Chapter 2 Section 2.1 -Section 2.2 and Appendix 
1. 
 
6.2.3 Determining if salubrinal can inhibit active Caspases-2,-4 and -8 in PERK pathway in 
6OHDA dDCN using WB analysis  
dDCN were grown and treated 30µM salubrinal, 100µM 6OHDA, 100µM 6OHDA and 30µM salubrinal 
for 2 hours, after which the fresh media was replaced and cells were left to recover overnight in 37 oC 
CO2 incubator. Cells were lysed and protein concentration was measured using the BCA kit. Fifty 
micrograms protein was loaded on 12% gel prior to SDS PAGE at 200 volts for 40 minutes, followed by 
immunoblotting on PVDF membrane. The membrane was blocked with 1% skimmed milk for an hour 
followed by incubation with primary antibodies, active Anti-Caspase-2 (1:2500, Millipore Hertfordshire 
UK), active Anti-Caspase-4 (1:300, Abcam Cambridge UK), and active Anti-Caspase-8 (1:1000, Millipore 
Hertfordshire UK) for overnight at 4oC. The membranes were washed with PBST and incubated with 
Goat-Anti-Rabbit HRP (1:1000, Millipore Hertfordshire UK) for an hour at RT. After washing the 
membranes with PBST, ECL system was employed and immunoblots bands were quantified with a 
densitometer scanner. Statistical analysis was carried out at p<0.05 using student T test followed by strip 
and reprobe with the house keeping gene GAPDH (Chapter 2 Section 2.3.4 and Chapter 2 Section 2.3.5 
correspondingly). Five independent experiments were performed for each treatment. A more detailed 
account of the reagents used can be found in Chapter 2 Section 2.1 - Section 2.2 and Appendix 1. 
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6.3 Results  
To determine if 6OHDA can trigger ER stress mediated apoptotic death in dDCN, the specific PERK 
inhibitor, salubrinal was used in untreated and 6OHDA-treated dDCN. Salubrinal was used to determine 
if it can increase cell survival or promote cell death via the ER stress pathway on 6OHDA-treated 
dDCN. Salubrinal prevented apoptotic death and promoted survival 6OHDA-treated dDCN (72% cell 
survival, p<0.01), compared to 6OHDA-treated dDCN, indicating that 6OHDA triggers death of 
dDCN, through an ER stress pathway. More specifically, 6OHDA activates PERK pathway leading to 
death of dDCN (Figure 6.1).   
 
Figure 6.1 : Determining the effect of salubrinal in 6OHDA-treated dDCN  
Salubrinal promoted survival of cells compared to cells that had been treated with 6OHDA by inhibiting 
the ER stress pathway, indicating the involvement of PERK pathway in dDCN. Proportion of cells 
surviving was determined by MTT absorbance at 570nm. Means of three experiments ± SEM shown. 
Table of values and statistical analysis can be found in Figure 6.2, Appendix 6.  
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To confirm if ER stress is not the only pathway which is causing death to 6OHDA-treated cells, 
different concentrations of salubrinal were used (30µM - 120µM). The results indicate that increasing the 
concentration of salubrinal did not completely inhibit death of 6OHDA-treated dDCN, strongly 
indicating that a second cell signalling pathway is involved which causes death of 6OHDA-treated 
dDCN (Figure 6.3). 
 
Figure 6.3 : Determining if further survival of 6OHDA-treated cells can occur by increasing the 
concentration of salubrinal  
Graph shows similar levels of survival of 6OHDA-treated cells occur at different salubrinal 
concentrations (30µM - 120µM). A gradual increase in salubrinal concentration did not provide further 
survival of 6OHDA-treated dDCN.  Proportion of cells surviving was determined by MTT absorbance 
at 570nm. Means of three experiments ± SEM shown. Table of values and statistical analysis can be 
found in Figure 6.4, Appendix 6. 
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To determine if suppression of UPR prevents activation of Caspases in 6OHDA dDCN, the broad 
Caspase inhibitor zVADfmk was used. In addition, the combination of zVADfmk and salubrinal was 
used to determine if the combination can provide more protection and decrease overall cell death of 
6OHDA-treated dDCN (Figure 6.5). The combination of zVADfmk and salubrinal promoted further 
survival of 6OHDA-treated dDCN (91% cell survival) compared to using only zVADfmk (56% cell 
survival) or salubrinal (78% cell survival) on its own. The additional survival of treated dDCN when 
using both inhibitors indicated that ER stress is not the only pathway that is causing apoptotic death of 
dDCN. Furthermore, the results suggest that Caspase activation is still occurring even when UPR is 
inhibited in 6OHDA-treated dDCN (Figure 6.5). 
 
Figure 6.5: Determining the effect of salubrinal and zVADfmk on 6OHDA-treated dDCN  
A significant increase in survival was determined in cells that had been treated 6OHDA +salubrinal+ 
zVADfmk treated dDCN (91% cell survival p <0.01). Proportion of cells surviving was determined by 
MTT absorbance at 570nm. Means of three experiments ± SEM shown. Table of values and statistical 
analysis can be found in Figure 6.6, Appendix 6.  
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Chapter 5 had shown 6OHDA triggered Caspase-2 activation in dDCN, via NFκB classical pathway. 
The next aim was to determine if PERK pathway influences activity of Caspase-2 in 6OHDA-treated 
dDCN. To achieve this aim, zVDVADfmk and salubrinal inhibitor were used separately and together in 
6OHDA-treated dDCN. The results demonstrated that 6OHDA dDCN that were treated with 
zVDVADfmk, salubrinal or both salubrinal and zVDVADfmk had similar levels of cell survival, 
suggesting 6OHDA triggered PERK and Caspase-2 activation via the same pathway in dDCN (Figure 
6.7).   
 
Figure 6.7 : Caspase-2 is active in ER stress pathway in 6OHDA-treated dDCN 
 A 65% cell survival rate was found in salubrinal treated dDCN, whereas 67% cell survival was measured 
in zVDVADfmk treated dDCN. A 71% cell survival was determined in 6OHDA+ salubrinal+ 
zVDVADfmk treated dDCN, suggesting no additional benefit of targeting both PERK ER Stress and 
Caspase-2. Proportion of cells surviving was determined by MTT absorbance at 570nm. Means of three 
experiments ± SEM shown. Table of values and statistical analysis can be found in Figure 6.8, Appendix 
6. 
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A closer examination of the findings revealed no additional benefit in survival of 6OHDA-treated 
dDCN when both inhibitors were used. The results strongly signify that using salubrinal inhibitor can 
inhibit Caspase-2 activity and so zVDVADfmk is not required, suggesting that Caspase-2 is active in 
PERK ER stress pathway in dDCN (Figure 6.9). 
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Figure 6.9 : Caspase-2 is active in ER stress mediated death of 6OHDA-treated dDCN 
Suppressing Caspase-2 pathway did not provide more survival of 6OHDA dDCN, illustrating that 
Caspase-2 and PERK are one pathway. The survival of 6OHDA dDCN did not significantly increase 
when zVDVADfmk was added with salubrinal, demonstrating that zVDVADfmk does not have an 
additional effect to slow death and promote cell survival (Comparison 6 p >0.05). No additional effect in 
cell survival was found when salubrinal was added to zVDVADfmk, indicating that PERK is following 
the same pathway as Caspase-2 in 6OHDA dDCN (Comparison 5 p>0.05). Furthermore, the use of the 
salubrinal inhibitor can be used to suppress both Caspase-2 and PERK activity in 6OHDA dDCN. 
Proportion of cells surviving was determined by MTT absorbance at 570nm. Means of three 
experiments ± SEM shown. Table of values and statistical analysis can be found in Figure 6.8, Appendix 
6. 
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Co-localisation studies were carried out to investigate if suppression of Caspase-2 activity can inhibit 
PERK activation in dDCN. Caspase-2 was found active in only in untreated and 6OHDA-treated 
dDCN (Figure 6.10). Active Caspase-2 was present in a greater proportion of TH-positive cells 
following 6OHDA treatment, indicating that 6OHDA triggers Caspase-2 in dDCN. Furthermore, active 
Caspase-2 was absent in salubrinal treated, zVDVADfmk treated, 6OHDA+salubrinal treated, 
6OHDA+zVDVADfmk treated, 6OHDA+salubrinal+zVDVADfmk treated dDCN. This indicated 
that activation of Caspase-2 is dependent upon stimulation of PERK pathway resulting in death of 
dDCN via ER stress.  
 
Figure 6.10 : Salubrinal and zVDVADfmk suppressed active Caspase-2 in 6OHDA-treated 
dDCN 
TH was present in untreated and 6OHDA-treated dDCN (green). A loss of dendrites was observed in 
TH positive dDCN that had been exposed to dDCN. Active Caspase-2 (red stain) was present in 
untreated and 6OHDA-treated TH positive dDCN (red). There were more Caspase-2 positive cells 
present in 6OHDA-treated dDCN, compared to untreated dDCN.  Active Caspase-2 was absent in 
salubrinal treated, 6OHDA+salubrinal treated dDCN. This indicates that inhibiting the PERK pathway 
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can suppress Caspase-2 activity in dDCN. Stimulation of Caspase-2 is dependent on activation of PERK 
ER stress pathway in dDCN. Furthermore, active Caspase-2 was absent in zVDVADfmk treated, 
6OHDA+zVDVADfmk treated dDCN, signifying that Caspase-2 activity is successfully suppressed in 
dDCN when using Caspase-2 inhibitor. Active Caspase-2 was not detected in salubrinal+ zVDVADfmk 
treated, 6OHDA + salubrinal + zVDVADfmk treated dDCN. Caspase-2 activation can be suppressed 
by directly inhibiting Caspase-2 or via inhibiting PERK ER stress pathway in untreated and 6OHDA-
treated dDCN.  Positive staining for cell bodies (White Arrow) in untreated (- 6OHDA) and treated (+ 
6OHDA) dDCN. Table of values can be found in Figure 6.11, Appendix 6.  
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To confirm if salubrinal can completely suppress Caspase-2 activation of treated dDCN WB analysis was 
carried out (Figure 6.12). Active Caspase-2 was absent in salubrinal treated, 6OHDA+salubrinal treated 
treated dDCN, indicating that 6OHDA triggers activation of Caspase-2 via PERK pathway in ER 
mediated death of dDCN.  
 
Figure 6.12 : Caspase-2 is suppressed by salubrinal in 6OHDA-treated dDCN 
A) Illustrative example of GAPDH in untreated, salubrinal, 6OHDA, salubrinal + 6OHDA treated dDCN. 
B) Illustrative example of active Caspase-2 in untreated, salubrinal, 6OHDA, salubrinal + 6OHDA treated 
dDCN. 
C) Quantitatively, there was an increase in active Caspase-2 detected in 6OHDA-treated dDCN, compared 
to untreated dDCN (p<0.05). The absence of active Caspase-2 in salubrinal treated and 
6OHDA+salubrinal treated dDCN, suggest that Caspase-2 activity is dependent upon PERK pathway. 
Means of five experiments ± SEM shown. Table of densitometry values and statistical analysis can be 
found in Figure 6.13, Appendix 6.  
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Recent research has shown that Caspase-4 is involved in ER mediated death of DCN. It was important 
to determine if Caspase-4 was involved in ER mediated death of 6OHDA-treated dDCN.  The findings 
illustrated that further cell survival was achieved in 6OHDA+salubrinal+zLEVDfmk treated dDCN, 
indicating 6OHDA triggers Caspase-4 and PERK activation via different mechanisms dDCN (Figure 
6.14). 
 
Figure 6.14 : 6OHDA triggered Caspase-4 activity in dDCN  
A 68% cell survival was determined in 6OHDA+ salubrinal treated dDCN, showing 6OHDA triggered 
PERK pathway. A 60% cell survival was measured in 6OHDA+ zLEVDfmk treated dDCN, 
demonstrating 6OHDA triggered Caspase-4 activation in dDCN. A further 77% survival of 6OHDA+ 
salubrinal + zLEVDfmk treated dDCN, indicating that PERK pathway does not influence Caspase-4 
activation in dDCN. zLEVDfmk in combination with salubrinal promoted further survival of 6OHDA-
treated dDCN, indicating an additional benefit of targeting ER stress pathway and Caspase-4. 
Proportion of cells surviving was determined by MTT absorbance at 570nm. Means of three 
experiments ± SEM shown. Table of values and statistical analysis can be found in Figure 6.15, 
Appendix 6. 
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The aim was to determine if Caspase-4 activity is influenced by PERK ER stress pathway in 6OHDA 
dDCN, via use of salubrinal and zLEVDfmk inhibitors (Figure 6.16).  The combination of salubrinal 
and Caspase-4 inhibitor provided further cell survival, suggesting that Caspase-4 is not following PERK 
pathway of ER stress and could be activated by another pathway, resulting in death of dDCN. 
Suppressing Caspase-4 pathway in addition to PERK pathway had an added effect in more cells 
surviving, indicating that there are two pathways.  
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Figure 6.16 :  Activation of Caspase-4 is independent of PERK pathway in 6OHDA dDCN. 
Survival of 6OHDA dDCN increased when salubrinal was added to zLEVDfmk, indicating that PERK 
ER stress pathway does not influence stimulation of Caspase-4 in 6OHDA-treated dDCN (comparison 
5 p<0.01). zLEVDfmk inhibited Caspase-4 activity promoting more survival of 6OHDA dDCN. 
Further cell survival of 6OHDA dDCN, was determined when zLEVDfmk was added with salubrinal 
(Comparison 6 p<0.01).The additional effect of more cells survival when Caspase-4 inhibitor and PERK 
inhibitor are combined indicates that there are two pathways that are contributing to death of 6OHDA 
dDCN. Furthermore, both inhibitors are required to be used to suppress both pathways so more cell 
survival can be achieved. Proportion of cells surviving was determined by MTT absorbance at 570nm. 
Means of three experiments ± SEM shown. Table of values and statistical analysis can be found in 
Figure 6.15, Appendix 6. 
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Double IF analysis was carried out to determine the presence and absence of Caspase-4 in untreated and 
6OHDA-treated dDCN (Figure 6.17). Caspase-4 was present in untreated, salubrinal treated, 6OHDA-
treated, 6OHDA+salubrinal treated dDCN, demonstrating that salubrinal did not suppress Caspase-4 
activation in dDCN. This puts forward the notion that Caspase-4 is not following the PERK pathway of 
ER mediated death of dDCN, indicating that another pathway is causing death of dDCN via Caspase-4 
activation. Furthermore, active Caspase-4 was absent in zLEVDfmk treated, 6OHDA+zLEVDfmk 
treated, 6OHDA+salubrinal+ zLEVDfmk treated dDCN. This shows that both Caspase-4 inhibitor and 
salubrinal need to be used to minimise death. 
 
Figure 6.17: Salubrinal does not inhibit active Caspase-4 in 6OHDA-treated dDCN 
Presence of TH positive cells was observed untreated and 6OHDA-treated dDCN (green).  
Active Caspase-4 was present in the same TH positive cells of untreated and 6OHDA-treated dDCN, 
signifying that Caspase-4 is actively present in dDCN (red). There were more active Caspase-4 positive 
cells in present in TH positive 6OHDA-treated dDCN, when compared to TH positive untreated (- 
6OHDA) dDCN, indicating 6OHDA enhanced further activation of Caspase-4 in dDCN.  
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Active Caspase-4 detected in salubrinal treated, 6OHDA+salubrinal treated dDCN. This indicates that 
inhibiting the PERK ER stress pathway does not influence Caspase-4 activity in dDCN. Stimulation of 
Caspase-4 is independent on activation of PERK pathway in dDCN. In contrast, active Caspase-4 was 
absent in zLEVDfmk treated, 6OHDA+zLEVDfmk treated dDCN, signifying that Caspase-4 activity is 
successfully suppressed in dDCN when using Caspase-4 competitive irreversible inhibitor. Caspase-4 
was not found in salubrinal+ zLEVDfmk treated, 6OHDA+salubrinal +zLEVDfmk treated dDCN. 
The Caspase-4 inhibitor, zLEVDfmk had directly suppressed Caspase-4 activation in untreated and 
6OHDA-treated dDCN.  Positive staining for cell bodies (White Arrow) in untreated (- 6OHDA) and 
treated (+ 6OHDA) dDCN. Table of values can be found in Figure 6.18, Appendix 6.  
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WB analysis was carried out to confirm if salubrinal could not suppress Caspase-4 activity in 6OHDA-
treated dDCN (Figure 6.19). Active Caspase-4 was present in untreated, salubrinal treated, 6OHDA-
treated, 6OHDA+salubrinal treated dDCN. An increase in the amount of active Caspase-4 was detected 
in 6OHDA-treated dDCN, compared to untreated dDCN. The ineffectiveness of salubrinal against 
activation of Caspase-4 further supports the notion that Caspase-4 is independent of ER mediated death 
of 6OHDA-treated dDCN. 6OHDA triggered Caspase-4 activation, but this was achieved, through a 
different route and not via PERK pathway.  
 
Figure 6.19 : PERK pathway does not influence Caspase-4 activation in 6OHDA dDCN 
A) Illustrative example of GAPDH in untreated, salubrinal, 6OHDA, salubrinal + 6OHDA treated dDCN. 
B) Illustrative example of active Caspase-4 in untreated, salubrinal, 6OHDA, salubrinal + 6OHDA treated 
dDCN. 
C) Quantitatively, a 67% increase in active Caspase-4 was detected in 6OHDA-treated dDCN, compared to 
untreated dDCN (p<0.05). Salubrinal neither prevented nor reduced the amount of active Caspase-4 in 
present in salubrinal treated and 6OHDA+salubrinal treated dDCN (p>0.05), indicating that PERK 
pathway does not influence Caspase-4 stimulation in 6OHDA-treated dDCN. Means of five 
experiments ± SEM shown. Table of densitometry values and statistical analysis can be found in Figure 
6.20, Appendix 6. 
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The involvement of Caspases-2,-4 and PERK activity was further determined in 6OHDA-treated dDCN, 
using different combinations of zVDVADfmk, zLEVDfmk and salubrinal (Figure 6.19). ANOVA 
analysis indicated a significant difference in survival of 6OHDA dDCN that were treated with 
zVDVADfmk, zLEVDfmk and salubrinal (p <0.01, Figure 6.21, Appendix 6). Subsequent T tests were 
used to identify key inhibitors that had the most effect in promoting survival and slowing death of 
6OHDA dDCN. 
No additional effect in cell survival was measured in 6OHDA +zVDVADfmk +salubrinal treated 
dDCN, suggesting that activation of Caspase-2 is completely dependent on PERK and suppression of 
PERK ER stress pathway will inhibit Caspase-2 activation in dDCN. There was no significant difference 
to slow death and promote cell survival in 6OHDA+ zVDVADfmk +salubrinal dDCN, indicating that 
the use of salubrinal inhibitor can suppress both PERK  and Caspase- activity in dDCN(p >0.01, Figure 
6.22).  
In comparison, additional cell survival of 6OHDA dDCN was determined when salubrinal was added 
with zLEVDfmk, demonstrating that salubrinal has an additional effect to slow death and promote cell 
survival. Further cell survival of 6OHDA+zLEVDfmk+salubrinal treated dDCN, signifying that both 
inhibitors can promote further survival and slow death of 6OHDA dDCN, via suppressing two different 
routes. The additional effect of more cells survival when Caspase-4 inhibitor and PERK inhibitor are 
combined indicates that there are two pathways that are contributing to death of 6OHDA dDCN (p 
<0.01, Figure 6.22). 
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Figure 6.22 : zLEVDfmk and salubrinal reduced further death of 6OHDA-treated dDCN  
6OHDA triggered activation of PERK ER stress, Caspases-2 and -4 in dDCN. Salubrinal suppressed 
Caspase-2 and PERK pathway of 6OHDA-treated dDCN. A further increase in survival and decreased 
death was measured in 6OHDA+zLEVDfmk +salubrinal treated dDCN, indicating that Caspase-4 and 
PERK are separate pathways that are causing apoptotic death of 6OHDA-treated dDCN. Salubrinal and 
zLEVDfmk protected more cells from death of 6OHDA-treated dDCN, indicating that both these 
inhibitors are required to suppress two pathways that are causing apoptotic death of 6OHDA dDCN. 
Proportion of cells surviving was determined by MTT absorbance at 570nm. Means of three 
experiments ± SEM shown. Table of values and statistical analysis can be found in Figure 6.21, 
Appendix 6. 
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A closer examination of Caspase-4 activity in relation to PERK indicated that Caspase-4 is independent 
on stimulation of PERK pathway (Comparison 9 p<0.05 Figure 6.23). The amount cell survival of 
6OHDA+salubrinal+zVDVADfmk treated dDCN, compared to 6OHDA+zVDVADfmk treated 
dDCN (Comparison 10 p>0.05), was not statistically significant, indicated activation of Caspase-2 is 
dependent on PERK pathway. The results demonstrated 6OHDA triggered activation of Caspases-2 and 
-4 via different pathways. Moreover, further survival of 6OHDA dDCN, was determined when 
salubrinal was added with zLEVDfmk, demonstrating that both inhibitors are required to be used to 
suppress pathways, promoting cell survival and slowing death.  
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Figure 6.23: The involvement of Caspases-4 and-2 activity in ER mediated 6OHDA dDCN 
The additional effect of more cells survival when Caspases-2 and-4 inhibitors are combined indicates that there 
Caspase-2 and -4 are two separate pathways that are contributing to death of 6OHDA dDCN (Comparison 6 
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p<0.05). Furthermore, both inhibitors are required to be used to suppress both pathways so more cell survival 
can be achieved. A further increase in survival and reduction in death of cells was determined in 6OHDA+ 
zVDVADfmk+ salubrinal treated dDCN, when compared to 6OHDA+ salubrinal +zVDVADfmk+ 
zLEVDfmk treated dDCN (Comparison 7 p<0.05), demonstrating salubrinal + zLEVDfmk need to be used 
together to successfully inhibit Caspase-4 and PERK activity in 6OHDA-treated dDCN.   In contrast, there 
was no significant difference observed in cell survival in 6OHDA+ zLEVDfmk + salubrinal treated dDCN, 
when compared to 6OHDA+ salubrinal +zVDVADfmk+ zLEVDfmk treated dDCN (Comparison 8 p>0.05), 
indicating PERK stimulates Caspase-2 activation in 6OHDA-treated dDCN. A greater benefit in cell survival 
was achieved when salubrinal and zLEVDfmk was used together as it successfully inhibited two separate 
pathways in 6OHDA-treated dDCN (Comparison 9, p <0.05). There was no additional benefit in reducing 
death of cells when zVDVADfmk and salubrinal inhibitor were combined, indicating that only the salubrinal 
inhibitor is required to suppress both PERK and Caspase-2 pathway in 6OHDA-treated dDCN (Comparison 
10, p>0.05). Proportion of cells surviving was determined by MTT absorbance at 570nm. Means of three 
experiments ± SEM shown. Table of values and statistical analysis can be found in Figure 6.21, Appendix 6. 
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The results indicated that Caspase-2 is activated by ER mediated death of 6OHDA-treated dDCN 
(Figure 6.24). Specifically 6OHDA has been able to stimulate Caspase-2 activation through the PERK 
pathway of ER stress. Surprisingly, Caspase-4 was not active in PERK pathway of ER mediated death of 
6OHDA-treated dDCN. This suggests that 6OHDA triggers Caspase-4 activation through a different 
route which may or may not be ER stress related. Before exploring other potential pathways that could 
be stimulated by 6OHDA, another Caspase of interest was explored, to determine it’s involved in ER 
mediated death of dDCN.  
 
 
 
 
 
 
 
 
Figure 6.24 : The involvement of Caspases-2 and -4 in ER mediated death of 6OHDA-treated 
dDCN 
Caspase-2 is involved in ER mediated cell death. Salubrinal was able to suppress Caspase-2 activity 
indicating that Caspase-2 is active in PERK pathway of ER stress. In comparison, Caspase-4 activity was 
not inhibited by salubrinal, suggesting that Caspase-4 is active in another route (such as ATF, IRE1) of 
the ER stress pathway or another pathway.  
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To date research has not investigated if Caspase-8 is associated with ER stress in DCN. It was essential 
to determine if Caspase-8 is active in the ER mediated death of 6OHDA-treated dDCN, using inhibitors 
salubrinal and zIETDfmk. The combination of salubrinal and zIETDfmk inhibitor had additional 
benefit to further increase survival of 6OHDA-treated dDCN, indicated that Caspase-8 and PERK are 
following different pathways (Figure 6.25)  
 
Figure 6.25:  6OHDA triggers Caspase-8 activation in dDCN  
A 63% cell survival was determined in 6OHDA+ salubrinal treated dDCN, showing 6OHDA triggered 
PERK pathway. A 72% cell survival was measured in 6OHDA+ zIETDfmk treated dDCN, 
demonstrating 6OHDA triggered Caspase-8 activation in dDCN. A further 85% survival of 6OHDA+ 
salubrinal + zIETDfmk treated dDCN, indicating that PERK pathway does not influence Caspase-8 
activation in dDCN. zIETDfmk in combination with salubrinal promoted further survival of 6OHDA-
treated dDCN, indicating an additional benefit of targeting ER stress pathway and Caspase-8. 
Proportion of cells surviving was determined by MTT absorbance at 570nm. Means of three 
experiments ± SEM shown. Table of values and statistical analysis can be found in Figure 6.26, 
Appendix 6. 
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Further analysis of demonstrated  an additional effect in cell survival of 6OHDA +salubrinal + 
zIETDfmk treated dDCN, suggesting that 6OHDA triggers Caspase-8 and PERK ER stress activity via 
different cell signalling mechanisms causing death of dDCN. Both salubrinal and zIETDfmk used 
together have an additional benefit to increase survival and reduce death of 6OHDA dDCN (Figure 
6.27). 
 Treatment 1 Treatment 2 Treatment 3 Treatment 4  
 6OHDA 
6OHDA 
SALUBRINAL 
6OHDA 
zIETDfmk 
6OHDA 
SALUBRINAL 
zIETDfmk 
p-value 
obtained 
Comparison 1 + + - - 0.001 
Comparison 2 + - + - 0.002 
Comparison 3 + - - + 0.0003 
 
Comparison 4 
- + + - 0.007 
 
Comparison 5 
- + - + 0.0004 
 
Comparison 6 
- - + + 0.002 
 
Figure 6.27: Caspase-8 is not involved ER stress pathway in 6OHDA-treated dDCN 
Survival of 6OHDA dDCN increased when salubrinal was added to zIETDfmk, indicating that PERK 
ER stress pathway does not influence stimulation of Caspase-8 in 6OHDA-treated dDCN (Comparison 
5 p<0.01). Further survival and decrease in death of 6OHDA dDCN was achieved when zIETDfmk 
was added to salubrinal, indicating that 6OHDA stimulated Caspase-8 and PERK ER stress pathways 
via different mechanisms (Comparison 6 p<0.01). The additional effect of more cells survival when 
Caspase-8 inhibitor and salubrinal inhibitor were combined indicates that there are two pathways that are 
contributing to death of 6OHDA dDCN. Furthermore, both inhibitors are required to be used to 
suppress both pathways so more cell survival can be achieved. Proportion of cells surviving was 
determined by MTT absorbance at 570nm. Means of three experiments ± SEM shown. Table of values 
and statistical analysis can be found in Figure 6.26, Appendix 6.  
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Double IF analysis was carried out to determine the presence and absence of Caspase-8 in untreated and 
6OHDA-treated dDCN after treated with salubrinal. Caspase-8 was present in untreated, salubrinal 
treated, 6OHDA-treated and 6OHDA+salubrinal treated dDCN, indicating that salubrinal did not 
suppress Caspase-8 activation in dDCN. This strongly indicates that Caspase-8 is not following the 
PERK pathway of ER mediated death of dDCN (Figure 6.28).  
 
Figure 6.28 Salubrinal does not inhibit active Caspase-8 in 6OHDA-treated dDCN 
Presence of TH positive cells was observed untreated and 6OHDA-treated dDCN (green).  
Active Caspase-8 was present in untreated and 6OHDA-treated dDCN (red). An increase in the 
proportion of active Caspase-8 positive cells was determined in 6OHDA-treated dDCN, when 
compared to untreated (- 6OHDA) dDCN, indicating 6OHDA enhanced further activation of Caspase-
8 in dDCN. Active Caspase-8 was present in the same TH positive cells of untreated and 6OHDA-
treated dDCN, signifying that Caspase-8 is actively present in dDCN.  
Active Caspase-8 was observed in salubrinal treated and 6OHDA+salubrinal treated dDCN, indicating 
that stimulation of Caspase-8 is independent from activation of PERK pathway in dDCN. In contrast, 
active Caspase-8 was absent in zIETDfmk treated and 6OHDA+zIETDfmk treated dDCN, signifying 
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that Caspase-8 activity is successfully suppressed in dDCN when using Caspase-8 inhibitor. Caspase-8 
was not found in salubrinal+ zIETDfmk treated and 6OHDA+salubrinal+zIETDfmk treated dDCN. 
The Caspase-8 inhibitor, zIETDfmk had directly suppressed Caspase-8 activation in untreated and 
6OHDA-treated dDCN.  Positive staining for cell bodies (White Arrow) in untreated (- 6OHDA) and 
treated (+ 6OHDA) dDCN. Table of values can be found in Figure 6.29, Appendix 6.  
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WB analysis was carried out to determine if salubrinal inhibited Caspase-8 activity in 6OHDA-treated 
dDCN (Figure 6.30). Salubrinal did not prevent nor reduce the amount of Caspase-8 in 6OHDA-treated 
dDCN, illustrating that salubrinal does not influence Caspase-8 activation. The ineffectiveness of 
salubrinal against activation of Caspase-8 further supports the notion that Caspase-8 is independent of 
PERK pathway and does not follow ER mediated death of treated dDCN. 6OHDA triggered Caspase-8 
activation but this was being achieved through a different route and not via PERK pathway.  
 
Figure 6.30 : PERK pathway does not suppress Caspase-8 activation in 6OHDA dDCN 
A) Illustrative example of GAPDH in untreated, salubrinal, 6OHDA, salubrinal + 6OHDA treated dDCN. 
B) Illustrative example of active Caspase-8 in untreated, salubrinal, 6OHDA, salubrinal + 6OHDA treated 
dDCN. 
C) Quantitatively, an 81% increase in active Caspase-8 was detected in 6OHDA-treated dDCN, compared 
to untreated dDCN (p<0.05). Salubrinal neither prevented nor reduced the amount of active Caspase-8 
in present in salubrinal treated, 6OHDA+salubrinal treated dDCN (p>0.05), indicating that PERK 
pathway does not influence Caspase-8 stimulation in 6OHDA-treated dDCN. Means of three 
experiments ± SEM shown. Table of densitometry values and statistical analysis can be found in Figure 
6.31, Appendix 6. 
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To investigate if further survival of 6OHDA-treated dDCN could be achieved by suppression of 
Caspases-2,-4,-8 and PERK activity, 6OHDA-treated dDCN were treated with different combinations 
of salubrinal, zVDVADfmk, zLEVDfmk and zIETDfmk. ANOVA analysis illustrated a considerable 
difference in survival of 6OHDA dDCN that were treated with zVDVADfmk, zIETDfmk, zLEVDfmk 
and salubrinal (p <0.01, Figure 6.32, Appendix 6). T tests were used to discover which inhibitors were 
most effective  in promoting survival and reducing  death of 6OHDA dDCN. The results demonstrate 
that the use of Caspase inhibitors, zLEVDfmk and zIETDfmk, along with salubrinal provide more 
protection and survival of 6OHDA-treated dDCN then using a single inhibitor or two inhibitors 
(p<0.01 Figure 6.33). 
Similar cell survival was determined in 6OHDA+salubrinal treated, 6OHDA+zVDVADfmk treated,  
6OHDA+salubrinal+zVDVADfmk treated dDCN (cell survival 64%, 61% and 66%), indicating PERK 
directly influences Caspase-2 activity. The amount of cell survival was not significant when 
zVDVADfmk inhibitor was added to salubrinal inhibitor, suggesting the addition of zVDVADfmk did 
not provide an additional effect to slow death and increase survival of 6OHDA-treated dDCN(p>0.05 
Figure 6.33). There was no significant difference to slow death and promote cell survival in 
6OHDA+zVDVADfmk+salubrinal treated dDCN, indicating that the use of salubrinal inhibitor can 
suppress both PERK and Caspase-2 activity, therefore zVDVADfmk is not required to inhibit death of 
dDCN. 
In comparison, more cell survival was achieved in 6OHDA + zLEVDfmk + salubrinal treated dDCN, 
compared to 6OHDA + salubrinal treated dDCN (77% cell survival, p<0.01 Figure 6.33). This showed 
that PERK does not influence Caspase-4 activity and suppression of Caspase-4 and PERK can provide 
additional benefit. There was a significant difference to slow death and promote cell survival in 6OHDA 
dDCN that were treated with both zLEVDfmk and salubrinal inhibitors, indicating that the use of both 
zLEVDfmk and salubrinal inhibitors can suppress both PERK and Caspase-4 activity in dDCN. The 
results demonstrate that the use of Caspase-4 inhibitors along with salubrinal promotes more protection 
and survival of 6OHDA-treated cells then using one inhibitor.  
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Furthermore, additional cell survival was determined in 6OHDA+ salubrinal+ zIETDfmk treated 
dDCN, compared to 6OHDA +  salubrinal treated dDCN, demonstrating that salubrinal has an 
additional effect to slow death and promote cell survival (p<0.01 Figure 6.33). Further cell survival of 
6OHDA dDCN, was determined when zIETDfmk was added with salubrinal, signifying that both 
inhibitors can promote further survival and slow death of 6OHDA dDCN, via suppressing two different 
routes. The additional effect of more cells survival when Caspase-8 inhibitor and PERK inhibitor are 
combined indicates that there are two pathways that are contributing to death of 6OHDA dDCN. 
 
Figure 6.33 : zLEVDfmk zIETDfmk  and salubrinal reduced death of 6OHDA dDCN 
Untreated and 6OHDA-treated dDCN were treated with different combinations of salubrinal, 
zVDVADfmk, zLEVDfmk and zIETDfmk to determine if maximal cell survival could be achieved by 
suppression of Caspases-2,-4,-8 and PERK activity. The use of Caspase inhibitors, zLEVDfmk and 
zIETDfmk, along with salubrinal provide more protection and survival of 6OHDA-treated dDCN then 
using a single inhibitor or two inhibitors. Proportion of cells surviving was determined by MTT 
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absorbance at 570nm. Means of three experiments ± SEM shown. Table of values and statistical analysis 
can be found in Figure 6.32, Appendix 6. 
A closer examination of the results portrayed that 6OHDA triggered activation of Caspases-2, -4 and -8 
using diverse pathways (Figure 6.34, Appendix 6).  Moreover, further survival of 6OHDA dDCN, was 
determined when salubrinal was added with zVDVADfmk and zIETDfmk, demonstrating that these 
three inhibitors are required to be used to suppress pathways, thereby promoting cell survival and 
slowing death.  
 
The findings demonstrated more  survival of cell  in 6OHDA + salubrinal + zLEVDfmk+ zIETDfmk 
+ zVDVADfmk treated dDCN,, when compared to 6OHDA +salubrinal + zVDVADfmk treated 
dDCN (Comparison 8, p<0.01, Figure 6.34, Appendix 6), indicating suppression of Caspase-4 and -8 as 
well as PERK reduces death of 6OHDA-treated dDCN.  
Similarly, suppression of Caspases-8, 2 and PERK can decrease death of and promote survival of 
6OHDA dDCN. cells that were treated with 6OHDA +  salubrinal + zIETDfmk + zLEVDfmk dDCN 
had a higher survival rate compared to 6OHDA-treated + salubrinal + zLEVDfmk dDCN, showing 
using three inhibitors to reduce death of cells is more effective than using two inhibitors (Comparison 9, 
p<0.01, Figure 6.34, Appendix 6). Furthermore, 6OHDA + salubrinal + zLEVDfmk+ zIETDfmk + 
zVDVADfmk treated dDCN had increased cell survival, when compared to 6OHDA +salubrinal  + 
zIETDfmk treated dDCN, indicating that the use of three inhibitors to suppress cell signalling pathways 
that cause death of dDCN is more effective than using two inhibitors (Comparison 10, p<0.01, Figure 
6.34, Appendix 6).  
 
The results portrayed a difference in cell survival between 6OHDA+salubrinal+zLEVDfmk treated 
dDCN and 6OHDA+salubrinal +zVDVADfmk treated dDCN (Comparison 11, p<0.05, Figure 6.34, 
Appendix 56), indicating Caspase-4 activity does not directly influence Caspase-2 activity and the 
stimulation of these Caspases are most likely through different mechanisms.  Furthermore, a significant 
difference in cell survival was determined in 6OHDA+salubrinal+zVDVADfmk treated dDCN, when 
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compared to 6OHDA+salurbianl +zIETDfmk treated dDCN (Comparison 12, p<0.01, Figure 6.34, 
Appendix 6), indicating activation of that Caspases-2 is in dependent on and activation on Caspase-8 and 
vice versa dDCN.  A significant increase in cell survival was determined in 6OHDA+salubrinal 
+zLEVDfmk treated dDCN, when compared to 6OHDA+salubrinal +zIETDfmk treated with dDCN 
(Comparison 13, p<0.01, Figure 6.36, Appendix 6), indicating that 6OHDA triggers Caspases-4 and-8 
activation in dDCN, through different mechanisms and one Caspase is not dependent on the other to be 
activated. 
 
There was no significant difference in cell survival in 6OHDA +zVDVADfmk treated dDCN, when 
compared to 6OHDA + salubrinal + zVDVADfmk treated dDCN (Comparison 14, p>0.05, Figure 
6.34, Appendix 6), indicating activation of Caspase-2 is dependent on PERK pathway. Suppression of 
PERK pathway had inhibited Caspase-2 activity, indicating that the use of salubrinal inhibitor can 
suppress both PERK and Caspase-2 activity in 6OHDA-treated dDCN. In contrast, a difference in cell 
survival was found between  6OHDA+zLEVDfmk treated dDCN, compared to 6OHDA + salubrinal 
+ zLEVDfmk treated dDCN, suggesting that PERK and Caspase-4 follow separate routes that result in 
the death of 6OHDA dDCN(Comparison 15, p<0.01, Figure 6.34, Appendix 6).  This showed that the 
use of salubrinal and zLEVDfmk inhibitor is effective to reduce death and increase survival of 6OHDA 
dDCN. Additionally, an additional effect in cell survival was found in 6OHDA+ zIETDfmk treated 
dDCN, when compared to 6OHDA + salubrinal + zIETDfmk treated dDCN, signifying PERK and 
Caspase-8 follow the different apoptotic pathway in 6OHDA dDCN. Suppression of these two 
pathways using salubrinal and zIETDfmk inhibitors would be more efficient to reduce death of 
6OHDA dDCN (Comparison 16, p<0.05, Figure 6.34, Appendix 6). 
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The results indicated that Caspase-2 is activated by ER mediated death of 6OHDA-treated dDCN. 
Specifically 6OHDA stimulated Caspase-2 activation through the PERK pathway of ER stress resulting 
in death of dDCN (Figure 6.35). In comparison, Caspases-4 and -8 were not active in PERK pathway of 
ER mediated death of 6OHDA-treated dDCN, suggesting 6OHDA triggers Caspases-4 and-8 activation, 
through a different route, which may or may not be ER stress related. It was also found that there was 
no cross talk between Caspases-2,-4 and -8 and each specific Caspase is stimulated by a different 
pathway in 6OHDA dDCN. 
 
 
 
 
 
 
 
 
 
Figure 6.35 : 6OHDA triggers activation of Caspase-2 via PERK ER stress pathway and 
stimulation of Caspases-4 and-8 in dDCN 
Caspase-2 is involved in PERK pathway of ER mediated death of 6OHDA-treated dDCN. Salubrinal 
suppressed Caspase-2 activity, indicating that Caspase-2 is active in PERK pathway of ER stress. In 
comparison, Caspases-4 and-8 activity was not inhibited by salubrinal, suggesting 6OHDA triggers 
Caspases-4 and- 8 activities via separate mechanisms resulting in apoptotic death of dDCN.  
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The results from the previous Chapter had shown that 6OHDA triggers an additional pathway apart 
from NFκB classical pathway in dDCN. The importance of NFκB activity was determined in PERK ER 
stress mediated apoptotic death of 6OHDA-treated dDCN. The findings illustrated that further cell 
survival was achieved in 6OHDA+IKK+salubrinal treated dDCN, indicating 6OHDA triggers PERK 
and NFB activation via different mechanisms (Figure 6.36) 
 
 
Figure 6.36: 6OHDA promotes NFB and PERK ER Stress mediated death of dDCN 
PERK activity in NFB classical pathway were determined in untreated and 6OHDA-treated, 
6OHDA+IKK, 6OHDA+salubrinal, 6OHDA+IKK+salubrinal treated dDCN. 6OHDA triggered 
PERK activation in dDCN. A 65% cell survival was determined in 6OHDA+salubrinal treated dDCN.  
A 52% cell survival was determined in 6OHDA+IKK treated dDCN. An 80% cell survival was 
determined in 6OHDA+IKK+salubrinal treated dDCN, indicating an additional benefit of targeting 
NFB classical pathway and PERK pathway. Proportion of cells surviving was determined by MTT 
absorbance at 570nm. Means of three experiments ± SEM shown. Table of values and statistical analysis 
can be found in Figure 6.37, Appendix 6. 
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The combination of IKK and salubrinal was used to investigate if IKK and salubrinal follow the same 
pathway or if there is any cross talk in these pathways in 6OHDA-treated dDCN (Figure 6.38). Findings 
indicated that 6OHDA triggers NFB mediated and ER mediated death of dDCN, via the NFB 
classical pathway and PERK pathway (respectively). These results indicated that 6OHDA is provoking 
death of dDCN via two separate independent routes. This can be further explained by the fact that if ER 
stress and NFB were following the same pathway, then the addition of IKK to salubrinal would not 
provide more survival of 6OHDA-treated dDCN.  An additional effect in further survival of 6OHDA 
dDCN was measured when both IKK and salubrinal were used.  
 Treatment 1 Treatment 2 Treatment 3 Treatment 4  
 6OHDA 
6OHDA 
IKK 
6OHDA 
SALUBRINAL 
6OHDA 
IKK 
SALUBRINAL 
p-value 
obtained 
Comparison  1 + + - - 0.0023 
Comparison  2 + - + - 0.0006 
Comparison  3 + - - + 0.00002 
Comparison  4 - + + - 0.0006 
Comparison  5 - + - + 0.0004 
Comparison  6 - - + + 0.0011 
 
Figure 6.38: NFB does not influence PERK activation in 6OHDAinduced dDCN 
Additional cell survival of 6OHDA dDCN was determined when salubrinal was added with IKK, 
demonstrating that salubrinal has an additional effect to slow death and promote cell survival 
(Comparison 6, p<0.01). Further cell survival of 6OHDA dDCN, was determined when IKK was added 
with salubrinal, signifying that both inhibitors can promote further survival and slow death of 6OHDA 
dDCN, via suppressing two different routes (Comparison 5, p<0.01). The additional effect of more cells 
survival when NFKB inhibitor and PERK inhibitor are combined indicates that there are two separate 
pathways that are contributing to death of 6OHDA dDCN. Proportion of cells surviving was 
determined by MTT absorbance at 570nm. Means of three experiments ± SEM shown. Table of values 
and statistical analysis can be found in Figure 6.37, Appendix 6. 
 
- 253 - 
 
The results indicated that 6OHDA stimulated NFκB classical pathway and PERK pathway of ER stress 
resulting in death of dDCN. Furthermore, the findings demonstrated that there was no cross talk 
between PERK and NFκB activities suggesting that 6OHDA triggers these two pathways separately 
resulting in apoptotic death of dDCN (Figure 6.39). 
 
 
 
 
 
 
 
 
 
Figure 6.39: 6OHDA triggers PERK and NFB classical pathway in dDCN 
6OHDA stimulates activation of PERK and NFB classical pathway, resulting in apoptotic death of 
dDCN. This finding was determined using specific inhibitors, salubrinal and IKK in 6OHDA-treated 
dDCN, using MTT assay. Salubrinal inhibited activation of PERK pathway and promoted survival of 
6OHDA-treated dDCN. Similarly, IKK suppressed activation of NFB classical pathway, thereby 
reducing 6OHDA-treated dDCN. The suppression of NFB classical and PERK pathway had increased 
survival of 6OHDA-treated dDCN, suggesting that NFB classical pathway does not influence PERK 
pathway and vice versa in 6OHDA-treated dDCN. 
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To determine if NFB and ER stress were the main pathways that cause apoptotic death in  
It was essential to determine if 6OHDA triggered a third pathway that significantly contributed to 
apoptotic death of dDCN. Suppression of PERK ER stress pathway promoted survival and slowed 
death of cells that had been treated with 6OHDA+salubrinal. Similarly, an increase in cell survival was 
measured in 6OHDA+IKK treated dDCN, via inhibiting NFκB activity. zVADfmk had slowed death 
and promoted survival of 6OHDA dDCN, signifying that 6OHDA triggered Caspase mediated 
apoptotic death of dDCN. More survival of cells was achieved when cells were treated with 
6OHDA+IKK+salubiranl+zVADfmk, indicating that suppressing Caspases, NFκB and PERK 
pathways can reduced apoptotic death of dDCN (Figure 6.40).  
 
Figure 6.40: Salubrinal IKK and zVADfmk promoted further survival of 6OHDA dDCN 
A 51% cell survival was found in 6OHDA+ zVADfmk treated dDCN, emphasising Caspase mediated 
death of 6OHDA dDCN. A 56% cell survival was determined in 6OHDA+IKK treated dDCN. A 73% 
cell survival was determined in 6OHDA+salubrinal treated dDCN. A 90% cell survival was determined 
in 6OHDA+zVADfmk+IKK+salubrinal treated dDCN, indicating an additional benefit of targeting 
NFB, PERK and Caspases pathways. Proportion of cells surviving was determined by MTT 
absorbance at 570nm. Means of three experiments ± SEM shown. Table of values and statistical analysis 
can be found in Figure 6.41, Appendix 6. 
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A closer analysis of the results revealed 6OHDA triggered NFκB, PERK and Caspase pathways resulting 
in apoptotic death of dDCN. An additional effect in cell survival was measured in 6OHDA salubrinal 
+IKK +zVADfmk treated dDCN, suggesting that PERK  and NFκB pathway cause death of 6OHDA 
dDCN, but there are other potential pathways that cause death of dDCN. 6OHDA triggers another 
pathway apart from PERK ER Stress and NFκB classical pathway that results in apoptotic death of 
dDCN.  There is a high possibility that this potential pathway is related to Caspase-4 activation that is 
contributing to apoptotic death of dDCN (Figure 6.42).  
 
 Treatment 1 Treatment 2 Treatment 3 Treatment 4 Treatment 5  
 6OHDA 
6OHDA 
zVADfmk 
 
6OHDA 
SALUBRINAL 
6OHDA 
IKK  
6OHDA 
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Figure 6.42: 6OHDA promoted PERK ER Stress, NFκB and Caspase mediated apoptotic death 
of dDCN 
More cell survival was achieved when zVADfmk was added to 6OHDA+salubrinal+IKK treated dDCN, 
indicating that 6OHDA triggers another Caspase cell signalling pathway causing apoptotic death of 
dDCN (Comparison 5 p<0.05).  A higher level of survival and decrease in death of cells was achieved 
when salubrinal was added to 6OHDA+IKK+zVADfmk, treated dDCN, demonstrating that salubrinal 
has an additional effect to slow death and promote cell survival (Comparison 6 p<0.05).Further cell 
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survival of cells was measured when IKK was added to 6OHDA+salubrinal+ zVADfmk treated dDCN, 
signifying that all three inhibitors can promote further survival and slow death of 6OHDA dDCN, via 
suppressing three different routes (Comparison 7 p<0.01). The additional effect of more cells survival 
when Caspase, NFKB and PERK inhibitors are combined indicates that there are three separate 
pathways that are contributing to death of 6OHDA dDCN. Proportion of cells surviving was 
determined by MTT absorbance at 570nm. Means of three experiments ± SEM shown. Table of values 
and statistical analysis can be found in Figure 6.41, Appendix 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 257 - 
 
6.4 Discussion  
One of the main aims was to determine the impact the PERK ER stress pathway had in 6OHDA 
dDCN. Collectively the results demonstrated 6OHDA triggers PERK pathway resulting in ER mediated 
death of dDCN (Figure 6.1-6.5). Furthermore, the PERK ER stress pathway was one of the major 
routes that caused apoptotic death rather than survival of dDCN, when triggered by 6OHDA (Figure 
6.39). Moreover, activation of PERK promoted stimulation of Caspase-2 in 6OHDA dDCN (Figure 6.7-
Figure 6.12).  
 
These findings are similar to previous research by Arduíno et al (2009a) that demonstrated activation of 
Caspase-2 in tunicamycin treated neuronal cells using WB analysis. IF and WB analysis revealed PERK is 
an upstream protein which promotes activation of Caspase-2 in dDCN. IF, WB and inhibitor analysis 
demonstrated that suppression of PERK protein had inhibited Caspase-2 activation, resulting in an 
increase in survival of 6OHDA dDCN. Previous research by Jiang et al (2010) portrayed salubrinal had 
reduced Caspase-3 activity and protected cells from ER stress mediated apoptosis sodium butyrate 
treated PD cells. In comparison, the current study showed salubrinal had suppressed Caspase-2 activity 
leading to an increase in cell survival and slowing death of 6OHDA dDCN (pages 226-230).  
 
Furthermore, work by Chinta et al (2009) demonstrated that salubrinal had decreased p-eIF2α, CHOP, 
XBP-1 and Caspase-3 activation in paraquat induced N27 dopaminergic cell line. Paraquat caused an 
increase of ROS in the cell which can lead to cell death via oxidative stress. 6OHDA has been known to 
promote elevated ROS levels provoking death of DCN. In the current study stimulation of PERK 
leading to Caspase-2 activity and death of dDCN may have been due to an elevation of ROS caused by 
6OHDA. The elevated accumulation of ROS may have caused misfolding and impairment of proteins 
leading to initiation of PERK ER stress pathway, which promoted Caspase-2 activation leading to 
apoptotic death of dDCN. To confirm this, future studies could explore the levels and what types of 
ROS are involved in death of 6OHDA dDCN over a time frame. This would indicate at what point 
ROS accumulation can cause the ER stress pathway to switch from promoting cell survival to cell death.  
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Another factor that could be investigated is the impact salubrinal inhibitor has on ROS levels itself in 
6OHDA-treated dDCN.   
 
The current study is the first to determine if active Caspase-8 is involved in ER mediated death of 
6OHDA dDCN. IF and WB analysis illustrated Caspase-8 activation in presence of the PERK inhibitor 
salubrinal, signifying that stimulation of Caspase-8 is achieved through a different pathway and  is not 
connected to the PERK pathway in 6OHDA dDCN (Figure 6.28-Figure 6.30). A closer examination of 
Caspase-8 activation in relevance to PERK pathway in 6OHDA dDCN, revealed that suppressing 
PERK pathway and inhibiting Caspase-8 pathway promoted further cell survival of dDCN (Figure 6.25- 
Figure 6.27). In addition, the current study is the first to explore if there is any cross talk between 
Caspases-2,-4 and -8 with relevance to PERK ER mediated death of dDCN. Cell viability assays that had 
been treated with different combinations of inhibitor had shown that there was no cross talk between 
caspases-2,-4 and -8 in 6OHDA dDCN (Figure 6.33-Figure 6.35).  
 
Work by Smith et al (2005) found that Caspase-12 participates in ER stress mediated death of DCN. 
Salubrinal partially inhibited death of DCN by suppression of Caspase-12, indicating that ER stress 
caused death of DCN but other pathways such as the mitochondrial pathway also contributed to death 
of DCN. In comparison, to work carried out by Smith et al (2005), Caspase-12 was not detected but 
Caspase-4 was active in 6OHDA-treated dDCN in the current study. However, Caspase-12 was present 
in PD-Ex (refer to Chapter 3) but not in found in 6OHDA dDCN, therefore another ER associated 
protein, Caspase-4 was used as a substitution.  One possible reason why Caspase-12 was not detected in 
dDCN could be because the human cell has large deletions of essential homologous of Caspase-12, 
whilst in animal model all the essential codons to promote Caspase-12 protein are expressed so Caspase-
12 is usually actively expressed in PD animal model and not in human PD model (Hertz 2009).  
Similar to Smith et al (2005), this research has demonstrated that ER stress causes death of 6OHDA 
DCN but other pathways also contribute to death of dDCN. Suppression of PERK pathway as well as 
Caspases-4 and -8 can promote further survival of more cells, demonstrating the involvement of other 
 
- 259 - 
 
pathways (Figure 6.33-Figure 6.35).  Smith et al (2005) suggested that the intrinsic pathway may be 
involved in death of DCN, whilst results from this research indicate an involvement of NFB classical 
pathway. Another pathway that could be explored is the intrinsic pathway in relation to ER mediated 
and NFB mediated death of dDCN. 
A surprising outcome was achieved in the current study which illustrated the lack of relation of Caspase-
4 in PERK ER mediated death of 6OHDA dDCN. IF and WB analysis had shown that salubrinal had 
not suppressed Caspase-4 activation in 6OHDA dDCN (Figure 6.17-Figure 6.19). Cell survival analysis 
using inhibitors had revealed activation of Caspase-4 pathway causes death of dDCN but the stimulation 
of Caspase-4 activity is independent from PERK pathway in 6OHDA-treated cells (Figure 6.14-Figure 
6.16). These findings are in contrast to research carried out by Lee et al (2010) that illustrated increased 
levels of CHOP, p-PERK, p-IRE-1, p-EIF2α , XBP-1, Caspases-3 and -4 in tunicamycin treated SK-N-
SH cells using colorimetric Caspase specific assays, indicating that Caspase-4 is triggered by PERK 
pathway. Furthermore, salubrinal had reduced Caspase-4 activity in tunicamycin treated SK-N-SH cells.  
 
The reason for PERK pathway did not influence Caspase-4 activity in dDCN could be due to the type 
of neurotoxin used. 6OHDA may have triggered Caspase-4 pathway through calcium mechanisms 
instead of PERK pathway in dDCN. This potential idea can be supported by research performed by 
Arduíno et al (2009b) which had shown that MPTP leakage of calcium from the ER into the 
mitochondria provoked activation of Caspases-2,-3,-4 and -9 resulting in death of neuronal PD cells. WB 
and colorimetric assays had shown increased levels of Caspases-2,-3,-4 and -9 over a time course in 
MPTP PD cells. 
 
Similarly, research by Higuchi et al (2005) has shown that calcium promoted Caspase-4 and Calpain 
activation in transgenic mice that had been injected with kainic acid. IF analysis revealed degeneration of 
axonal and dendrites as well as an up regulation of Caspase and Calpain activation signifying that 
elevated calcium levels provokes Calpain and Caspase stimulation resulting in degeneration of neuronal 
axons and. Although no work has been carried out in Calpain, Caspase and Caspase activation in dDCN, 
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it is plausible that calcium imbalance and Calpain proteins interact and effect Caspase activation and 
death of dDCN. It is possible that 6OHDA may have triggered Caspase-4 activation through a calcium 
related pathway in dDCN. Although suppression of Caspase-2 can be achieved by inhibiting the PERK 
pathway, further understanding of the PERK ER stress pathway in cell death and survival needs to be 
established. The PERK ER stress pathway is vital for normal cellular processes and so the complete 
suppression of this pathway may result in other potential problems.  
 
Currently there has not been any research determining if there is a link between NFB pathway and 
PERK ER stress pathway in 6OHDA-treated dDCN. The aim of this research was to investigate any 
cross talk of NFB classical and PERK ER stress pathway in 6OHDA-treated dDCN. The results 
demonstrated that 6OHDA triggered NFκB classical pathway and ER stress pathway via independent 
different routes resulting in death of dDCN (Figure 6.36). Activation of NFB pathway did not 
influence activation of ER stress pathway or vice versa, emphasising that the pathways are activated by 
6OHDA independently in dDCN (Figure 6.39).   
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6.5 Conclusion  
6OHDA triggers activation of PERK pathway resulting in ER mediated death of dDCN (Figure 6.1-6.5). 
IF and WB analysis revealed that stimulation of the PERK pathway encourages activation of Caspase-2 
activity contributing to death of 6OHDA-treated dDCN (Figure 6.10-Figure 6.12). IF, WB and cell 
viability assays illustrated that suppression of PERK pathway inhibits stimulation of Caspase-2, resulting 
in an increase in survival of 6OHDA dDCN. IF, WB and cell viability assays demonstrated that 6OHDA 
triggered activation of Caspases-4 and-8 independently to the PERK ER stress pathway in dDCN. 
Suppression of PERK, Caspases-4 and -8, using a combination of salubrinal, zLEVDfmk and 
zIETDfmk inhibiters had protected DCN from death and significantly increased survival of 6OHDA-
treated dDCN Figure (Figure 6.33-Figure 6.34). The PERK ER stress pathway is one of the main routes 
that contribute to apoptotic death of 6OHDA dDCN (Figure 6.35). However, 6OHDA provokes other 
potential pathways that result in Caspase mediated death of 6OHDA dDCN via apoptotic routes (Figure 
6.40- Figure 6.42). Further research to identify other key proteins in the PERK ER stress pathway would 
aid to provide better targets to slow death and provide protection of DCN (Figure 7.1).  
Furthermore, inhibitor cell viability assay have shown suppression of PERK ER Stress and NFκB 
classical pathway had resulted in a significant amount of survival and decrease in 6OHDA dDCN, 
indicating 6OHDA promotes NFκB and PERK ER mediated apoptotic death of dDCN (Figure 6.36). 
However, activation of NFB and PERK pathway were independent of one another and 6OHDA had 
provoked activation of NFB and PERK, via different routes (Figure 6.39).   
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Chapter 7: 
General Discussion 
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7.0 Summary of Results  
Different types of exercise have been explored ranging from Nordic walking to dancing (tango, waltz, 
and foxtrot), muscle and strength resistance and different environments (land versus water) in PD 
patients (Fritz et al 2011, Stallibrass et al 2002, Hackney and Earhart 2009a, Hackney and Earhart 2007, 
Hackney and Earhart 2010, Li et al 2012, Earhart, 2009b, Dreu et al 2012, Vivas et al 2011). All these 
exercises have shown some improvement not only decreasing key features that are present in PD such as 
gait, tremors and bradykinesia, but also improving quality of life of the PD patient in terms of forming 
social networks and integrating well into their lifestyle. Although there are extensive clinical studies 
carried out on treadmill exercise showing improvement in PD symptoms (Tomsilon et al 2012, Herman 
et al 2007, Canning et al 2012). However, there is a lack of biochemical understanding to how exercise is 
affecting PD patients at a cellular level and on key proteins involved in the development and progression 
of PD. Hence, there is a lack of research exploring the potential pathways, which exercise can activate 
and suppress to provide such positive and even negative effects. The current study is the first to explore 
the effect of treadmill exercise on Caspases, along with CAMK-IV protein in different brain regions of 
MPTP rat model using WB analysis (Chapter 3 Figure 3.2-Figure 3.48).  
 
The results of this research had demonstrated a general reduction or absence active Caspase as well as 
increase in active CAMK-IV levels in different brain regions of PD animal model that underwent 
endurance exercise (Chapter 3). More specifically, treadmill exercise may have inhibited activation of 
Caspases-2, -8 and -12 in the midbrain and striatum of PD animal model (Chapter 3 Figure 3.22, Figure 
3.26, Figure 3.32, Figure 3.36 and Figure 3.40). There is a possibility that exercise may be acting as an 
initiator that triggers different proteins or it may activate specific proteins that directly suppress Caspase 
activation, leading to a decrease in death of DCN. There also exist the possibility that exercise triggers 
proteins, which in turn stimulate other proteins that activate another generation of proteins leading to 
suppression of Caspases, indicating that exercise reduces death of neuronal cells and that may be due to 
different Caspase pathways.  To determine how exercise is reducing and inhibiting activation of Caspases, 
the first step was to investigate stimulation of Caspases. Only through discovering what key proteins are 
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important in Caspase activation and establishing which pathways Caspases are involved in that result in 
death of DCN, can improved therapies and treatments be created in the future. In addition, establishing 
which pathways the Caspases follow and understanding the key events that occur in Caspase activation 
new targets for treatment can be achieved. Exercise may have had decreased and suppressed specific 
Caspases, such as Caspases-12,-8 and -2 in PD animal models, putting forward an idea that suppression 
of specific pathways may inhibit and slow down the rate of death of DCN in PD (Chapter 3 Figure 3.2, 
Figure 3.6, Figure 3.10-Figure 3.16, Figure 3.20-Figure 3.26, Figure 3.3-Figure 3.36 and Figure 3.40). To 
explore this notion further in vitro work, using dopaminergic stem cells was employed.  
 
In attempt to answer these questions, the first step was to establish how Caspases are activated in DCN 
of studied PD model. To achieve this, the aim was to identify the pathway or pathways that trigger 
Caspase activation in DCN of PD. It was important to determine how Caspase-2, -4 and -8 are activated 
and which pathways they follow were investigated using ReNcell VM stem cell line that had been 
differentiated in DCN and treated with 6OHDA (Chapter 4).   
 
In the current study the universal Caspase inhibitor, zVADfmk had demonstrated that 6OHDA 
triggered Caspase mediated death of dDCN(Chapter 4, Chaudhry and Ahmed 2013). TUNEL staining 
had confirmed that 6OHDA triggered apoptotic death of dDCN. TUNEL assay with wide range 
inhibitors showed involvement of NFκB, PERK, Caspases-2,-4 and -8 in apoptotic death of 6OHDA 
dDCN (Chapter 4 Figure 4.17 and Figure 4.19). In addition, co localisation studies showed active 
Caspases-2,-3 and-8 were present in 6OHDA-treated dDCN, indicating 6OHDA triggers Caspases-2 
and -8 followed by Caspase-3 in dDCN (Chapter Figure 4.4-Figure 4.7). WB analysis showed 
zVADfmk decreased Caspase-2,-3 and -8 levels in dDCN (Chapter 4 Figure 4.11-Figure 4.15). 
Therefore, it was appropriate to conclude that 6OHDA had triggered apoptotic death of dDCN 
successfully establishing a suitable PD model to investigate potential pathways that stimulate Caspases 
(Chapter 4, Chaudhry and Ahmed 2013). 
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In order to understand potential pathways which cause Caspase activation leading to death of dDCN, the 
NFB pathway was explored (Chapter 5). The IKK inhibitor that is specific to prevent activation of 
NFκB classical pathway was used to explore the impact NFκB classical pathway has on Caspase 
activation in 6OHDA-treated dDCN(Chapter 5 Figure 5.15-Figure 5.43). Co-localisation studies 
illustrated that 6OHDA triggered activation of Caspases-2, -3 and -8, along with active NFB expression 
in dDCN (Chapter 5 Figure 5.6). The specific NFB inhibitor, IKK was used to investigate if the NFB 
classical pathway promoted activation of Caspases-2, -4 and -8 resulting in apoptotic death of dDCN 
(Chapter 5 Figure 5.15- Figure 5.41). Cell viability, IF and WB analysis revealed that IKK inhibited 
Caspases-2 and-8 activities and promoted survival of treated dDCN (Chapter 5 Figure 5.15-Figure 5.32). 
In comparison, Caspase-4 was not affected by IKK inhibitor as IKK was not able to suppress Caspase-4 
activity suggesting that Caspase-4 is stimulated via alternative pathway (Chapter 5 Figure 5.33-Figure 
5.41). In addition, the combination of Caspase-4 inhibitor and IKK increased cell survival of 6OHDA-
treated dDCN, indicating that there are two separate pathways that are causing apoptosis of 6OHDA-
treated dDCN (Chapter 5, Figure 5.41-Figure 5.43).  
 
Subsequently, it was essential to determine if ER stress was involved in Caspase activation in 6OHDA-
treated dDCN (Chapter 6). Salubrinal, a specific inhibitor of the ER stress pathway was used to 
investigate if the PERK pathway promoted activation of Caspases-2,-4 and -8, resulting in apoptotic 
death of dDCN (Chapter 6 Figure 6.7-Figure 6.35). Cell viability, IF and WB analysis revealed that 
salubrinal inhibited Caspase-2 activity and promoted survival of treated dDCN. 6OHDA triggered 
activation of Caspase-2, via PERK pathway in dDCN (Chapter 6 Figure 6.7-Figure 6.12). In comparison, 
Caspases-4 and-8 was not inhibited by salubrinal suggesting that PERK pathway does not influence 
activation of these Caspases in 6OHDA-treated dDCN (Chapter 6 Figure 6.14-Figure 6.33). Collectively, 
the results illustrated that the PERK ER stress pathway plays a vital role in death of 6OHDA dDCN 
(Chapter 6 Figure 6.35). IF and cell viability assays using a range of specific inhibitors demonstrated that 
6OHDA stimulates activation of Caspases-2,-4 and -8 independently and that there is no cross talk 
between these Caspases in dDCN (Chapter 6, Figure 6.7-Figure 6.35).  
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It was vital to investigate if NFB classical pathway and ER stress pathway are dependent of each other 
and if one pathway provokes activation of the other pathway in 6OHDA-treated dDCN (Chapter 6). To 
achieve this aim, specific inhibitors, IKK and salubrinal were used to determine if NFB and PERK ER 
stress pathway followed the same route or if they independently promoted death of 6OHDA-treated 
dDCN by separate routes. The results demonstrated that 6OHDA triggered NFB classical pathway and 
ER stress pathway via independent different routes, resulting in death of dDCN. Activation of NFB 
classical pathway did not influence activation of ER stress pathway or vice versa, emphasizing that both 
pathways are activated by 6OHDA independently (Chapter 6, Figure 6.39).  To confirm this, the 
combination of IKK and salubrinal prevented further death and increased more cell survival of 
6OHDA-treated dDCN then using one inhibitor alone (Chapter 6 Figure 6.36-Figure 6.42). The 
additional effect measured when combining both inhibitors highlighted that 6OHDA triggers NFB and 
ER stress activation through different pathways resulting in death of dDCN. Inhibition of the PERK 
ER stress pathway using salubrinal and suppression of NFB pathway using IKK gives a greater increase 
of cell survival, compared to inhibiting one pathway alone (Figure 6.36-Figure 6.42. 6OHDA equally 
triggers two main pathways the PERK ER stress and NFB classical pathway resulting in death of 
dDCN (Chapter 6 Figure 6.36-Figure 6.42).   
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Results obtained from animal data and cell line illustrate the presence of Caspases in vivo and in vitro 
PD model.  The findings from MPTP-treated animal model and 6OHDA-treated cell line demonstrate 
Caspase activation. MPTP-treated animal model demonstrated an increase in Caspases-2,-3,-8,-9 and -12 
in different brain regions. In contrast, 6OHDA stimulated Caspases-2,-3,-4 and -8 in dDCN. In 
differentiated cell line, specific Caspases inhibitors such as zLEVDfmk, zVDVADfmk, zIETDfmk and 
zVADfmk were used to competitively inhibit Caspases activation. In PD animal model, endurance 
exercise was used to determine if it can act as a potential inhibitor to suppress Caspase activation in 
different brain regions. An increase in activity of the calcium binding protein CAMK-IV was found in the 
midbrain and striatum of MPTP-treated rats that underwent six week endurance exercise.  
 
Prevention of PERK ER Stress and NFB pathway had significantly increased survival and slowed death 
of 6OHDA-treated dDCN but there was still cell death occurring, indicating that it is possible that there 
is another potential route that is needed to be identified (Figure 7.1). Activation of Caspase-4 remains to 
be investigated and it is possible that calcium may influence Caspase-4 activity resulting in apoptotic 
death of dDCN (Figure 7.1). The final outcomes of both PD animal model and cell model indicate a 
positive direction to explore the impact of calcium for future studies. Calcium regulation plays a vital role 
in ER function. Calcium imbalance could lead to UPS and ER stress and activation of Caspase mediated 
death of dDCN. Research has shown Calpain can activate Caspases due to calcium imbalance (Ozcan 
and Tabas 2012). It is plausible that Calpain can activate Caspases resulting in apoptotic death of dDCN 
via calcium mechanisms.  
 
 
 
 
 
 
 
 
- 268 - 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 7.1 : 6OHDA Triggers Caspase Mediated Apoptotic Death of dDCN, via PERK ER 
stress and NFB Pathway 
It was important to determine how Caspases are activated, which pathways they follow and if there is a 
major or several pathways, which cause Caspase activation leading to death of dDCN. 
6OHDA triggered activation of PERK ER Stress and NFκB classical pathway in dDCN. PERK ER 
Stress pathway stimulates activation Caspase-2 in 6OHDA-treated dDCN. NFκB classical pathway 
stimulates activation of Caspases-2 and -8 6OHDA-treated dDCN. 6OHDA stimulated Caspase-4 
leading to apoptotic death of dDCN. Inhibition of PERK ER stress pathway suppresses Caspase-2 
activity in 6OHDA-treated dDCN. Complete suppression of NFκB classical pathway inhibited Caspase-
2 and -8 activation in 6OHDA-treated dDCN. Identifying proteins that are downstream from PERK ER 
stress and NFκB but are upstream from Caspases-2 and -8 will give a better understanding and  provide 
potential targets that can be used to safely inhibit apoptotic death of DCN without disturbing normal 
cellular function.  
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7.1 Future Work  
The results from the current study have shown that 6OHDA triggers Caspase-2, -3, -4 and -8 activation 
via ER and NFB mediated death of dDCN (Figure 7.1). Suppression of NFB pathway and ER stress 
pathway using specific inhibitors IKK and salubrinal prevented downstream events to take place, such as 
Caspase activation, resulting in survival of dDCN. WB analysis demonstrated that exercise had shown a 
link between elevated CAMK-IV levels and reduced activation of Caspases in midbrain and striatum of 
PD animal model (Chapter 3 Figure 3.50-Figure 3.51). The results from the current study have exposed 
further questions that need to be explored, discovered and addressed (as discussed below). The results 
from the study have shown that PERK, and NFB are upstream factors which cause death of dDCN, 
but the question remains how they are exactly activated (Figure 7.1). Do other proteins trigger activation 
of PERK, and NFB or is there activation a direct result of elevated production of ROS caused by 
6OHDA in dDCN? Even more curious is determining how ER stress and NFB, which are both 
initially promoting survival of dDCN, can switch to provoking death of dDCN. Although the results 
show that ER stress pathway and NFB pathway are triggered by 6OHDA separately, it may be that the 
two pathways have a common switch, that is more upstream, which when activated, results in death of 
dDCN.  
 
Collectively, results from PD animal model and in dDCN have shown that calcium plays a crucial role in 
PD, and have shown the need to explore the influence of calcium in 6OHDA-treated DCN. A future 
aim would be to determine how calcium switches from having favourable to adverse effects in 6OHDA-
treated dDCN. What key events are involved and are there several proteins that promote calcium to 
switch from encouraging cell survival to cause cell death of dDCN. Moreover, is elevated ROS 
production directly provoking the calcium switch, resulting in Caspases dependent death in dDCN or if 
there is a presence in a series of events that occur before calcium levels are increased? Calpain are calcium 
dependent proteins found in the cytosol of cells and have been associated with Caspase activation as a 
result of calcium imbalance and ER stress (Fan et al 2005, Higuchi et al 2005, Chaudhry and Ahmed 
2014, Ozcan and Tabas 2012,  Itohara and Saido 2005). To extend the current study, it would be of 
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interest to explore the role of Calpain in calcium-dependent death of dDCN. The aim could be to 
determine if Calpain works as an upstream protein, if it can activate a specific Caspase and its role in 
calcium or ER stress mediated death of 6OHDA-treated dDCN.  
 
Calcium is vital for synaptic transmission as well as production of neurotransmitters, yet elevated calcium 
levels may trigger Caspases dependant death of dDCN (Cali et al 2011, Surmeier 2009, Subramaniam 
and Chesselet 2013, Cesaro and Defebvre 2014). Specifically, the concentration of calcium in the ER and 
cytosol could be measured to determine if 6OHDA can trigger leakage of calcium from the ER stores 
into the cytosol in a time frame of 0 to 24 hour cycle. The data obtained would provide important 
information at which time frame calcium can promote apoptotic death of DCN. The calcium inhibitor 
nimodipine may be used to determine if calcium levels have an influence in treated DCN (Li et al 2009). 
Another future aim would be to determine if Caspases-2,-4 and -8 were present in tunicamycin or 
thapsigargin induced dDCN. This would determine if PERK and changes in calcium level influence 
death of dDCN.  
 
Although the results with the use of inhibitors, have clearly demonstrated that specific Caspases follow 
particular routes, a different approach could have also been used to understand the mechanism which 
activates Caspase in dDCN. ELISA Caspase specific assays (Life Technologies UK) could have been 
performed to detect and measure the level of Caspases-2, -3, -8 and -12 in 6OHDA dDCN. Electron 
microscopy could have been used to examine different layers of each brain region of PD animal model, 
in depth as this would provide further background on how treadmill exercise is affecting each brain 
region of PD animal model. Research has shown that PD patients find it difficult to express emotion, 
which may be due to disruption of the cranial nerves, more specifically the facial nerve being affected 
(Mu et al 2013, Thomas and Le 2004). Another exploration would be to determine the effect of 
Caspases and the pathways in relation to cranial nerves in PD in vitro and in animal model. Does 
activation of Caspases cause disruption of the facial nerve and to what extent is the damage? Are both 
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the ER stress pathway and NFB pathway causing destruction of the facial nerve or if there is another 
pathway that contributing death of dDCN? 
  
The complete suppression of PERK ER stress and NFB classical pathway inhibited activation of 
Caspases-2 and -8 in 6OHDA dDCN. However, total inhibition of these pathways may contribute or 
ignite new problems at a cellular and physiological level, as both pathways are involved in a diverse range 
of processes that regulate healthy cells (Asanuma et al 2004, Cassarino et al 2000, Yamamoto and 
Gaynor 2001, Todd et al 2008, Oakes and Papa 2014, Sano and Reed 2013). Therefore, there is a need to 
further understand and define the involvement of other proteins that act downstream from NFB and 
PERK, but upstream to the Caspases. These newly identified proteins would be better targets to safely 
suppress Caspase activation and slow death of 6OHDA dDCN, without impacting other cellular 
mechanisms (Figure 7.1). 
 
It is essential to understand at which point NFB and PERK switches from cell survival to apoptotic 
route need to be determined, which key markers and proteins are involved need to be established 
(Chaudhry and Ahmed 2014).  To achieve this , a time interval study , could be carried out to identify 
which well known ER proteins such as PERK, eIF2-α, CHOP, XBP1, GRP78 and Caspases-2,-3,-4 and-
8 are present in 6OHDA-treated dDCN. The presence and absence of these proteins may aid in 
establishing a pathway by indicating which proteins are present and absent at a particular time using the 
cleaved and active form of these proteins in WB analysis. The time interval would start at 0 times and 
the interval would be every half hour for a 24 hour cycle which would determine at which time frame 
each specific protein is either up regulated or down regulated, present or absent after treatment with 
6OHDA. This set up could also be carried out when cells are treated with tunicamycin or thapsigargin 
for a 24 hours cycle and comparisons can be made. The results obtained would determine the 
involvement of key proteins that are acting upstream and/or downstream and would give a clearer image 
as to how Caspases are being activated in 6OHDA-induced dDCN. It may be that there is an upstream 
key protein that overlaps two proteins or is common in both PERK and NFB pathway, which has the 
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potential to trigger the Caspases, can be revealed. Subsequently, this protein can be targeted and 
manipulated to prevent and slow death of dDCN. The NFB pathway and PERK ER stress pathway are 
both vital in other normal cellular functions, therefore the total suppression of these pathways would 
inhibit specific Caspase activation, but it may hold the potential to cause other cellular abnormalities, 
which could be more disastrous.  Taken this into account, a future aim would be to identify key proteins 
that act downstream from NFκB and PERK but act upstream from the Caspases, and to target these 
proteins (Figure 7.1).  
 
 In addition, isolation of cellular components such as mitochondria, ER , cytosol and nucleus may give a 
better understanding as to how 6OHDA can triggers Caspase activation  and death of dDCN. Isolation 
of ER can be achieved using ER isolation kit (Sigma-Aldrich UK 2011) where suspended cells undergo a 
series of separation using centrifugation followed by fractionating the columns centrifuged x 600g for 10 
minutes. The supernatant would be removed, and cells would be incubated for 20 minutes with 
hypotonic extraction buffer (10mM HEPES, 25mM potassium chloride, 1mM  EGTA, analytical water, 
protease inhibitor cocktail)  at 4°C. Subsequently, cells would be centrifuged x 600g for 10 minutes after 
which the supernatant would be removed. Isotonic buffer (10mM HEPES, 25mM potassium chloride , 
1mM  EGTA, 250mM sucrose, analytical water, protease inhibitor cocktail) would be added and cells 
would be homogenised using Dounce homogeniser. The homogenate would be centrifuged x 1000g for 
15 minutes at 4°C. The supernatant would be transferred to another tube and the post mitochondrial 
fraction would be ultracentrifuged for 60 minutes x 100, 000g. The supernatant would be removed and 
the pellet (microsomal fraction) would be homogenised completely in isotonic extraction buffer. 
Microsomal fraction would contain the crude ER. Calcium activation kit could be used to measure the 
amount of calcium in the ER, cytosol, nuclei and mitochondria in untreated and treated DCN. Another 
method to measure amount of calcium in whole DCN is with the use of fluorescent probes. Treated and 
untreated cells could be collected and centrifuged at 1000rpm for 3 minutes. The old medium would be 
removed and cell pellet would be resuspended in Fluo4 direct assay buffer in 96 well plate. The plate 
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would be incubated at 37°C and 5% CO2 for 60 minutes to allow the cells to settle. Finally, the 
fluorescence would be measured at excitation at 494 nm and emission at 516 nm. 
 
The effect of 6OHDA caused in the purified cellular components can be looked at over a time interval 
and the effect of Caspases-2,-4 and -8 can be studied. To expand on this work Caspase and Calpain 
inhibitors can be used to determine if they can reduce death of 6OHDA-treated DCN. Calcium and 
Calpain involvement can be explored in 6OHDA dDCN and its involvement with Caspase activation 
and death of dDCN can be determined. This study has not explored the intrinsic pathway 
(mitochondrial) and its involvement in DCN. Is calcium a cause or effect of collapse of mitochondria? 
What is the impact of exercise on mitochondrial dependant activation of the Caspases in DCN? Previous 
research has shown that Caspase-12 can trigger Caspase-9 followed by Caspase-3 (Alteri 2010, 
Nakamura et al 2012, Chowdhury 2013, Chaudhry and Ahmed 2014, McIlwain et al 2013). In this study, 
Caspase-12 was looked at in animal model and was substituted with Caspase 4 in dDCN. It would be 
interesting to investigate if Caspase-4 able to promote Caspase-9 activation without the presence of the 
mitochondria. Does Caspase-12 or any other Caspases intensify death of DCN, via mitochondrial death 
of dDCN?  
 
Another important aspect to determine is the amount and type of ROS that are causing death of 
dopaminergic neurons after 6OHDA treatment. This could be achieved using specific cellular ROS 
detection kit (Abcam UK 2015), which would measure the amount of ROS in the cell. After diffusion in 
to the cell, DCFDA is deacetylated by cellular esterases to a non-fluorescent compound, which is later 
oxidized by ROS into 2’, 7’-dichlorofluorescin (DCF). DCF is a highly fluorescent compound, which can 
be detected by fluorescence spectroscopy with maximum excitation and emission spectra of 495nm and 
529nm respectively. After cells have reached 85% confluence cells would treated as before (100µM 
6OHDA 2 hour exposure). Cells would be collected, centrifuged and washed with cold PBS buffer 
following incubation with 20µM DCFDA for 30 minutes at 37°C  in the dark. Cells would be washed 
again with PBS and supplementary buffer containing 10% FBS. Absorbance would be read at excitation 
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wavelength at 485 nm and emission wavelength at 535 nm. Quantitative analysis would be achieved 
using microplate reader to measure the amount of hydroxyl, peroxyl and other ROS activity inside the 
cell before and after treatment. Hydrogen peroxide may be used as a positive control.  
 
Furthermore, the amount of ROS and RNS may be measured using Oxiselect InVitro ROS/RNS Assay 
kit (Cambridge Bioscience UK 2015). Cells would be treated with 6OHDA at 2 hours after reaching 
85% confluence. Cells would be collected, centrifuged at 10000g for 5 minutes and washed with PBS. 
Fresh PBS would be added to the cells along with catalase. The quenching fluorogenic probe, 
dichlorodihydrofluorescin DiOxyQ (DCFH-DiOxyQ) would be added to the homogenate with priming 
solution, mixed and left to incubate for 30 minutes at RT. The stabilising solution would be added to the 
cells and mixed to stabilise to its reactive DCFH form. The RNS and ROS react to DCFH and is 
oxidised to DCF and absorbances would be measured at 485nm excitation wavelength. Quantitative 
analysis could be achieved to measure the levels of hydrogen peroxide, peroxyl radical, nitric oxide, and 
peroxynitrite anion against a DCF standard curve.  
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7.2 Clinical relevance  
Although previous and current research has shown that treadmill exercise can decrease PD symptoms 
they have not been clear as to how exercise is able to cause such benefits. Furthermore current research 
has looked at the consequence of exercise but not the cause of the positive effects (Tomsilon et al 2012, 
Herman et al 2007, Canning et al 2012). Only through understanding how exercise can improve PD, can 
effective treatments be made. An in-depth knowledge on what impact exercise has on DCN, which 
pathways it can stimulate and suppress and specific proteins to inhibits or activate in DCN are crucial to 
understand.   
The results from the proposed study will provide further answers to which pathways (ER, mitochondrial, 
NFB) play a major role in regulating Caspases causing apoptotic cell death in PD, and if by inhibiting 
one or two major pathways can reduce further cell death in PD. Through understanding the molecular 
pathways regulating cell death in DCN in PD, new potential targets for therapy, such as specific drugs 
which target particular proteins of the major pathways, may be identified, which may ultimately reduce 
further death of DCN and slow PD progression (Figure 7.1). At present L-DOPA is used in 
combination with physical therapy as a form of treatment for PD patients (Singer et al 2012, LeWitt 
2015, Pourmoghaddam et al 2015). This proposed study may have the potential to seek for more 
efficient drugs which can suppress Caspase activation by targeting key targets in the pathways that the 
Caspases follow. These new specific targeted drugs could be used with treadmill exercise to achieve 
maximum effect, by slowing down or inhibiting further death of DCN.  
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Appendix 1 
Reagents  
 
 
 
 
 
 
 
 
 
 
  Product Name Supplier 
 
Use 
 
Antibodies     
 AB1872 
Anti-Caspase 1 
(Rabbit) 
Abcam 
330 Cambridge Science 
Park 
Cambridge 
CB4 0FL 
UK 
WB 
 AB7979 
Anti-Caspase 2 
Active 
(Rabbit) 
Abcam 
330 Cambridge Science 
Park 
Cambridge 
CB4 0FL 
UK 
WB 
IF 
 AB3623 
Anti-Caspase 3 
Cleaved 
(Rabbit) 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
IF 
WB 
 04-439 
Anti-Caspase 3 
Active 
(Rabbit) 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
IF 
 AB52183 
Anti-Caspase 4 
Active 
(Rabbit) 
Abcam 
330 Cambridge Science 
Park 
Cambridge 
CB4 0FL 
UK 
IF 
WB 
 AB97318 
Anti-Caspase 4 
(Rabbit) 
Abcam 
330 Cambridge Science 
Park 
Cambridge 
CB4 0FL 
UK 
IF 
WB 
 AB25897 
Anti-Caspase 8 
Active 
(Rabbit) 
Abcam 
330 Cambridge Science 
Park 
Cambridge 
CB4 0FL 
UK 
IF 
WB 
 
 
 
 04-444 
Anti-Caspase 9 
Active 
(Rabbit) 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
WB 
 AB62484 
Anti-Caspase 12 
Cleaved 
(Rabbit) 
Abcam 
330 Cambridge Science 
Park 
Cambridge 
CB4 0FL 
UK 
WB 
 04-1078 
Anti-CAMK IV 
Active 
(Rabbit) 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
WB 
 MAB3026 
Anti-NFκB 
Cleaved 
(Mouse) 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
IF 
WB 
 
 
MAB318 
 
Anti-Tyrosine 
Hydroxylase 
(Mouse) 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
IF 
 AB152 
Anti-Tyrosine 
Hydroxylase 
(Rabbit) 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
IF 
 AQ300R 
Sheep Anti Mouse 
IgG Rhodamine 
 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
IF 
 
 
 AP123R 
Goat Anti Rabbit 
IgG 
Rhodamine 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
IF 
 AQ300F 
Sheep Anti Mouse 
IgG FITC 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
IF 
 AB6791 
Sheep anti Rabbit 
IgG FITC 
 
Abcam 
330 Cambridge Science 
Park 
Cambridge 
CB4 0FL 
UK 
IF 
 AP192F 
Donkey Anti Mouse 
IgG FITC 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
IF 
 12-348 
Goat anti Rabbit 
HRP conjugate 
 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
WB 
 AP192P 
Donkey Anti-Mouse 
HRP conjugate 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
WB 
     
     
Cell Culture     
 SCM008 ReNVM cell 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
Cell culture 
 
 
 
 SCM005 
ReNcell NSC 
Maintenance 
Medium 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
Cell culture 
 SCM007 
ReNcell NSC 
Freezing Medium 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
Cell culture 
 L2020 Laminin 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
Cell culture 
 D5796 DMEM 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
Cell culture 
 
A6964 
 
Accutase 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
Cell culture 
 
GF003 
 
EGF 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
Cell culture 
 GF144 FGF 
Millipore Ltd 
3-5 The Courtyards 
Hatters Lane 
Watford 
Hertfordshire 
WD18 8YH 
UK 
Cell culture 
 
 
 H116 6OHDA 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
Cell culture 
 S-1000 Goat serum 
Vector Laboratories 
3 Accent Park 
Pakewell Road 
Southgate 
Peterborough 
PE2 6XS 
UK 
IF 
 158127 Paraformaldehyde 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
IF 
 N150 Triton X 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
IF 
 T8787 BSA 
Vector Laboratories 
3 Accent Park 
Pakewell Road 
Southgate 
Peterborough 
PE2 6XS 
UK 
IF 
 158127 
Vector shield 
Mounting Medium 
Vector Laboratories 
3 Accent Park 
Pakewell Road 
Southgate 
Peterborough 
PE2 6XS 
UK 
IF 
     
 BT30006 MTT 
Cambridge BioScience   
Munro House   
Trafalgar Way   
Bar Hill   
Cambridge, CB23 8SQ   
UK 
Calorimetric 
 
 
 
 
 
G7351 
 
CaspACE assay  
system 
Promega 
Delta House 
Southampton Science 
Park 
Southampton 
SO16 7NS 
UK 
Calorimetric 
 482830K TUNEL 
Trevigen 
8405 Helgerman Ct 
Gauthersburg 
Maryland 
MD 20877 
USA 
TUNEL assay 
 401479 
Insolution IKK2 
inhibitor 
Merck Chemicals Ltd   
Boulevard Industrial 
Park  
Padge Road 
Nottingham 
NG9 2JR 
UK 
TUNEL assay 
Calorimetric 
IF 
WB 
 SC-202332 Salubrinal 
Santa Cruz 
Biotechnology 
Bergheimer Str.89-2 
69115 Heidelberg 
Germany 
TUNEL assay 
Calorimetric 
IF 
WB 
 
G7351 
 
zVADfmk 
Promega 
Delta House 
Southampton Science 
Park 
Southampton 
SO16 7NS 
UK 
TUNEL assay 
Calorimetric 
IF 
WB 
 107920 zATADfmk 
Merck Chemicals Ltd   
Boulevard Industrial 
Park  
Padge Road 
Nottingham 
NG9 2JR 
UK 
TUNEL assay 
Calorimetric 
IF 
WB c 
 218755 zLEVDfmk 
Merck Chemicals Ltd   
Boulevard Industrial 
Park  
Padge Road 
Nottingham 
NG9 2JR 
UK 
TUNEL assay 
Calorimetric 
IF 
WB 
 
 
 218759 zIETDfmk 
Merck Chemicals Ltd   
Boulevard Industrial 
Park  
Padge Road 
Nottingham 
NG9 2JR 
UK 
TUNEL assay 
Calorimetric 
IF 
WB 
 218744 zVDVADfmk 
Merck Chemicals Ltd   
Boulevard Industrial 
Park  
Padge Road 
Nottingham 
NG9 2JR 
UK 
TUNEL assay 
Calorimetric 
IF 
WB 
     
     
 302050 Tris  base 
Severn Biotech 
Unit 2 
Park Lane 
Kidderminster 
Worcestershire 
DY11 6TJ 
UK 
WB 
 303310 SDS 
Severn Biotech 
Unit 2 
Park Lane 
Kidderminster 
Worcestershire 
DY11 6TJ 
UK 
WB 
 302125 Glycine 
Severn Biotech 
Unit 2 
Park Lane 
Kidderminster 
Worcestershire 
DY11 6TJ 
UK 
WB 
 30-20-60 
30% acryl amide 
Mix 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
WB 
 30-33-10 
Ammonium 
persulphate 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
WB 
 
 
 
 30-21-60 BSA 
Perbio Science 
Unit 9, Atley Way 
North Nelson Industrial 
Estate Cramlington 
Northumberland 
NE231WA 
UK 
WB 
 A3574 
BCA Protein Assay 
Kit 
Pierce Biotechnology 
3747 Meridian Road 
Rockford 
 IL 61105 
 USA 
Protein Assay 
 A3678 DTT 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
WB 
 23209 TEMED 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
WB 
 23227 Glycerol 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
WB 
 43819 Bromophenol Blue 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
WB 
 P5493 Prestained marker 
Invitrogen 
3 Fountain Drive  
Inchinnan Business 
Park  
Paisley   
PA4 9RF 
UK 
WB 
 T9281 Coomaisse 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
WB 
 
 
Gillingham 
Dorset 
SP8 4XT 
UK 
 G8773 Glacial acetic acid 
Fisher Scientific 
Bishop Meadow Road 
Loughborough 
Leicestershire 
LE11 5RG 
UK 
WB 
 B5525 Methanol 
Fisher Scientific 
Bishop Meadow Road 
Loughborough 
Leicestershire 
LE11 5RG 
UK 
WB 
 B7920 Analytical water 
Fisher Scientific 
Bishop Meadow Road 
Loughborough 
Leicestershire 
LE11 5RG 
UK 
WB 
 
A040025 
 
Ponceau solution 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
WB 
 M/3950/15 EDTA 
Severn Biotech 
Unit 2 
Park Lane 
Kidderminster 
Worcestershire 
DY11 6TJ 
UK 
WB 
 W/0100/21 ECL solution 
Perbio Science 
Unit 9, Atley Way 
North Nelson Industrial 
Estate Cramlington 
Northumberland 
NE231WA 
UK 
WB 
 81462 PBS 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
Cell Culture 
IF 
WB 
 P1379 Tween20 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
WB 
 
 
 
Dorset 
SP8 4XT 
UK 
 30-232-60 
Kodak developer 
solution 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
WB 
 
34087 
 
Kodak fixer solution 
Sigma-Aldrich Ltd 
The Old Brickyard 
New Road 
Gillingham 
Dorset 
SP8 4XT 
UK 
WB 
 FMXOB0101824 
Kodak MXB Blue 
film 18 x 24 
Xograph Healthcare 
Xograph House 
Ebley Road 
Stonehouse 
Gloucestershire 
GL10 2LU 
UK 
 
WB 
 P8307 
Kodak 18 x 24 
cassette 
Xograph Healthcare 
Xograph House 
Ebley Road 
Stonehouse 
Gloucestershire 
GL10 2LU 
UK 
 
WB 
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Appendix 3 
Data Analysis : PD Animal Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Investigating the Amount of Active Caspase-2 in Brain Cortex of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
 
 
DETERMINING CASPASE- 2 
ACTIVITIES IN BRAIN CORTEX OF C, 
Ex, PD & PD-Ex GROUP 
  
ANOV
A 
      
 
MEAN 
C 
MEAN 
Ex 
MEAN 
PD 
MEAN 
PD-Ex  
  
Grou
ps 
Co
unt 
Su
m 
Av
era
ge 
Va
ria
nce 
  
Active 
Caspase-
2 Assay 1 
0.98 1.11 1.78 1.25 
  
MEA
N C 5 
6.3
97
35
57 
1.2
79
471
1 
0.0
30
58
58 
  
Active 
Caspase-
2 Assay 2 
1.28 1.17 1.75 1.03 
  
MEA
N Ex 5 
5.7
62
98
82 
1.1
52
59
76 
0.0
575
68 
  
Active 
Caspase-
2 Assay 3 
1.35 1.50 1.81 1.15 
  
MEA
N PD 5 
8.4
47
231 
1.6
89
44
62 
0.0
162
38 
  
Active 
Caspase-
2 Assay 4 
1.43 1.15 1.61 1.40 
  
MEA
N PD-
Ex  5 
5.7
92
515
6 
1.1
58
50
31 
0.0
30
753
7 
  Active 
Caspase-
2 Assay 5 
1.35 0.83 1.51 0.96 
         Mean of 
All 
Assays  
1.28 1.15 1.69 1.16 
  
ANOV
A 
      
Mean of 
All 
Assays % 
100 90 132 91 
  
Sourc
e of 
Varia
tion SS df MS F 
P-
val
ue 
F 
cri
t 
SD 0.17 0.24 0.13 0.18 
  
Betwe
en 
Group
s 
0.9
611
89
4 3 
0.3
20
39
65 
9.4
83
01
36 
0.0
00
775
8 
3.2
38
871
5 
SD (%) 17.49 23.99 12.74 17.54 
  
Withi
n 
Group
s 
0.5
40
581
7 16 
0.0
33
78
64 
   T Test  
  
0.003 0.001 
         
       
Total 
1.5
017
711 19         
               
 
 
 
 
 
 
Figure 3.5: Investigating the Amount of Cleaved Caspase-3 in Brain Cortex of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
 
              
 
DETERMINING CASPASE-3 
ACTIVITIES IN BRAIN CORTEX OF C, 
Ex, PD & PD-Ex GROUP 
  
ANOVA 
     
 
MEAN 
C 
MEAN 
Ex 
MEAN 
PD 
MEAN 
PD-Ex  
  
Grou
ps 
Co
unt 
Su
m 
Av
era
ge 
Va
ria
nce 
  
Cleaved 
Caspase-
3 Assay 1 
1.23 1.19 1.49 0.91 
  
MEA
N C 5 
7.0
29
83
89 
1.4
05
96
78 
0.0
129
09 
  
Cleaved 
Caspase-
3 Assay 2 
1.38 1.11 1.78 1.18 
  
MEA
N Ex 5 
5.4
511
03
7 
1.0
90
22
07 
0.0
179
851 
  
Cleaved 
Caspase-
3 Assay 3 
1.48 1.10 1.92 1.33 
  
MEA
N PD 5 
8.6
47
24
49 
1.7
29
44
9 
0.0
24
72
93 
  
Cleaved 
Caspase-
3 Assay 4 
1.42 1.19 1.70 0.86 
  
MEA
N PD-
Ex  5 
5.1
43
27
67 
1.0
28
65
53 
0.0
45
86
64 
  Cleaved 
Caspase-
3 Assay 5 
1.52 0.86 1.76 0.86 
         Mean of 
All 
Assays  
1.41 1.09 1.73 1.03 
  
ANO
VA 
      
Mean of 
All 
Assays % 
100 78 123 73 
  
Sourc
e of 
Varia
tion SS df MS F 
P-
val
ue 
F 
cri
t 
SD 0.11 0.13 0.16 0.21 
  
Betwe
en 
Group
s 
1.5
62
76
96 3 
0.5
20
92
32 
20.
531
07
6 
9.8
61
E-
06 
3.2
38
87
15 
SD (%) 11.36 13.41 15.73 21.42 
  
Withi
n 
Group
s 
0.4
05
95
88 16 
0.0
25
37
24 
   T Test  
  
0.007 0.001 
          
 
 
 
      
Total 
1.9
68
72
84 19         
               
 
 
 
 
 
 
 
 
Figure 3.7: Investigating the Amount of Active Caspase-8 in Brain Cortex of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
 
 
 
DETERMINING CASPASE-8 
ACTIVITIES IN BRAIN CORTEX OF 
C, Ex, PD & PD-Ex GROUP 
   
ANOV
A 
      
 
MEA
N C 
MEAN 
Ex 
MEAN 
PD 
MEAN 
PD-Ex  
   
Group
s 
Co
unt 
Su
m 
Ave
rag
e 
Var
ian
ce 
  Active 
Caspase-
8 Assay 
1 
1.30 1.59 1.89 1.20 
   
MEAN 
C 5 
7.0
472
26
9 
1.4
094
454 
0.0
089
505 
  Active 
Caspase-
8 Assay 
2 
1.36 1.17 1.61 1.09 
   
MEAN 
Ex 5 
6.7
874
274 
1.3
574
855 
0.0
250
107 
  Active 
Caspase-
8 Assay 
3 
1.49 1.41 1.89 1.27 
   
MEAN 
PD 5 
9.0
92
001
1 
1.81
84
00
2 
0.0
161
62 
  Active 
Caspase-
8 Assay 
4 
1.36 1.34 1.79 1.17 
   
MEAN 
PD-Ex  5 
5.6
124
467 
1.12
248
93 
0.0
227
123 
  Active 
Caspase-
8 Assay 
5 
1.52 1.28 1.91 0.88 
          Mean of 
All 
Assays  
1.41 1.36 1.82 1.12 
   
ANOV
A 
      Mean of 
All 
Assays 
% 
100 96 129 80 
   
Source 
of 
Variat
ion SS df MS F 
P-
val
ue 
F 
crit 
SD 
0.09 0.16 0.13 0.15 
   
Betwe
en 
Group
s 
1.2
553
06
5 3 
0.4
184
355 
22.
979
749 
4.8
29
E-
06 
3.2
38
871
5 
SD (%) 
9.46 15.81 12.71 15.07 
   
Within 
Group
s 
0.2
913
421 16 
0.0
182
08
9 
   T Test  
  
0.001 0.0001 
          
        
Total 
1.5
46
64
86 19         
                
 
 
 
 
 
 
Figure 3.9: Investigating the Amount of Active Caspase-9 in Brain Cortex of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
 
 
DETERMINING CASPASE-9 
ACTIVITIES IN BRAIN CORTEX OF 
C, Ex, PD & PD-Ex GROUP 
    
ANOV
A 
      
 
MEA
N C 
MEAN 
Ex 
MEAN 
PD 
MEAN 
PD-Ex  
    
Group
s 
Co
unt 
Su
m 
Ave
rag
e 
Va
ria
nce 
  Active 
Caspase
-9 Assay 
1 
1.32 1.27 1.26 1.68 
    
MEAN 
C 5 
6.2
461
28
8 
1.2
492
258 
0.0
100
74 
  Active 
Caspase
-9 Assay 
2 
1.16 1.16 1.20 1.71 
    
MEAN 
Ex 5 
6.3
58
87
97 
1.2
717
759 
0.0
077
523 
  Active 
Caspase
-9 Assay 
3 
1.14 1.22 1.47 1.66 
    
MEAN 
PD 5 
6.8
128
69
4 
1.3
625
739 
0.0
159
185 
  Active 
Caspase
-9 Assay 
4 
1.37 1.33 1.41 1.66 
    
MEAN 
PD-Ex  5 
8.4
571
29
6 
1.6
914
259 
0.0
016
44
6 
  Active 
Caspase
-9 Assay 
5 
1.26 1.38 1.48 1.75 
           Mean of 
All 
Assays  
1.25 1.27 1.36 1.69 
    
ANOV
A 
      Mean of 
All 
Assays 
% 
100 102 109 135 
    
Sourc
e of 
Variat
ion SS df MS F 
P-
val
ue 
F 
crit 
SD 0.10 0.09 0.13 0.04 
    
Betwe
en 
Group
s 
0.6
267
392 3 
0.2
08
913
1 
23.
613
06 
4.0
54
E-
06 
3.2
38
871
5 
SD (%) 10.04 8.80 12.62 4.06 
    
Withi
n 
Group
s 
0.1
415
576 16 
0.0
08
847
4 
   T Test  
  
0.2 0.003 
           
 
    
    
Total 
0.7
68
29
68 19         
 
    
            
 
 
 
 
 
 
 
 
Figure 3.11: Investigating the Amount of Cleaved Caspase-12 in Brain Cortex of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
 
 
DETERMINING CASPASE-12 
ACTIVITIES IN BRAIN CORTEX OF 
C, Ex, PD & PD-Ex GROUP 
  
ANOV
A 
      
 
MEA
N C 
MEAN 
Ex 
MEAN 
PD 
MEAN 
PD-Ex  
  
Group
s 
Co
unt 
Su
m 
Ave
rag
e 
Var
ian
ce 
  Cleaved 
Caspase-
12 Assay 1 
1.18 1.13 1.51 0.94 
  
MEAN 
C 5 
5.6
718
128 
1.13
436
26 
0.0
014
014 
  Cleaved 
Caspase-
12 Assay 
2 
1.12 1.33 1.66 0.84 
  
MEAN 
Ex 5 
5.7
651
633 
1.15
303
27 
0.0
207
25 
  Cleaved 
Caspase-
12 Assay 
3 
1.17 1.16 1.36 0.81 
  
MEAN 
PD 5 
7.2
974
625 
1.4
594
925 
0.0
164
355 
  Cleaved 
Caspase-
12 Assay 
4 
1.10 1.20 1.35 0.81 
  
MEAN 
PD-Ex  5 
4.2
60
617
1 
0.8
521
234 
0.0
027
787 
  Cleaved 
Caspase-
12 Assay 
5 
1.10 0.94 1.43 0.86 
         Mean of 
All 
Assays  
1.13 1.15 1.46 0.85 
         Mean of 
All 
Assays % 
100 102 129 75 
  
ANOV
A 
      
SD 0.04 0.14 0.13 0.05 
  
Source 
of 
Variat
ion SS df MS F 
P-
val
ue 
F 
crit 
SD (%) 3.74 14.40 12.82 5.27 
  
Betwee
n 
Group
s 
0.9
238
477 3 
0.3
079
492 
29.
796
264 
8.7
63
E-
07 
3.2
38
871
5 
T Test  
  
0.003 0.0001 
  
Within 
Group
s 
0.1
653
626 16 
0.0
103
352 
   
 
    
         
       
Total 
1.0
892
103 19         
 
 
 
 
 
 
Figure 3.13: Investigating the Amount of Active Caspase-2 in Cerebellum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.15: Investigating the Amount of Cleaved Caspase-3 in Cerebellum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.17: Investigating the Amount of Active Caspase-8 in Cerebellum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
 
 
DETERMINING CASPASE-8 
ACTIVITIES IN CEREBELLUM OF C, 
Ex, PD & PD-Ex GROUP 
   
ANO
VA 
      
 
MEAN 
C 
MEAN 
Ex 
MEAN 
PD 
MEAN 
PD-Ex  
   
Grou
ps 
Co
unt 
Su
m 
Av
era
ge 
Va
ria
nce 
  
Active 
Caspase-
8 Assay 1 
1.24 0.91 1.51 1.02 
   
MEA
N C 5 
6.0
116
53
7 
1.2
02
33
07 
0.0
03
82
86 
  Active 
Caspase-
8 Assay 
2 
1.20 0.97 1.49 1.20 
   
MEA
N Ex 5 
5.1
66
77
3 
1.0
33
35
46 
0.0
111
417 
  Active 
Caspase-
8 Assay 
3 
1.24 1.00 1.44 1.27 
   
MEA
N PD 5 
7.5
00
25
63 
1.5
00
05
13 
0.0
01
28
51 
  Active 
Caspase-
8 Assay 
4 
1.24 1.13 1.53 1.14 
   
MEA
N PD-
Ex  5 
5.9
02
97
02 
1.1
80
59
4 
0.0
112
27
8 
  Active 
Caspase-
8 Assay 
5 
1.10 1.16 1.53 1.27 
          Mean of 
All 
Assays  
1.20 1.03 1.50 1.18 
          Mean of 
All 
Assays % 
100 86 125 98 
   
ANO
VA 
      
SD 
0.06 0.11 0.04 0.11 
   
Sourc
e of 
Varia
tion SS df MS F 
P-
val
ue 
F 
cri
t 
SD (%) 
6.19 10.56 3.58 10.60 
   
Betwe
en 
Grou
ps 
0.5
74
00
13 3 
0.1
91
33
38 
27.
84
74
67 
1.3
77
E-
06 
3.2
38
87
15 
T Test  
  
0.0000
1 0.001 
   
Withi
n 
Grou
ps 
0.1
09
93
25 16 
0.0
06
87
08 
   
               
        
Total 
0.6
83
93
38 19         
 
 
 
 
 
 
 
Figure 3.19: Investigating the Amount of Active Caspase-9 in Cerebellum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.21: Investigating the Amount of Cleaved Caspase-12 in Cerebellum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.23: Investigating the Amount of Active Caspase-2 in Midbrain of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.25: Investigating the Amount of Cleaved Caspase-3 in Midbrain of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.27: Investigating the Amount of Active Caspase-8 in Midbrain of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.29: Investigating the Amount of Active Caspase-9 in Midbrain of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.31: Investigating the Amount of Cleaved Caspase-12 in Midbrain of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.33: Investigating the Amount of Active Caspase-2 in Striatum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.35: Investigating the Amount of Cleaved Caspase-3 in Striatum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.37: Investigating the Amount of Active Caspase-8 in Striatum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.39: Investigating the Amount of Active Caspase-9 in Striatum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.41: Investigating the Amount of Cleaved Caspase-12 in Striatum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.43: Investigating the Amount of Active CAMK-IV in Cerebellum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.45: Investigating the Amount of Active CAMK-IV in Brain Cortex of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.47: Investigating the Amount of Active CAMK-IV in Midbrain of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Figure 3.49: Investigating the Amount of Active CAMK-IV in Striatum of 
Untreated, Exercised. MPTP and MPTP Treated with Exercise Rat PD model 
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Appendix 4 
Data Analysis : ReNcell VM 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: 6OHDA Triggered Death of dDCN 
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Figure  4.6: 6OHDA Increased Induction of Activated Caspases-2,-3 and -8 in 
dDCN 
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Figure 4.8: The Proportion of Active Caspases-2 and -8 in Caspase-3 positive 
Untreated and Treated 6OHDA dDCN  
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Figure 4.10: 6OHDA Triggered Caspase Mediated Death of dDCN 
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Figure 4.12: zVADfmk Reduced Amount of Active Caspase-2 in 6OHDA Treated 
dDCN 
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Figure 4.14: zVADfmk Reduced Amount of Active Caspase-3 in 6OHDA Treated 
dDCN 
 
 
DETERMINING THE AMOUNT OF CLEAVED CASPASE-3 IN 
6OHDA TREATED dDCN 
 
 
MEAN NOT 
TREATED 
MEAN 6OHDA & 
zVADfmk 
MEAN 
6OHDA 
MEAN 6OHDA & 
zVADfmk 
Cleaved Caspase-3 
Assay 1 
1.117 0.216 1.725 0.668 
Cleaved Caspase-3 
Assay 2 
0.957 0.269 1.899 0.925 
Cleaved Caspase-3 
Assay 3 
1.188 0.345 1.559 0.713 
Mean of All Assays 1.087 0.276 1.728 0.769 
Mean of All Assays 
% 
100 25 159 70 
SD 0.12 0.06 0.17 0.14 
SD (%) 11.83 6.48 17.01 13.74 
T Test 
   
0.002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: zVADfmk Reduced Amount of Active Caspase-8 in 6OHDA Treated 
dDCN 
 
 
DETERMINING THE AMOUNT OF ACTIVE CASPASE-8 IN 6OHDA 
TREATED dDCN 
 
 
MEAN NOT 
TREATED 
MEAN 6OHDA & 
zVADfmk 
MEAN 
6OHDA 
MEAN 6OHDA & 
zVADfmk 
Active Caspase-8 
Assay 1 
0.952 0.217 1.713 1.048 
Active Caspase-8 
Assay 2 
1.036 0.365 1.973 1.150 
Active Caspase-8 
Assay 3 
1.019 0.362 1.842 1.099 
Mean of All 
Assays 
1.003 0.315 1.843 1.099 
Mean of All 
Assays % 
100.0 31 184 110 
SD 0.0442 0.0849 0.1298 0.0509 
SD (%) 4.4204 8.4872 12.9768 5.0933 
T Test 
   
0.005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: 6OHDA Triggered Caspases, PERK and NFκB Apoptotic Death of 
dDCN  
 
 
 
DETERMINING IF 6OHDA TRIGGERS APOPTOTIC DEATH IN dDCN 
 
 
MEAN 
NOT 
TREAT
ED 
MEA
N 
6OH
DA 
MEAN 
6OHDA & 
SALUBRI
NAL 
MEAN 
6OHD
A & 
IKK 
MEAN 
6OHDA 
& 
zVADfm
k 
MEAN 
6OHDA & 
zLEVDfm
k 
MEAN 
6OHDA 
& 
zIETDfm
k 
MEAN 
6OHDA & 
zVDVADf
mk 
Mean 
of 
Assay 1 
0.79 2.15 1.05 1.36 0.98 1.14 1.26 1.04 
Mean 
of 
Assay 
2 
0.82 2.19 1.09 1.27 0.99 1.13 1.30 1.06 
Mean 
of 
Assay 
3 
0.77 2.10 1.08 1.28 1.00 1.14 1.27 1.08 
Mean 
of All 
Assays 
0.79 2.15 1.07 1.31 0.99 1.14 1.28 1.06 
Mean 
of All 
Assays 
% 
100 271 136 165 125 144 161 134 
SD 0.023 0.047 0.021 0.047 0.011 0.005 0.019 0.017 
(n) 3 3 3 3 3 3 3 3 
SQR 1.73 1.73 1.73 1.73 1.73 1.73 1.73 1.73 
SE 0.013 0.027 0.012 0.027 0.006 0.003 0.011 0.010 
SE % 1.343 2.711 1.187 2.689 0.611 0.295 1.069 0.976 
T Test 
  
0.00009 
0.0000
3 
0.0003 0.0006 0.0002 0.0002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anova 
      
       
SUMMARY 
      
Groups Count Sum Average Variance 
  
Mean 6OHDA 24 
51.485333
33 
2.14522222
2 
0.0030866
83   
Mean 6OHDA and 
Salubrinal  
24 
25.760333
33 
1.07334722
2 
0.0024072
61   
Mean 6OHDA and IKK 24 
31.332333
33 
1.30551388
9 
0.0035846
76   
Mean 6OHDA and 
zVADfmk 
24 
23.692666
67 
0.98719444
4 
0.0012392
07   
Mean 6OHDA and 
zLEVDfmk 
24 27.332 
1.13883333
3 
0.0009817
29   
Mean 6OHDA and 
zIETDfmk 
24 
30.621666
67 
1.27590277
8 
0.0022391
93   
Mean 6OHDA and 
zVDVADfmk 
24 25.403 
1.05845833
3 
0.0009129
55   
       
       
ANOVA 
      
Source of Variation SS df MS F P-value F crit 
Between Groups 
22.7193812
6 
6 
3.78656354
3 
1834.10519
2 
2.037E-
145 
2.1553022
64 
Within Groups 
0.3323891
85 
161 
0.0020645
29    
       
Total 
23.051770
44 
167         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5 
Data Analysis : NFB 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Presence of NFB Expressed in Untreated and 6OHDA Treated 
dDCN 
 
 
 
 
DETERMINING THE PROPORTION p65 NFB EXPRESSED IN TH POSITIVE 
NOT TREATED AND 6OHDA dDCN 
 
 
Non Treated (No 6OHDA)  Treated (6OHDA) 
 
Active TH Cleaved NFB Active TH Cleaved NFB 
Mean of 
Assay 1  
34.60 17.06 9.67 10.00 
Mean of 
Assay 2 
36.13 18.22 10.13 11.00 
Mean of 
Assay 3 
32.73 20.36 11.93 10.60 
Mean of All 
Assays  
34.49 18.55 10.58 10.53 
Mean of All 
Assays % 
100.00 53.78 30.67 30.54 
Total Ratio  0.54 1.00 
Total Ratio 
(%) 
54 100 
T TEST  0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: 6OHDA Triggers Activation NFB in dDCN 
 
 
 
6OHDA INCREASED ACTIVATION OF NFκB IN dDCN 
 
MEAN NOT 
TREATED 
MEAN TREATED                       
6OHDA 
Cleaved NFĸB Assay 
1 
0.824 
1.360 
Cleaved NFĸB Assay 
2 
0.686 
1.217 
Cleaved NFĸB Assay 
3 
0.955 
1.349 
Cleaved NFĸB Assay 
4 
0.363 
1.438 
Cleaved NFĸB Assay 
5 
0.310 
1.542 
Mean Assay 0.627 1.381 
Mean Assay(%) 100 220 
SD 0.28 0.12 
SD (%) 28.31 11.99 
T Test 
 
0.002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Proportion of Active Caspases-2,-3 and -8 Expressed in NFκB 
Positive Untreated and 6OHDA Treated dDCN 
 
 
 
DETERMINING THE PROPORTION OF ACTIVE CASPASES-2,-3 AND -8 EXPRESSED 
IN NFB POSITIVE NOT TREATED AND 6OHDA dDCN 
 
 
Non Treated  
(No 6OHDA) 
 Treated  
(6OHDA ) 
Non Treated  
(No 6OHDA) 
 Treated  
(6OHDA) 
Non Treated  
(No 6OHDA) 
 Treated  
(6OHDA) 
 
Clea
ved 
NF
B 
Active 
Caspa
se-2 
Clea
ved 
NF
B 
Active 
Caspa
se-2 
Clea
ved 
NF
B 
Cleave
d 
Caspas
e-3 
Clea
ved 
NF
B 
Cleave
d 
Caspas
e-3 
Clea
ved 
NF
B 
Active 
Caspa
se-8 
Clea
ved 
NF
B 
Active 
Caspa
se-8 
Mean 
of 
Assay 1  
36.6
7 
19.33 
10.0
0 
8.13 
41.9
3 
11.00 
10.4
7 
5.47 19.67 7.60 9.87 9.87 
Mean 
of 
Assay 2 
42.3
3 
16.01 8.00 8.33 
41.4
0 
11.20 9.93 6.00 
24.2
0 
8.21 
10.4
0 
10.40 
Mean 
of 
Assay 3 
41.9
3 
18.56 
10.8
7 
8.80 
39.6
7 
12.00 
10.5
3 
5.27 
26.4
0 
8.13 
12.0
0 
12.00 
Mean 
of All 
Assays  
40.3
1 
17.97 9.62 8.42 
41.0
0 
11.40 10.31 5.58 
23.4
2 
10.31 
10.7
6 
10.76 
Mean 
of All 
Assays 
% 
100.
00 
44.57 
23.8
7 
20.89 
100.
00 
30.60 25.15 13.60 
100.
00 
34.03 
45.9
2 
45.92 
Total 
Ratio  
0.45 0.88 0.31 0.54 0.34 1.00 
Total 
Ratio 
(%) 
45 88 31 54 34 100 
T TEST  0.02 0.02 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Optimising the Concentration of IKK in 6OHDA Treated dDCN 
 
 
 
 
DETERMINING THE EFFECT OF IKK IN 6OHDA dDCN  
 
  
MEA
N 
NOT 
TREA
TED 
M
EA
N 
IK
K 
ME
AN 
6O
HD
A  
MEAN 
6OHD
A & 
IKK 
10µM 
MEAN 
6OHDA 
& IKK 
30µM 
MEAN 
6OHD
A & 
IKK 
50µM 
MEAN 
6OHD
A & 
IKK 
70µM 
MEAN 
6OHDA 
& IKK 
80µM 
MEAN 
6OHDA 
& IKK 
100µM 
MEAN 
6OHDA 
& IKK 
120µM 
Mean 
of 
Assay 
1  
2.26 
2.2
6 
0.73 0.75 0.78 0.71 1.29 1.33 1.32 1.33 
Mean 
of 
Assay 
2 
2.27 
2.2
0 
0.69 0.66 0.67 0.71 1.31 1.35 1.38 1.37 
Mean 
of 
Assay 
3 
2.29 
2.2
6 
0.65 0.70 0.69 0.73 1.25 1.29 1.27 1.19 
Mean 
of All 
Assay
s  
2.27 
2.2
4 
0.69 0.70 0.71 0.72 1.29 1.32 1.32 1.30 
Mean 
of All 
Assay
s % 
100 99 30 31 31 32 57 58 58 57 
SD 
0.018 
0.0
31 
0.04
1 0.045 0.059 0.010 0.030 0.033 0.054 0.097 
(n) 3 3 3 3 3 3 3 3 3 3 
SQR  
1.732 
1.7
32 
1.73
2 1.732 1.732 1.732 1.732 1.732 1.732 1.732 
SE  
0.010 
0.0
18 
0.02
3 0.026 0.034 0.006 0.017 0.019 0.031 0.056 
SE % 
1.033 
1.7
67 
2.34
4 2.621 3.427 0.597 1.708 1.903 3.139 5.611 
T 
Test        
0.0001 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: IKK and zVADfmk Promote Survival of 6OHDA Treated dDCN 
  
 
 
6OHDA TRIGGERS NFκB CLASSICAL AND CASPASE MEDIATED DEATH OF 
dDCN 
 
  
MEAN 
NOT 
TREATED 
MEAN 
IKK 
MEAN 
zVADfmk  
MEAN 
6OHDA  
MEAN 
6OHDA & 
zVADfmk 
MEAN 
6OHDA 
& IKK 
MEAN 6OHDA 
& zVADfmk & 
IKK  
Mean of 
Assay 1  
2.059 2.035 2.103 0.535 1.004 1.285 1.539 
Mean of 
Assay 2 
2.121 2.099 2.051 0.671 0.955 1.203 1.545 
Mean of 
Assay 3 
2.114 2.109 2.123 0.631 1.205 0.934 1.539 
Mean of 
All 
Assays  
2.098 2.081 2.092 0.612 1.055 1.141 1.541 
Mean of 
All 
Assays 
% 
100 99 100 29 50 54 73 
SD 0.03 0.04 0.04 0.07 0.13 0.18 0.00 
(n) 3 3 3 3 3 3 3 
SQR  1.73 1.73 1.73 1.73 1.73 1.73 1.73 
SE  0.02 0.02 0.02 0.04 0.08 0.11 0.00 
SE % 1.97 2.31 2.15 4.04 7.65 10.60 0.20 
T Test          0.014 0.026 0.002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: Determining the Amount of Cleaved NFB in IKK Treated 6OHDA 
dDCN 
 
 
 
CLEAVED NFB IS SUPPRESSED BY IKK IN 6OHDA dDCN 
 
MEAN NOT 
TREATED 
MEAN 
IKK  
MEAN 
6OHDA 
MEAN 6OHDA & 
IKK  
Cleaved NFĸB Assay 1 
0.918 0.000 1.488 
0.000 
Cleaved NFĸB Assay 2 
1.069 0.000 1.572 
0.000 
Cleaved NFĸB Assay 3 
1.148 0.000 1.444 
0.000 
Mean Assay 
1.045 0.000 1.502 0.000 
Mean Assay(%) 
100 0 144 
0 
SD 
0.12 0.00 0.07 0.00 
SD (%) 
11.69 0.00 6.50 
0.00 
T Test   
0.009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: IKK and zIETDfmk Promote Survival of 6OHDA Treated dDCN 
  
 
 
DETERMINING IF CASPASE-8 IS ACTIVE IN NFκB CLASSICAL PATHWAY OF 
6OHDA dDCN 
 
  
MEAN 
NOT 
TREATED 
MEA
N 
IKK 
MEAN 
zIETDf
mk 
MEAN 
6OHD
A  
MEAN 
6OHDA & 
IKK 
MEAN 
6OHDA & 
zIETDfmk 
MEAN 6OHDA 
& IKK & 
zIETDfmk 
Mean of 
Assay 1  
2.109 2.108 2.157 0.694 1.215 1.206 1.272 
Mean of 
Assay 2 
2.091 2.116 2.124 0.694 1.282 1.298 1.266 
Mean of 
Assay 3 
2.115 2.102 2.102 0.657 1.328 1.456 1.482 
Mean of 
All 
Assays  
2.105 2.109 2.128 0.682 1.275 1.320 1.340 
Mean of 
All 
Assays % 
100 100 101 32 61 63 64 
SD 0.013 0.007 0.028 0.022 0.057 0.126 0.123 
(n) 3 3 3 3 3 3 3 
SQR  1.73 1.73 1.73 1.73 1.73 1.73 1.73 
SE  0.01 0.00 0.02 0.01 0.03 0.07 0.07 
SE % 0.74 0.38 1.60 1.24 3.28 7.29 7.11 
T Test          0.001 0.01 0.01 
     
0.62 
 
      
0.472 0.852 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19: Proportion of Active Caspase-8 Expressed in NFκB Positive 
6OHDA, IKK, zIETDfmk Treated dDCN 
 
 
 
DETERMINING THE PROPORTION OF ACTIVE CASPASES-8 EXPRESSED IN 
NFκB NOT TREATED AND 6OHDA TREATED dDCN 
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Figure 5.21 : Determining the Amount of Active Caspase-8 in IKK Treated 
6OHDA dDCN 
  
 
 
ACTIVE CASPASE-8 IS SUPPRESSED BY IKK IN 6OHDA 
dDCN 
 
 
MEAN NOT 
TREATED 
MEAN 
IKK  
MEAN 
6OHDA 
MEAN 6OHDA & 
IKK  
Active Caspase-8 
Assay 1 
0.883 0.000 2.164 
0.000 
Active Caspase-8 
Assay 2 
0.924 0.000 1.937 
0.000 
Active Caspase-8 
Assay 3 
1.133 0.000 1.515 
0.000 
Mean Assay 0.980 0.000 1.872 0.000 
Mean Assay(%) 100 0 191 0 
SD 0.13 0.00 0.33 0.00 
SD (%) 13.43 0.00 32.91 0.00 
T Test    
0.029 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23: IKK and zVDVADfmk Promote Survival of 6OHDA Treated dDCN 
 
 
 
DETERMINING IF CASPASE-2 IS ACTIVE IN NFκB CLASSICAL PATHWAY OF 
6OHDA dDCN 
 
  
MEAN 
NOT 
TREATE
D 
MEA
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IKK 
MEAN 
zVDVAD
fmk 
MEAN 
6OHD
A  
MEAN 
6OHDA 
& IKK 
MEAN 
6OHDA & 
zVDVADfmk 
MEAN 6OHDA 
& IKK & 
zVDVADfmk 
Mean of 
Assay 1  
2.07 2.03 2.09 0.65 1.23 1.63 1.67 
Mean of 
Assay 2 
2.10 2.11 2.11 0.67 1.16 1.59 1.66 
Mean of 
Assay 3 
2.03 2.05 2.06 0.56 1.16 1.40 1.52 
Mean of 
All 
Assays  
2.07 2.06 2.09 0.62 1.18 1.54 1.61 
Mean of 
All 
Assays % 
100 100 101 30 57 75 78 
SD 0.04 0.04 0.03 0.06 0.04 0.13 0.08 
(n) 3.00 3.00 3.00 3.00 3.00 3.00 3.00 
SQR  1.73 1.73 1.73 1.73 1.73 1.73 1.73 
SE  0.02 0.02 0.01 0.03 0.02 0.07 0.05 
SE % 2.18 2.45 1.50 3.47 2.41 7.23 4.76 
T Test          0.0004 0.002 0.0001 
     
0.03   
      
0.004 0.449 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.26: Proportion of Active Caspase-2 Expressed in NFκB Positive 
6OHDA, IKK, zVDVADfmk Treated dDCN 
 
 
 
 
DETERMINING THE PROPORTION OF ACTIVE CASPASES-2 EXPRESSED NFκB 
POSITIVE NOT TREATED AND 6OHDA TREATED dDCN 
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Figure 5.28: Determining the Amount of Active Caspase-2 in IKK Treated 
6OHDA dDCN 
  
 
ACTIVE CASPASE-2 IS SUPPRESSED BY IKK IN 6OHDA dDCN 
 
MEAN NOT 
TREATED 
MEAN 
IKK  
MEAN 
6OHDA 
MEAN 6OHDA & 
IKK  
Active Caspase-2 
Assay 1 0.830 0.000 1.647 
0.000 
Active Caspase-2 
Assay 2 0.869 0.000 1.252 
0.000 
Active Caspase-2 
Assay 3 0.643 0.000 1.352 
0.000 
Mean Assay 0.781 0.000 1.417 0.000 
Mean Assay(%) 100 0 181 0 
SD 0.12 0.00 0.21 0.00 
SD (%) 12.06 0.00 20.55 0.00 
T Test  
  
0.016 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.29: zVDVADfmk and IKK Provide Further Survival of 6OHDA Treated 
dDCN 
  
  
 
DETERMINING IF CASPASES-2 AND -8 ARE ACTIVE IN NFκB CLASSICAL PATHWAY 
OF 6OHDA dDCN 
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Figure 5.34 : IKK and zLEVDfmk Promote Survival of 6OHDA Treated dDCN 
 
 
 
DETERMINING IF CASPASE-4 IS ACTIVE IN NFκB CLASSICAL PATHWAY OF 
6OHDA dDCN 
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MEAN 
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IKK  
MEAN 
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zLEVDfmk  
MEAN 6OHDA 
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Assay 1  
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Mean of 
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Figure 5.37: Proportion of Active Caspase-4 Expressed in NFκB Positive 
6OHDA, IKK, zLEVDfmk Treated dDCN 
 
 
 
DETERMINING THE PROPORTION OF ACTIVE CASPASES-4 EXPRESSED IN 
NFκB NOT TREATED AND 6OHDA TREATED dDCN 
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Figure 5.39: Determining the Amount of Active Caspase-4 in IKK Treated 
6OHDA dDCN 
  
 
 
DETERMINING THE AMOUNT OF ACTIVE  CASPASE-4 IN IKK 
TREATED 6OHDA dDCN 
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TREATED 
MEAN 
IKK  
MEAN 
6OHDA 
MEAN 6OHDA & 
IKK  
Active Caspase-4 Assay 
1 
1.013 0.983 1.666 1.760 
Active Caspase-4 Assay 
2 
0.940 0.877 2.123 1.899 
Active Caspase-4 Assay 
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SD 0.106 0.222 0.247 0.212 
SD (%) 10.56 22.23 24.66 21.23 
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0.013 0.607 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.40: zLEVDfmk and IKK Provide Further Survival of 6OHDA Treated 
dDCN 
 
  
 
DETERMINING THE EFFECT OF CASPASES-2 AND -8 ACTIVITIES  IN NFκB CLASSICAL 
PATHWAY OF 6OHDA dDCN 
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Figure 5.42 
Various treatments used by  combining different 
inhibitors such as  IKK, zVDVADfmk, zLEVDfmk 
and zIETDfmk to determine if maximal cell survival 
could be achieved by suppression of Caspases-2,-4,-8 
and NFB activity in 6OHD treated dDCN 
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Appendix 6 
Data Analysis : ER Stress 
 
 
 
 
 
 
 
 
 
Figure 6.2:  Salubrinal Promoted Survival of 6OHDA Treated dDCN 
 
DETERMINING THE EFFECT OF SALUBRINAL IN 6OHDA dDCN 
 
MEAN NOT 
TREATED 
MEAN 
SALUBRINAL 
MEAN 
6OHDA 
MEAN 6OHDA & 
SALUBRINAL 
Mean of Assay 1 1.613 1.500 0.561 1.042 
Mean of Assay 2 1.523 1.391 0.533 1.117 
Mean of Assay 3 1.344 1.278 0.707 1.078 
Mean of All 
Assays 
1.494 1.390 0.600 1.079 
Mean of All 
Assays % 
100 93 40 72 
SD 0.14 0.11 0.09 0.04 
(n) 3.000 3.000 3.000 3.000 
SQR 1.732 1.732 1.732 1.732 
SE 0.08 0.06 0.05 0.02 
SE % 7.90 6.42 5.38 2.17 
T Test 
   
0.006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Optimising the Concentration of Salubrinal in 6OHDA Treated 
dDCN 
 
 
DETERMINING THE EFFECT OF SALUBRINAL AND zVADfmk IN 6OHDA dDCN 
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T Test 
  
0.01 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6:  Salubrinal and zVADfmk Promote Survival of 6OHDA Treated 
dDCN 
 
 
 
 
DETERMINING THE EFFECT OF SALUBRINAL AND zVADfmk IN 6OHDA 
dDCN 
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Assay 2 
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All 
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SE 0.06 0.05 0.07 0.03 0.04 0.02 0.05 
SE % 5.74 5.47 6.59 2.67 3.58 1.68 5.07 
T Test 
 
0.001 0.00004 0.0002 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 :  Salubrinal and zVDVADfmk Promote Survival of 6OHDA Treated 
dDCN 
 
 
 
DETERMINING IF CASPASE-2 IS ACTIVE IN ER STRESS PATHWAY OF 
6OHDA dDCN 
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Figure 6.11: Proportion of Active Caspase-2 Expressed in TH  Positive 6OHDA, 
IKK, zVDVADfmk Treated dDCN 
 
 
 
DETERMINING THE PROPORTION OF ACTIVE CASPASES-2 EXPRESSED NOT 
TREATED AND 6OHDA TREATED dDCN 
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Figure 6.13: Determining the Amount of Active Caspase-2 in Salubrinal Treated 
6OHDA dDCN 
 
 
 
ACTIVE CASPASE-2 IS SUPPRESSED BY SALUBRINAL IN 6OHDA dDCN 
 
 
MEAN NOT 
TREATED 
MEAN 
SALUBRINAL 
MEAN 
6OHDA 
MEAN 6OHDA & 
SALUBRINAL 
Active Caspase-2 Assay 
1 
1.069 0.000 1.702 0 
Active Caspase-2 Assay 
2 
1.117 0.000 1.604 0 
Active Caspase-2 Assay 
3 
0.959 0.000 1.746 0 
Active Caspase-2 Assay 
4 
0.529 0.000 1.529 0 
Active Caspase-2 Assay 
5 
0.421 0.000 2.416 0 
Mean of All Assays  0.819 0.000 1.799 0.000 
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Figure 6.15 : Salubrinal and zLEVDfmk Promote Survival of 6OHDA Treated 
dDCN 
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Figure 6.18: Proportion of Active Caspase-4 Expressed in TH  Positive 6OHDA, 
IKK, zLEVDfmk Treated dDCN 
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Figure 6.20: Determining the Amount of Active Caspase-4 in Salubrinal 
Treated 6OHDA dDCN 
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Figure 6.21: zLEVDfmk and Salubrinal Provide Further Survival of 6OHDA 
Treated dDCN  
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Figure 6.26 :  Salubrinal and zIETDfmk Promote Survival of 6OHDA Treated 
dDCN 
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Figure 6.29: Proportion of Active Caspase-8 Expressed in TH Positive 6OHDA, 
IKK, zIETDfmk Treated dDCN 
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Figure 6.31: Determining the Amount of Active Caspase-8 in Salubrinal 
Treated 6OHDA dDCN 
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Figure 6.32: zLEVDfmk, zIETDfmk and Salubrinal Provide Further Survival of 
6OHDA Treated dDCN  
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Figure 6.34 
 
Various treatments used by  combining different inhibitors such as  salubrinal, 
zVDVADfmk, zLEVDfmk and zIETDfmk to determine if maximal cell survival 
could be achieved by suppression of Caspases-2,-4,-8 and PERK activity in 
6OHD treated dDCN 
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Figure 6.37: IKK and Salubrinal Provide Further Survival of 6OHDA Treated 
dDCN 
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Figure 6.41: zVADfmk, IKK and Salubrinal Provide Further Survival of 6OHDA 
Treated dDCN  
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